FromID,ToID,Relation_value,Relation_type,Relation_Context_ClinicalPhase
18,19,phosphodiesterase inhibitor,MoA,Phase 1
20,19,phosphodiesterase inhibitor,MoA,Phase 1
21,19,phosphodiesterase inhibitor,MoA,Phase 1
22,19,phosphodiesterase inhibitor,MoA,Phase 1
23,19,phosphodiesterase inhibitor,MoA,Phase 1
24,25,benzodiazepine receptor agonist,MoA,Phase 3
26,25,benzodiazepine receptor agonist,MoA,Phase 3
20,27,phosphodiesterase inhibitor,MoA,Phase 1
22,27,phosphodiesterase inhibitor,MoA,Phase 1
28,29,tachykinin antagonist,MoA,Preclinical
30,31,glycogen synthase kinase inhibitor,MoA,Preclinical
32,31,glycogen synthase kinase inhibitor,MoA,Preclinical
33,34,retinoid receptor ligand,MoA,Preclinical
35,36,purinergic receptor antagonist,MoA,Preclinical
37,38,histone lysine methyltransferase inhibitor,MoA,Preclinical
39,38,histone lysine methyltransferase inhibitor,MoA,Preclinical
9,40,dopamine receptor agonist,MoA,Preclinical
41,42,purinergic receptor antagonist,MoA,Preclinical
43,44,nicotinic receptor agonist,MoA,Preclinical
45,46,adrenergic receptor agonist,MoA,Preclinical
47,46,adrenergic receptor agonist,MoA,Preclinical
48,46,adrenergic receptor agonist,MoA,Preclinical
49,50,AKT inhibitor,MoA,Preclinical
51,50,AKT inhibitor,MoA,Preclinical
52,50,AKT inhibitor,MoA,Preclinical
53,54,transient receptor potential channel antagonist,MoA,Preclinical
55,56,sodium channel blocker,MoA,Preclinical
41,57,purinergic receptor antagonist,MoA,Preclinical
41,58,purinergic receptor antagonist,MoA,Preclinical
59,60,acetylcholine receptor allosteric modulator,MoA,Preclinical
61,60,acetylcholine receptor allosteric modulator,MoA,Preclinical
43,60,acetylcholine receptor allosteric modulator,MoA,Preclinical
55,62,sodium channel blocker,MoA,Preclinical
63,64,diacylglycerol O acyltransferase inhibitor,MoA,Preclinical
65,66,stearoyl-CoA desaturase inhibitor,MoA,Preclinical
67,68,transient receptor potential channel antagonist,MoA,Preclinical
69,70,histamine receptor antagonist,MoA,Preclinical
71,70,histamine receptor antagonist,MoA,Preclinical
72,70,histamine receptor antagonist,MoA,Preclinical
73,70,histamine receptor antagonist,MoA,Preclinical
74,70,histamine receptor antagonist,MoA,Preclinical
75,70,histamine receptor antagonist,MoA,Preclinical
76,70,histamine receptor antagonist,MoA,Preclinical
8,70,histamine receptor antagonist,MoA,Preclinical
11,70,histamine receptor antagonist,MoA,Preclinical
12,70,histamine receptor antagonist,MoA,Preclinical
14,70,histamine receptor antagonist,MoA,Preclinical
15,70,histamine receptor antagonist,MoA,Preclinical
77,70,histamine receptor antagonist,MoA,Preclinical
78,70,histamine receptor antagonist,MoA,Preclinical
79,80,GABA receptor positive allosteric modulator,MoA,Preclinical
81,80,GABA receptor positive allosteric modulator,MoA,Preclinical
82,80,GABA receptor positive allosteric modulator,MoA,Preclinical
84,85,metalloproteinase inhibitor,MoA,Phase 3
86,87,gonadotropin releasing factor hormone receptor antagonist,MoA,Phase 3
88,89,sphingosine kinase inhibitor,MoA,Phase 2
97,98,histamine receptor antagonist,MoA,Phase 1
99,98,histamine receptor antagonist,MoA,Phase 1
100,98,histamine receptor antagonist,MoA,Phase 1
101,102,platelet activating factor receptor antagonist,MoA,Phase 1
103,104,calcium channel blocker,MoA,Phase 2
105,104,calcium channel blocker,MoA,Phase 2
106,104,calcium channel blocker,MoA,Phase 2
107,108,adenosine kinase inhibitor,MoA,Preclinical
9,109,dopamine receptor agonist,MoA,Phase 2
110,111,BCL inhibitor,MoA,Phase 1/Phase 2
112,111,BCL inhibitor,MoA,Phase 1/Phase 2
113,111,BCL inhibitor,MoA,Phase 1/Phase 2
114,115,tubulin polymerization inhibitor,MoA,Phase 2
116,117,estrogen receptor agonist,MoA,Preclinical
118,119,retinoid receptor agonist,MoA,Preclinical
120,121,PAR agonist,MoA,Preclinical
122,123,PARP inhibitor,MoA,Preclinical
124,125,retinoid receptor agonist,MoA,Preclinical
118,125,retinoid receptor agonist,MoA,Preclinical
126,127,PDGFR tyrosine kinase receptor inhibitor,MoA,Preclinical
128,127,PDGFR tyrosine kinase receptor inhibitor,MoA,Preclinical
129,127,PDGFR tyrosine kinase receptor inhibitor,MoA,Preclinical
130,127,PDGFR tyrosine kinase receptor inhibitor,MoA,Preclinical
131,127,PDGFR tyrosine kinase receptor inhibitor,MoA,Preclinical
132,133,urotensin receptor agonist,MoA,Preclinical
136,137,PI3K inhibitor,MoA,Phase 1
138,137,PI3K inhibitor,MoA,Phase 1
160,164,glutamate receptor antagonist,MoA,Preclinical
167,168,polarization inhibitor,MoA,Phase 3
202,203,lipoxygenase inhibitor,MoA,Phase 2
204,203,lipoxygenase inhibitor,MoA,Phase 2
217,218,cholesterol inhibitor,MoA,Phase 3
219,218,cholesterol inhibitor,MoA,Phase 3
228,229,gamma glutamyltransferase inhibitor,MoA,Phase 2
241,242,orexin receptor antagonist,MoA,Phase 1
243,242,orexin receptor antagonist,MoA,Phase 1
244,245,FGFR inhibitor|VEGFR inhibitor,MoA,Phase 1
246,245,FGFR inhibitor|VEGFR inhibitor,MoA,Phase 1
247,248,HDAC inhibitor,MoA,Phase 1/Phase 2
249,248,HDAC inhibitor,MoA,Phase 1/Phase 2
250,248,HDAC inhibitor,MoA,Phase 1/Phase 2
251,248,HDAC inhibitor,MoA,Phase 1/Phase 2
252,248,HDAC inhibitor,MoA,Phase 1/Phase 2
255,256,aldose reductase inhibitor,MoA,Phase 2
255,258,TGF beta receptor inhibitor,MoA,Phase 3
259,258,TGF beta receptor inhibitor,MoA,Phase 3
260,258,TGF beta receptor inhibitor,MoA,Phase 3
261,258,TGF beta receptor inhibitor,MoA,Phase 3
262,258,TGF beta receptor inhibitor,MoA,Phase 3
263,264,CC chemokine receptor antagonist,MoA,Phase 2
118,265,retinoid receptor agonist,MoA,Phase 1
222,265,retinoid receptor agonist,MoA,Phase 1
11,266,serotonin receptor agonist|serotonin receptor antagonist,MoA,Phase 2
14,266,serotonin receptor agonist|serotonin receptor antagonist,MoA,Phase 2
267,268,protein synthesis stimulant,MoA,Preclinical
269,268,protein synthesis stimulant,MoA,Preclinical
270,268,protein synthesis stimulant,MoA,Preclinical
271,268,protein synthesis stimulant,MoA,Preclinical
272,268,protein synthesis stimulant,MoA,Preclinical
273,268,protein synthesis stimulant,MoA,Preclinical
281,282,adenosine receptor agonist,MoA,Launched
283,282,adenosine receptor agonist,MoA,Launched
284,282,adenosine receptor agonist,MoA,Launched
285,282,adenosine receptor agonist,MoA,Launched
107,282,adenosine receptor agonist,MoA,Launched
286,282,adenosine receptor agonist,MoA,Launched
287,282,adenosine receptor agonist,MoA,Launched
288,282,adenosine receptor agonist,MoA,Launched
20,282,adenosine receptor agonist,MoA,Launched
22,282,adenosine receptor agonist,MoA,Launched
289,282,adenosine receptor agonist,MoA,Launched
290,282,adenosine receptor agonist,MoA,Launched
291,282,adenosine receptor agonist,MoA,Launched
292,282,adenosine receptor agonist,MoA,Launched
293,282,adenosine receptor agonist,MoA,Launched
280,282,adenosine receptor agonist,MoA,Launched
294,295,adenosine receptor agonist,MoA,Phase 2
296,295,adenosine receptor agonist,MoA,Phase 2
297,295,adenosine receptor agonist,MoA,Phase 2
298,295,adenosine receptor agonist,MoA,Phase 2
192,295,adenosine receptor agonist,MoA,Phase 2
299,295,adenosine receptor agonist,MoA,Phase 2
300,295,adenosine receptor agonist,MoA,Phase 2
301,295,adenosine receptor agonist,MoA,Phase 2
302,295,adenosine receptor agonist,MoA,Phase 2
281,295,adenosine receptor agonist,MoA,Phase 2
283,295,adenosine receptor agonist,MoA,Phase 2
284,295,adenosine receptor agonist,MoA,Phase 2
303,295,adenosine receptor agonist,MoA,Phase 2
304,295,adenosine receptor agonist,MoA,Phase 2
305,295,adenosine receptor agonist,MoA,Phase 2
285,295,adenosine receptor agonist,MoA,Phase 2
306,295,adenosine receptor agonist,MoA,Phase 2
307,295,adenosine receptor agonist,MoA,Phase 2
308,295,adenosine receptor agonist,MoA,Phase 2
49,295,adenosine receptor agonist,MoA,Phase 2
309,295,adenosine receptor agonist,MoA,Phase 2
310,295,adenosine receptor agonist,MoA,Phase 2
311,295,adenosine receptor agonist,MoA,Phase 2
312,295,adenosine receptor agonist,MoA,Phase 2
313,295,adenosine receptor agonist,MoA,Phase 2
314,295,adenosine receptor agonist,MoA,Phase 2
315,295,adenosine receptor agonist,MoA,Phase 2
316,295,adenosine receptor agonist,MoA,Phase 2
317,295,adenosine receptor agonist,MoA,Phase 2
318,295,adenosine receptor agonist,MoA,Phase 2
319,295,adenosine receptor agonist,MoA,Phase 2
320,295,adenosine receptor agonist,MoA,Phase 2
321,295,adenosine receptor agonist,MoA,Phase 2
322,295,adenosine receptor agonist,MoA,Phase 2
323,295,adenosine receptor agonist,MoA,Phase 2
324,295,adenosine receptor agonist,MoA,Phase 2
325,295,adenosine receptor agonist,MoA,Phase 2
290,295,adenosine receptor agonist,MoA,Phase 2
326,295,adenosine receptor agonist,MoA,Phase 2
327,295,adenosine receptor agonist,MoA,Phase 2
328,295,adenosine receptor agonist,MoA,Phase 2
329,295,adenosine receptor agonist,MoA,Phase 2
330,295,adenosine receptor agonist,MoA,Phase 2
280,295,adenosine receptor agonist,MoA,Phase 2
331,295,adenosine receptor agonist,MoA,Phase 2
334,335,solute carrier family member inhibitor,MoA,Preclinical
336,337,adiponectin receptor agonist,MoA,Preclinical
338,337,adiponectin receptor agonist,MoA,Preclinical
339,340,opioid receptor agonist,MoA,Phase 2
7,341,dopamine receptor antagonist|serotonin receptor agonist,MoA,Phase 2
11,341,dopamine receptor antagonist|serotonin receptor agonist,MoA,Phase 2
202,343,11-beta hydroxysteroid dehydrogenase inhibitor,MoA,Preclinical
204,343,11-beta hydroxysteroid dehydrogenase inhibitor,MoA,Preclinical
160,344,glutamate receptor negative allosteric modulator,MoA,Phase 2
160,345,glutamate receptor modulator,MoA,Preclinical
346,347,EGFR inhibitor|VEGFR inhibitor,MoA,Phase 1/Phase 2
348,347,EGFR inhibitor|VEGFR inhibitor,MoA,Phase 1/Phase 2
349,347,EGFR inhibitor|VEGFR inhibitor,MoA,Phase 1/Phase 2
350,347,EGFR inhibitor|VEGFR inhibitor,MoA,Phase 1/Phase 2
351,347,EGFR inhibitor|VEGFR inhibitor,MoA,Phase 1/Phase 2
244,347,EGFR inhibitor|VEGFR inhibitor,MoA,Phase 1/Phase 2
7,352,dopamine receptor agonist,MoA,Phase 3
354,355,estrogen receptor antagonist,MoA,Phase 2
116,355,estrogen receptor antagonist,MoA,Phase 2
356,355,estrogen receptor antagonist,MoA,Phase 2
357,355,estrogen receptor antagonist,MoA,Phase 2
358,355,estrogen receptor antagonist,MoA,Phase 2
359,355,estrogen receptor antagonist,MoA,Phase 2
360,355,estrogen receptor antagonist,MoA,Phase 2
361,355,estrogen receptor antagonist,MoA,Phase 2
362,363,sortilin inhibitor,MoA,Preclinical
364,365,insulin growth factor receptor inhibitor,MoA,Preclinical
366,367,PARP inhibitor,MoA,Preclinical
346,368,EGFR inhibitor|JAK inhibitor,MoA,Preclinical
369,368,EGFR inhibitor|JAK inhibitor,MoA,Preclinical
370,368,EGFR inhibitor|JAK inhibitor,MoA,Preclinical
371,372,tyrosine kinase inhibitor,MoA,Preclinical
373,374,isocitrate dehydrogenase inhibitor,MoA,Preclinical
375,376,isocitrate dehydrogenase inhibitor,MoA,Preclinical
377,378,cell cycle inhibitor,MoA,Phase 2
4,379,nitric oxide synthase inhibitor,MoA,Phase 3
380,379,nitric oxide synthase inhibitor,MoA,Phase 3
381,379,nitric oxide synthase inhibitor,MoA,Phase 3
332,379,nitric oxide synthase inhibitor,MoA,Phase 3
153,379,nitric oxide synthase inhibitor,MoA,Phase 3
194,379,nitric oxide synthase inhibitor,MoA,Phase 3
382,379,nitric oxide synthase inhibitor,MoA,Phase 3
382,383,imidazoline receptor ligand,MoA,Preclinical
224,384,retinoid receptor antagonist,MoA,Phase 3
225,384,retinoid receptor antagonist,MoA,Phase 3
226,384,retinoid receptor antagonist,MoA,Phase 3
124,385,retinoid receptor agonist,MoA,Phase 1/Phase 2
389,390,free fatty acid receptor antagonist,MoA,Preclinical
47,391,adrenergic receptor ligand,MoA,Preclinical
392,393,prostanoid receptor antagonist,MoA,Preclinical
394,393,prostanoid receptor antagonist,MoA,Preclinical
395,393,prostanoid receptor antagonist,MoA,Preclinical
396,393,prostanoid receptor antagonist,MoA,Preclinical
397,398,core binding factor inhibitor,MoA,Preclinical
330,399,tyrosine kinase inhibitor,MoA,Preclinical
7,400,dopamine receptor antagonist,MoA,Preclinical
8,400,dopamine receptor antagonist,MoA,Preclinical
9,400,dopamine receptor antagonist,MoA,Preclinical
401,402,SIRT inhibitor,MoA,Preclinical
403,404,lipoxygenase inhibitor,MoA,Phase 3
405,406,p38 MAPK inhibitor,MoA,Preclinical
227,409,apoptosis stimulant|STAT inhibitor,MoA,Preclinical
410,411,serotonin receptor antagonist,MoA,Phase 2
412,413,gonadotropin releasing factor hormone receptor antagonist,MoA,Launched
426,427,aldehyde dehydrogenase activator,MoA,Preclinical
232,428,topoisomerase inhibitor,MoA,Phase 3
437,438,phosphatidylglycerophosphatase inhibitor,MoA,Preclinical
452,453,Aurora kinase inhibitor,MoA,Phase 3
67,456,cytokine production inhibitor,MoA,Phase 2
53,456,cytokine production inhibitor,MoA,Phase 2
67,462,TRPV agonist,MoA,Preclinical
241,465,orexin receptor antagonist,MoA,Phase 3
243,465,orexin receptor antagonist,MoA,Phase 3
467,468,anticancer agent,MoA,Preclinical
77,471,serotonin receptor antagonist,MoA,Withdrawn
472,473,protease inhibitor,MoA,Phase 3
477,478,cytochrome P450 inhibitor|HMGCR inhibitor,MoA,Preclinical
479,480,omega 3 fatty acid stimulant,MoA,Phase 3
481,480,omega 3 fatty acid stimulant,MoA,Phase 3
482,480,omega 3 fatty acid stimulant,MoA,Phase 3
483,480,omega 3 fatty acid stimulant,MoA,Phase 3
389,480,omega 3 fatty acid stimulant,MoA,Phase 3
171,480,omega 3 fatty acid stimulant,MoA,Phase 3
484,480,omega 3 fatty acid stimulant,MoA,Phase 3
53,480,omega 3 fatty acid stimulant,MoA,Phase 3
100,485,histamine receptor agonist,MoA,Preclinical
100,486,histamine receptor agonist,MoA,Preclinical
13,487,serotonin receptor agonist,MoA,Preclinical
488,487,serotonin receptor agonist,MoA,Preclinical
489,487,serotonin receptor agonist,MoA,Preclinical
14,487,serotonin receptor agonist,MoA,Preclinical
15,487,serotonin receptor agonist,MoA,Preclinical
16,487,serotonin receptor agonist,MoA,Preclinical
490,487,serotonin receptor agonist,MoA,Preclinical
79,491,benzodiazepine receptor agonist,MoA,Withdrawn
255,500,aldose reductase inhibitor,MoA,Preclinical
14,501,serotonin receptor antagonist,MoA,Phase 2
61,502,nicotinic receptor agonist,MoA,Phase 2
503,502,nicotinic receptor agonist,MoA,Phase 2
244,504,MET inhibitor|VEGFR inhibitor,MoA,Phase 1
430,504,MET inhibitor|VEGFR inhibitor,MoA,Phase 1
246,504,MET inhibitor|VEGFR inhibitor,MoA,Phase 1
507,508,HSP inhibitor,MoA,Phase 2
512,513,CDK inhibitor,MoA,Phase 2
371,513,CDK inhibitor,MoA,Phase 2
90,513,CDK inhibitor,MoA,Phase 2
514,513,CDK inhibitor,MoA,Phase 2
92,513,CDK inhibitor,MoA,Phase 2
515,513,CDK inhibitor,MoA,Phase 2
516,513,CDK inhibitor,MoA,Phase 2
517,513,CDK inhibitor,MoA,Phase 2
346,513,CDK inhibitor,MoA,Phase 2
262,513,CDK inhibitor,MoA,Phase 2
461,518,glycine transporter inhibitor,MoA,Phase 1
519,520,cannabinoid receptor agonist,MoA,Preclinical
521,520,cannabinoid receptor agonist,MoA,Preclinical
403,522,lipoxygenase inhibitor,MoA,Phase 2
519,523,cannabinoid receptor antagonist,MoA,Preclinical
524,523,cannabinoid receptor antagonist,MoA,Preclinical
525,523,cannabinoid receptor antagonist,MoA,Preclinical
519,526,cannabinoid receptor antagonist,MoA,Preclinical
521,526,cannabinoid receptor antagonist,MoA,Preclinical
525,526,cannabinoid receptor antagonist,MoA,Preclinical
519,527,cyclooxygenase inhibitor|FAAH inhibitor|TRPV antagonist,MoA,Preclinical
521,527,cyclooxygenase inhibitor|FAAH inhibitor|TRPV antagonist,MoA,Preclinical
528,527,cyclooxygenase inhibitor|FAAH inhibitor|TRPV antagonist,MoA,Preclinical
53,527,cyclooxygenase inhibitor|FAAH inhibitor|TRPV antagonist,MoA,Preclinical
124,529,retinoid receptor agonist,MoA,Preclinical
519,530,cannabinoid receptor antagonist,MoA,Preclinical
521,530,cannabinoid receptor antagonist,MoA,Preclinical
153,531,potassium channel blocker,MoA,Preclinical
537,538,CC chemokine receptor antagonist,MoA,Preclinical
263,539,CC chemokine receptor antagonist,MoA,Phase 3
537,539,CC chemokine receptor antagonist,MoA,Phase 3
457,542,xanthine oxidase inhibitor,MoA,Phase 2
543,544,PERK inhibitor,MoA,Preclinical
430,545,tyrosine kinase inhibitor,MoA,Phase 1
546,547,MDM inhibitor,MoA,Phase 2
138,548,PI3K inhibitor,MoA,Phase 2
430,549,MET inhibitor,MoA,Phase 2
550,551,CC chemokine receptor antagonist,MoA,Phase 2
53,552,TRPV antagonist,MoA,Phase 1
553,554,MAP kinase inhibitor,MoA,Phase 1
555,554,MAP kinase inhibitor,MoA,Phase 1
556,554,MAP kinase inhibitor,MoA,Phase 1
405,554,MAP kinase inhibitor,MoA,Phase 1
483,557,free fatty acid receptor agonist,MoA,Phase 1
90,558,CDK inhibitor|FLT3 inhibitor,MoA,Phase 1
92,558,CDK inhibitor|FLT3 inhibitor,MoA,Phase 1
128,558,CDK inhibitor|FLT3 inhibitor,MoA,Phase 1
53,559,TRPV antagonist,MoA,Preclinical
138,560,PI3K inhibitor,MoA,Phase 2
430,561,MET inhibitor,MoA,Preclinical
452,562,Aurora kinase inhibitor,MoA,Phase 1
563,562,Aurora kinase inhibitor,MoA,Phase 1
564,562,Aurora kinase inhibitor,MoA,Phase 1
565,566,protein arginine N-methyltransferase inhibitor,MoA,Preclinical
567,568,adrenergic receptor agonist,MoA,Phase 3
569,570,monoamine oxidase inhibitor,MoA,Phase 1
571,570,monoamine oxidase inhibitor,MoA,Phase 1
571,589,dopamine receptor agonist,MoA,Withdrawn
410,589,dopamine receptor agonist,MoA,Withdrawn
255,597,nitric oxide synthase inhibitor,MoA,Phase 3
598,597,nitric oxide synthase inhibitor,MoA,Phase 3
599,597,nitric oxide synthase inhibitor,MoA,Phase 3
598,600,nitric oxide synthase inhibitor,MoA,Preclinical
605,606,dihydrofolate reductase inhibitor,MoA,Phase 3
607,606,dihydrofolate reductase inhibitor,MoA,Phase 3
512,608,CDK inhibitor|tyrosine kinase inhibitor,MoA,Preclinical
371,608,CDK inhibitor|tyrosine kinase inhibitor,MoA,Preclinical
514,608,CDK inhibitor|tyrosine kinase inhibitor,MoA,Preclinical
277,611,inosine monophosphate dehydrogenase inhibitor,MoA,Phase 2
612,611,inosine monophosphate dehydrogenase inhibitor,MoA,Phase 2
598,613,cyclin D inhibitor,MoA,Preclinical
571,619,serotonin transporter (SERT) inhibitor,MoA,Phase 3
620,619,serotonin transporter (SERT) inhibitor,MoA,Phase 3
410,619,serotonin transporter (SERT) inhibitor,MoA,Phase 3
289,650,Pim kinase inhibitor,MoA,Phase 1
651,652,glutamate receptor modulator,MoA,Preclinical
232,655,topoisomerase inhibitor,MoA,Phase 3
656,655,topoisomerase inhibitor,MoA,Phase 3
153,662,glutamate receptor agonist,MoA,Preclinical
663,664,glutamate receptor agonist,MoA,Preclinical
153,664,glutamate receptor agonist,MoA,Preclinical
665,666,glutamate receptor agonist,MoA,Phase 2
663,666,glutamate receptor agonist,MoA,Phase 2
667,666,glutamate receptor agonist,MoA,Phase 2
668,666,glutamate receptor agonist,MoA,Phase 2
99,675,histamine receptor agonist,MoA,Preclinical
129,677,FLT3 inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RAD51 inhibitor|RET tyrosine kinase inhibitor,MoA,Phase 2
430,677,FLT3 inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RAD51 inhibitor|RET tyrosine kinase inhibitor,MoA,Phase 2
678,679,caspase activator,MoA,Phase 2
680,681,cannabinoid receptor agonist|lipoxygenase inhibitor,MoA,Preclinical
519,681,cannabinoid receptor agonist|lipoxygenase inhibitor,MoA,Preclinical
521,681,cannabinoid receptor agonist|lipoxygenase inhibitor,MoA,Preclinical
632,682,tropomyosin receptor kinase inhibitor,MoA,Preclinical
683,684,cholesteryl ester transfer protein inhibitor,MoA,Phase 3
687,688,growth hormone secretagogue receptor agonist,MoA,Phase 3
103,689,cannabinoid receptor agonist,MoA,Phase 2
105,689,cannabinoid receptor agonist,MoA,Phase 2
106,689,cannabinoid receptor agonist,MoA,Phase 2
519,689,cannabinoid receptor agonist,MoA,Phase 2
521,689,cannabinoid receptor agonist,MoA,Phase 2
690,689,cannabinoid receptor agonist,MoA,Phase 2
524,689,cannabinoid receptor agonist,MoA,Phase 2
525,689,cannabinoid receptor agonist,MoA,Phase 2
691,689,cannabinoid receptor agonist,MoA,Phase 2
692,689,cannabinoid receptor agonist,MoA,Phase 2
693,689,cannabinoid receptor agonist,MoA,Phase 2
694,689,cannabinoid receptor agonist,MoA,Phase 2
53,689,cannabinoid receptor agonist,MoA,Phase 2
696,697,androgen receptor modulator,MoA,Phase 1
698,699,tumor necrosis factor production inhibitor,MoA,Phase 2
700,699,tumor necrosis factor production inhibitor,MoA,Phase 2
701,699,tumor necrosis factor production inhibitor,MoA,Phase 2
702,699,tumor necrosis factor production inhibitor,MoA,Phase 2
672,699,tumor necrosis factor production inhibitor,MoA,Phase 2
703,704,protein synthesis inhibitor,MoA,Phase 2
7,705,glutamate receptor agonist,MoA,Launched
665,705,glutamate receptor agonist,MoA,Launched
663,705,glutamate receptor agonist,MoA,Launched
667,705,glutamate receptor agonist,MoA,Launched
668,705,glutamate receptor agonist,MoA,Launched
14,705,glutamate receptor agonist,MoA,Launched
45,708,lipid peroxidase inhibitor,MoA,Phase 3
709,710,DNA synthesis inhibitor,MoA,Preclinical
711,710,DNA synthesis inhibitor,MoA,Preclinical
712,710,DNA synthesis inhibitor,MoA,Preclinical
713,710,DNA synthesis inhibitor,MoA,Preclinical
714,710,DNA synthesis inhibitor,MoA,Preclinical
715,710,DNA synthesis inhibitor,MoA,Preclinical
716,710,DNA synthesis inhibitor,MoA,Preclinical
717,710,DNA synthesis inhibitor,MoA,Preclinical
718,710,DNA synthesis inhibitor,MoA,Preclinical
719,710,DNA synthesis inhibitor,MoA,Preclinical
720,710,DNA synthesis inhibitor,MoA,Preclinical
721,710,DNA synthesis inhibitor,MoA,Preclinical
722,710,DNA synthesis inhibitor,MoA,Preclinical
244,723,PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,MoA,Launched
131,723,PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,MoA,Launched
12,724,serotonin receptor agonist,MoA,Phase 1
275,725,adenosine receptor antagonist,MoA,Preclinical
726,727,neuropeptide receptor antagonist,MoA,Phase 1
728,729,corticotropin releasing factor receptor antagonist,MoA,Preclinical
731,732,CDC inhibitor,MoA,Preclinical
733,734,ATP synthase inhibitor,MoA,Preclinical
67,735,transient receptor potential channel antagonist,MoA,Preclinical
736,737,apolipoprotein expression enhancer,MoA,Phase 3
101,738,platelet activating factor receptor antagonist,MoA,Phase 3
739,740,RET tyrosine kinase inhibitor,MoA,Phase 3
244,740,RET tyrosine kinase inhibitor,MoA,Phase 3
129,740,RET tyrosine kinase inhibitor,MoA,Phase 3
741,740,RET tyrosine kinase inhibitor,MoA,Phase 3
696,742,androgen receptor antagonist|anti-inflammatory agent,MoA,Phase 1/Phase 2
129,743,KIT inhibitor,MoA,Preclinical
227,743,KIT inhibitor,MoA,Preclinical
744,745,glucose dependent insulinotropic receptor agonist,MoA,Phase 1
744,746,glucose dependent insulinotropic receptor agonist,MoA,Phase 1
633,747,sigma receptor antagonist,MoA,Phase 2
49,748,AKT inhibitor,MoA,Preclinical
749,748,AKT inhibitor,MoA,Preclinical
750,748,AKT inhibitor,MoA,Preclinical
255,751,casein kinase inhibitor|cell proliferation inhibitor,MoA,Preclinical
696,751,casein kinase inhibitor|cell proliferation inhibitor,MoA,Preclinical
92,751,casein kinase inhibitor|cell proliferation inhibitor,MoA,Preclinical
752,751,casein kinase inhibitor|cell proliferation inhibitor,MoA,Preclinical
596,751,casein kinase inhibitor|cell proliferation inhibitor,MoA,Preclinical
753,751,casein kinase inhibitor|cell proliferation inhibitor,MoA,Preclinical
754,751,casein kinase inhibitor|cell proliferation inhibitor,MoA,Preclinical
757,758,NADPH oxidase inhibitor,MoA,Phase 1
759,760,carboxylesterase inhibitor,MoA,Preclinical
176,760,carboxylesterase inhibitor,MoA,Preclinical
761,762,p53 activator,MoA,Phase 3
764,765,matrix metalloprotease inhibitor|tumor necrosis factor production inhibitor,MoA,Phase 2
766,765,matrix metalloprotease inhibitor|tumor necrosis factor production inhibitor,MoA,Phase 2
767,765,matrix metalloprotease inhibitor|tumor necrosis factor production inhibitor,MoA,Phase 2
84,765,matrix metalloprotease inhibitor|tumor necrosis factor production inhibitor,MoA,Phase 2
153,772,glutamate receptor antagonist,MoA,Phase 3
773,774,krüppel-like factor expression enhancer,MoA,Phase 1
775,776,serine/threonine kinase inhibitor,MoA,Preclinical
777,778,phosphoinositide dependent kinase inhibitor,MoA,Preclinical
779,778,phosphoinositide dependent kinase inhibitor,MoA,Preclinical
780,778,phosphoinositide dependent kinase inhibitor,MoA,Preclinical
309,783,ALK tyrosine kinase receptor inhibitor,MoA,Phase 2
346,783,ALK tyrosine kinase receptor inhibitor,MoA,Phase 2
74,784,acetylcholine receptor antagonist,MoA,Preclinical
32,785,glycogen synthase kinase inhibitor,MoA,Preclinical
786,787,monocarboxylate transporter inhibitor,MoA,Preclinical
788,787,monocarboxylate transporter inhibitor,MoA,Preclinical
789,790,phosphoinositide dependent kinase inhibitor,MoA,Phase 1
247,791,HDAC inhibitor,MoA,Phase 1
792,793,cytochrome P450 inhibitor,MoA,Phase 1
794,793,cytochrome P450 inhibitor,MoA,Phase 1
795,793,cytochrome P450 inhibitor,MoA,Phase 1
796,793,cytochrome P450 inhibitor,MoA,Phase 1
797,793,cytochrome P450 inhibitor,MoA,Phase 1
361,793,cytochrome P450 inhibitor,MoA,Phase 1
174,793,cytochrome P450 inhibitor,MoA,Phase 1
798,793,cytochrome P450 inhibitor,MoA,Phase 1
799,793,cytochrome P450 inhibitor,MoA,Phase 1
801,802,melanin inhibitor,MoA,Phase 2/Phase 3
1,803,adrenergic receptor antagonist,MoA,Preclinical
3,803,adrenergic receptor antagonist,MoA,Preclinical
4,803,adrenergic receptor antagonist,MoA,Preclinical
210,804,MEK inhibitor,MoA,Preclinical
805,804,MEK inhibitor,MoA,Preclinical
806,807,CDK inhibitor,MoA,Preclinical
90,807,CDK inhibitor,MoA,Preclinical
808,809,thrombin inhibitor,MoA,Withdrawn
74,810,acetylcholine receptor agonist,MoA,Preclinical
73,811,acetylcholine receptor agonist,MoA,Preclinical
74,811,acetylcholine receptor agonist,MoA,Preclinical
75,811,acetylcholine receptor agonist,MoA,Preclinical
76,811,acetylcholine receptor agonist,MoA,Preclinical
73,812,acetylcholine receptor agonist,MoA,Phase 1
74,812,acetylcholine receptor agonist,MoA,Phase 1
75,812,acetylcholine receptor agonist,MoA,Phase 1
76,812,acetylcholine receptor agonist,MoA,Phase 1
815,816,farnesyltransferase inhibitor,MoA,Launched
701,816,farnesyltransferase inhibitor,MoA,Launched
18,818,phosphodiesterase inhibitor,MoA,Phase 3
749,820,AKT inhibitor,MoA,Phase 1
821,822,kinesin-like spindle protein inhibitor,MoA,Phase 1
348,823,EGFR inhibitor,MoA,Phase 2/Phase 3
171,834,astrocyte modulating agent,MoA,Phase 2/Phase 3
835,834,astrocyte modulating agent,MoA,Phase 2/Phase 3
836,837,bromodomain inhibitor,MoA,Preclinical
744,838,glucose dependent insulinotropic receptor agonist,MoA,Preclinical
839,840,rho associated kinase inhibitor,MoA,Preclinical
841,842,SHIP2 phosphatase inhibitor,MoA,Preclinical
483,843,free fatty acid receptor agonist,MoA,Preclinical
844,845,interleukin inhibitor,MoA,Preclinical
476,846,PI3K inhibitor,MoA,Preclinical
474,847,PI3K inhibitor,MoA,Preclinical
476,847,PI3K inhibitor,MoA,Preclinical
805,848,MEK inhibitor,MoA,Phase 2
849,848,MEK inhibitor,MoA,Phase 2
850,851,potassium channel blocker,MoA,Phase 1
852,851,potassium channel blocker,MoA,Phase 1
853,851,potassium channel blocker,MoA,Phase 1
171,854,cyclooxygenase inhibitor,MoA,Preclinical
696,855,androgen receptor enhancer,MoA,Phase 2
856,857,calcineurin inhibitor,MoA,Preclinical
262,862,apoptosis stimulant,MoA,Preclinical
510,863,opioid receptor agonist,MoA,Phase 3
461,864,glycine transporter inhibitor,MoA,Phase 1
309,876,ALK tyrosine kinase receptor inhibitor,MoA,Phase 1
346,877,EGFR inhibitor,MoA,Phase 1
348,877,EGFR inhibitor,MoA,Phase 1
97,878,histamine receptor antagonist,MoA,Withdrawn
879,878,histamine receptor antagonist,MoA,Withdrawn
617,878,histamine receptor antagonist,MoA,Withdrawn
598,880,nitric oxide synthase inhibitor,MoA,Phase 1
881,880,nitric oxide synthase inhibitor,MoA,Phase 1
14,882,serotonin receptor antagonist,MoA,Preclinical
512,883,CDK inhibitor,MoA,Phase 2
371,883,CDK inhibitor,MoA,Phase 2
90,883,CDK inhibitor,MoA,Phase 2
514,883,CDK inhibitor,MoA,Phase 2
92,883,CDK inhibitor,MoA,Phase 2
517,883,CDK inhibitor,MoA,Phase 2
452,884,Aurora kinase inhibitor|JAK inhibitor,MoA,Phase 2
563,884,Aurora kinase inhibitor|JAK inhibitor,MoA,Phase 2
369,884,Aurora kinase inhibitor|JAK inhibitor,MoA,Phase 2
370,884,Aurora kinase inhibitor|JAK inhibitor,MoA,Phase 2
885,884,Aurora kinase inhibitor|JAK inhibitor,MoA,Phase 2
886,884,Aurora kinase inhibitor|JAK inhibitor,MoA,Phase 2
395,889,cyclooxygenase inhibitor,MoA,Phase 2
369,892,JAK inhibitor|STAT inhibitor,MoA,Phase 2
227,892,JAK inhibitor|STAT inhibitor,MoA,Phase 2
18,893,phosphodiesterase inhibitor,MoA,Phase 2
20,893,phosphodiesterase inhibitor,MoA,Phase 2
21,893,phosphodiesterase inhibitor,MoA,Phase 2
22,893,phosphodiesterase inhibitor,MoA,Phase 2
894,895,integrin antagonist,MoA,Phase 2
896,895,integrin antagonist,MoA,Phase 2
897,895,integrin antagonist,MoA,Phase 2
898,895,integrin antagonist,MoA,Phase 2
906,907,glutamate receptor agonist,MoA,Preclinical
238,908,endothelin receptor antagonist,MoA,Phase 3
73,910,acetylcholine receptor antagonist,MoA,Preclinical
74,910,acetylcholine receptor antagonist,MoA,Preclinical
75,910,acetylcholine receptor antagonist,MoA,Preclinical
76,910,acetylcholine receptor antagonist,MoA,Preclinical
170,910,acetylcholine receptor antagonist,MoA,Preclinical
49,911,protein kinase inhibitor,MoA,Phase 1
749,911,protein kinase inhibitor,MoA,Phase 1
750,911,protein kinase inhibitor,MoA,Phase 1
839,911,protein kinase inhibitor,MoA,Phase 1
912,911,protein kinase inhibitor,MoA,Phase 1
913,911,protein kinase inhibitor,MoA,Phase 1
507,914,HSP inhibitor,MoA,Phase 2
749,915,AKT inhibitor,MoA,Preclinical
32,915,AKT inhibitor,MoA,Preclinical
51,915,AKT inhibitor,MoA,Preclinical
52,915,AKT inhibitor,MoA,Preclinical
452,918,Aurora kinase inhibitor,MoA,Preclinical
921,922,autotaxin inhibitor,MoA,Preclinical
346,923,protein tyrosine kinase inhibitor,MoA,Phase 1
348,923,protein tyrosine kinase inhibitor,MoA,Phase 1
28,924,tachykinin antagonist,MoA,Phase 2
925,926,gamma secretase inhibitor,MoA,Phase 2
176,928,ACAT inhibitor,MoA,Phase 3
931,932,angiotensin receptor agonist,MoA,Preclinical
134,933,Bruton's tyrosine kinase (BTK) inhibitor,MoA,Phase 2
934,933,Bruton's tyrosine kinase (BTK) inhibitor,MoA,Phase 2
612,935,inosine monophosphate dehydrogenase inhibitor,MoA,Phase 2
936,935,inosine monophosphate dehydrogenase inhibitor,MoA,Phase 2
678,942,caspase inhibitor,MoA,Preclinical
41,943,purinergic receptor antagonist,MoA,Preclinical
944,945,hedgehog pathway inhibitor,MoA,Preclinical
946,947,RAF inhibitor,MoA,Preclinical
948,947,RAF inhibitor,MoA,Preclinical
97,952,histamine receptor antagonist,MoA,Preclinical
253,953,purine antagonist,MoA,Preclinical
171,955,cyclooxygenase inhibitor,MoA,Withdrawn
30,962,glycogen synthase kinase inhibitor,MoA,Phase 1
32,962,glycogen synthase kinase inhibitor,MoA,Phase 1
289,963,Pim kinase inhibitor,MoA,Phase 1
964,963,Pim kinase inhibitor,MoA,Phase 1
965,963,Pim kinase inhibitor,MoA,Phase 1
966,967,purinergic receptor antagonist,MoA,Preclinical
61,968,acetylcholine receptor agonist,MoA,Phase 2
503,968,acetylcholine receptor agonist,MoA,Phase 2
969,970,JAK inhibitor,MoA,Phase 1
369,970,JAK inhibitor,MoA,Phase 1
370,970,JAK inhibitor,MoA,Phase 1
971,972,CRTH receptor antagonist,MoA,Phase 2
781,973,mTOR inhibitor,MoA,Phase 2
32,974,glycogen synthase kinase inhibitor,MoA,Preclinical
212,975,IKK inhibitor,MoA,Preclinical
309,976,ALK tyrosine kinase receptor inhibitor|insulin growth factor receptor inhibitor,MoA,Preclinical
364,976,ALK tyrosine kinase receptor inhibitor|insulin growth factor receptor inhibitor,MoA,Preclinical
696,977,androgen receptor modulator,MoA,Phase 1
346,978,EGFR inhibitor,MoA,Phase 2/Phase 3
979,980,beta-secretase inhibitor,MoA,Phase 1
786,981,monocarboxylate transporter inhibitor,MoA,Phase 1
63,982,diacylglycerol kinase inhibitor,MoA,Preclinical
983,984,glutamate receptor antagonist,MoA,Phase 1
985,984,glutamate receptor antagonist,MoA,Phase 1
986,984,glutamate receptor antagonist,MoA,Phase 1
987,984,glutamate receptor antagonist,MoA,Phase 1
988,984,glutamate receptor antagonist,MoA,Phase 1
989,984,glutamate receptor antagonist,MoA,Phase 1
990,984,glutamate receptor antagonist,MoA,Phase 1
991,984,glutamate receptor antagonist,MoA,Phase 1
992,984,glutamate receptor antagonist,MoA,Phase 1
993,984,glutamate receptor antagonist,MoA,Phase 1
690,984,glutamate receptor antagonist,MoA,Phase 1
994,984,glutamate receptor antagonist,MoA,Phase 1
995,984,glutamate receptor antagonist,MoA,Phase 1
996,984,glutamate receptor antagonist,MoA,Phase 1
997,984,glutamate receptor antagonist,MoA,Phase 1
998,984,glutamate receptor antagonist,MoA,Phase 1
999,984,glutamate receptor antagonist,MoA,Phase 1
1000,984,glutamate receptor antagonist,MoA,Phase 1
524,984,glutamate receptor antagonist,MoA,Phase 1
1001,984,glutamate receptor antagonist,MoA,Phase 1
153,984,glutamate receptor antagonist,MoA,Phase 1
154,984,glutamate receptor antagonist,MoA,Phase 1
155,984,glutamate receptor antagonist,MoA,Phase 1
156,984,glutamate receptor antagonist,MoA,Phase 1
157,984,glutamate receptor antagonist,MoA,Phase 1
159,984,glutamate receptor antagonist,MoA,Phase 1
211,984,glutamate receptor antagonist,MoA,Phase 1
1002,984,glutamate receptor antagonist,MoA,Phase 1
1003,984,glutamate receptor antagonist,MoA,Phase 1
1004,984,glutamate receptor antagonist,MoA,Phase 1
1005,984,glutamate receptor antagonist,MoA,Phase 1
1006,984,glutamate receptor antagonist,MoA,Phase 1
1007,984,glutamate receptor antagonist,MoA,Phase 1
461,984,glutamate receptor antagonist,MoA,Phase 1
1008,1009,FGFR inhibitor,MoA,Phase 2/Phase 3
350,1009,FGFR inhibitor,MoA,Phase 2/Phase 3
351,1009,FGFR inhibitor,MoA,Phase 2/Phase 3
1010,1009,FGFR inhibitor,MoA,Phase 2/Phase 3
364,1009,FGFR inhibitor,MoA,Phase 2/Phase 3
244,1009,FGFR inhibitor,MoA,Phase 2/Phase 3
1011,1012,CC chemokine receptor antagonist,MoA,Phase 2
49,1013,AKT inhibitor,MoA,Phase 3
749,1013,AKT inhibitor,MoA,Phase 3
750,1013,AKT inhibitor,MoA,Phase 3
617,1014,CDK inhibitor,MoA,Phase 1
1015,1016,XIAP inhibitor,MoA,Preclinical
1017,1016,XIAP inhibitor,MoA,Preclinical
1018,1016,XIAP inhibitor,MoA,Preclinical
474,1019,PI3K inhibitor,MoA,Phase 1
136,1019,PI3K inhibitor,MoA,Phase 1
138,1019,PI3K inhibitor,MoA,Phase 1
476,1019,PI3K inhibitor,MoA,Phase 1
1020,1021,ATR kinase inhibitor,MoA,Phase 2
153,1022,glutamate receptor antagonist,MoA,Phase 2
1023,1024,pyruvate dehydrogenase kinase inhibitor,MoA,Phase 1
63,1025,diacylglycerol O acyltransferase inhibitor,MoA,Phase 1
1026,1027,CHK inhibitor,MoA,Phase 1
1028,1027,CHK inhibitor,MoA,Phase 1
781,1029,mTOR inhibitor,MoA,Phase 1
136,1030,PI3K inhibitor,MoA,Phase 1
138,1030,PI3K inhibitor,MoA,Phase 1
1031,1032,MEK inhibitor,MoA,Phase 1
474,1033,PI3K inhibitor,MoA,Phase 1
138,1033,PI3K inhibitor,MoA,Phase 1
346,1034,EGFR inhibitor,MoA,Phase 2
348,1034,EGFR inhibitor,MoA,Phase 2
1035,1034,EGFR inhibitor,MoA,Phase 2
160,1036,glutamate receptor antagonist,MoA,Preclinical
354,1037,estrogen receptor agonist,MoA,Phase 1
1038,1039,elastase inhibitor,MoA,Phase 2
1044,1045,RAGE receptor antagonist,MoA,Phase 3
852,1051,potassium channel blocker,MoA,Phase 3
1054,1055,SRC inhibitor,MoA,Preclinical
1059,1060,DYRK inhibitor,MoA,Preclinical
1020,1061,ATR kinase inhibitor,MoA,Preclinical
781,1061,ATR kinase inhibitor,MoA,Preclinical
1062,1063,histone lysine methyltransferase inhibitor,MoA,Preclinical
346,1064,EGFR inhibitor,MoA,Preclinical
369,1065,JAK inhibitor,MoA,Preclinical
1066,1067,polynucleotide kinase/phosphatase inhibitor,MoA,Preclinical
1068,1069,ICAM1 expression inhibitor,MoA,Preclinical
178,1069,ICAM1 expression inhibitor,MoA,Preclinical
45,1070,adrenergic receptor agonist,MoA,Preclinical
474,1071,PI3K inhibitor,MoA,Preclinical
41,1072,purinergic receptor antagonist,MoA,Preclinical
5,1073,dopamine receptor agonist,MoA,Preclinical
63,1074,diacylglycerol O acyltransferase inhibitor,MoA,Preclinical
200,1081,PPAR receptor antagonist,MoA,Preclinical
301,1082,Bcr-Abl kinase inhibitor|LYN tyrosine kinase inhibitor,MoA,Phase 2
1083,1082,Bcr-Abl kinase inhibitor|LYN tyrosine kinase inhibitor,MoA,Phase 2
1084,1082,Bcr-Abl kinase inhibitor|LYN tyrosine kinase inhibitor,MoA,Phase 2
476,1085,phosphoinositide dependent kinase inhibitor,MoA,Preclinical
403,1086,lipoxygenase inhibitor,MoA,Preclinical
1087,1086,lipoxygenase inhibitor,MoA,Preclinical
1088,1086,lipoxygenase inhibitor,MoA,Preclinical
1089,1086,lipoxygenase inhibitor,MoA,Preclinical
179,1086,lipoxygenase inhibitor,MoA,Preclinical
672,1086,lipoxygenase inhibitor,MoA,Preclinical
457,1086,lipoxygenase inhibitor,MoA,Preclinical
234,1091,DNA polymerase inhibitor,MoA,Phase 2
200,1092,insulin sensitizer|PPAR receptor partial agonist,MoA,Phase 3
1093,1094,cathepsin inhibitor,MoA,Phase 2
1097,1098,BAX activator,MoA,Preclinical
1099,1100,nociceptin/orphanin FQ receptor antagonist,MoA,Preclinical
232,1101,topoisomerase inhibitor,MoA,Phase 1/Phase 2
452,1102,Aurora kinase inhibitor,MoA,Phase 2/Phase 3
563,1102,Aurora kinase inhibitor,MoA,Phase 2/Phase 3
563,1103,Aurora kinase inhibitor,MoA,Phase 2/Phase 3
598,1104,nuclear factor erythroid derived|like (NRF2) activator,MoA,Phase 1
200,1104,nuclear factor erythroid derived|like (NRF2) activator,MoA,Phase 1
200,1105,nuclear factor erythroid derived|like (NRF2) activator,MoA,Phase 3
227,1105,nuclear factor erythroid derived|like (NRF2) activator,MoA,Phase 3
160,1107,glutamate receptor antagonist,MoA,Phase 2
1108,1109,matrix metalloprotease inhibitor,MoA,Phase 3
1110,1109,matrix metalloprotease inhibitor,MoA,Phase 3
197,1109,matrix metalloprotease inhibitor,MoA,Phase 3
1111,1109,matrix metalloprotease inhibitor,MoA,Phase 3
1112,1109,matrix metalloprotease inhibitor,MoA,Phase 3
1113,1109,matrix metalloprotease inhibitor,MoA,Phase 3
100,1114,histamine receptor antagonist,MoA,Phase 2
1097,1115,cytochrome C release inhibitor,MoA,Preclinical
639,1116,L-type calcium channel activator,MoA,Preclinical
213,1117,NFkB pathway inhibitor,MoA,Preclinical
870,1118,NFkB pathway inhibitor,MoA,Preclinical
1119,1120,guanylyl cyclase activator,MoA,Preclinical
1121,1120,guanylyl cyclase activator,MoA,Preclinical
69,1122,adenosine receptor agonist,MoA,Preclinical
275,1122,adenosine receptor agonist,MoA,Preclinical
276,1122,adenosine receptor agonist,MoA,Preclinical
277,1122,adenosine receptor agonist,MoA,Preclinical
1123,1124,phosphodiesterase inhibitor,MoA,Preclinical
1125,1126,SYK inhibitor,MoA,Preclinical
234,1127,hypoxia inducible factor inhibitor,MoA,Phase 1
1129,1130,bromodomain inhibitor,MoA,Preclinical
581,1131,urokinase inhibitor,MoA,Preclinical
53,1132,TRPV antagonist,MoA,Preclinical
1133,1134,complement inhibitor|serine protease inhibitor,MoA,Phase 1
633,1135,adrenergic receptor antagonist,MoA,Preclinical
633,1136,sigma receptor antagonist,MoA,Preclinical
45,1137,adrenergic receptor antagonist,MoA,Phase 2
925,1141,gamma secretase inhibitor,MoA,Phase 1
77,1150,serotonin receptor antagonist,MoA,Phase 3
957,1150,serotonin receptor antagonist,MoA,Phase 3
1151,1152,AMPK inhibitor,MoA,Launched
477,1157,gluconeogenesis inhibitor,MoA,Withdrawn
577,1171,sodium channel blocker,MoA,Phase 2
580,1171,sodium channel blocker,MoA,Phase 2
582,1171,sodium channel blocker,MoA,Phase 2
583,1171,sodium channel blocker,MoA,Phase 2
584,1171,sodium channel blocker,MoA,Phase 2
585,1171,sodium channel blocker,MoA,Phase 2
484,1171,sodium channel blocker,MoA,Phase 2
332,1182,cholinergic receptor antagonist,MoA,Preclinical
1183,1184,CCK receptor antagonist,MoA,Phase 1
1185,1184,CCK receptor antagonist,MoA,Phase 1
1193,1194,LDL receptor activator,MoA,Launched
698,1195,interleukin inhibitor,MoA,Preclinical
672,1195,interleukin inhibitor,MoA,Preclinical
1196,1197,beta amyloid synthesis inhibitor,MoA,Preclinical
79,1198,benzodiazepine receptor ligand,MoA,Launched
149,1198,benzodiazepine receptor ligand,MoA,Launched
1112,1199,apoptosis stimulant,MoA,Launched
84,1199,apoptosis stimulant,MoA,Launched
339,1200,opioid receptor antagonist,MoA,Preclinical
510,1200,opioid receptor antagonist,MoA,Preclinical
511,1200,opioid receptor antagonist,MoA,Preclinical
781,1201,protein synthesis stimulant,MoA,Launched
230,1203,topoisomerase inhibitor,MoA,Phase 2
1212,1213,GLP receptor positive allosteric modulator,MoA,Preclinical
1215,1216,apoptosis stimulant|NFkB pathway inhibitor,MoA,Phase 1/Phase 2
781,1221,PI3K inhibitor,MoA,Phase 1/Phase 2
474,1221,PI3K inhibitor,MoA,Phase 1/Phase 2
136,1221,PI3K inhibitor,MoA,Phase 1/Phase 2
476,1221,PI3K inhibitor,MoA,Phase 1/Phase 2
1222,1223,ATPase inhibitor,MoA,Preclinical
1224,1225,ribosomal protein inhibitor,MoA,Preclinical
1226,1225,ribosomal protein inhibitor,MoA,Preclinical
875,1225,ribosomal protein inhibitor,MoA,Preclinical
885,1225,ribosomal protein inhibitor,MoA,Preclinical
836,1227,PLK inhibitor,MoA,Phase 2
1228,1227,PLK inhibitor,MoA,Phase 2
1229,1227,PLK inhibitor,MoA,Phase 2
1230,1227,PLK inhibitor,MoA,Phase 2
726,1231,JNK inhibitor,MoA,Preclinical
452,1232,Aurora kinase inhibitor|MEK inhibitor,MoA,Phase 1
563,1232,Aurora kinase inhibitor|MEK inhibitor,MoA,Phase 1
564,1232,Aurora kinase inhibitor|MEK inhibitor,MoA,Phase 1
805,1232,Aurora kinase inhibitor|MEK inhibitor,MoA,Phase 1
849,1232,Aurora kinase inhibitor|MEK inhibitor,MoA,Phase 1
1233,1234,calcitonin antagonist,MoA,Phase 2
1235,1234,calcitonin antagonist,MoA,Phase 2
1236,1234,calcitonin antagonist,MoA,Phase 2
1237,1238,telomerase inhibitor,MoA,Preclinical
346,1239,EGFR inhibitor,MoA,Preclinical
346,1240,EGFR inhibitor,MoA,Phase 1
348,1240,EGFR inhibitor,MoA,Phase 1
79,1242,GABA receptor antagonist,MoA,Preclinical
140,1242,GABA receptor antagonist,MoA,Preclinical
141,1242,GABA receptor antagonist,MoA,Preclinical
81,1242,GABA receptor antagonist,MoA,Preclinical
142,1242,GABA receptor antagonist,MoA,Preclinical
143,1242,GABA receptor antagonist,MoA,Preclinical
1243,1242,GABA receptor antagonist,MoA,Preclinical
507,1249,HSP inhibitor,MoA,Phase 2
690,1251,GABA receptor modulator,MoA,Preclinical
994,1251,GABA receptor modulator,MoA,Preclinical
996,1251,GABA receptor modulator,MoA,Preclinical
77,1251,GABA receptor modulator,MoA,Preclinical
957,1251,GABA receptor modulator,MoA,Preclinical
490,1255,serotonin receptor agonist,MoA,Preclinical
1256,1257,glutamate receptor positive allosteric modulator,MoA,Preclinical
1258,1259,NFkB pathway inhibitor,MoA,Phase 2
1260,1259,NFkB pathway inhibitor,MoA,Phase 2
1261,1259,NFkB pathway inhibitor,MoA,Phase 2
1263,1264,integrin antagonist,MoA,Phase 2
897,1264,integrin antagonist,MoA,Phase 2
1263,1265,integrin inhibitor,MoA,Preclinical
897,1265,integrin inhibitor,MoA,Preclinical
1266,1267,vitamin B,MoA,Launched
267,1267,vitamin B,MoA,Launched
1268,1267,vitamin B,MoA,Launched
1269,1267,vitamin B,MoA,Launched
1270,1267,vitamin B,MoA,Launched
1271,1267,vitamin B,MoA,Launched
1272,1267,vitamin B,MoA,Launched
1273,1267,vitamin B,MoA,Launched
1274,1267,vitamin B,MoA,Launched
1275,1276,dipeptidyl peptidase inhibitor,MoA,Phase 2
1015,1278,XIAP inhibitor,MoA,Phase 2
1018,1278,XIAP inhibitor,MoA,Phase 2
1068,1279,lymphocyte function-associated antigen negative modulator,MoA,Preclinical
1280,1281,tyrosine phosphatase inhibitor,MoA,Phase 2
49,1282,PKC inhibitor,MoA,Preclinical
32,1282,PKC inhibitor,MoA,Preclinical
1283,1282,PKC inhibitor,MoA,Preclinical
828,1282,PKC inhibitor,MoA,Preclinical
553,1282,PKC inhibitor,MoA,Preclinical
555,1282,PKC inhibitor,MoA,Preclinical
405,1282,PKC inhibitor,MoA,Preclinical
726,1282,PKC inhibitor,MoA,Preclinical
1284,1282,PKC inhibitor,MoA,Preclinical
839,1282,PKC inhibitor,MoA,Preclinical
1285,1282,PKC inhibitor,MoA,Preclinical
1286,1282,PKC inhibitor,MoA,Preclinical
696,1290,synthetic estrogen,MoA,Phase 1
354,1290,synthetic estrogen,MoA,Phase 1
116,1290,synthetic estrogen,MoA,Phase 1
356,1290,synthetic estrogen,MoA,Phase 1
200,1290,synthetic estrogen,MoA,Phase 1
354,1291,autotaxin inhibitor,MoA,Withdrawn
116,1291,autotaxin inhibitor,MoA,Withdrawn
1292,1291,autotaxin inhibitor,MoA,Withdrawn
1007,1293,glycine transporter inhibitor,MoA,Phase 3
461,1293,glycine transporter inhibitor,MoA,Phase 3
37,1295,histone lysine methyltransferase inhibitor,MoA,Preclinical
39,1295,histone lysine methyltransferase inhibitor,MoA,Preclinical
1296,1297,MEK inhibitor,MoA,Preclinical
1296,1298,MEK inhibitor,MoA,Preclinical
1299,1298,MEK inhibitor,MoA,Preclinical
1300,1301,ATPase inhibitor,MoA,Preclinical
1302,1301,ATPase inhibitor,MoA,Preclinical
1010,1304,FGFR inhibitor,MoA,Preclinical
521,1305,cannabinoid receptor inverse agonist,MoA,Preclinical
1306,1307,CC chemokine receptor antagonist,MoA,Preclinical
238,1308,endothelin receptor antagonist,MoA,Phase 2
1309,1310,potassium channel activator,MoA,Preclinical
512,1311,CDK inhibitor,MoA,Preclinical
371,1311,CDK inhibitor,MoA,Preclinical
1312,1313,fatty acid binding protein inhibitor,MoA,Preclinical
210,1314,IKK inhibitor,MoA,Preclinical
212,1314,IKK inhibitor,MoA,Preclinical
371,1315,CDK inhibitor|cell cycle inhibitor|MCL1 inhibitor,MoA,Phase 1
515,1315,CDK inhibitor|cell cycle inhibitor|MCL1 inhibitor,MoA,Phase 1
517,1315,CDK inhibitor|cell cycle inhibitor|MCL1 inhibitor,MoA,Phase 1
1316,1317,melanocortin receptor agonist,MoA,Preclinical
49,1318,IGF-1 inhibitor,MoA,Preclinical
1319,1318,IGF-1 inhibitor,MoA,Preclinical
371,1318,IGF-1 inhibitor,MoA,Preclinical
421,1318,IGF-1 inhibitor,MoA,Preclinical
348,1318,IGF-1 inhibitor,MoA,Preclinical
364,1318,IGF-1 inhibitor,MoA,Preclinical
244,1318,IGF-1 inhibitor,MoA,Preclinical
1283,1318,IGF-1 inhibitor,MoA,Preclinical
828,1318,IGF-1 inhibitor,MoA,Preclinical
430,1318,IGF-1 inhibitor,MoA,Preclinical
130,1318,IGF-1 inhibitor,MoA,Preclinical
131,1318,IGF-1 inhibitor,MoA,Preclinical
612,1320,inosine monophosphate dehydrogenase inhibitor,MoA,Preclinical
936,1320,inosine monophosphate dehydrogenase inhibitor,MoA,Preclinical
1321,1322,integrin antagonist,MoA,Phase 2
1323,1322,integrin antagonist,MoA,Phase 2
346,1324,EGFR inhibitor|protein tyrosine kinase inhibitor,MoA,Phase 1
348,1324,EGFR inhibitor|protein tyrosine kinase inhibitor,MoA,Phase 1
349,1324,EGFR inhibitor|protein tyrosine kinase inhibitor,MoA,Phase 1
224,1325,retinoid receptor agonist,MoA,Preclinical
1068,1326,ICAM1 antagonist|leukocyte function-associated antigen receptor antagonist,MoA,Preclinical
346,1327,EGFR inhibitor|VEGFR inhibitor,MoA,Phase 2
348,1327,EGFR inhibitor|VEGFR inhibitor,MoA,Phase 2
128,1327,EGFR inhibitor|VEGFR inhibitor,MoA,Phase 2
244,1327,EGFR inhibitor|VEGFR inhibitor,MoA,Phase 2
49,1328,IGF-1 inhibitor,MoA,Phase 2
364,1328,IGF-1 inhibitor,MoA,Phase 2
1329,1330,AXL kinase inhibitor|c-Met inhibitor|FLT3 inhibitor|hepatocyte growth factor receptor inhibitor|macrophage migration inhibiting factor inhibitor|tyrosine kinase inhibitor,MoA,Phase 1/Phase 2
1331,1330,AXL kinase inhibitor|c-Met inhibitor|FLT3 inhibitor|hepatocyte growth factor receptor inhibitor|macrophage migration inhibiting factor inhibitor|tyrosine kinase inhibitor,MoA,Phase 1/Phase 2
430,1330,AXL kinase inhibitor|c-Met inhibitor|FLT3 inhibitor|hepatocyte growth factor receptor inhibitor|macrophage migration inhibiting factor inhibitor|tyrosine kinase inhibitor,MoA,Phase 1/Phase 2
1332,1330,AXL kinase inhibitor|c-Met inhibitor|FLT3 inhibitor|hepatocyte growth factor receptor inhibitor|macrophage migration inhibiting factor inhibitor|tyrosine kinase inhibitor,MoA,Phase 1/Phase 2
1333,1330,AXL kinase inhibitor|c-Met inhibitor|FLT3 inhibitor|hepatocyte growth factor receptor inhibitor|macrophage migration inhibiting factor inhibitor|tyrosine kinase inhibitor,MoA,Phase 1/Phase 2
244,1334,c-Met inhibitor|VEGFR inhibitor,MoA,Phase 1
430,1334,c-Met inhibitor|VEGFR inhibitor,MoA,Phase 1
1335,1336,smoothened receptor antagonist,MoA,Phase 2
1337,1338,CDC inhibitor,MoA,Phase 1/Phase 2
289,1338,CDC inhibitor,MoA,Phase 1/Phase 2
1339,1340,lysophosphatidic acid receptor antagonist,MoA,Phase 2
11,1341,sigma receptor antagonist,MoA,Phase 2
499,1342,IP1 prostacyclin receptor agonist,MoA,Preclinical
45,1343,adrenergic receptor antagonist|serotonin receptor antagonist,MoA,Preclinical
47,1343,adrenergic receptor antagonist|serotonin receptor antagonist,MoA,Preclinical
48,1343,adrenergic receptor antagonist|serotonin receptor antagonist,MoA,Preclinical
11,1343,adrenergic receptor antagonist|serotonin receptor antagonist,MoA,Preclinical
339,1344,opioid receptor antagonist,MoA,Preclinical
510,1344,opioid receptor antagonist,MoA,Preclinical
511,1344,opioid receptor antagonist,MoA,Preclinical
11,1386,serotonin receptor agonist,MoA,Preclinical
45,1387,dopamine receptor agonist,MoA,Phase 2
48,1387,dopamine receptor agonist,MoA,Phase 2
1,1387,dopamine receptor agonist,MoA,Phase 2
6,1387,dopamine receptor agonist,MoA,Phase 2
7,1387,dopamine receptor agonist,MoA,Phase 2
8,1387,dopamine receptor agonist,MoA,Phase 2
9,1387,dopamine receptor agonist,MoA,Phase 2
11,1387,dopamine receptor agonist,MoA,Phase 2
15,1387,dopamine receptor agonist,MoA,Phase 2
238,1388,endothelin receptor antagonist,MoA,Phase 2
240,1389,endothelin receptor antagonist,MoA,Phase 1
1390,1391,Ras GTPase inhibitor,MoA,Preclinical
1392,1391,Ras GTPase inhibitor,MoA,Preclinical
39,1393,histone lysine methyltransferase inhibitor,MoA,Preclinical
1224,1394,ribosomal protein inhibitor,MoA,Preclinical
1226,1394,ribosomal protein inhibitor,MoA,Preclinical
875,1394,ribosomal protein inhibitor,MoA,Preclinical
821,1395,kinesin inhibitor,MoA,Preclinical
1396,1397,protein synthesis inhibitor,MoA,Preclinical
1398,1397,protein synthesis inhibitor,MoA,Preclinical
1404,1405,dihydroorotate dehydrogenase inhibitor,MoA,Phase 2
79,1406,GABA benzodiazepine site receptor partial agonist,MoA,Phase 2
140,1406,GABA benzodiazepine site receptor partial agonist,MoA,Phase 2
141,1406,GABA benzodiazepine site receptor partial agonist,MoA,Phase 2
81,1406,GABA benzodiazepine site receptor partial agonist,MoA,Phase 2
142,1406,GABA benzodiazepine site receptor partial agonist,MoA,Phase 2
143,1406,GABA benzodiazepine site receptor partial agonist,MoA,Phase 2
806,1409,cyclin D inhibitor,MoA,Phase 1
421,1414,FGFR inhibitor|VEGFR inhibitor,MoA,Phase 3
1008,1414,FGFR inhibitor|VEGFR inhibitor,MoA,Phase 3
939,1414,FGFR inhibitor|VEGFR inhibitor,MoA,Phase 3
617,1414,FGFR inhibitor|VEGFR inhibitor,MoA,Phase 3
244,1414,FGFR inhibitor|VEGFR inhibitor,MoA,Phase 3
351,1415,FGFR inhibitor|VEGFR inhibitor,MoA,Phase 3
11,1416,serotonin receptor antagonist,MoA,Preclinical
12,1416,serotonin receptor antagonist,MoA,Preclinical
13,1416,serotonin receptor antagonist,MoA,Preclinical
488,1416,serotonin receptor antagonist,MoA,Preclinical
489,1416,serotonin receptor antagonist,MoA,Preclinical
14,1416,serotonin receptor antagonist,MoA,Preclinical
15,1416,serotonin receptor antagonist,MoA,Preclinical
16,1416,serotonin receptor antagonist,MoA,Preclinical
624,1416,serotonin receptor antagonist,MoA,Preclinical
1417,1418,cholesterol inhibitor,MoA,Phase 1
165,1419,adrenergic receptor agonist,MoA,Phase 2
417,1419,adrenergic receptor agonist,MoA,Phase 2
567,1419,adrenergic receptor agonist,MoA,Phase 2
1,1420,adrenergic receptor antagonist,MoA,Preclinical
3,1420,adrenergic receptor antagonist,MoA,Preclinical
4,1420,adrenergic receptor antagonist,MoA,Preclinical
1421,1422,phosphodiesterase inhibitor,MoA,Preclinical
1423,1422,phosphodiesterase inhibitor,MoA,Preclinical
510,1424,opioid receptor agonist,MoA,Preclinical
488,1425,serotonin receptor agonist,MoA,Preclinical
489,1425,serotonin receptor agonist,MoA,Preclinical
174,1427,cyclooxygenase inhibitor,MoA,Withdrawn
171,1427,cyclooxygenase inhibitor,MoA,Withdrawn
417,1432,adrenergic receptor agonist,MoA,Phase 3
73,1433,glycine receptor antagonist,MoA,Preclinical
74,1433,glycine receptor antagonist,MoA,Preclinical
75,1433,glycine receptor antagonist,MoA,Preclinical
76,1433,glycine receptor antagonist,MoA,Preclinical
170,1433,glycine receptor antagonist,MoA,Preclinical
515,1434,CDK inhibitor,MoA,Preclinical
1435,1436,ATPase inhibitor,MoA,Preclinical
1437,1438,mitotic kinesin inhibitor,MoA,Preclinical
571,1439,dopamine reuptake inhibitor,MoA,Withdrawn
620,1439,dopamine reuptake inhibitor,MoA,Withdrawn
410,1439,dopamine reuptake inhibitor,MoA,Withdrawn
24,1440,GABA receptor antagonist,MoA,Phase 1
1441,1442,integrin inhibitor,MoA,Preclinical
897,1442,integrin inhibitor,MoA,Preclinical
569,1443,imidazoline receptor ligand,MoA,Preclinical
1248,1443,imidazoline receptor ligand,MoA,Preclinical
1143,1448,cyclooxygenase inhibitor,MoA,Withdrawn
251,1448,cyclooxygenase inhibitor,MoA,Withdrawn
474,1455,PI3K inhibitor,MoA,Phase 3
476,1455,PI3K inhibitor,MoA,Phase 3
165,1457,adrenergic receptor antagonist,MoA,Phase 1
1462,1463,tripeptidyl peptidase inhibitor,MoA,Preclinical
6,1464,dopamine receptor antagonist,MoA,Phase 2
7,1464,dopamine receptor antagonist,MoA,Phase 2
8,1464,dopamine receptor antagonist,MoA,Phase 2
9,1464,dopamine receptor antagonist,MoA,Phase 2
10,1464,dopamine receptor antagonist,MoA,Phase 2
11,1464,dopamine receptor antagonist,MoA,Phase 2
14,1464,dopamine receptor antagonist,MoA,Phase 2
407,1467,EGFR inhibitor|SRC inhibitor,MoA,Preclinical
1470,1471,glutathione transferase inhibitor,MoA,Phase 1
188,1472,carbonic anhydrase inhibitor,MoA,Phase 1
754,1474,11-beta hydroxysteroid dehydrogenase inhibitor,MoA,Preclinical
1280,1475,tyrosine phosphatase inhibitor,MoA,Preclinical
1476,1475,tyrosine phosphatase inhibitor,MoA,Preclinical
1477,1475,tyrosine phosphatase inhibitor,MoA,Preclinical
403,1478,lipoxygenase inhibitor,MoA,Phase 1
403,1479,lipoxygenase inhibitor,MoA,Preclinical
339,1480,opioid receptor agonist,MoA,Phase 2
511,1480,opioid receptor agonist,MoA,Phase 2
339,1481,opioid receptor agonist,MoA,Preclinical
569,1482,monoamine oxidase inhibitor,MoA,Preclinical
14,1483,serotonin receptor agonist,MoA,Preclinical
15,1483,serotonin receptor agonist,MoA,Preclinical
16,1483,serotonin receptor agonist,MoA,Preclinical
371,1484,IKK inhibitor,MoA,Preclinical
1026,1484,IKK inhibitor,MoA,Preclinical
32,1484,IKK inhibitor,MoA,Preclinical
244,1484,IKK inhibitor,MoA,Preclinical
1023,1484,IKK inhibitor,MoA,Preclinical
789,1484,IKK inhibitor,MoA,Preclinical
371,1485,pyruvate dehydrogenase kinase inhibitor,MoA,Preclinical
1026,1485,pyruvate dehydrogenase kinase inhibitor,MoA,Preclinical
32,1485,pyruvate dehydrogenase kinase inhibitor,MoA,Preclinical
244,1485,pyruvate dehydrogenase kinase inhibitor,MoA,Preclinical
1023,1485,pyruvate dehydrogenase kinase inhibitor,MoA,Preclinical
789,1485,pyruvate dehydrogenase kinase inhibitor,MoA,Preclinical
366,1486,PARP inhibitor,MoA,Preclinical
1487,1488,CC chemokine receptor antagonist,MoA,Preclinical
1284,1489,protein kinase inhibitor,MoA,Preclinical
1506,1507,calcium-activated chloride channel inhibitor,MoA,Preclinical
403,1508,HIV integrase inhibitor|lipoxygenase inhibitor|nitric oxide production inhibitor|tumor necrosis factor production inhibitor,MoA,Preclinical
1509,1508,HIV integrase inhibitor|lipoxygenase inhibitor|nitric oxide production inhibitor|tumor necrosis factor production inhibitor,MoA,Preclinical
213,1510,HIV integrase inhibitor,MoA,Preclinical
1530,1531,calcium sensing receptor negative allosteric modulator,MoA,Preclinical
1052,1532,motilin receptor agonist,MoA,Phase 2
49,1533,calcium/calmodulin dependent protein kinase inhibitor,MoA,Preclinical
1534,1533,calcium/calmodulin dependent protein kinase inhibitor,MoA,Preclinical
1535,1533,calcium/calmodulin dependent protein kinase inhibitor,MoA,Preclinical
1536,1533,calcium/calmodulin dependent protein kinase inhibitor,MoA,Preclinical
53,1539,TRPV activator,MoA,Phase 1
230,1540,topoisomerase inhibitor,MoA,Phase 3
49,1544,EGFR inhibitor,MoA,Phase 3
346,1544,EGFR inhibitor,MoA,Phase 3
348,1544,EGFR inhibitor,MoA,Phase 3
349,1544,EGFR inhibitor,MoA,Phase 3
1545,1546,mineralocorticoid receptor antagonist,MoA,Withdrawn
69,1547,adenosine receptor agonist,MoA,Phase 2
53,1551,TRPV agonist,MoA,Preclinical
1552,1551,TRPV agonist,MoA,Preclinical
1555,1556,ribonucleotide reductase inhibitor,MoA,Phase 2
1593,1594,calcium channel blocker,MoA,Phase 3
1047,1595,angiotensin antagonist,MoA,Phase 1
1596,1597,WNT signaling inhibitor,MoA,Preclinical
97,1598,histamine receptor antagonist,MoA,Phase 1
1602,1603,NADPH quinone oxidoreductase inhibitor,MoA,Phase 2
586,1604,sodium/hydrogen exchanger inhibitor,MoA,Phase 3
417,1607,adrenergic receptor agonist,MoA,Phase 2
7,1608,dopamine receptor agonist,MoA,Phase 2
569,1611,monoamine oxidase inhibitor,MoA,Withdrawn
1248,1611,monoamine oxidase inhibitor,MoA,Withdrawn
1618,1619,GTPase inhibitor,MoA,Preclinical
1620,1621,glucosidase inhibitor,MoA,Phase 2
1622,1621,glucosidase inhibitor,MoA,Phase 2
1623,1624,cathepsin inhibitor,MoA,Preclinical
1349,1624,cathepsin inhibitor,MoA,Preclinical
1625,1624,cathepsin inhibitor,MoA,Preclinical
476,1626,PI3K inhibitor,MoA,Preclinical
696,1627,androgen receptor antagonist,MoA,Phase 3
1628,1629,valosin-containing protein inhibitor,MoA,Phase 1
1630,1631,glutaminase inhibitor,MoA,Phase 2
1256,1632,glutamate receptor positive allosteric modulator,MoA,Preclinical
403,1633,lipoxygenase inhibitor,MoA,Phase 1
781,1634,DNA protein kinase inhibitor|mTOR inhibitor,MoA,Phase 2
781,1635,mTOR inhibitor,MoA,Phase 2
726,1636,JNK inhibitor,MoA,Phase 1
1637,1638,apoptosis stimulant,MoA,Preclinical
1639,1638,apoptosis stimulant,MoA,Preclinical
1640,1641,G protein signaling inhibitor,MoA,Preclinical
1642,1641,G protein signaling inhibitor,MoA,Preclinical
1640,1643,G protein signaling inhibitor,MoA,Preclinical
1640,1644,G protein signaling inhibitor,MoA,Preclinical
43,1645,acetylcholine receptor allosteric modulator,MoA,Preclinical
1596,1646,WNT signaling inhibitor,MoA,Preclinical
507,1647,HSP inhibitor,MoA,Preclinical
1648,1647,HSP inhibitor,MoA,Preclinical
452,1649,Aurora kinase inhibitor,MoA,Preclinical
563,1649,Aurora kinase inhibitor,MoA,Preclinical
564,1649,Aurora kinase inhibitor,MoA,Preclinical
452,1650,Aurora kinase inhibitor,MoA,Preclinical
563,1650,Aurora kinase inhibitor,MoA,Preclinical
564,1650,Aurora kinase inhibitor,MoA,Preclinical
503,1651,nicotinic receptor agonist,MoA,Preclinical
222,1652,retinoid receptor agonist,MoA,Preclinical
222,1653,retinoid receptor agonist,MoA,Preclinical
512,1654,CDK inhibitor|glycogen synthase kinase inhibitor,MoA,Preclinical
514,1654,CDK inhibitor|glycogen synthase kinase inhibitor,MoA,Preclinical
32,1654,CDK inhibitor|glycogen synthase kinase inhibitor,MoA,Preclinical
517,1655,CDK inhibitor,MoA,Preclinical
160,1656,glutamate receptor positive allosteric modulator,MoA,Preclinical
1099,1657,opioid receptor agonist,MoA,Phase 3
511,1657,opioid receptor agonist,MoA,Phase 3
126,1658,KIT inhibitor|VEGFR inhibitor,MoA,Phase 3
939,1658,KIT inhibitor|VEGFR inhibitor,MoA,Phase 3
128,1658,KIT inhibitor|VEGFR inhibitor,MoA,Phase 3
940,1658,KIT inhibitor|VEGFR inhibitor,MoA,Phase 3
244,1658,KIT inhibitor|VEGFR inhibitor,MoA,Phase 3
129,1658,KIT inhibitor|VEGFR inhibitor,MoA,Phase 3
130,1658,KIT inhibitor|VEGFR inhibitor,MoA,Phase 3
131,1658,KIT inhibitor|VEGFR inhibitor,MoA,Phase 3
946,1668,RAF inhibitor,MoA,Phase 1/Phase 2
948,1668,RAF inhibitor,MoA,Phase 1/Phase 2
369,1669,JAK inhibitor,MoA,Preclinical
309,1670,ALK tyrosine kinase receptor inhibitor,MoA,Phase 1
1183,1676,CCK receptor agonist,MoA,Preclinical
1218,1677,ACAT inhibitor|cholesterol inhibitor,MoA,Phase 2
1678,1679,triacylglycerol lipase inhibitor,MoA,Phase 3
114,1684,microtubule stimulant|tubulin polymerization inhibitor,MoA,Phase 1
1685,1686,rap guanine nucleotide exchange factor inhibitor,MoA,Preclinical
752,1687,chloride channel blocker,MoA,Preclinical
69,1688,adenosine receptor agonist,MoA,Phase 2
275,1688,adenosine receptor agonist,MoA,Phase 2
276,1688,adenosine receptor agonist,MoA,Phase 2
277,1688,adenosine receptor agonist,MoA,Phase 2
69,1689,adenosine receptor antagonist,MoA,Preclinical
276,1689,adenosine receptor antagonist,MoA,Preclinical
277,1689,adenosine receptor antagonist,MoA,Preclinical
1512,1690,ATM kinase inhibitor|ATR kinase inhibitor,MoA,Preclinical
1020,1690,ATM kinase inhibitor|ATR kinase inhibitor,MoA,Preclinical
546,1691,MDM inhibitor,MoA,Phase 1
165,1692,adrenergic receptor agonist,MoA,Phase 1
417,1692,adrenergic receptor agonist,MoA,Phase 1
567,1692,adrenergic receptor agonist,MoA,Phase 1
24,1693,GABA receptor modulator,MoA,Preclinical
165,1694,adrenergic receptor antagonist,MoA,Preclinical
567,1694,adrenergic receptor antagonist,MoA,Preclinical
484,1695,mitochondrial Na+/Ca2+ exchanger antagonist|sodium/calcium exchange inhibitor,MoA,Preclinical
154,1696,glutamate receptor antagonist,MoA,Phase 1
155,1696,glutamate receptor antagonist,MoA,Phase 1
156,1696,glutamate receptor antagonist,MoA,Phase 1
157,1696,glutamate receptor antagonist,MoA,Phase 1
346,1697,EGFR inhibitor,MoA,Preclinical
346,1698,EGFR inhibitor|PKC inhibitor,MoA,Preclinical
1699,1698,EGFR inhibitor|PKC inhibitor,MoA,Preclinical
24,1700,GABA receptor antagonist,MoA,Preclinical
26,1700,GABA receptor antagonist,MoA,Preclinical
1078,1700,GABA receptor antagonist,MoA,Preclinical
1079,1700,GABA receptor antagonist,MoA,Preclinical
1080,1700,GABA receptor antagonist,MoA,Preclinical
24,1701,GABA receptor antagonist,MoA,Preclinical
26,1701,GABA receptor antagonist,MoA,Preclinical
1078,1701,GABA receptor antagonist,MoA,Preclinical
1079,1701,GABA receptor antagonist,MoA,Preclinical
1080,1701,GABA receptor antagonist,MoA,Preclinical
563,1702,MAP kinase inhibitor,MoA,Preclinical
1283,1702,MAP kinase inhibitor,MoA,Preclinical
1703,1702,MAP kinase inhibitor,MoA,Preclinical
1704,1702,MAP kinase inhibitor,MoA,Preclinical
1705,1702,MAP kinase inhibitor,MoA,Preclinical
512,1706,CDK inhibitor,MoA,Preclinical
371,1706,CDK inhibitor,MoA,Preclinical
1707,1708,neuropeptide receptor antagonist,MoA,Preclinical
512,1709,CDK inhibitor,MoA,Preclinical
24,1710,GABA receptor modulator,MoA,Preclinical
69,1711,adenosine receptor antagonist,MoA,Preclinical
275,1711,adenosine receptor antagonist,MoA,Preclinical
276,1711,adenosine receptor antagonist,MoA,Preclinical
277,1711,adenosine receptor antagonist,MoA,Preclinical
79,1712,benzodiazepine receptor agonist|GABA benzodiazepine site receptor partial agonist,MoA,Phase 1
140,1712,benzodiazepine receptor agonist|GABA benzodiazepine site receptor partial agonist,MoA,Phase 1
141,1712,benzodiazepine receptor agonist|GABA benzodiazepine site receptor partial agonist,MoA,Phase 1
81,1712,benzodiazepine receptor agonist|GABA benzodiazepine site receptor partial agonist,MoA,Phase 1
142,1712,benzodiazepine receptor agonist|GABA benzodiazepine site receptor partial agonist,MoA,Phase 1
143,1712,benzodiazepine receptor agonist|GABA benzodiazepine site receptor partial agonist,MoA,Phase 1
69,1713,adenosine receptor agonist,MoA,Preclinical
275,1713,adenosine receptor agonist,MoA,Preclinical
276,1713,adenosine receptor agonist,MoA,Preclinical
277,1713,adenosine receptor agonist,MoA,Preclinical
79,1714,GABA receptor antagonist,MoA,Preclinical
145,1714,GABA receptor antagonist,MoA,Preclinical
149,1714,GABA receptor antagonist,MoA,Preclinical
1008,1715,fibroblast growth factor inhibitor,MoA,Phase 2
350,1715,fibroblast growth factor inhibitor,MoA,Phase 2
351,1715,fibroblast growth factor inhibitor,MoA,Phase 2
786,1716,monocarboxylate transporter inhibitor,MoA,Preclinical
925,1719,gamma secretase modulator,MoA,Phase 2
1509,1720,glutamate inhibitor|macrophage migration inhibiting factor inhibitor,MoA,Preclinical
1026,1722,CHK inhibitor,MoA,Preclinical
30,1723,glycogen synthase kinase inhibitor,MoA,Preclinical
32,1723,glycogen synthase kinase inhibitor,MoA,Preclinical
512,1724,glycogen synthase kinase inhibitor,MoA,Preclinical
30,1724,glycogen synthase kinase inhibitor,MoA,Preclinical
32,1724,glycogen synthase kinase inhibitor,MoA,Preclinical
828,1724,glycogen synthase kinase inhibitor,MoA,Preclinical
332,1727,acetylcholine receptor antagonist,MoA,Preclinical
79,1729,GABA receptor modulator,MoA,Withdrawn
205,1747,acetylcholinesterase inhibitor,MoA,Launched
205,1771,acetylcholine precursor,MoA,Phase 3
759,1771,acetylcholine precursor,MoA,Phase 3
207,1771,acetylcholine precursor,MoA,Phase 3
1772,1771,acetylcholine precursor,MoA,Phase 3
1773,1771,acetylcholine precursor,MoA,Phase 3
1774,1771,acetylcholine precursor,MoA,Phase 3
357,1771,acetylcholine precursor,MoA,Phase 3
1775,1771,acetylcholine precursor,MoA,Phase 3
160,1776,glutamate receptor agonist,MoA,Preclinical
1777,1778,serine/threonine kinase inhibitor,MoA,Preclinical
255,1779,breast cancer resistance protein inhibitor,MoA,Phase 1
92,1779,breast cancer resistance protein inhibitor,MoA,Phase 1
596,1779,breast cancer resistance protein inhibitor,MoA,Phase 1
753,1779,breast cancer resistance protein inhibitor,MoA,Phase 1
346,1780,EGFR inhibitor,MoA,Preclinical
781,1780,EGFR inhibitor,MoA,Preclinical
900,1781,aryl hydrocarbon receptor antagonist,MoA,Preclinical
781,1782,PI3K inhibitor,MoA,Phase 1
474,1782,PI3K inhibitor,MoA,Phase 1
136,1782,PI3K inhibitor,MoA,Phase 1
138,1782,PI3K inhibitor,MoA,Phase 1
476,1782,PI3K inhibitor,MoA,Phase 1
124,1783,retinoid receptor binder,MoA,Preclinical
118,1783,retinoid receptor binder,MoA,Preclinical
1784,1785,GAT inhibitor,MoA,Phase 1
1786,1787,ACAT inhibitor,MoA,Phase 1
176,1787,ACAT inhibitor,MoA,Phase 1
174,1788,fatty acid synthase inhibitor,MoA,Withdrawn
174,1791,cyclooxygenase inhibitor,MoA,Preclinical
171,1791,cyclooxygenase inhibitor,MoA,Preclinical
525,1792,G protein-coupled receptor antagonist,MoA,Preclinical
1793,1794,protein kinase inhibitor,MoA,Preclinical
1451,1795,G protein-coupled receptor antagonist,MoA,Preclinical
829,1796,MAP kinase phosphatase inhibitor,MoA,Preclinical
200,1797,PPAR receptor agonist,MoA,Phase 2
1798,1799,dehydropeptidase inhibitor,MoA,Launched
896,1801,integrin antagonist,MoA,Phase 3
898,1801,integrin antagonist,MoA,Phase 3
18,1803,phosphodiesterase inhibitor,MoA,Phase 3
20,1803,phosphodiesterase inhibitor,MoA,Phase 3
22,1803,phosphodiesterase inhibitor,MoA,Phase 3
603,1804,phosphodiesterase inhibitor,MoA,Preclinical
604,1804,phosphodiesterase inhibitor,MoA,Preclinical
1806,1807,transient receptor potential channel agonist,MoA,Preclinical
165,1808,adrenergic receptor agonist,MoA,Preclinical
417,1808,adrenergic receptor agonist,MoA,Preclinical
567,1808,adrenergic receptor agonist,MoA,Preclinical
1119,1815,guanylate cyclase activator,MoA,Phase 2
1121,1815,guanylate cyclase activator,MoA,Phase 2
1816,1817,leukotriene receptor antagonist,MoA,Phase 2
14,1818,serotonin receptor antagonist,MoA,Preclinical
1820,1821,P glycoprotein inhibitor,MoA,Preclinical
67,1822,aldose reductase inhibitor|TRPV agonist,MoA,Preclinical
1718,1823,CAR antagonist,MoA,Preclinical
1824,1823,CAR antagonist,MoA,Preclinical
200,1823,CAR antagonist,MoA,Preclinical
764,1825,metalloproteinase inhibitor,MoA,Phase 3
766,1825,metalloproteinase inhibitor,MoA,Phase 3
767,1825,metalloproteinase inhibitor,MoA,Phase 3
1112,1825,metalloproteinase inhibitor,MoA,Phase 3
1826,1825,metalloproteinase inhibitor,MoA,Phase 3
1113,1825,metalloproteinase inhibitor,MoA,Phase 3
84,1825,metalloproteinase inhibitor,MoA,Phase 3
1,1829,histamine receptor antagonist,MoA,Preclinical
4,1829,histamine receptor antagonist,MoA,Preclinical
100,1829,histamine receptor antagonist,MoA,Preclinical
623,1829,histamine receptor antagonist,MoA,Preclinical
77,1829,histamine receptor antagonist,MoA,Preclinical
156,1830,glutamate receptor potentiator,MoA,Preclinical
157,1830,glutamate receptor potentiator,MoA,Preclinical
45,1831,adrenergic receptor agonist,MoA,Preclinical
1256,1834,glutamate receptor agonist,MoA,Preclinical
1835,1834,glutamate receptor agonist,MoA,Preclinical
1836,1834,glutamate receptor agonist,MoA,Preclinical
651,1834,glutamate receptor agonist,MoA,Preclinical
1837,1834,glutamate receptor agonist,MoA,Preclinical
881,1838,nitric oxide stimulant,MoA,Phase 1
14,1839,serotonin receptor agonist,MoA,Phase 2
14,1840,serotonin receptor agonist,MoA,Withdrawn
77,1840,serotonin receptor agonist,MoA,Withdrawn
490,1840,serotonin receptor agonist,MoA,Withdrawn
617,1840,serotonin receptor agonist,MoA,Withdrawn
1824,1844,constitutive androstane receptor (CAR) agonist,MoA,Preclinical
255,1847,coagulation factor inhibitor,MoA,Preclinical
1848,1847,coagulation factor inhibitor,MoA,Preclinical
270,1847,coagulation factor inhibitor,MoA,Preclinical
1849,1847,coagulation factor inhibitor,MoA,Preclinical
1850,1847,coagulation factor inhibitor,MoA,Preclinical
190,1847,coagulation factor inhibitor,MoA,Preclinical
1851,1847,coagulation factor inhibitor,MoA,Preclinical
1852,1847,coagulation factor inhibitor,MoA,Preclinical
1853,1847,coagulation factor inhibitor,MoA,Preclinical
1000,1847,coagulation factor inhibitor,MoA,Preclinical
1854,1847,coagulation factor inhibitor,MoA,Preclinical
1855,1847,coagulation factor inhibitor,MoA,Preclinical
1856,1847,coagulation factor inhibitor,MoA,Preclinical
1857,1847,coagulation factor inhibitor,MoA,Preclinical
1858,1847,coagulation factor inhibitor,MoA,Preclinical
1859,1847,coagulation factor inhibitor,MoA,Preclinical
1509,1847,coagulation factor inhibitor,MoA,Preclinical
23,1847,coagulation factor inhibitor,MoA,Preclinical
580,1847,coagulation factor inhibitor,MoA,Preclinical
1860,1847,coagulation factor inhibitor,MoA,Preclinical
1861,1847,coagulation factor inhibitor,MoA,Preclinical
1862,1847,coagulation factor inhibitor,MoA,Preclinical
1054,1847,coagulation factor inhibitor,MoA,Preclinical
1863,1847,coagulation factor inhibitor,MoA,Preclinical
1864,1847,coagulation factor inhibitor,MoA,Preclinical
490,1865,serotonin receptor agonist,MoA,Preclinical
1866,1867,actin related protein inhibitor,MoA,Preclinical
1868,1867,actin related protein inhibitor,MoA,Preclinical
1869,1867,actin related protein inhibitor,MoA,Preclinical
1870,1867,actin related protein inhibitor,MoA,Preclinical
1871,1867,actin related protein inhibitor,MoA,Preclinical
1872,1867,actin related protein inhibitor,MoA,Preclinical
1873,1867,actin related protein inhibitor,MoA,Preclinical
369,1874,NFkB pathway inhibitor,MoA,Phase 1
1875,1874,NFkB pathway inhibitor,MoA,Phase 1
1876,1877,casein kinase inhibitor,MoA,Preclinical
79,1878,benzodiazepine receptor agonist,MoA,Phase 1
140,1878,benzodiazepine receptor agonist,MoA,Phase 1
141,1878,benzodiazepine receptor agonist,MoA,Phase 1
142,1878,benzodiazepine receptor agonist,MoA,Phase 1
145,1878,benzodiazepine receptor agonist,MoA,Phase 1
149,1878,benzodiazepine receptor agonist,MoA,Phase 1
510,1895,chelating agent,MoA,Withdrawn
97,1896,histamine receptor antagonist,MoA,Preclinical
99,1896,histamine receptor antagonist,MoA,Preclinical
100,1896,histamine receptor antagonist,MoA,Preclinical
623,1896,histamine receptor antagonist,MoA,Preclinical
852,1908,potassium channel blocker,MoA,Phase 2
879,1908,potassium channel blocker,MoA,Phase 2
569,1919,monoamine oxidase inhibitor,MoA,Phase 2
796,1924,potassium channel activator,MoA,Preclinical
567,1926,adrenergic receptor agonist,MoA,Phase 2
1927,1926,adrenergic receptor agonist,MoA,Phase 2
1928,1926,adrenergic receptor agonist,MoA,Phase 2
1929,1926,adrenergic receptor agonist,MoA,Phase 2
86,1930,p38 MAPK inhibitor,MoA,Preclinical
405,1930,p38 MAPK inhibitor,MoA,Preclinical
665,1931,glutamate receptor antagonist,MoA,Phase 1
663,1931,glutamate receptor antagonist,MoA,Phase 1
667,1931,glutamate receptor antagonist,MoA,Phase 1
668,1931,glutamate receptor antagonist,MoA,Phase 1
346,1932,EGFR inhibitor,MoA,Preclinical
134,1933,Bruton's tyrosine kinase (BTK) inhibitor,MoA,Preclinical
155,1934,glutamate receptor antagonist,MoA,Preclinical
447,1935,sodium channel blocker,MoA,Phase 1
450,1935,sodium channel blocker,MoA,Phase 1
2077,2078,adenylyl cyclase activator,MoA,Phase 2
2079,2078,adenylyl cyclase activator,MoA,Phase 2
979,2080,beta-secretase inhibitor,MoA,Preclinical
781,2081,DNA dependent protein kinase inhibitor,MoA,Preclinical
1526,2081,DNA dependent protein kinase inhibitor,MoA,Preclinical
521,2088,cannabinoid receptor inverse agonist,MoA,Preclinical
202,2089,PKC inhibitor|protein tyrosine kinase inhibitor,MoA,Phase 2
1280,2089,PKC inhibitor|protein tyrosine kinase inhibitor,MoA,Phase 2
202,2090,mineralocorticoid receptor agonist,MoA,Preclinical
2091,2090,mineralocorticoid receptor agonist,MoA,Preclinical
1545,2090,mineralocorticoid receptor agonist,MoA,Preclinical
696,2094,androgen receptor antagonist,MoA,Phase 3
2095,2096,MAPK-interacting kinase inhibitor,MoA,Preclinical
2095,2097,MAPK-interacting kinase inhibitor,MoA,Preclinical
293,2100,glycogen phosphorylase inhibitor,MoA,Preclinical
850,2101,potassium channel blocker,MoA,Preclinical
728,2102,corticotropin releasing factor receptor antagonist,MoA,Phase 1
766,2103,matrix metalloprotease inhibitor,MoA,Preclinical
767,2103,matrix metalloprotease inhibitor,MoA,Preclinical
1112,2103,matrix metalloprotease inhibitor,MoA,Preclinical
1826,2103,matrix metalloprotease inhibitor,MoA,Preclinical
84,2103,matrix metalloprotease inhibitor,MoA,Preclinical
683,2104,cholesteryl ester transfer protein inhibitor,MoA,Phase 1
1266,2105,acetyl-CoA carboxylase inhibitor,MoA,Preclinical
267,2105,acetyl-CoA carboxylase inhibitor,MoA,Preclinical
129,2106,PDGFR tyrosine kinase receptor inhibitor,MoA,Preclinical
130,2106,PDGFR tyrosine kinase receptor inhibitor,MoA,Preclinical
131,2106,PDGFR tyrosine kinase receptor inhibitor,MoA,Preclinical
348,2107,EGFR inhibitor|protein tyrosine kinase inhibitor,MoA,Phase 2
1218,2108,PPAR receptor agonist,MoA,Preclinical
293,2109,glycogen phosphorylase inhibitor,MoA,Preclinical
11,2110,serotonin receptor agonist,MoA,Preclinical
12,2111,serotonin receptor agonist,MoA,Preclinical
519,2112,cannabinoid receptor antagonist,MoA,Phase 3
28,2113,tachykinin antagonist,MoA,Phase 2
2114,2115,carboxypeptidase inhibitor,MoA,Preclinical
2116,2115,carboxypeptidase inhibitor,MoA,Preclinical
2117,2118,glutamate receptor antagonist,MoA,Preclinical
836,2119,bromodomain inhibitor,MoA,Phase 2
672,2120,tumor necrosis factor release inhibitor,MoA,Phase 2
2121,2122,histone lysine methyltransferase inhibitor,MoA,Preclinical
836,2123,bromodomain inhibitor,MoA,Preclinical
2121,2124,histone lysine methyltransferase inhibitor,MoA,Preclinical
2065,2125,pyruvate dehydrogenase inhibitor,MoA,Phase 3
153,2126,glutamate receptor antagonist,MoA,Phase 2
154,2126,glutamate receptor antagonist,MoA,Phase 2
155,2126,glutamate receptor antagonist,MoA,Phase 2
156,2126,glutamate receptor antagonist,MoA,Phase 2
157,2126,glutamate receptor antagonist,MoA,Phase 2
1509,2127,macrophage migration inhibiting factor inhibitor,MoA,Preclinical
126,2135,PDGFR tyrosine kinase receptor inhibitor,MoA,Phase 3
128,2135,PDGFR tyrosine kinase receptor inhibitor,MoA,Phase 3
129,2135,PDGFR tyrosine kinase receptor inhibitor,MoA,Phase 3
130,2135,PDGFR tyrosine kinase receptor inhibitor,MoA,Phase 3
131,2135,PDGFR tyrosine kinase receptor inhibitor,MoA,Phase 3
2139,2140,MTH1 inhibitor,MoA,Preclinical
227,2145,acetylcholinesterase inhibitor|STAT inhibitor,MoA,Preclinical
2146,2147,CDK inhibitor,MoA,Preclinical
620,2148,dopamine receptor agonist,MoA,Preclinical
287,2149,fructose biphosphate inhibitor,MoA,Phase 2
1263,2150,integrin antagonist,MoA,Phase 2
160,2151,glutamate receptor antagonist,MoA,Preclinical
766,2152,metalloproteinase inhibitor,MoA,Phase 2
767,2152,metalloproteinase inhibitor,MoA,Phase 2
1112,2152,metalloproteinase inhibitor,MoA,Phase 2
1826,2152,metalloproteinase inhibitor,MoA,Phase 2
84,2152,metalloproteinase inhibitor,MoA,Phase 2
979,2153,beta-secretase inhibitor,MoA,Phase 1
2154,2155,toll-like receptor inhibitor,MoA,Preclinical
2156,2157,toll-like receptor agonist,MoA,Preclinical
2158,2157,toll-like receptor agonist,MoA,Preclinical
346,2159,EGFR inhibitor,MoA,Phase 1
348,2159,EGFR inhibitor,MoA,Phase 1
1018,2160,apoptosis inhibitor,MoA,Phase 1
249,2161,PI3K inhibitor,MoA,Phase 2
2162,2161,PI3K inhibitor,MoA,Phase 2
944,2163,smoothened receptor antagonist,MoA,Phase 1
2164,2163,smoothened receptor antagonist,MoA,Phase 1
1335,2163,smoothened receptor antagonist,MoA,Phase 1
1196,2165,cyclooxygenase inhibitor|histone acetyltransferase inhibitor|lipoxygenase inhibitor|NFkB pathway inhibitor,MoA,Launched
185,2165,cyclooxygenase inhibitor|histone acetyltransferase inhibitor|lipoxygenase inhibitor|NFkB pathway inhibitor,MoA,Launched
186,2165,cyclooxygenase inhibitor|histone acetyltransferase inhibitor|lipoxygenase inhibitor|NFkB pathway inhibitor,MoA,Launched
187,2165,cyclooxygenase inhibitor|histone acetyltransferase inhibitor|lipoxygenase inhibitor|NFkB pathway inhibitor,MoA,Launched
188,2165,cyclooxygenase inhibitor|histone acetyltransferase inhibitor|lipoxygenase inhibitor|NFkB pathway inhibitor,MoA,Launched
190,2165,cyclooxygenase inhibitor|histone acetyltransferase inhibitor|lipoxygenase inhibitor|NFkB pathway inhibitor,MoA,Launched
1616,2165,cyclooxygenase inhibitor|histone acetyltransferase inhibitor|lipoxygenase inhibitor|NFkB pathway inhibitor,MoA,Launched
1617,2165,cyclooxygenase inhibitor|histone acetyltransferase inhibitor|lipoxygenase inhibitor|NFkB pathway inhibitor,MoA,Launched
75,2165,cyclooxygenase inhibitor|histone acetyltransferase inhibitor|lipoxygenase inhibitor|NFkB pathway inhibitor,MoA,Launched
421,2165,cyclooxygenase inhibitor|histone acetyltransferase inhibitor|lipoxygenase inhibitor|NFkB pathway inhibitor,MoA,Launched
2166,2165,cyclooxygenase inhibitor|histone acetyltransferase inhibitor|lipoxygenase inhibitor|NFkB pathway inhibitor,MoA,Launched
2167,2165,cyclooxygenase inhibitor|histone acetyltransferase inhibitor|lipoxygenase inhibitor|NFkB pathway inhibitor,MoA,Launched
767,2165,cyclooxygenase inhibitor|histone acetyltransferase inhibitor|lipoxygenase inhibitor|NFkB pathway inhibitor,MoA,Launched
84,2165,cyclooxygenase inhibitor|histone acetyltransferase inhibitor|lipoxygenase inhibitor|NFkB pathway inhibitor,MoA,Launched
598,2165,cyclooxygenase inhibitor|histone acetyltransferase inhibitor|lipoxygenase inhibitor|NFkB pathway inhibitor,MoA,Launched
174,2165,cyclooxygenase inhibitor|histone acetyltransferase inhibitor|lipoxygenase inhibitor|NFkB pathway inhibitor,MoA,Launched
171,2165,cyclooxygenase inhibitor|histone acetyltransferase inhibitor|lipoxygenase inhibitor|NFkB pathway inhibitor,MoA,Launched
457,2165,cyclooxygenase inhibitor|histone acetyltransferase inhibitor|lipoxygenase inhibitor|NFkB pathway inhibitor,MoA,Launched
969,2168,JAK inhibitor,MoA,Phase 1
369,2168,JAK inhibitor,MoA,Phase 1
370,2168,JAK inhibitor,MoA,Phase 1
633,2169,sigma receptor agonist,MoA,Phase 2
275,2170,adenosine receptor agonist,MoA,Preclinical
426,2171,aldehyde dehydrogenase inhibitor,MoA,Phase 1
52,2172,PKA activator,MoA,Preclinical
2173,2174,casein kinase inhibitor,MoA,Phase 1/Phase 2
2175,2174,casein kinase inhibitor,MoA,Phase 1/Phase 2
2176,2174,casein kinase inhibitor,MoA,Phase 1/Phase 2
2177,2174,casein kinase inhibitor,MoA,Phase 1/Phase 2
165,2181,adrenergic receptor antagonist,MoA,Phase 2
11,2181,adrenergic receptor antagonist,MoA,Phase 2
13,2181,adrenergic receptor antagonist,MoA,Phase 2
719,2187,protein synthesis inhibitor,MoA,Preclinical
1222,2192,ATPase inhibitor,MoA,Preclinical
452,2205,Aurora kinase inhibitor,MoA,Phase 1
563,2205,Aurora kinase inhibitor,MoA,Phase 1
244,2205,Aurora kinase inhibitor,MoA,Phase 1
2206,2207,sphingosine 1-phosphate receptor agonist,MoA,Preclinical
2206,2208,sphingosine 1-phosphate receptor antagonist,MoA,Preclinical
2209,2210,neuropeptide receptor antagonist,MoA,Preclinical
2211,2212,sphingosine 1-phosphate receptor agonist,MoA,Preclinical
2213,2214,sphingosine 1-phosphate receptor agonist,MoA,Preclinical
2215,2216,sphingosine 1-phosphate receptor agonist,MoA,Preclinical
114,2222,tubulin polymerization inhibitor,MoA,Phase 2
2228,2229,microtubule inhibitor,MoA,Phase 2
969,2230,JAK inhibitor,MoA,Phase 3
369,2230,JAK inhibitor,MoA,Phase 3
370,2230,JAK inhibitor,MoA,Phase 3
5,2231,dopamine receptor agonist,MoA,Phase 2
2232,2233,leucine rich repeat kinase inhibitor,MoA,Preclinical
476,2234,PI3K inhibitor,MoA,Preclinical
2242,2243,toll-like receptor inhibitor,MoA,Preclinical
2167,2244,histone acetyltransferase inhibitor,MoA,Preclinical
2246,2247,enkephalinase inhibitor,MoA,Preclinical
2248,2247,enkephalinase inhibitor,MoA,Preclinical
219,2247,enkephalinase inhibitor,MoA,Preclinical
690,2249,glutamate receptor agonist,MoA,Launched
153,2249,glutamate receptor agonist,MoA,Launched
154,2249,glutamate receptor agonist,MoA,Launched
155,2249,glutamate receptor agonist,MoA,Launched
156,2249,glutamate receptor agonist,MoA,Launched
157,2249,glutamate receptor agonist,MoA,Launched
2250,2249,glutamate receptor agonist,MoA,Launched
2251,2252,TGF beta receptor inhibitor,MoA,Preclinical
2253,2252,TGF beta receptor inhibitor,MoA,Preclinical
2254,2252,TGF beta receptor inhibitor,MoA,Preclinical
114,2255,microtubule inhibitor,MoA,Preclinical
2256,2257,benzodiazepine receptor agonist,MoA,Preclinical
247,2267,HDAC inhibitor,MoA,Phase 1
249,2267,HDAC inhibitor,MoA,Phase 1
250,2267,HDAC inhibitor,MoA,Phase 1
1145,2267,HDAC inhibitor,MoA,Phase 1
1146,2267,HDAC inhibitor,MoA,Phase 1
251,2267,HDAC inhibitor,MoA,Phase 1
1147,2267,HDAC inhibitor,MoA,Phase 1
252,2267,HDAC inhibitor,MoA,Phase 1
1148,2267,HDAC inhibitor,MoA,Phase 1
346,2268,EGFR inhibitor,MoA,Launched
348,2268,EGFR inhibitor,MoA,Launched
349,2268,EGFR inhibitor,MoA,Launched
2271,2272,estrogen receptor agonist,MoA,Phase 2
2273,2272,estrogen receptor agonist,MoA,Phase 2
356,2272,estrogen receptor agonist,MoA,Phase 2
1744,2272,estrogen receptor agonist,MoA,Phase 2
426,2274,antioxidant,MoA,Phase 1
511,2275,opioid receptor agonist,MoA,Phase 2
683,2277,cholesteryl ester transfer protein inhibitor,MoA,Phase 3
1917,2309,thromboxane receptor antagonist,MoA,Phase 3
2310,2311,KDM2A inhibitor,MoA,Preclinical
2312,2311,KDM2A inhibitor,MoA,Preclinical
2313,2311,KDM2A inhibitor,MoA,Preclinical
1011,2316,CC chemokine receptor antagonist,MoA,Phase 2
452,2318,Aurora kinase inhibitor|growth factor receptor inhibitor,MoA,Phase 2
563,2318,Aurora kinase inhibitor|growth factor receptor inhibitor,MoA,Phase 2
564,2318,Aurora kinase inhibitor|growth factor receptor inhibitor,MoA,Phase 2
1008,2318,Aurora kinase inhibitor|growth factor receptor inhibitor,MoA,Phase 2
631,2318,Aurora kinase inhibitor|growth factor receptor inhibitor,MoA,Phase 2
741,2318,Aurora kinase inhibitor|growth factor receptor inhibitor,MoA,Phase 2
2319,2318,Aurora kinase inhibitor|growth factor receptor inhibitor,MoA,Phase 2
421,2322,non-nucleoside reverse transcriptase inhibitor,MoA,Phase 3
1938,2322,non-nucleoside reverse transcriptase inhibitor,MoA,Phase 3
2324,2325,hypoxia inducible factor inhibitor,MoA,Phase 3
2327,2328,phospholipase inhibitor,MoA,Phase 3
200,2329,PPAR receptor antagonist,MoA,Phase 2
238,2333,endothelin receptor antagonist,MoA,Phase 3
75,2340,acetylcholine receptor antagonist,MoA,Preclinical
2342,2343,thromboxane synthase inhibitor,MoA,Phase 2
2342,2344,thromboxane synthase inhibitor,MoA,Phase 2
678,2345,ATPase inhibitor,MoA,Preclinical
469,2346,dipeptidyl peptidase inhibitor,MoA,Phase 1
483,2347,free fatty acid receptor antagonist,MoA,Preclinical
129,2348,KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor,MoA,Phase 1
130,2348,KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor,MoA,Phase 1
2349,2350,potassium channel activator,MoA,Preclinical
2351,2350,potassium channel activator,MoA,Preclinical
853,2350,potassium channel activator,MoA,Preclinical
1846,2352,chloride channel blocker|gap junction modulator|glutamate inhibitor,MoA,Preclinical
2353,2354,discoidin domain receptor inhibitor,MoA,Preclinical
2355,2354,discoidin domain receptor inhibitor,MoA,Preclinical
370,2358,JAK inhibitor,MoA,Phase 2/Phase 3
2360,2361,focal adhesion kinase inhibitor,MoA,Phase 2
781,2366,mTOR inhibitor,MoA,Phase 3
205,2368,acetylcholinesterase inhibitor,MoA,Phase 3
1345,2373,proteasome inhibitor,MoA,Phase 1/Phase 2
472,2373,proteasome inhibitor,MoA,Phase 1/Phase 2
421,2373,proteasome inhibitor,MoA,Phase 1/Phase 2
1038,2373,proteasome inhibitor,MoA,Phase 1/Phase 2
1087,2377,membrane permeability inhibitor,MoA,Phase 2
477,2378,HMGCR inhibitor,MoA,Phase 1
2379,2380,phosphodiesterase inhibitor,MoA,Preclinical
1545,2383,progestogen hormone,MoA,Preclinical
45,2384,adrenergic receptor agonist|dopamine receptor agonist,MoA,Preclinical
6,2384,adrenergic receptor agonist|dopamine receptor agonist,MoA,Preclinical
7,2384,adrenergic receptor agonist|dopamine receptor agonist,MoA,Preclinical
97,2385,histamine receptor antagonist,MoA,Preclinical
16,2400,acetylcholine receptor agonist,MoA,Phase 2
423,2406,mineralocorticoid receptor agonist,MoA,Preclinical
1545,2406,mineralocorticoid receptor agonist,MoA,Preclinical
205,2407,acetylcholinesterase inhibitor|monoamine oxidase inhibitor,MoA,Phase 1
752,2413,membrane integrity inhibitor,MoA,Preclinical
2414,2413,membrane integrity inhibitor,MoA,Preclinical
1836,2413,membrane integrity inhibitor,MoA,Preclinical
651,2413,membrane integrity inhibitor,MoA,Preclinical
1837,2413,membrane integrity inhibitor,MoA,Preclinical
2287,2413,membrane integrity inhibitor,MoA,Preclinical
789,2413,membrane integrity inhibitor,MoA,Preclinical
289,2413,membrane integrity inhibitor,MoA,Preclinical
52,2413,membrane integrity inhibitor,MoA,Preclinical
360,2413,membrane integrity inhibitor,MoA,Preclinical
293,2413,membrane integrity inhibitor,MoA,Preclinical
262,2413,membrane integrity inhibitor,MoA,Preclinical
2415,2413,membrane integrity inhibitor,MoA,Preclinical
2416,2413,membrane integrity inhibitor,MoA,Preclinical
2250,2413,membrane integrity inhibitor,MoA,Preclinical
2417,2413,membrane integrity inhibitor,MoA,Preclinical
2418,2413,membrane integrity inhibitor,MoA,Preclinical
1183,2421,CCK receptor antagonist,MoA,Phase 3
277,2423,calmodulin antagonist,MoA,Phase 2
160,2434,glutamate receptor agonist,MoA,Preclinical
1220,2435,PPAR receptor inverse agonist,MoA,Preclinical
388,2436,melatonin receptor antagonist,MoA,Preclinical
323,2438,adenosine kinase inhibitor,MoA,Phase 1
324,2438,adenosine kinase inhibitor,MoA,Phase 1
116,2439,estrogen receptor agonist,MoA,Preclinical
6,2445,dopamine reuptake inhibitor,MoA,Phase 3
569,2445,dopamine reuptake inhibitor,MoA,Phase 3
1248,2445,dopamine reuptake inhibitor,MoA,Phase 3
354,2455,estrogen receptor agonist,MoA,Withdrawn
116,2455,estrogen receptor agonist,MoA,Withdrawn
2273,2455,estrogen receptor agonist,MoA,Withdrawn
356,2455,estrogen receptor agonist,MoA,Withdrawn
463,2459,ATPase inhibitor,MoA,Preclinical
174,2462,prostanoid receptor agonist,MoA,Phase 2
171,2462,prostanoid receptor agonist,MoA,Phase 2
6,2463,dopamine receptor agonist,MoA,Phase 2
7,2463,dopamine receptor agonist,MoA,Phase 2
8,2463,dopamine receptor agonist,MoA,Phase 2
9,2463,dopamine receptor agonist,MoA,Phase 2
10,2463,dopamine receptor agonist,MoA,Phase 2
2117,2467,glutamate receptor agonist,MoA,Preclinical
160,2467,glutamate receptor agonist,MoA,Preclinical
99,2472,histamine receptor agonist,MoA,Preclinical
100,2472,histamine receptor agonist,MoA,Preclinical
623,2472,histamine receptor agonist,MoA,Preclinical
97,2476,acetylcholine receptor antagonist,MoA,Preclinical
575,2480,angiotensin converting enzyme activator,MoA,Phase 3
917,2480,angiotensin converting enzyme activator,MoA,Phase 3
1537,2480,angiotensin converting enzyme activator,MoA,Phase 3
512,2482,CDK inhibitor,MoA,Phase 3
371,2482,CDK inhibitor,MoA,Phase 3
514,2482,CDK inhibitor,MoA,Phase 3
517,2482,CDK inhibitor,MoA,Phase 3
493,2484,prostanoid receptor agonist,MoA,Withdrawn
495,2484,prostanoid receptor agonist,MoA,Withdrawn
496,2484,prostanoid receptor agonist,MoA,Withdrawn
497,2484,prostanoid receptor agonist,MoA,Withdrawn
392,2484,prostanoid receptor agonist,MoA,Withdrawn
971,2484,prostanoid receptor agonist,MoA,Withdrawn
394,2484,prostanoid receptor agonist,MoA,Withdrawn
395,2484,prostanoid receptor agonist,MoA,Withdrawn
396,2484,prostanoid receptor agonist,MoA,Withdrawn
498,2484,prostanoid receptor agonist,MoA,Withdrawn
1254,2484,prostanoid receptor agonist,MoA,Withdrawn
1917,2484,prostanoid receptor agonist,MoA,Withdrawn
550,2485,apoptosis stimulant,MoA,Preclinical
598,2491,nitric oxide synthase inhibitor,MoA,Preclinical
881,2491,nitric oxide synthase inhibitor,MoA,Preclinical
160,2493,glutamate receptor negative allosteric modulator,MoA,Phase 2
11,2494,dopamine reuptake inhibitor|serotonin reuptake inhibitor,MoA,Launched
14,2494,dopamine reuptake inhibitor|serotonin reuptake inhibitor,MoA,Launched
16,2494,dopamine reuptake inhibitor|serotonin reuptake inhibitor,MoA,Launched
185,2504,immunostimulant,MoA,Phase 3
188,2504,immunostimulant,MoA,Phase 3
190,2504,immunostimulant,MoA,Phase 3
153,2505,sigma receptor agonist,MoA,Preclinical
154,2505,sigma receptor agonist,MoA,Preclinical
155,2505,sigma receptor agonist,MoA,Preclinical
633,2505,sigma receptor agonist,MoA,Preclinical
153,2506,glutamate receptor antagonist,MoA,Preclinical
154,2506,glutamate receptor antagonist,MoA,Preclinical
155,2506,glutamate receptor antagonist,MoA,Preclinical
156,2506,glutamate receptor antagonist,MoA,Preclinical
157,2506,glutamate receptor antagonist,MoA,Preclinical
43,2507,adrenergic receptor agonist,MoA,Preclinical
160,2508,glutamate receptor modulator,MoA,Preclinical
303,2509,ALK tyrosine kinase receptor inhibitor,MoA,Preclinical
244,2510,VEGFR inhibitor,MoA,Preclinical
1663,2511,elastase inhibitor,MoA,Phase 2
665,2512,glutamate receptor antagonist,MoA,Preclinical
663,2512,glutamate receptor antagonist,MoA,Preclinical
906,2512,glutamate receptor antagonist,MoA,Preclinical
153,2512,glutamate receptor antagonist,MoA,Preclinical
154,2512,glutamate receptor antagonist,MoA,Preclinical
155,2512,glutamate receptor antagonist,MoA,Preclinical
403,2514,lipoxygenase inhibitor,MoA,Phase 2
483,2519,PPAR receptor agonist,MoA,Launched
174,2519,PPAR receptor agonist,MoA,Launched
171,2519,PPAR receptor agonist,MoA,Launched
296,2523,MRP inhibitor|P glycoprotein inhibitor,MoA,Phase 3
879,2524,potassium channel blocker,MoA,Withdrawn
617,2524,potassium channel blocker,MoA,Withdrawn
2525,2524,potassium channel blocker,MoA,Withdrawn
797,2524,potassium channel blocker,MoA,Withdrawn
114,2527,tubulin polymerization inhibitor,MoA,Phase 2
11,2532,serotonin receptor agonist,MoA,Phase 2
12,2532,serotonin receptor agonist,MoA,Phase 2
13,2532,serotonin receptor agonist,MoA,Phase 2
488,2532,serotonin receptor agonist,MoA,Phase 2
489,2532,serotonin receptor agonist,MoA,Phase 2
14,2532,serotonin receptor agonist,MoA,Phase 2
17,2532,serotonin receptor agonist,MoA,Phase 2
624,2532,serotonin receptor agonist,MoA,Phase 2
553,2534,p38 MAPK inhibitor,MoA,Phase 2
555,2534,p38 MAPK inhibitor,MoA,Phase 2
556,2534,p38 MAPK inhibitor,MoA,Phase 2
405,2534,p38 MAPK inhibitor,MoA,Phase 2
303,2536,AMPK inhibitor,MoA,Preclinical
2537,2536,AMPK inhibitor,MoA,Preclinical
2538,2536,AMPK inhibitor,MoA,Preclinical
2336,2536,AMPK inhibitor,MoA,Preclinical
856,2536,AMPK inhibitor,MoA,Preclinical
939,2536,AMPK inhibitor,MoA,Preclinical
128,2536,AMPK inhibitor,MoA,Preclinical
244,2536,AMPK inhibitor,MoA,Preclinical
1283,2536,AMPK inhibitor,MoA,Preclinical
1703,2536,AMPK inhibitor,MoA,Preclinical
290,2536,AMPK inhibitor,MoA,Preclinical
1224,2536,AMPK inhibitor,MoA,Preclinical
1054,2536,AMPK inhibitor,MoA,Preclinical
126,2541,EGFR inhibitor|FGFR inhibitor|FLT3 inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,MoA,Phase 3
346,2541,EGFR inhibitor|FGFR inhibitor|FLT3 inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,MoA,Phase 3
1008,2541,EGFR inhibitor|FGFR inhibitor|FLT3 inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,MoA,Phase 3
350,2541,EGFR inhibitor|FGFR inhibitor|FLT3 inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,MoA,Phase 3
351,2541,EGFR inhibitor|FGFR inhibitor|FLT3 inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,MoA,Phase 3
939,2541,EGFR inhibitor|FGFR inhibitor|FLT3 inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,MoA,Phase 3
128,2541,EGFR inhibitor|FGFR inhibitor|FLT3 inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,MoA,Phase 3
940,2541,EGFR inhibitor|FGFR inhibitor|FLT3 inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,MoA,Phase 3
1672,2541,EGFR inhibitor|FGFR inhibitor|FLT3 inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,MoA,Phase 3
244,2541,EGFR inhibitor|FGFR inhibitor|FLT3 inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,MoA,Phase 3
129,2541,EGFR inhibitor|FGFR inhibitor|FLT3 inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,MoA,Phase 3
130,2541,EGFR inhibitor|FGFR inhibitor|FLT3 inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,MoA,Phase 3
131,2541,EGFR inhibitor|FGFR inhibitor|FLT3 inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,MoA,Phase 3
69,2550,adenosine receptor antagonist,MoA,Phase 1
275,2550,adenosine receptor antagonist,MoA,Phase 1
276,2550,adenosine receptor antagonist,MoA,Phase 1
277,2550,adenosine receptor antagonist,MoA,Phase 1
417,2551,sodium channel activator,MoA,Phase 2
852,2552,potassium channel blocker,MoA,Preclinical
296,2553,histamine receptor antagonist,MoA,Phase 3
97,2553,histamine receptor antagonist,MoA,Phase 3
156,2554,glutamate receptor antagonist,MoA,Preclinical
157,2554,glutamate receptor antagonist,MoA,Preclinical
366,2555,PARP inhibitor,MoA,Preclinical
2556,2555,PARP inhibitor,MoA,Preclinical
625,2557,serotonin receptor antagonist,MoA,Preclinical
2251,2558,CDK inhibitor,MoA,Preclinical
354,2559,selective estrogen receptor modulator (SERM),MoA,Phase 3
251,2571,HDAC inhibitor,MoA,Preclinical
252,2571,HDAC inhibitor,MoA,Preclinical
2520,2572,toll-like receptor agonist,MoA,Preclinical
2573,2574,structural glycoprotein antagonist,MoA,Phase 1
898,2574,structural glycoprotein antagonist,MoA,Phase 1
171,2576,cyclooxygenase inhibitor,MoA,Phase 1
474,2580,PI3K inhibitor,MoA,Launched
136,2580,PI3K inhibitor,MoA,Launched
138,2580,PI3K inhibitor,MoA,Launched
476,2580,PI3K inhibitor,MoA,Launched
2583,2584,dynamin inhibitor,MoA,Preclinical
2585,2584,dynamin inhibitor,MoA,Preclinical
2586,2584,dynamin inhibitor,MoA,Preclinical
2583,2587,dynamin inhibitor,MoA,Preclinical
2273,2589,estrogen-related receptor agonist,MoA,Preclinical
356,2589,estrogen-related receptor agonist,MoA,Preclinical
2590,2591,gamma secretase modulator,MoA,Phase 1
2592,2591,gamma secretase modulator,MoA,Phase 1
2593,2591,gamma secretase modulator,MoA,Phase 1
879,2594,potassium channel blocker,MoA,Phase 1
617,2594,potassium channel blocker,MoA,Phase 1
1350,2595,calpain inhibitor|cysteine protease inhibitor,MoA,Preclinical
2596,2597,calcium-activated chloride channel inhibitor,MoA,Preclinical
366,2598,PARP inhibitor,MoA,Preclinical
255,2600,aldose reductase inhibitor,MoA,Preclinical
99,2601,histamine receptor antagonist,MoA,Withdrawn
2602,2603,cyclooxygenase inhibitor|glutathione peroxidase agonist|H+/K+-ATPase inhibitor|nitric oxide synthase inhibitor,MoA,Phase 2/Phase 3
507,2604,HSP inhibitor,MoA,Preclinical
1648,2604,HSP inhibitor,MoA,Preclinical
124,2605,retinoid receptor agonist,MoA,Preclinical
118,2605,retinoid receptor agonist,MoA,Preclinical
222,2605,retinoid receptor agonist,MoA,Preclinical
200,2611,PPAR receptor agonist,MoA,Phase 2
2615,2616,polycomb protein inhibitor,MoA,Preclinical
2617,2618,hemoglobin oxygen release stimulant,MoA,Phase 3
2499,2618,hemoglobin oxygen release stimulant,MoA,Phase 3
275,2619,adrenergic receptor antagonist,MoA,Phase 2
200,2620,PPAR receptor agonist,MoA,Phase 2
346,2627,EGFR inhibitor,MoA,Phase 2
1256,2628,glutamate receptor agonist,MoA,Phase 2
1835,2628,glutamate receptor agonist,MoA,Phase 2
1836,2628,glutamate receptor agonist,MoA,Phase 2
1837,2628,glutamate receptor agonist,MoA,Phase 2
2629,2630,neuropilin receptor antagonist,MoA,Preclinical
2432,2631,Ras GTPase inhibitor,MoA,Preclinical
2632,2631,Ras GTPase inhibitor,MoA,Preclinical
1,2633,sodium/hydrogen exchanger inhibitor|transient receptor potential polycystic inhibitor,MoA,Preclinical
577,2633,sodium/hydrogen exchanger inhibitor|transient receptor potential polycystic inhibitor,MoA,Preclinical
580,2633,sodium/hydrogen exchanger inhibitor|transient receptor potential polycystic inhibitor,MoA,Preclinical
598,2634,nitric oxide synthase inhibitor,MoA,Preclinical
881,2634,nitric oxide synthase inhibitor,MoA,Preclinical
2121,2635,histone lysine methyltransferase inhibitor,MoA,Preclinical
296,2636,P glycoprotein inhibitor,MoA,Phase 1
2637,2638,exportin antagonist,MoA,Phase 1
2639,2640,antineoplastic agent,MoA,Phase 3
1218,2641,PPAR receptor agonist,MoA,Phase 3
1220,2641,PPAR receptor agonist,MoA,Phase 3
200,2641,PPAR receptor agonist,MoA,Phase 3
86,2642,gonadotropin releasing factor hormone receptor antagonist,MoA,Launched
441,2643,bone formation stimulant,MoA,Phase 3
1244,2644,oxidative stress inducer,MoA,Phase 3
966,2648,purinergic receptor antagonist,MoA,Phase 2
153,2649,glutamate receptor antagonist,MoA,Phase 3
155,2649,glutamate receptor antagonist,MoA,Phase 3
185,2650,glutathione transferase inhibitor|non-nucleoside reverse transcriptase inhibitor,MoA,Phase 2
186,2650,glutathione transferase inhibitor|non-nucleoside reverse transcriptase inhibitor,MoA,Phase 2
187,2650,glutathione transferase inhibitor|non-nucleoside reverse transcriptase inhibitor,MoA,Phase 2
188,2650,glutathione transferase inhibitor|non-nucleoside reverse transcriptase inhibitor,MoA,Phase 2
189,2650,glutathione transferase inhibitor|non-nucleoside reverse transcriptase inhibitor,MoA,Phase 2
190,2650,glutathione transferase inhibitor|non-nucleoside reverse transcriptase inhibitor,MoA,Phase 2
1413,2650,glutathione transferase inhibitor|non-nucleoside reverse transcriptase inhibitor,MoA,Phase 2
2651,2650,glutathione transferase inhibitor|non-nucleoside reverse transcriptase inhibitor,MoA,Phase 2
1616,2650,glutathione transferase inhibitor|non-nucleoside reverse transcriptase inhibitor,MoA,Phase 2
191,2650,glutathione transferase inhibitor|non-nucleoside reverse transcriptase inhibitor,MoA,Phase 2
1617,2650,glutathione transferase inhibitor|non-nucleoside reverse transcriptase inhibitor,MoA,Phase 2
2173,2650,glutathione transferase inhibitor|non-nucleoside reverse transcriptase inhibitor,MoA,Phase 2
32,2650,glutathione transferase inhibitor|non-nucleoside reverse transcriptase inhibitor,MoA,Phase 2
52,2650,glutathione transferase inhibitor|non-nucleoside reverse transcriptase inhibitor,MoA,Phase 2
1284,2650,glutathione transferase inhibitor|non-nucleoside reverse transcriptase inhibitor,MoA,Phase 2
1699,2650,glutathione transferase inhibitor|non-nucleoside reverse transcriptase inhibitor,MoA,Phase 2
1468,2650,glutathione transferase inhibitor|non-nucleoside reverse transcriptase inhibitor,MoA,Phase 2
1125,2650,glutathione transferase inhibitor|non-nucleoside reverse transcriptase inhibitor,MoA,Phase 2
2652,2653,bradykinin receptor antagonist,MoA,Preclinical
79,2654,GABA receptor positive allosteric modulator,MoA,Phase 3
140,2654,GABA receptor positive allosteric modulator,MoA,Phase 3
141,2654,GABA receptor positive allosteric modulator,MoA,Phase 3
81,2654,GABA receptor positive allosteric modulator,MoA,Phase 3
142,2654,GABA receptor positive allosteric modulator,MoA,Phase 3
143,2654,GABA receptor positive allosteric modulator,MoA,Phase 3
145,2654,GABA receptor positive allosteric modulator,MoA,Phase 3
149,2654,GABA receptor positive allosteric modulator,MoA,Phase 3
11,2655,serotonin receptor agonist,MoA,Phase 2
12,2655,serotonin receptor agonist,MoA,Phase 2
1018,2658,HCV inhibitor|XIAP inhibitor,MoA,Preclinical
430,2659,hepatocyte growth factor receptor inhibitor,MoA,Phase 2
624,2660,serotonin receptor agonist,MoA,Preclinical
2661,2662,phosphodiesterase inhibitor,MoA,Phase 1
1047,2663,angiotensin receptor antagonist,MoA,Preclinical
2665,2666,protein synthesis inhibitor,MoA,Phase 2
2173,2667,11-beta hydroxysteroid dehydrogenase inhibitor,MoA,Preclinical
2669,2670,caspase inhibitor,MoA,Phase 2
678,2670,caspase inhibitor,MoA,Phase 2
2671,2670,caspase inhibitor,MoA,Phase 2
79,2675,GABA receptor modulator,MoA,Phase 3
2677,2678,PARP inhibitor,MoA,Preclinical
2679,2678,PARP inhibitor,MoA,Preclinical
354,2680,estrogen receptor antagonist,MoA,Phase 2
2684,2685,dihydropyrimidine dehydrogenase inhibitor,MoA,Phase 3
2686,2685,dihydropyrimidine dehydrogenase inhibitor,MoA,Phase 3
457,2685,dihydropyrimidine dehydrogenase inhibitor,MoA,Phase 3
452,2687,Aurora kinase inhibitor|FLT3 inhibitor|VEGFR inhibitor,MoA,Phase 2
128,2687,Aurora kinase inhibitor|FLT3 inhibitor|VEGFR inhibitor,MoA,Phase 2
244,2687,Aurora kinase inhibitor|FLT3 inhibitor|VEGFR inhibitor,MoA,Phase 2
130,2687,Aurora kinase inhibitor|FLT3 inhibitor|VEGFR inhibitor,MoA,Phase 2
2360,2687,Aurora kinase inhibitor|FLT3 inhibitor|VEGFR inhibitor,MoA,Phase 2
1054,2687,Aurora kinase inhibitor|FLT3 inhibitor|VEGFR inhibitor,MoA,Phase 2
69,2693,phosphodiesterase inhibitor,MoA,Phase 3
275,2693,phosphodiesterase inhibitor,MoA,Phase 3
276,2693,phosphodiesterase inhibitor,MoA,Phase 3
277,2693,phosphodiesterase inhibitor,MoA,Phase 3
18,2693,phosphodiesterase inhibitor,MoA,Phase 3
20,2693,phosphodiesterase inhibitor,MoA,Phase 3
247,2696,HDAC inhibitor,MoA,Phase 3
249,2696,HDAC inhibitor,MoA,Phase 3
250,2696,HDAC inhibitor,MoA,Phase 3
1148,2696,HDAC inhibitor,MoA,Phase 3
49,2701,PKC inhibitor,MoA,Phase 3
32,2701,PKC inhibitor,MoA,Phase 3
1284,2701,PKC inhibitor,MoA,Phase 3
1699,2701,PKC inhibitor,MoA,Phase 3
358,2701,PKC inhibitor,MoA,Phase 3
2702,2701,PKC inhibitor,MoA,Phase 3
2703,2704,endoplasmic reticulum oxidation inhibitor,MoA,Preclinical
553,2705,p38 MAPK inhibitor,MoA,Preclinical
405,2705,p38 MAPK inhibitor,MoA,Preclinical
2706,2707,"indoleamine 2,3-dioxygenase inhibitor",MoA,Phase 3
2370,2723,steroid,MoA,Preclinical
979,2724,bacterial DNA gyrase inhibitor,MoA,Phase 2
1674,2724,bacterial DNA gyrase inhibitor,MoA,Phase 2
1038,2725,bacterial DNA gyrase inhibitor,MoA,Phase 2/Phase 3
2167,2725,bacterial DNA gyrase inhibitor,MoA,Phase 2/Phase 3
1674,2725,bacterial DNA gyrase inhibitor,MoA,Phase 2/Phase 3
1946,2725,bacterial DNA gyrase inhibitor,MoA,Phase 2/Phase 3
2726,2725,bacterial DNA gyrase inhibitor,MoA,Phase 2/Phase 3
1112,2725,bacterial DNA gyrase inhibitor,MoA,Phase 2/Phase 3
114,2738,microtubule stabilizing agent|tubulin polymerization inhibitor,MoA,Phase 3
114,2739,microtubule stabilizing agent|tubulin polymerization inhibitor,MoA,Phase 2
2740,2741,trace amine associated receptor antagonist,MoA,Preclinical
2743,2744,amyloid protein inhibitor|antiamyloidogenic agent,MoA,Phase 3
2747,2748,histone lysine methyltransferase inhibitor,MoA,Phase 1
2747,2749,histone lysine methyltransferase inhibitor,MoA,Preclinical
2121,2750,histone lysine methyltransferase inhibitor,MoA,Preclinical
2121,2751,histone lysine methyltransferase inhibitor,MoA,Preclinical
2752,2753,protein arginine N-methyltransferase inhibitor,MoA,Preclinical
2754,2755,protein arginine N-methyltransferase inhibitor,MoA,Preclinical
754,2756,estrogen receptor agonist,MoA,Preclinical
354,2757,estrogen receptor agonist,MoA,Launched
116,2757,estrogen receptor agonist,MoA,Launched
1125,2758,mediator release inhibitor|SYK inhibitor,MoA,Preclinical
124,2759,retinoid receptor antagonist,MoA,Preclinical
2760,2761,ion channel antagonist,MoA,Preclinical
346,2762,EGFR inhibitor|tyrosine kinase inhibitor,MoA,Preclinical
441,2763,vitamin D receptor agonist,MoA,Phase 1
1008,2764,FGFR inhibitor,MoA,Launched
350,2764,FGFR inhibitor,MoA,Launched
351,2764,FGFR inhibitor,MoA,Launched
1010,2764,FGFR inhibitor,MoA,Launched
1299,2768,MAP kinase inhibitor,MoA,Preclinical
354,2770,estrogen receptor agonist,MoA,Phase 2
116,2770,estrogen receptor agonist,MoA,Phase 2
339,2776,acetylcholinesterase inhibitor,MoA,Preclinical
511,2776,acetylcholinesterase inhibitor,MoA,Preclinical
1685,2777,EPAC inhibitor,MoA,Preclinical
2778,2777,EPAC inhibitor,MoA,Preclinical
354,2782,selective estrogen receptor modulator (SERM),MoA,Phase 3
354,2786,contraceptive agent,MoA,Preclinical
82,2796,phosphodiesterase inhibitor,MoA,Phase 2
18,2796,phosphodiesterase inhibitor,MoA,Phase 2
2797,2798,beta catenin inhibitor|porcupine inhibitor,MoA,Phase 1
7,2808,dopamine receptor antagonist,MoA,Preclinical
8,2808,dopamine receptor antagonist,MoA,Preclinical
9,2808,dopamine receptor antagonist,MoA,Preclinical
8,2812,dopamine receptor agonist,MoA,Phase 3
2820,2821,carnitine palmitoyltransferase inhibitor,MoA,Phase 2
474,2826,PI3K inhibitor,MoA,Preclinical
136,2826,PI3K inhibitor,MoA,Preclinical
138,2826,PI3K inhibitor,MoA,Preclinical
476,2826,PI3K inhibitor,MoA,Preclinical
124,2828,protein synthesis inhibitor,MoA,Withdrawn
226,2828,protein synthesis inhibitor,MoA,Withdrawn
1196,2831,catalase stimulant,MoA,Preclinical
2832,2831,catalase stimulant,MoA,Preclinical
683,2833,cholesteryl ester transfer protein inhibitor,MoA,Phase 3
665,2834,glutamate receptor negative allosteric modulator,MoA,Launched
1280,2834,glutamate receptor negative allosteric modulator,MoA,Launched
395,2835,prostaglandin inhibitor,MoA,Phase 2
498,2835,prostaglandin inhibitor,MoA,Phase 2
53,2837,ATPase inhibitor|TRPV agonist,MoA,Preclinical
43,2838,acetylcholine receptor agonist,MoA,Phase 3
304,2839,TGF beta receptor inhibitor,MoA,Phase 2
2840,2839,TGF beta receptor inhibitor,MoA,Phase 2
1286,2841,SIRT inhibitor,MoA,Phase 2
2842,2843,growth hormone releasing factor agonist,MoA,Phase 2
687,2843,growth hormone releasing factor agonist,MoA,Phase 2
230,2844,topoisomerase inhibitor,MoA,Phase 3
2847,2848,cadherin antagonist,MoA,Phase 2
801,2849,nootropic agent,MoA,Withdrawn
23,2850,phosphodiesterase inhibitor,MoA,Phase 3
2677,2851,WNT signaling inhibitor negative control,MoA,Preclinical
1911,2852,glutathione transferase inhibitor,MoA,Phase 2
2857,2858,utrophin enhancer,MoA,Phase 2
366,2859,PARP inhibitor,MoA,Phase 2
122,2859,PARP inhibitor,MoA,Phase 2
2677,2859,PARP inhibitor,MoA,Phase 2
2679,2859,PARP inhibitor,MoA,Phase 2
11,2860,serotonin receptor agonist,MoA,Phase 2
2862,2863,glucosidase inhibitor,MoA,Phase 2
14,2866,dopamine receptor antagonist|serotonin receptor antagonist,MoA,Phase 2
2867,2868,Ras GTPase inhibitor,MoA,Phase 1
174,2875,cyclooxygenase inhibitor,MoA,Launched
171,2875,cyclooxygenase inhibitor,MoA,Launched
2570,2879,tryptophan hydroxylase inhibitor,MoA,Preclinical
2880,2879,tryptophan hydroxylase inhibitor,MoA,Preclinical
2881,2879,tryptophan hydroxylase inhibitor,MoA,Preclinical
15,2882,calcium channel blocker,MoA,Preclinical
160,2884,glutamate receptor antagonist,MoA,Phase 2
417,2892,adrenergic receptor agonist,MoA,Withdrawn
124,2894,apoptosis stimulant|retinoid receptor agonist,MoA,Phase 3
348,2896,EGFR inhibitor,MoA,Preclinical
185,2897,antioxidant,MoA,Phase 2
186,2897,antioxidant,MoA,Phase 2
187,2897,antioxidant,MoA,Phase 2
188,2897,antioxidant,MoA,Phase 2
190,2897,antioxidant,MoA,Phase 2
1616,2897,antioxidant,MoA,Phase 2
1617,2897,antioxidant,MoA,Phase 2
1718,2899,FXR agonist,MoA,Preclinical
2324,2901,hypoxia inducible factor prolyl hydroxylase inhibitor,MoA,Phase 2
2902,2901,hypoxia inducible factor prolyl hydroxylase inhibitor,MoA,Phase 2
234,2901,hypoxia inducible factor prolyl hydroxylase inhibitor,MoA,Phase 2
2324,2903,hypoxia inducible factor prolyl hydroxylase inhibitor,MoA,Phase 3
2902,2903,hypoxia inducible factor prolyl hydroxylase inhibitor,MoA,Phase 3
2904,2903,hypoxia inducible factor prolyl hydroxylase inhibitor,MoA,Phase 3
2256,2905,inositol monophosphatase inhibitor,MoA,Preclinical
2256,2906,benzodiazepine receptor agonist,MoA,Preclinical
1220,2907,PPAR receptor antagonist|WNT signaling inhibitor,MoA,Preclinical
200,2907,PPAR receptor antagonist|WNT signaling inhibitor,MoA,Preclinical
255,2908,aldose reductase inhibitor,MoA,Phase 3
821,2909,kinesin inhibitor|kinesin-like spindle protein inhibitor,MoA,Phase 3
969,2910,JAK inhibitor,MoA,Phase 3
369,2910,JAK inhibitor,MoA,Phase 3
370,2910,JAK inhibitor,MoA,Phase 3
2872,2910,JAK inhibitor,MoA,Phase 3
357,2915,phospholipase inhibitor,MoA,Preclinical
1775,2915,phospholipase inhibitor,MoA,Preclinical
1263,2916,integrin antagonist,MoA,Phase 2
92,2918,Aurora kinase inhibitor,MoA,Preclinical
1674,2918,Aurora kinase inhibitor,MoA,Preclinical
339,2919,opioid receptor agonist,MoA,Preclinical
511,2920,opioid receptor agonist,MoA,Phase 2
171,2921,cyclooxygenase inhibitor,MoA,Phase 2
2922,2923,niacinamide phosphoribosyltransferase inhibitor,MoA,Phase 2
28,2924,tachykinin antagonist,MoA,Phase 2
78,2924,tachykinin antagonist,MoA,Phase 2
1309,2941,potassium channel agonist,MoA,Phase 3
853,2941,potassium channel agonist,MoA,Phase 3
629,2941,potassium channel agonist,MoA,Phase 3
1191,2941,potassium channel agonist,MoA,Phase 3
2303,2941,potassium channel agonist,MoA,Phase 3
1252,2952,chloride channel blocker,MoA,Preclinical
2596,2952,chloride channel blocker,MoA,Preclinical
696,2952,chloride channel blocker,MoA,Preclinical
1562,2952,chloride channel blocker,MoA,Preclinical
1564,2952,chloride channel blocker,MoA,Preclinical
1565,2952,chloride channel blocker,MoA,Preclinical
1566,2952,chloride channel blocker,MoA,Preclinical
1567,2952,chloride channel blocker,MoA,Preclinical
1568,2952,chloride channel blocker,MoA,Preclinical
1569,2952,chloride channel blocker,MoA,Preclinical
1570,2952,chloride channel blocker,MoA,Preclinical
1571,2952,chloride channel blocker,MoA,Preclinical
1572,2952,chloride channel blocker,MoA,Preclinical
1573,2952,chloride channel blocker,MoA,Preclinical
1574,2952,chloride channel blocker,MoA,Preclinical
1575,2952,chloride channel blocker,MoA,Preclinical
1576,2952,chloride channel blocker,MoA,Preclinical
1577,2952,chloride channel blocker,MoA,Preclinical
1578,2952,chloride channel blocker,MoA,Preclinical
1579,2952,chloride channel blocker,MoA,Preclinical
1580,2952,chloride channel blocker,MoA,Preclinical
1581,2952,chloride channel blocker,MoA,Preclinical
1582,2952,chloride channel blocker,MoA,Preclinical
1583,2952,chloride channel blocker,MoA,Preclinical
1584,2952,chloride channel blocker,MoA,Preclinical
1585,2952,chloride channel blocker,MoA,Preclinical
1586,2952,chloride channel blocker,MoA,Preclinical
580,2952,chloride channel blocker,MoA,Preclinical
174,2952,chloride channel blocker,MoA,Preclinical
171,2952,chloride channel blocker,MoA,Preclinical
1744,2952,chloride channel blocker,MoA,Preclinical
799,2952,chloride channel blocker,MoA,Preclinical
2953,2952,chloride channel blocker,MoA,Preclinical
301,2954,Bcr-Abl kinase inhibitor,MoA,Phase 3
131,2954,Bcr-Abl kinase inhibitor,MoA,Phase 3
11,2970,serotonin receptor agonist,MoA,Phase 1
12,2970,serotonin receptor agonist,MoA,Phase 1
2592,2972,gamma secretase inhibitor,MoA,Phase 3
979,2972,gamma secretase inhibitor,MoA,Phase 3
2973,2972,gamma secretase inhibitor,MoA,Phase 3
925,2972,gamma secretase inhibitor,MoA,Phase 3
2974,2972,gamma secretase inhibitor,MoA,Phase 3
174,2972,gamma secretase inhibitor,MoA,Phase 3
171,2972,gamma secretase inhibitor,MoA,Phase 3
939,2990,VEGFR inhibitor,MoA,Phase 2
940,2990,VEGFR inhibitor,MoA,Phase 2
244,2990,VEGFR inhibitor,MoA,Phase 2
430,2990,VEGFR inhibitor,MoA,Phase 2
1753,2992,alcohol dehydrogenase inhibitor,MoA,Preclinical
1542,2992,alcohol dehydrogenase inhibitor,MoA,Preclinical
101,2995,platelet activating factor receptor antagonist,MoA,Phase 3
2077,2996,adenylyl cyclase activator,MoA,Launched
2079,2996,adenylyl cyclase activator,MoA,Launched
2997,2996,adenylyl cyclase activator,MoA,Launched
2999,3000,tubulin polymerization inhibitor|VE-cadherin antagonist,MoA,Phase 3
3007,3008,WNT5a peptide mimetic,MoA,Phase 2
639,3009,calcium channel activator,MoA,Preclinical
643,3009,calcium channel activator,MoA,Preclinical
1044,3010,RAGE receptor antagonist,MoA,Preclinical
238,3011,endothelin receptor antagonist,MoA,Phase 1
828,3012,MAP kinase inhibitor,MoA,Preclinical
829,3012,MAP kinase inhibitor,MoA,Preclinical
3013,3014,serine/threonine kinase inhibitor,MoA,Preclinical
3015,3014,serine/threonine kinase inhibitor,MoA,Preclinical
3016,3014,serine/threonine kinase inhibitor,MoA,Preclinical
3017,3014,serine/threonine kinase inhibitor,MoA,Preclinical
2237,3018,elastase inhibitor,MoA,Preclinical
1038,3018,elastase inhibitor,MoA,Preclinical
565,3026,protein arginine N-methyltransferase inhibitor,MoA,Preclinical
2342,3027,thromboxane synthase inhibitor,MoA,Phase 1
2254,3029,TGF beta receptor inhibitor,MoA,Phase 2
205,3030,acetylcholinesterase inhibitor,MoA,Preclinical
2784,3031,G protein-coupled receptor agonist,MoA,Preclinical
2784,3032,estrogen receptor antagonist,MoA,Preclinical
79,3046,GABA receptor antagonist,MoA,Preclinical
140,3046,GABA receptor antagonist,MoA,Preclinical
141,3046,GABA receptor antagonist,MoA,Preclinical
81,3046,GABA receptor antagonist,MoA,Preclinical
142,3046,GABA receptor antagonist,MoA,Preclinical
143,3046,GABA receptor antagonist,MoA,Preclinical
149,3046,GABA receptor antagonist,MoA,Preclinical
79,3049,benzodiazepine receptor agonist,MoA,Phase 3
140,3049,benzodiazepine receptor agonist,MoA,Phase 3
141,3049,benzodiazepine receptor agonist,MoA,Phase 3
81,3049,benzodiazepine receptor agonist,MoA,Phase 3
142,3049,benzodiazepine receptor agonist,MoA,Phase 3
143,3049,benzodiazepine receptor agonist,MoA,Phase 3
146,3049,benzodiazepine receptor agonist,MoA,Phase 3
3050,3049,benzodiazepine receptor agonist,MoA,Phase 3
3051,3049,benzodiazepine receptor agonist,MoA,Phase 3
3052,3049,benzodiazepine receptor agonist,MoA,Phase 3
696,3062,androgen receptor modulator,MoA,Phase 3
95,3062,androgen receptor modulator,MoA,Phase 3
185,3064,beta amyloid protein neurotoxicity inhibitor|PPAR receptor agonist,MoA,Preclinical
186,3064,beta amyloid protein neurotoxicity inhibitor|PPAR receptor agonist,MoA,Preclinical
187,3064,beta amyloid protein neurotoxicity inhibitor|PPAR receptor agonist,MoA,Preclinical
188,3064,beta amyloid protein neurotoxicity inhibitor|PPAR receptor agonist,MoA,Preclinical
190,3064,beta amyloid protein neurotoxicity inhibitor|PPAR receptor agonist,MoA,Preclinical
1616,3064,beta amyloid protein neurotoxicity inhibitor|PPAR receptor agonist,MoA,Preclinical
1617,3064,beta amyloid protein neurotoxicity inhibitor|PPAR receptor agonist,MoA,Preclinical
179,3064,beta amyloid protein neurotoxicity inhibitor|PPAR receptor agonist,MoA,Preclinical
110,3067,caspase activator,MoA,Phase 2
24,3068,benzodiazepine receptor agonist,MoA,Preclinical
26,3068,benzodiazepine receptor agonist,MoA,Preclinical
79,3068,benzodiazepine receptor agonist,MoA,Preclinical
140,3068,benzodiazepine receptor agonist,MoA,Preclinical
141,3068,benzodiazepine receptor agonist,MoA,Preclinical
142,3068,benzodiazepine receptor agonist,MoA,Preclinical
145,3068,benzodiazepine receptor agonist,MoA,Preclinical
149,3068,benzodiazepine receptor agonist,MoA,Preclinical
990,3068,benzodiazepine receptor agonist,MoA,Preclinical
1078,3068,benzodiazepine receptor agonist,MoA,Preclinical
1079,3068,benzodiazepine receptor agonist,MoA,Preclinical
1080,3068,benzodiazepine receptor agonist,MoA,Preclinical
1784,3068,benzodiazepine receptor agonist,MoA,Preclinical
174,3069,cyclooxygenase inhibitor|prostanoid receptor agonist,MoA,Phase 2
171,3069,cyclooxygenase inhibitor|prostanoid receptor agonist,MoA,Phase 2
79,3070,GABA receptor modulator,MoA,Phase 3
140,3070,GABA receptor modulator,MoA,Phase 3
141,3070,GABA receptor modulator,MoA,Phase 3
81,3070,GABA receptor modulator,MoA,Phase 3
142,3070,GABA receptor modulator,MoA,Phase 3
143,3070,GABA receptor modulator,MoA,Phase 3
507,3071,HSP inhibitor,MoA,Phase 3
3072,3073,GLI antagonist,MoA,Preclinical
3072,3074,GLI antagonist,MoA,Preclinical
3075,3074,GLI antagonist,MoA,Preclinical
996,3077,glutamate receptor antagonist,MoA,Phase 3
153,3077,glutamate receptor antagonist,MoA,Phase 3
154,3077,glutamate receptor antagonist,MoA,Phase 3
155,3077,glutamate receptor antagonist,MoA,Phase 3
156,3077,glutamate receptor antagonist,MoA,Phase 3
157,3077,glutamate receptor antagonist,MoA,Phase 3
158,3077,glutamate receptor antagonist,MoA,Phase 3
159,3077,glutamate receptor antagonist,MoA,Phase 3
1047,3078,dopamine reuptake inhibitor,MoA,Preclinical
620,3078,dopamine reuptake inhibitor,MoA,Preclinical
620,3079,dopamine reuptake inhibitor,MoA,Preclinical
49,3080,AKT inhibitor,MoA,Phase 3
749,3080,AKT inhibitor,MoA,Phase 3
750,3080,AKT inhibitor,MoA,Phase 3
3081,3080,AKT inhibitor,MoA,Phase 3
1015,3082,XIAP inhibitor,MoA,Phase 1
1017,3082,XIAP inhibitor,MoA,Phase 1
3083,3082,XIAP inhibitor,MoA,Phase 1
1018,3082,XIAP inhibitor,MoA,Phase 1
474,3084,Pim kinase inhibitor,MoA,Phase 1
354,3085,selective estrogen receptor destabilizer,MoA,Phase 2
134,3086,Bruton's tyrosine kinase (BTK) inhibitor,MoA,Phase 1
946,3087,RAF inhibitor,MoA,Preclinical
474,3088,PI3K inhibitor,MoA,Phase 2
136,3088,PI3K inhibitor,MoA,Phase 2
138,3088,PI3K inhibitor,MoA,Phase 2
476,3088,PI3K inhibitor,MoA,Phase 2
2337,3089,mTOR inhibitor|PI3K inhibitor,MoA,Phase 2
3090,3089,mTOR inhibitor|PI3K inhibitor,MoA,Phase 2
781,3089,mTOR inhibitor|PI3K inhibitor,MoA,Phase 2
474,3089,mTOR inhibitor|PI3K inhibitor,MoA,Phase 2
136,3089,mTOR inhibitor|PI3K inhibitor,MoA,Phase 2
138,3089,mTOR inhibitor|PI3K inhibitor,MoA,Phase 2
476,3089,mTOR inhibitor|PI3K inhibitor,MoA,Phase 2
1125,3089,mTOR inhibitor|PI3K inhibitor,MoA,Phase 2
828,3091,MAP kinase inhibitor,MoA,Phase 1
829,3091,MAP kinase inhibitor,MoA,Phase 1
507,3092,HSP inhibitor,MoA,Preclinical
507,3094,HSP inhibitor,MoA,Preclinical
2688,3096,apoptosis inhibitor|DNA synthesis inhibitor,MoA,Phase 1
1555,3096,apoptosis inhibitor|DNA synthesis inhibitor,MoA,Phase 1
1548,3096,apoptosis inhibitor|DNA synthesis inhibitor,MoA,Phase 1
1212,3099,GLP receptor agonist,MoA,Preclinical
752,3100,tyrosine kinase inhibitor,MoA,Phase 2/Phase 3
354,3100,tyrosine kinase inhibitor,MoA,Phase 2/Phase 3
116,3100,tyrosine kinase inhibitor,MoA,Phase 2/Phase 3
2271,3100,tyrosine kinase inhibitor,MoA,Phase 2/Phase 3
2273,3100,tyrosine kinase inhibitor,MoA,Phase 2/Phase 3
356,3100,tyrosine kinase inhibitor,MoA,Phase 2/Phase 3
2091,3100,tyrosine kinase inhibitor,MoA,Phase 2/Phase 3
3101,3100,tyrosine kinase inhibitor,MoA,Phase 2/Phase 3
200,3100,tyrosine kinase inhibitor,MoA,Phase 2/Phase 3
3102,3100,tyrosine kinase inhibitor,MoA,Phase 2/Phase 3
232,3100,tyrosine kinase inhibitor,MoA,Phase 2/Phase 3
1744,3100,tyrosine kinase inhibitor,MoA,Phase 2/Phase 3
155,3105,glutamate receptor downregulator,MoA,Phase 3
2646,3106,glucosylceramidase inhibitor,MoA,Preclinical
230,3107,topoisomerase inhibitor,MoA,Phase 1
789,3109,PKC inhibitor,MoA,Preclinical
289,3109,PKC inhibitor,MoA,Preclinical
919,3109,PKC inhibitor,MoA,Preclinical
361,3109,PKC inhibitor,MoA,Preclinical
3110,3111,gamma glutamyltransferase Inhibitor,MoA,Preclinical
3112,3113,GGTase inhibitor,MoA,Preclinical
128,3114,FLT3 inhibitor,MoA,Launched
690,3116,GABA receptor antagonist,MoA,Preclinical
996,3116,GABA receptor antagonist,MoA,Preclinical
690,3117,platelet activating factor receptor antagonist,MoA,Phase 3
994,3117,platelet activating factor receptor antagonist,MoA,Phase 3
995,3117,platelet activating factor receptor antagonist,MoA,Phase 3
996,3117,platelet activating factor receptor antagonist,MoA,Phase 3
77,3117,platelet activating factor receptor antagonist,MoA,Phase 3
957,3117,platelet activating factor receptor antagonist,MoA,Phase 3
171,3118,NFkB pathway inhibitor|nitric oxide synthase inhibitor,MoA,Phase 1
617,3119,angiogenesis inhibitor|apoptosis stimulant,MoA,Launched
247,3120,HDAC inhibitor,MoA,Phase 3
249,3120,HDAC inhibitor,MoA,Phase 3
250,3120,HDAC inhibitor,MoA,Phase 3
1145,3120,HDAC inhibitor,MoA,Phase 3
1146,3120,HDAC inhibitor,MoA,Phase 3
251,3120,HDAC inhibitor,MoA,Phase 3
1147,3120,HDAC inhibitor,MoA,Phase 3
252,3120,HDAC inhibitor,MoA,Phase 3
1148,3120,HDAC inhibitor,MoA,Phase 3
3121,3122,glucokinase activator,MoA,Preclinical
3123,3124,NADPH oxidase inhibitor,MoA,Phase 2
757,3124,NADPH oxidase inhibitor,MoA,Phase 2
3125,3126,transglutaminase inhibitor,MoA,Preclinical
752,3127,DeltaF508-CFTR Correctors,MoA,Withdrawn
696,3132,androgen receptor modulator,MoA,Phase 1
696,3133,androgen receptor modulator,MoA,Phase 1
3137,3138,antioxidant,MoA,Phase 3
3110,3138,antioxidant,MoA,Phase 3
1087,3138,antioxidant,MoA,Phase 3
3139,3138,antioxidant,MoA,Phase 3
3140,3138,antioxidant,MoA,Phase 3
3141,3138,antioxidant,MoA,Phase 3
3142,3138,antioxidant,MoA,Phase 3
3143,3138,antioxidant,MoA,Phase 3
3144,3138,antioxidant,MoA,Phase 3
3145,3138,antioxidant,MoA,Phase 3
3146,3138,antioxidant,MoA,Phase 3
3147,3138,antioxidant,MoA,Phase 3
3148,3138,antioxidant,MoA,Phase 3
1609,3138,antioxidant,MoA,Phase 3
211,3138,antioxidant,MoA,Phase 3
3149,3138,antioxidant,MoA,Phase 3
3150,3138,antioxidant,MoA,Phase 3
3151,3138,antioxidant,MoA,Phase 3
3152,3138,antioxidant,MoA,Phase 3
3153,3138,antioxidant,MoA,Phase 3
3154,3138,antioxidant,MoA,Phase 3
3155,3138,antioxidant,MoA,Phase 3
3156,3138,antioxidant,MoA,Phase 3
3157,3138,antioxidant,MoA,Phase 3
3158,3138,antioxidant,MoA,Phase 3
3159,3138,antioxidant,MoA,Phase 3
3160,3138,antioxidant,MoA,Phase 3
3161,3138,antioxidant,MoA,Phase 3
1911,3138,antioxidant,MoA,Phase 3
3162,3138,antioxidant,MoA,Phase 3
3163,3138,antioxidant,MoA,Phase 3
3164,3138,antioxidant,MoA,Phase 3
3165,3138,antioxidant,MoA,Phase 3
3166,3138,antioxidant,MoA,Phase 3
3167,3138,antioxidant,MoA,Phase 3
3168,3138,antioxidant,MoA,Phase 3
3169,3138,antioxidant,MoA,Phase 3
3170,3138,antioxidant,MoA,Phase 3
672,3172,tumor necrosis factor release inhibitor,MoA,Phase 3
856,3174,immunophilin ligand,MoA,Preclinical
2922,3175,NAMPT inhibitor,MoA,Phase 1/Phase 2
301,3176,Bcr-Abl kinase inhibitor,MoA,Preclinical
1083,3176,Bcr-Abl kinase inhibitor,MoA,Preclinical
301,3177,Bcr-Abl kinase inhibitor,MoA,Preclinical
1083,3177,Bcr-Abl kinase inhibitor,MoA,Preclinical
631,3178,growth factor receptor inhibitor,MoA,Preclinical
632,3178,growth factor receptor inhibitor,MoA,Preclinical
2698,3178,growth factor receptor inhibitor,MoA,Preclinical
3121,3179,glucokinase inhibitor|protein kinase inhibitor,MoA,Preclinical
330,3179,glucokinase inhibitor|protein kinase inhibitor,MoA,Preclinical
510,3180,opioid receptor antagonist,MoA,Preclinical
511,3180,opioid receptor antagonist,MoA,Preclinical
1284,3181,protein kinase inhibitor,MoA,Preclinical
1699,3181,protein kinase inhibitor,MoA,Preclinical
358,3181,protein kinase inhibitor,MoA,Preclinical
2702,3181,protein kinase inhibitor,MoA,Preclinical
361,3181,protein kinase inhibitor,MoA,Preclinical
3182,3183,ARF inhibitor,MoA,Preclinical
244,3184,VEGFR inhibitor,MoA,Phase 2
430,3184,VEGFR inhibitor,MoA,Phase 2
110,3187,BCL inhibitor|MCL1 inhibitor,MoA,Phase 2
1215,3188,G protein-coupled receptor agonist,MoA,Preclinical
856,3189,FKBP inhibitor,MoA,Preclinical
2922,3190,NAMPT inhibitor,MoA,Preclinical
389,3191,G protein-coupled receptor modulator,MoA,Preclinical
521,3192,cannabinoid receptor agonist,MoA,Preclinical
521,3193,cannabinoid receptor agonist,MoA,Preclinical
8,3194,dopamine receptor antagonist,MoA,Preclinical
490,3195,serotonin receptor antagonist,MoA,Preclinical
11,3196,serotonin receptor antagonist,MoA,Preclinical
12,3196,serotonin receptor antagonist,MoA,Preclinical
13,3196,serotonin receptor antagonist,MoA,Preclinical
488,3196,serotonin receptor antagonist,MoA,Preclinical
489,3196,serotonin receptor antagonist,MoA,Preclinical
14,3196,serotonin receptor antagonist,MoA,Preclinical
15,3196,serotonin receptor antagonist,MoA,Preclinical
16,3196,serotonin receptor antagonist,MoA,Preclinical
624,3196,serotonin receptor antagonist,MoA,Preclinical
2573,3197,integrin antagonist,MoA,Preclinical
898,3197,integrin antagonist,MoA,Preclinical
3198,3199,tachykinin antagonist,MoA,Preclinical
78,3199,tachykinin antagonist,MoA,Preclinical
1718,3200,estrogen receptor agonist|FXR antagonist|progesterone receptor agonist,MoA,Launched
69,3201,adenosine receptor agonist,MoA,Phase 1
275,3201,adenosine receptor agonist,MoA,Phase 1
490,3206,serotonin receptor antagonist,MoA,Preclinical
13,3207,serotonin receptor agonist,MoA,Preclinical
3208,3209,ubiquitin ligase inhibitor,MoA,Preclinical
870,3209,ubiquitin ligase inhibitor,MoA,Preclinical
24,3210,GABA receptor modulator,MoA,Preclinical
69,3211,adenosine receptor antagonist,MoA,Phase 1
275,3211,adenosine receptor antagonist,MoA,Phase 1
276,3211,adenosine receptor antagonist,MoA,Phase 1
277,3211,adenosine receptor antagonist,MoA,Phase 1
2520,3212,toll-like receptor agonist,MoA,Phase 2
1125,3213,SYK inhibitor,MoA,Phase 2
3214,3215,histone demethylase inhibitor,MoA,Preclinical
3216,3217,histone lysine demethylase inhibitor,MoA,Preclinical
3214,3217,histone lysine demethylase inhibitor,MoA,Preclinical
3218,3219,histone lysine demethylase inhibitor,MoA,Preclinical
30,3220,glycogen synthase kinase inhibitor|lipoxygenase inhibitor,MoA,Preclinical
32,3220,glycogen synthase kinase inhibitor|lipoxygenase inhibitor,MoA,Preclinical
1220,3221,PPAR receptor antagonist,MoA,Preclinical
476,3222,PI3K inhibitor,MoA,Phase 1
452,3223,Aurora kinase inhibitor,MoA,Phase 1
563,3223,Aurora kinase inhibitor,MoA,Phase 1
564,3223,Aurora kinase inhibitor,MoA,Phase 1
1820,3223,Aurora kinase inhibitor,MoA,Phase 1
421,3223,Aurora kinase inhibitor,MoA,Phase 1
3224,3225,glucose dependent insulinotropic receptor agonist,MoA,Phase 2
132,3226,urotensin receptor antagonist,MoA,Preclinical
11,3227,serotonin receptor antagonist,MoA,Phase 2
12,3227,serotonin receptor antagonist,MoA,Phase 2
13,3227,serotonin receptor antagonist,MoA,Phase 2
309,3228,insulin growth factor receptor inhibitor,MoA,Preclinical
364,3228,insulin growth factor receptor inhibitor,MoA,Preclinical
1672,3228,insulin growth factor receptor inhibitor,MoA,Preclinical
1224,3228,insulin growth factor receptor inhibitor,MoA,Preclinical
364,3229,IGF-1 inhibitor|insulin growth factor receptor inhibitor|insulin receptor ligand,MoA,Preclinical
1672,3229,IGF-1 inhibitor|insulin growth factor receptor inhibitor|insulin receptor ligand,MoA,Preclinical
49,3230,AKT inhibitor,MoA,Phase 2
749,3230,AKT inhibitor,MoA,Phase 2
750,3230,AKT inhibitor,MoA,Phase 2
781,3231,mTOR inhibitor|PI3K inhibitor,MoA,Phase 1
474,3231,mTOR inhibitor|PI3K inhibitor,MoA,Phase 1
136,3231,mTOR inhibitor|PI3K inhibitor,MoA,Phase 1
138,3231,mTOR inhibitor|PI3K inhibitor,MoA,Phase 1
476,3231,mTOR inhibitor|PI3K inhibitor,MoA,Phase 1
680,3232,lipoxygenase inhibitor,MoA,Phase 2
1552,3233,transient receptor potential channel antagonist,MoA,Preclinical
1674,3234,fatty acid synthase inhibitor,MoA,Preclinical
3235,3236,epoxide hydolase inhibitor,MoA,Phase 1
3237,3238,bile acid transporter inhibitor,MoA,Phase 2
452,3239,phosphoinositide dependent kinase inhibitor,MoA,Preclinical
563,3239,phosphoinositide dependent kinase inhibitor,MoA,Preclinical
789,3239,phosphoinositide dependent kinase inhibitor,MoA,Preclinical
18,3240,phosphodiesterase inhibitor,MoA,Phase 2
2232,3241,leucine rich repeat kinase inhibitor,MoA,Preclinical
3242,3243,protein kinase inhibitor,MoA,Preclinical
3244,3243,protein kinase inhibitor,MoA,Preclinical
136,3245,PI3K inhibitor,MoA,Phase 2
839,3246,rho associated kinase inhibitor,MoA,Preclinical
912,3246,rho associated kinase inhibitor,MoA,Preclinical
3247,3248,bromodomain inhibitor,MoA,Preclinical
3249,3248,bromodomain inhibitor,MoA,Preclinical
2121,3250,histone lysine methyltransferase inhibitor,MoA,Phase 1
3251,3252,protein phosphatase inhibitor,MoA,Preclinical
2005,3253,lactate dehydrogenase inhibitor,MoA,Preclinical
3218,3254,histone lysine demethylase inhibitor,MoA,Phase 1/Phase 2
389,3255,free fatty acid receptor agonist,MoA,Preclinical
1220,3256,PPAR receptor antagonist,MoA,Preclinical
839,3257,rho associated kinase inhibitor,MoA,Preclinical
1228,3258,PLK inhibitor,MoA,Phase 1
2121,3259,histone lysine methyltransferase inhibitor,MoA,Preclinical
1705,3260,serum/glucocorticoid regulated kinase inhibitor,MoA,Preclinical
3261,3260,serum/glucocorticoid regulated kinase inhibitor,MoA,Preclinical
49,3262,AKT inhibitor,MoA,Phase 1
749,3262,AKT inhibitor,MoA,Phase 1
750,3262,AKT inhibitor,MoA,Phase 1
3017,3262,AKT inhibitor,MoA,Phase 1
3263,3262,AKT inhibitor,MoA,Phase 1
3264,3262,AKT inhibitor,MoA,Phase 1
360,3262,AKT inhibitor,MoA,Phase 1
3081,3262,AKT inhibitor,MoA,Phase 1
3265,3262,AKT inhibitor,MoA,Phase 1
423,3266,glucocorticoid receptor agonist,MoA,Preclinical
3267,3268,centromere associated protein inhibitor,MoA,Phase 1
126,3269,FLT3 inhibitor|tyrosine kinase inhibitor,MoA,Preclinical
128,3269,FLT3 inhibitor|tyrosine kinase inhibitor,MoA,Preclinical
129,3269,FLT3 inhibitor|tyrosine kinase inhibitor,MoA,Preclinical
131,3269,FLT3 inhibitor|tyrosine kinase inhibitor,MoA,Preclinical
43,3270,cholinergic receptor agonist,MoA,Phase 1/Phase 2
598,3277,nitric oxide synthase inhibitor,MoA,Phase 2
2130,3278,creatine kinase inhibitor,MoA,Phase 2
3280,3281,oxoeicosanoid receptor modulator,MoA,Preclinical
1784,3282,GABA uptake inhibitor,MoA,Preclinical
3283,3282,GABA uptake inhibitor,MoA,Preclinical
3284,3282,GABA uptake inhibitor,MoA,Preclinical
3285,3282,GABA uptake inhibitor,MoA,Preclinical
1220,3286,PPAR receptor agonist,MoA,Preclinical
483,3287,G protein-coupled receptor agonist,MoA,Preclinical
200,3288,PPAR receptor agonist,MoA,Preclinical
126,3289,cFMS kinase inhibitor,MoA,Preclinical
1038,3290,elastase inhibitor|leukocyte elastase inhibitor,MoA,Phase 1
3291,3292,LXR agonist,MoA,Preclinical
3293,3292,LXR agonist,MoA,Preclinical
521,3294,cannabinoid receptor agonist,MoA,Preclinical
1718,3295,FXR agonist,MoA,Preclinical
1707,3296,neuropeptide receptor antagonist,MoA,Preclinical
631,3297,growth factor receptor inhibitor,MoA,Preclinical
1218,3298,PPAR receptor agonist,MoA,Phase 2
1220,3298,PPAR receptor agonist,MoA,Phase 2
631,3299,leucine rich repeat kinase inhibitor|RAF inhibitor,MoA,Phase 1/Phase 2
948,3299,leucine rich repeat kinase inhibitor|RAF inhibitor,MoA,Phase 1/Phase 2
1243,3300,calcium channel activator,MoA,Preclinical
346,3301,EGFR inhibitor,MoA,Preclinical
348,3301,EGFR inhibitor,MoA,Preclinical
498,3302,prostanoid receptor antagonist,MoA,Preclinical
1218,3303,PPAR receptor antagonist,MoA,Preclinical
1218,3304,PPAR receptor agonist,MoA,Preclinical
1283,3305,ALK tyrosine kinase receptor inhibitor,MoA,Preclinical
405,3305,ALK tyrosine kinase receptor inhibitor,MoA,Preclinical
2840,3305,ALK tyrosine kinase receptor inhibitor,MoA,Preclinical
617,3306,melanin inhibitor,MoA,Phase 1
3307,3306,melanin inhibitor,MoA,Phase 1
521,3308,cannabinoid receptor agonist,MoA,Phase 2
1228,3309,PLK inhibitor,MoA,Preclinical
1230,3309,PLK inhibitor,MoA,Preclinical
483,3310,free fatty acid receptor agonist|G protein-coupled receptor agonist,MoA,Preclinical
389,3310,free fatty acid receptor agonist|G protein-coupled receptor agonist,MoA,Preclinical
3101,3311,PPAR receptor antagonist,MoA,Preclinical
200,3311,PPAR receptor antagonist,MoA,Preclinical
224,3311,PPAR receptor antagonist,MoA,Preclinical
665,3312,glutamate receptor antagonist,MoA,Preclinical
663,3312,glutamate receptor antagonist,MoA,Preclinical
667,3312,glutamate receptor antagonist,MoA,Preclinical
668,3312,glutamate receptor antagonist,MoA,Preclinical
301,3313,Bcr-Abl kinase inhibitor,MoA,Preclinical
1083,3313,Bcr-Abl kinase inhibitor,MoA,Preclinical
2677,3314,tankyrase inhibitor,MoA,Preclinical
2679,3314,tankyrase inhibitor,MoA,Preclinical
1777,3315,PKA inhibitor,MoA,Preclinical
51,3315,PKA inhibitor,MoA,Preclinical
52,3315,PKA inhibitor,MoA,Preclinical
921,3316,autotaxin inhibitor,MoA,Preclinical
665,3317,glutamate receptor agonist,MoA,Preclinical
665,3318,glutamate receptor antagonist,MoA,Preclinical
357,3324,phospholipase inhibitor,MoA,Phase 2
1775,3324,phospholipase inhibitor,MoA,Phase 2
569,3331,monoamine oxidase inhibitor,MoA,Preclinical
1248,3331,monoamine oxidase inhibitor,MoA,Preclinical
110,3332,BCL inhibitor,MoA,Preclinical
67,3333,TRPA1 channel blocker,MoA,Phase 1
1552,3334,transient receptor potential channel antagonist,MoA,Preclinical
3335,3336,ubiquitin ligase inhibitor,MoA,Preclinical
3337,3336,ubiquitin ligase inhibitor,MoA,Preclinical
3338,3336,ubiquitin ligase inhibitor,MoA,Preclinical
69,3339,adenosine receptor agonist,MoA,Preclinical
275,3339,adenosine receptor agonist,MoA,Preclinical
276,3339,adenosine receptor agonist,MoA,Preclinical
277,3339,adenosine receptor agonist,MoA,Preclinical
563,3341,Aurora kinase inhibitor,MoA,Preclinical
63,3342,ACAT inhibitor,MoA,Launched
3343,3342,ACAT inhibitor,MoA,Launched
2856,3342,ACAT inhibitor,MoA,Launched
3344,3342,ACAT inhibitor,MoA,Launched
563,3345,flavanone glycoside,MoA,Launched
381,3345,flavanone glycoside,MoA,Launched
207,3348,cholinergic receptor antagonist,MoA,Preclinical
59,3348,cholinergic receptor antagonist,MoA,Preclinical
61,3348,cholinergic receptor antagonist,MoA,Preclinical
2226,3348,cholinergic receptor antagonist,MoA,Preclinical
49,3349,AKT inhibitor|differentiation inducer|NFKB pathway inhibitor,MoA,Phase 2
417,3356,adrenergic receptor agonist,MoA,Phase 1
2778,3358,GTPase inhibitor,MoA,Preclinical
346,3359,EGFR inhibitor,MoA,Phase 1
2752,3360,protein arginine N-methyltransferase inhibitor,MoA,Preclinical
1228,3361,PLK inhibitor,MoA,Phase 1
153,3366,glutamate receptor agonist,MoA,Preclinical
154,3366,glutamate receptor agonist,MoA,Preclinical
155,3366,glutamate receptor agonist,MoA,Preclinical
156,3366,glutamate receptor agonist,MoA,Preclinical
157,3366,glutamate receptor agonist,MoA,Preclinical
403,3367,AKT inhibitor,MoA,Phase 3
174,3367,AKT inhibitor,MoA,Phase 3
171,3367,AKT inhibitor,MoA,Phase 3
3368,3369,protein kinase inhibitor,MoA,Preclinical
623,3370,histamine receptor agonist,MoA,Preclinical
205,3371,acetylcholinesterase inhibitor,MoA,Phase 2
51,3392,rho associated kinase inhibitor,MoA,Preclinical
52,3392,rho associated kinase inhibitor,MoA,Preclinical
839,3392,rho associated kinase inhibitor,MoA,Preclinical
460,3394,progesterone receptor agonist,MoA,Launched
205,3395,cholinesterase inhibitor,MoA,Preclinical
569,3398,monoamine oxidase inhibitor,MoA,Phase 2
1248,3398,monoamine oxidase inhibitor,MoA,Phase 2
407,3400,aldose reductase inhibitor,MoA,Preclinical
255,3400,aldose reductase inhibitor,MoA,Preclinical
212,3401,IKK inhibitor,MoA,Phase 1
698,3401,IKK inhibitor,MoA,Phase 1
672,3401,IKK inhibitor,MoA,Phase 1
253,3402,PARP inhibitor,MoA,Preclinical
1339,3403,lysophosphatidic acid receptor antagonist,MoA,Preclinical
3404,3403,lysophosphatidic acid receptor antagonist,MoA,Preclinical
3405,3406,bromodomain inhibitor,MoA,Phase 2
736,3406,bromodomain inhibitor,MoA,Phase 2
836,3406,bromodomain inhibitor,MoA,Phase 2
3405,3407,bromodomain inhibitor,MoA,Preclinical
736,3407,bromodomain inhibitor,MoA,Preclinical
836,3407,bromodomain inhibitor,MoA,Preclinical
3408,3409,bromodomain inhibitor,MoA,Preclinical
3410,3411,bromodomain inhibitor,MoA,Preclinical
2167,3411,bromodomain inhibitor,MoA,Preclinical
69,3412,adenosine receptor agonist,MoA,Phase 3
275,3412,adenosine receptor agonist,MoA,Phase 3
276,3412,adenosine receptor agonist,MoA,Phase 3
277,3412,adenosine receptor agonist,MoA,Phase 3
219,3414,hydroxycarboxylic acid receptor agonist,MoA,Preclinical
69,3415,phosphodiesterase inhibitor,MoA,Preclinical
1123,3415,phosphodiesterase inhibitor,MoA,Preclinical
604,3415,phosphodiesterase inhibitor,MoA,Preclinical
22,3415,phosphodiesterase inhibitor,MoA,Preclinical
23,3415,phosphodiesterase inhibitor,MoA,Preclinical
2497,3415,phosphodiesterase inhibitor,MoA,Preclinical
1421,3415,phosphodiesterase inhibitor,MoA,Preclinical
1523,3415,phosphodiesterase inhibitor,MoA,Preclinical
1525,3415,phosphodiesterase inhibitor,MoA,Preclinical
153,3416,glutamate receptor agonist,MoA,Preclinical
1417,3417,lipoprotein lipase activator,MoA,Phase 2
3424,3425,growth hormone secretagogue receptor agonist,MoA,Phase 2
687,3425,growth hormone secretagogue receptor agonist,MoA,Phase 2
629,3427,voltage-gated potassium channel activator,MoA,Preclinical
630,3427,voltage-gated potassium channel activator,MoA,Preclinical
629,3428,voltage-gated potassium channel activator,MoA,Preclinical
444,3429,sodium channel blocker,MoA,Preclinical
446,3429,sodium channel blocker,MoA,Preclinical
23,3430,phosphodiesterase inhibitor,MoA,Phase 3
23,3431,PPAR receptor antagonist,MoA,Phase 3
1596,3434,beta-catenin inhibitor,MoA,Preclinical
417,3435,adrenergic receptor antagonist,MoA,Phase 2
567,3435,adrenergic receptor antagonist,MoA,Phase 2
99,3436,histamine receptor antagonist,MoA,Phase 1
1917,3437,thromboxane receptor antagonist,MoA,Phase 2
1820,3438,opioid receptor agonist,MoA,Preclinical
339,3438,opioid receptor agonist,MoA,Preclinical
510,3438,opioid receptor agonist,MoA,Preclinical
511,3438,opioid receptor agonist,MoA,Preclinical
132,3438,opioid receptor agonist,MoA,Preclinical
567,3439,adrenergic receptor agonist,MoA,Preclinical
165,3440,adrenergic receptor antagonist,MoA,Phase 1
417,3440,adrenergic receptor antagonist,MoA,Phase 1
67,3441,TRPV agonist,MoA,Phase 1
694,3441,TRPV agonist,MoA,Phase 1
3442,3443,mucin production enhancer,MoA,Phase 3
1596,3448,beta catenin inhibitor|WNT signaling inhibitor,MoA,Preclinical
3449,3448,beta catenin inhibitor|WNT signaling inhibitor,MoA,Preclinical
2251,3450,casein kinase inhibitor,MoA,Preclinical
2253,3450,casein kinase inhibitor,MoA,Preclinical
3451,3450,casein kinase inhibitor,MoA,Preclinical
1876,3450,casein kinase inhibitor,MoA,Preclinical
3452,3453,insulin sensitizer,MoA,Phase 1
624,3454,serotonin receptor antagonist,MoA,Phase 3
546,3456,MDM inhibitor,MoA,Phase 3
761,3456,MDM inhibitor,MoA,Phase 3
1,3457,adrenergic receptor antagonist,MoA,Phase 3
171,3457,adrenergic receptor antagonist,MoA,Phase 3
2706,3459,"indoleamine 2,3-dioxygenase inhibitor",MoA,Preclinical
665,3460,glutamate receptor positive allosteric modulator,MoA,Preclinical
663,3460,glutamate receptor positive allosteric modulator,MoA,Preclinical
667,3460,glutamate receptor positive allosteric modulator,MoA,Preclinical
668,3460,glutamate receptor positive allosteric modulator,MoA,Preclinical
3461,3462,XIAP inhibitor,MoA,Phase 3
3463,3462,XIAP inhibitor,MoA,Phase 3
663,3464,glutamate receptor antagonist,MoA,Preclinical
665,3465,glutamate receptor antagonist,MoA,Preclinical
155,3466,adrenergic receptor antagonist|glutamate receptor antagonist,MoA,Launched
633,3468,sigma receptor agonist,MoA,Phase 2
212,3470,IKK inhibitor,MoA,Preclinical
212,3471,IKK inhibitor|SYK inhibitor,MoA,Preclinical
212,3472,IKK inhibitor|NFkB pathway inhibitor,MoA,Phase 1
3473,3474,matrix metalloprotease inhibitor,MoA,Phase 3
1108,3474,matrix metalloprotease inhibitor,MoA,Phase 3
766,3474,matrix metalloprotease inhibitor,MoA,Phase 3
197,3474,matrix metalloprotease inhibitor,MoA,Phase 3
767,3474,matrix metalloprotease inhibitor,MoA,Phase 3
2726,3474,matrix metalloprotease inhibitor,MoA,Phase 3
1112,3474,matrix metalloprotease inhibitor,MoA,Phase 3
1826,3474,matrix metalloprotease inhibitor,MoA,Phase 3
1113,3474,matrix metalloprotease inhibitor,MoA,Phase 3
84,3474,matrix metalloprotease inhibitor,MoA,Phase 3
100,3478,histamine receptor agonist,MoA,Preclinical
623,3478,histamine receptor agonist,MoA,Preclinical
1,3481,adrenergic receptor antagonist,MoA,Phase 1
3,3481,adrenergic receptor antagonist,MoA,Phase 1
100,3485,histamine receptor agonist,MoA,Preclinical
623,3485,histamine receptor agonist,MoA,Preclinical
100,3486,histamine receptor agonist,MoA,Phase 1
100,3487,histamine receptor antagonist,MoA,Preclinical
430,3488,c-Met inhibitor,MoA,Phase 3
2722,3489,calcineurin inhibitor,MoA,Preclinical
1306,3490,CC chemokine receptor antagonist,MoA,Phase 2
410,3492,selective serotonin reuptake inhibitor (SSRI),MoA,Withdrawn
569,3494,norepinephrine transporter inhibitor,MoA,Preclinical
1248,3494,norepinephrine transporter inhibitor,MoA,Preclinical
2091,3495,PPAR receptor agonist,MoA,Phase 2
1218,3495,PPAR receptor agonist,MoA,Phase 2
1220,3495,PPAR receptor agonist,MoA,Phase 2
200,3495,PPAR receptor agonist,MoA,Phase 2
79,3497,benzodiazepine receptor agonist,MoA,Phase 3
512,3498,CDK inhibitor|glycogen synthase kinase inhibitor,MoA,Phase 2/Phase 3
514,3498,CDK inhibitor|glycogen synthase kinase inhibitor,MoA,Phase 2/Phase 3
30,3498,CDK inhibitor|glycogen synthase kinase inhibitor,MoA,Phase 2/Phase 3
512,3499,CDK inhibitor|glycogen synthase kinase inhibitor,MoA,Preclinical
371,3499,CDK inhibitor|glycogen synthase kinase inhibitor,MoA,Preclinical
514,3499,CDK inhibitor|glycogen synthase kinase inhibitor,MoA,Preclinical
3500,3499,CDK inhibitor|glycogen synthase kinase inhibitor,MoA,Preclinical
32,3499,CDK inhibitor|glycogen synthase kinase inhibitor,MoA,Preclinical
185,3501,CDK inhibitor,MoA,Phase 2
186,3501,CDK inhibitor,MoA,Phase 2
187,3501,CDK inhibitor,MoA,Phase 2
188,3501,CDK inhibitor,MoA,Phase 2
1616,3501,CDK inhibitor,MoA,Phase 2
191,3501,CDK inhibitor,MoA,Phase 2
1617,3501,CDK inhibitor,MoA,Phase 2
900,3504,"aryl hydrocarbon receptor agonist|indoleamine 2,3-dioxygenase inhibitor",MoA,Phase 2/Phase 3
3507,3508,cyclooxygenase inhibitor|prostanoid receptor antagonist,MoA,Withdrawn
1011,3508,cyclooxygenase inhibitor|prostanoid receptor antagonist,MoA,Withdrawn
174,3508,cyclooxygenase inhibitor|prostanoid receptor antagonist,MoA,Withdrawn
171,3508,cyclooxygenase inhibitor|prostanoid receptor antagonist,MoA,Withdrawn
2706,3510,"indoleamine 2,3-dioxygenase inhibitor",MoA,Phase 2
3513,3514,Hec1 inhibitor,MoA,Preclinical
366,3515,PARP inhibitor,MoA,Phase 3
366,3516,neurotrophic agent,MoA,Launched
253,3516,neurotrophic agent,MoA,Launched
1215,3519,FXR agonist,MoA,Phase 1
896,3520,integrin antagonist,MoA,Phase 1
3521,3520,integrin antagonist,MoA,Phase 1
100,3523,histamine receptor antagonist,MoA,Preclinical
623,3523,histamine receptor antagonist,MoA,Preclinical
752,3524,CFTR channel antagonist,MoA,Phase 2
2324,3525,histone demethylase inhibitor,MoA,Preclinical
3526,3525,histone demethylase inhibitor,MoA,Preclinical
3527,3525,histone demethylase inhibitor,MoA,Preclinical
3214,3525,histone demethylase inhibitor,MoA,Preclinical
2324,3528,hypoxia inducible factor inhibitor,MoA,Preclinical
2310,3528,hypoxia inducible factor inhibitor,MoA,Preclinical
3529,3528,hypoxia inducible factor inhibitor,MoA,Preclinical
3013,3530,p21 activated kinase inhibitor,MoA,Preclinical
205,3531,acetylcholinesterase inhibitor,MoA,Phase 3
569,3534,monoamine oxidase inhibitor,MoA,Withdrawn
1248,3534,monoamine oxidase inhibitor,MoA,Withdrawn
11,3535,serotonin receptor agonist,MoA,Phase 3
240,3539,endothelin receptor antagonist,MoA,Preclinical
188,3540,steroid sulfatase inhibitor,MoA,Phase 2
3541,3540,steroid sulfatase inhibitor,MoA,Phase 2
11,3543,adrenergic receptor antagonist,MoA,Phase 1
12,3543,adrenergic receptor antagonist,MoA,Phase 1
421,3544,cytochrome P450 inhibitor,MoA,Phase 3
1509,3545,macrophage migration inhibiting factor inhibitor,MoA,Preclinical
3546,3547,gene expression stimulant,MoA,Phase 2
3548,3547,gene expression stimulant,MoA,Phase 2
79,3554,benzodiazepine receptor agonist,MoA,Preclinical
140,3554,benzodiazepine receptor agonist,MoA,Preclinical
141,3554,benzodiazepine receptor agonist,MoA,Preclinical
81,3554,benzodiazepine receptor agonist,MoA,Preclinical
142,3554,benzodiazepine receptor agonist,MoA,Preclinical
143,3554,benzodiazepine receptor agonist,MoA,Preclinical
3050,3554,benzodiazepine receptor agonist,MoA,Preclinical
3051,3554,benzodiazepine receptor agonist,MoA,Preclinical
3052,3554,benzodiazepine receptor agonist,MoA,Preclinical
24,3555,guanylate cyclase activator,MoA,Preclinical
174,3566,cyclooxygenase inhibitor,MoA,Withdrawn
171,3566,cyclooxygenase inhibitor,MoA,Withdrawn
821,3568,kinesin inhibitor,MoA,Phase 2
3570,3571,eukaryotic translation initiation factor inhibitor|PERK inhibitor,MoA,Preclinical
3242,3571,eukaryotic translation initiation factor inhibitor|PERK inhibitor,MoA,Preclinical
463,3572,ATPase inhibitor,MoA,Phase 2
3574,3575,neural stem cell inducer,MoA,Preclinical
969,3576,JAK inhibitor,MoA,Phase 3
3577,3578,TGF beta receptor inhibitor,MoA,Preclinical
900,3579,aryl hydrocarbon receptor agonist,MoA,Preclinical
1517,3580,phosphodiesterase inhibitor,MoA,Phase 1/Phase 2
3582,3583,GEF inhibitor,MoA,Preclinical
537,3584,CC chemokine receptor antagonist,MoA,Preclinical
3585,3586,ubiquitin C-terminal hydrolase inhibitor,MoA,Preclinical
2797,3594,porcupine inhibitor,MoA,Preclinical
370,3596,JAK inhibitor,MoA,Preclinical
510,3597,opioid receptor antagonist,MoA,Phase 1
620,3598,dopamine reuptake inhibitor,MoA,Preclinical
3599,3600,histone lysine demethylase inhibitor,MoA,Preclinical
925,3601,gamma secretase inhibitor,MoA,Preclinical
623,3602,histamine receptor antagonist,MoA,Preclinical
241,3603,orexin receptor antagonist,MoA,Preclinical
243,3603,orexin receptor antagonist,MoA,Preclinical
2117,3604,glutamate receptor antagonist,MoA,Preclinical
528,3605,FAAH inhibitor,MoA,Preclinical
53,3606,TRPV antagonist,MoA,Preclinical
247,3607,HDAC inhibitor,MoA,Phase 2
1143,3607,HDAC inhibitor,MoA,Phase 2
1144,3607,HDAC inhibitor,MoA,Phase 2
249,3607,HDAC inhibitor,MoA,Phase 2
250,3607,HDAC inhibitor,MoA,Phase 2
1145,3607,HDAC inhibitor,MoA,Phase 2
1146,3607,HDAC inhibitor,MoA,Phase 2
251,3607,HDAC inhibitor,MoA,Phase 2
1147,3607,HDAC inhibitor,MoA,Phase 2
252,3607,HDAC inhibitor,MoA,Phase 2
1148,3607,HDAC inhibitor,MoA,Phase 2
546,3607,HDAC inhibitor,MoA,Phase 2
1306,3608,CC chemokine receptor antagonist,MoA,Preclinical
7,3609,dopamine receptor antagonist,MoA,Phase 2
430,3610,tyrosine kinase inhibitor,MoA,Phase 1
1256,3611,glutamate receptor positive allosteric modulator,MoA,Phase 2
3612,3613,hypoxia inducible factor prolyl hydroxylase inhibitor,MoA,Preclinical
528,3614,FAAH inhibitor,MoA,Phase 2
41,3615,purinergic receptor antagonist,MoA,Preclinical
3616,3617,G protein-coupled receptor agonist,MoA,Preclinical
452,3618,CDK inhibitor,MoA,Preclinical
563,3618,CDK inhibitor,MoA,Preclinical
512,3618,CDK inhibitor,MoA,Preclinical
371,3618,CDK inhibitor,MoA,Preclinical
623,3619,histamine receptor antagonist,MoA,Preclinical
836,3620,bromodomain inhibitor,MoA,Preclinical
3621,3620,bromodomain inhibitor,MoA,Preclinical
1099,3622,opioid receptor antagonist,MoA,Phase 2
3623,3624,lysophospholipid receptor antagonist,MoA,Preclinical
2213,3624,lysophospholipid receptor antagonist,MoA,Preclinical
3625,3626,cytokine production inhibitor,MoA,Phase 2
698,3626,cytokine production inhibitor,MoA,Phase 2
700,3626,cytokine production inhibitor,MoA,Phase 2
672,3626,cytokine production inhibitor,MoA,Phase 2
521,3627,cannabinoid receptor inverse agonist,MoA,Phase 1
2677,3628,tankyrase inhibitor,MoA,Preclinical
2679,3628,tankyrase inhibitor,MoA,Preclinical
3629,3630,monoacylglycerol lipase inhibitor,MoA,Preclinical
3631,3632,WNT pathway inhibitor,MoA,Preclinical
3633,3632,WNT pathway inhibitor,MoA,Preclinical
32,3632,WNT pathway inhibitor,MoA,Preclinical
2677,3634,tankyrase inhibitor|WNT signaling inhibitor,MoA,Preclinical
2679,3634,tankyrase inhibitor|WNT signaling inhibitor,MoA,Preclinical
405,3635,p38 MAPK inhibitor,MoA,Preclinical
3629,3636,monoacylglucerol lipase inhibitor,MoA,Preclinical
528,3637,FAAH inhibitor|monoacylglycerol lipase inhibitor,MoA,Preclinical
3629,3637,FAAH inhibitor|monoacylglycerol lipase inhibitor,MoA,Preclinical
2379,3638,K-Ras inhibitor,MoA,Preclinical
463,3639,ATPase inhibitor,MoA,Phase 2
821,3640,kinesin-like spindle protein inhibitor,MoA,Preclinical
255,3641,bone resorption inhibitor|estrogen-related receptor inverse agonist,MoA,Preclinical
3642,3641,bone resorption inhibitor|estrogen-related receptor inverse agonist,MoA,Preclinical
403,3641,bone resorption inhibitor|estrogen-related receptor inverse agonist,MoA,Preclinical
696,3641,bone resorption inhibitor|estrogen-related receptor inverse agonist,MoA,Preclinical
753,3641,bone resorption inhibitor|estrogen-related receptor inverse agonist,MoA,Preclinical
1087,3641,bone resorption inhibitor|estrogen-related receptor inverse agonist,MoA,Preclinical
754,3641,bone resorption inhibitor|estrogen-related receptor inverse agonist,MoA,Preclinical
3643,3641,bone resorption inhibitor|estrogen-related receptor inverse agonist,MoA,Preclinical
665,3644,kainate receptor agonist,MoA,Preclinical
906,3644,kainate receptor agonist,MoA,Preclinical
1466,3644,kainate receptor agonist,MoA,Preclinical
3645,3644,kainate receptor agonist,MoA,Preclinical
3646,3644,kainate receptor agonist,MoA,Preclinical
3647,3644,kainate receptor agonist,MoA,Preclinical
230,3648,topoisomerase inhibitor,MoA,Phase 3
3649,3650,chondrocyte differentiation stimulator,MoA,Preclinical
484,3651,sodium/calcium exchange inhibitor,MoA,Preclinical
3652,3651,sodium/calcium exchange inhibitor,MoA,Preclinical
1744,3651,sodium/calcium exchange inhibitor,MoA,Preclinical
798,3651,sodium/calcium exchange inhibitor,MoA,Preclinical
1054,3653,SRC inhibitor,MoA,Preclinical
3654,3655,neprilysin inhibitor,MoA,Phase 2
1266,3656,ACAT inhibitor,MoA,Phase 2
267,3656,ACAT inhibitor,MoA,Phase 2
912,3657,rho associated kinase inhibitor,MoA,Phase 2
3658,3659,CDK inhibitor|glycogen synthase kinase inhibitor,MoA,Preclinical
512,3659,CDK inhibitor|glycogen synthase kinase inhibitor,MoA,Preclinical
514,3659,CDK inhibitor|glycogen synthase kinase inhibitor,MoA,Preclinical
32,3659,CDK inhibitor|glycogen synthase kinase inhibitor,MoA,Preclinical
179,3666,P selectin inhibitor,MoA,Preclinical
946,3667,RAF inhibitor,MoA,Preclinical
128,3667,RAF inhibitor,MoA,Preclinical
129,3667,RAF inhibitor,MoA,Preclinical
131,3667,RAF inhibitor,MoA,Preclinical
3668,3669,CDC inhibitor,MoA,Preclinical
3670,3669,CDC inhibitor,MoA,Preclinical
3671,3669,CDC inhibitor,MoA,Preclinical
3672,3673,hexokinase inhibitor,MoA,Preclinical
3674,3675,neural stem cell inducer,MoA,Preclinical
1339,3676,lysophosphatidic acid receptor antagonist,MoA,Preclinical
3404,3676,lysophosphatidic acid receptor antagonist,MoA,Preclinical
126,3677,c-Fms inhibitor,MoA,Preclinical
244,3677,c-Fms inhibitor,MoA,Preclinical
129,3677,c-Fms inhibitor,MoA,Preclinical
131,3677,c-Fms inhibitor,MoA,Preclinical
244,3678,KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,MoA,Preclinical
3679,3680,mannosidase inhibitor,MoA,Phase 1
3681,3680,mannosidase inhibitor,MoA,Phase 1
590,3682,lipoprotein antagonist,MoA,Preclinical
3683,3684,proteasome inhibitor,MoA,Preclinical
3685,3684,proteasome inhibitor,MoA,Preclinical
3629,3686,monoacylglucerol lipase inhibitor,MoA,Preclinical
49,3687,calcium/calmodulin dependent protein kinase inhibitor|purinergic receptor antagonist,MoA,Preclinical
1534,3687,calcium/calmodulin dependent protein kinase inhibitor|purinergic receptor antagonist,MoA,Preclinical
1026,3687,calcium/calmodulin dependent protein kinase inhibitor|purinergic receptor antagonist,MoA,Preclinical
1283,3687,calcium/calmodulin dependent protein kinase inhibitor|purinergic receptor antagonist,MoA,Preclinical
828,3687,calcium/calmodulin dependent protein kinase inhibitor|purinergic receptor antagonist,MoA,Preclinical
553,3687,calcium/calmodulin dependent protein kinase inhibitor|purinergic receptor antagonist,MoA,Preclinical
555,3687,calcium/calmodulin dependent protein kinase inhibitor|purinergic receptor antagonist,MoA,Preclinical
405,3687,calcium/calmodulin dependent protein kinase inhibitor|purinergic receptor antagonist,MoA,Preclinical
726,3687,calcium/calmodulin dependent protein kinase inhibitor|purinergic receptor antagonist,MoA,Preclinical
41,3687,calcium/calmodulin dependent protein kinase inhibitor|purinergic receptor antagonist,MoA,Preclinical
1284,3687,calcium/calmodulin dependent protein kinase inhibitor|purinergic receptor antagonist,MoA,Preclinical
839,3687,calcium/calmodulin dependent protein kinase inhibitor|purinergic receptor antagonist,MoA,Preclinical
1285,3687,calcium/calmodulin dependent protein kinase inhibitor|purinergic receptor antagonist,MoA,Preclinical
1705,3687,calcium/calmodulin dependent protein kinase inhibitor|purinergic receptor antagonist,MoA,Preclinical
1534,3688,calcium/calmodulin dependent protein kinase inhibitor,MoA,Preclinical
296,3689,BCRP inhibitor,MoA,Preclinical
1172,3689,BCRP inhibitor,MoA,Preclinical
2637,3690,exportin antagonist,MoA,Preclinical
2637,3691,exportin antagonist,MoA,Preclinical
309,3692,ALK inihibitor,MoA,Preclinical
939,3693,VEGFR inhibitor,MoA,Preclinical
940,3693,VEGFR inhibitor,MoA,Preclinical
244,3693,VEGFR inhibitor,MoA,Preclinical
2203,3694,BCRP inhibitor,MoA,Preclinical
781,3695,mTOR inhibitor,MoA,Preclinical
1512,3696,ATM kinase inhibitor,MoA,Preclinical
1526,3696,ATM kinase inhibitor,MoA,Preclinical
1512,3697,ATM kinase inhibitor,MoA,Preclinical
3698,3699,ribosyl cyclase inhibitor,MoA,Preclinical
301,3700,Abl kinase inhibitor|Aurora kinase inhibitor|FLT3 inhibitor,MoA,Phase 1
452,3700,Abl kinase inhibitor|Aurora kinase inhibitor|FLT3 inhibitor,MoA,Phase 1
563,3700,Abl kinase inhibitor|Aurora kinase inhibitor|FLT3 inhibitor,MoA,Phase 1
128,3700,Abl kinase inhibitor|Aurora kinase inhibitor|FLT3 inhibitor,MoA,Phase 1
69,3701,adenosine receptor antagonist,MoA,Phase 3
275,3701,adenosine receptor antagonist,MoA,Phase 3
276,3701,adenosine receptor antagonist,MoA,Phase 3
277,3701,adenosine receptor antagonist,MoA,Phase 3
1054,3702,SRC inhibitor|tubulin polymerization inhibitor,MoA,Phase 3
1451,3703,glutamate receptor antagonist,MoA,Phase 1
153,3703,glutamate receptor antagonist,MoA,Phase 1
154,3703,glutamate receptor antagonist,MoA,Phase 1
155,3703,glutamate receptor antagonist,MoA,Phase 1
3704,3705,WNT pathway inhibitor,MoA,Preclinical
3706,3707,bone morphogenic protein inhibitor,MoA,Preclinical
88,3708,sphingosine kinase inhibitor,MoA,Preclinical
208,3731,metallic radical formation stimulant,MoA,Launched
3732,3731,metallic radical formation stimulant,MoA,Launched
3733,3731,metallic radical formation stimulant,MoA,Launched
3734,3731,metallic radical formation stimulant,MoA,Launched
314,3731,metallic radical formation stimulant,MoA,Launched
3735,3731,metallic radical formation stimulant,MoA,Launched
3736,3731,metallic radical formation stimulant,MoA,Launched
3726,3731,metallic radical formation stimulant,MoA,Launched
315,3731,metallic radical formation stimulant,MoA,Launched
3737,3731,metallic radical formation stimulant,MoA,Launched
3738,3731,metallic radical formation stimulant,MoA,Launched
3739,3731,metallic radical formation stimulant,MoA,Launched
3740,3731,metallic radical formation stimulant,MoA,Launched
3741,3731,metallic radical formation stimulant,MoA,Launched
153,3731,metallic radical formation stimulant,MoA,Launched
154,3731,metallic radical formation stimulant,MoA,Launched
155,3731,metallic radical formation stimulant,MoA,Launched
156,3731,metallic radical formation stimulant,MoA,Launched
157,3731,metallic radical formation stimulant,MoA,Launched
824,3731,metallic radical formation stimulant,MoA,Launched
3742,3731,metallic radical formation stimulant,MoA,Launched
1861,3731,metallic radical formation stimulant,MoA,Launched
3743,3731,metallic radical formation stimulant,MoA,Launched
3744,3731,metallic radical formation stimulant,MoA,Launched
3745,3731,metallic radical formation stimulant,MoA,Launched
2117,3765,glutamate receptor agonist,MoA,Preclinical
160,3765,glutamate receptor agonist,MoA,Preclinical
1609,3765,glutamate receptor agonist,MoA,Preclinical
3766,3765,glutamate receptor agonist,MoA,Preclinical
3767,3765,glutamate receptor agonist,MoA,Preclinical
3768,3765,glutamate receptor agonist,MoA,Preclinical
3773,3774,glutamate receptor agonist,MoA,Launched
1948,3774,glutamate receptor agonist,MoA,Launched
2235,3774,glutamate receptor agonist,MoA,Launched
3775,3774,glutamate receptor agonist,MoA,Launched
314,3774,glutamate receptor agonist,MoA,Launched
3776,3774,glutamate receptor agonist,MoA,Launched
3777,3774,glutamate receptor agonist,MoA,Launched
3778,3774,glutamate receptor agonist,MoA,Launched
3779,3774,glutamate receptor agonist,MoA,Launched
3780,3774,glutamate receptor agonist,MoA,Launched
3781,3774,glutamate receptor agonist,MoA,Launched
3782,3774,glutamate receptor agonist,MoA,Launched
3783,3774,glutamate receptor agonist,MoA,Launched
3784,3774,glutamate receptor agonist,MoA,Launched
3785,3774,glutamate receptor agonist,MoA,Launched
3786,3774,glutamate receptor agonist,MoA,Launched
3787,3774,glutamate receptor agonist,MoA,Launched
3788,3774,glutamate receptor agonist,MoA,Launched
3762,3774,glutamate receptor agonist,MoA,Launched
1470,3774,glutamate receptor agonist,MoA,Launched
706,3774,glutamate receptor agonist,MoA,Launched
1630,3774,glutamate receptor agonist,MoA,Launched
3789,3774,glutamate receptor agonist,MoA,Launched
1984,3774,glutamate receptor agonist,MoA,Launched
1985,3774,glutamate receptor agonist,MoA,Launched
3790,3774,glutamate receptor agonist,MoA,Launched
3791,3774,glutamate receptor agonist,MoA,Launched
3740,3774,glutamate receptor agonist,MoA,Launched
3741,3774,glutamate receptor agonist,MoA,Launched
3712,3774,glutamate receptor agonist,MoA,Launched
3713,3774,glutamate receptor agonist,MoA,Launched
665,3774,glutamate receptor agonist,MoA,Launched
663,3774,glutamate receptor agonist,MoA,Launched
667,3774,glutamate receptor agonist,MoA,Launched
668,3774,glutamate receptor agonist,MoA,Launched
3792,3774,glutamate receptor agonist,MoA,Launched
3793,3774,glutamate receptor agonist,MoA,Launched
906,3774,glutamate receptor agonist,MoA,Launched
1466,3774,glutamate receptor agonist,MoA,Launched
3645,3774,glutamate receptor agonist,MoA,Launched
3646,3774,glutamate receptor agonist,MoA,Launched
3647,3774,glutamate receptor agonist,MoA,Launched
153,3774,glutamate receptor agonist,MoA,Launched
154,3774,glutamate receptor agonist,MoA,Launched
155,3774,glutamate receptor agonist,MoA,Launched
156,3774,glutamate receptor agonist,MoA,Launched
157,3774,glutamate receptor agonist,MoA,Launched
158,3774,glutamate receptor agonist,MoA,Launched
159,3774,glutamate receptor agonist,MoA,Launched
2117,3774,glutamate receptor agonist,MoA,Launched
1256,3774,glutamate receptor agonist,MoA,Launched
1835,3774,glutamate receptor agonist,MoA,Launched
2414,3774,glutamate receptor agonist,MoA,Launched
1836,3774,glutamate receptor agonist,MoA,Launched
651,3774,glutamate receptor agonist,MoA,Launched
1837,3774,glutamate receptor agonist,MoA,Launched
3794,3774,glutamate receptor agonist,MoA,Launched
3795,3774,glutamate receptor agonist,MoA,Launched
3796,3774,glutamate receptor agonist,MoA,Launched
3797,3774,glutamate receptor agonist,MoA,Launched
3798,3774,glutamate receptor agonist,MoA,Launched
3799,3774,glutamate receptor agonist,MoA,Launched
3800,3774,glutamate receptor agonist,MoA,Launched
3743,3774,glutamate receptor agonist,MoA,Launched
1846,3774,glutamate receptor agonist,MoA,Launched
3801,3774,glutamate receptor agonist,MoA,Launched
3802,3774,glutamate receptor agonist,MoA,Launched
3803,3774,glutamate receptor agonist,MoA,Launched
3804,3774,glutamate receptor agonist,MoA,Launched
3805,3774,glutamate receptor agonist,MoA,Launched
214,3774,glutamate receptor agonist,MoA,Launched
3806,3774,glutamate receptor agonist,MoA,Launched
1001,3813,serotonin receptor agonist,MoA,Phase 2
3814,3813,serotonin receptor agonist,MoA,Phase 2
3722,3813,serotonin receptor agonist,MoA,Phase 2
3815,3813,serotonin receptor agonist,MoA,Phase 2
3723,3813,serotonin receptor agonist,MoA,Phase 2
3724,3813,serotonin receptor agonist,MoA,Phase 2
2503,3820,dopamine beta hydroxylase inhibitor|eukaryotic translation initiation factor inhibitor,MoA,Preclinical
3821,3820,dopamine beta hydroxylase inhibitor|eukaryotic translation initiation factor inhibitor,MoA,Preclinical
1287,3822,nitric oxide synthase inhibitor,MoA,Phase 3
598,3822,nitric oxide synthase inhibitor,MoA,Phase 3
881,3823,nitric oxide synthase inhibitor,MoA,Phase 2/Phase 3
1287,3824,nitric oxide synthase inhibitor,MoA,Preclinical
598,3824,nitric oxide synthase inhibitor,MoA,Preclinical
881,3824,nitric oxide synthase inhibitor,MoA,Preclinical
3782,3825,glutamate receptor agonist,MoA,Launched
3826,3825,glutamate receptor agonist,MoA,Launched
3827,3825,glutamate receptor agonist,MoA,Launched
3828,3825,glutamate receptor agonist,MoA,Launched
3829,3825,glutamate receptor agonist,MoA,Launched
3830,3825,glutamate receptor agonist,MoA,Launched
3831,3825,glutamate receptor agonist,MoA,Launched
3832,3825,glutamate receptor agonist,MoA,Launched
2197,3825,glutamate receptor agonist,MoA,Launched
3833,3825,glutamate receptor agonist,MoA,Launched
3834,3825,glutamate receptor agonist,MoA,Launched
2198,3825,glutamate receptor agonist,MoA,Launched
3835,3825,glutamate receptor agonist,MoA,Launched
3836,3825,glutamate receptor agonist,MoA,Launched
3837,3825,glutamate receptor agonist,MoA,Launched
3838,3825,glutamate receptor agonist,MoA,Launched
2069,3825,glutamate receptor agonist,MoA,Launched
2070,3825,glutamate receptor agonist,MoA,Launched
3839,3825,glutamate receptor agonist,MoA,Launched
3840,3825,glutamate receptor agonist,MoA,Launched
3841,3825,glutamate receptor agonist,MoA,Launched
3783,3842,glutamate receptor agonist,MoA,Preclinical
663,3842,glutamate receptor agonist,MoA,Preclinical
906,3842,glutamate receptor agonist,MoA,Preclinical
1466,3842,glutamate receptor agonist,MoA,Preclinical
2117,3842,glutamate receptor agonist,MoA,Preclinical
1256,3842,glutamate receptor agonist,MoA,Preclinical
1835,3842,glutamate receptor agonist,MoA,Preclinical
160,3842,glutamate receptor agonist,MoA,Preclinical
651,3842,glutamate receptor agonist,MoA,Preclinical
1837,3842,glutamate receptor agonist,MoA,Preclinical
1707,3847,neuropeptide receptor antagonist,MoA,Preclinical
498,3848,prostanoid receptor antagonist,MoA,Preclinical
1220,3849,PPAR receptor agonist,MoA,Preclinical
3850,3851,glucagon receptor antagonist,MoA,Preclinical
1183,3852,CCK receptor antagonist,MoA,Phase 2
1185,3852,CCK receptor antagonist,MoA,Phase 2
2302,3852,CCK receptor antagonist,MoA,Phase 2
71,3853,oxytocin receptor antagonist,MoA,Phase 1
904,3853,oxytocin receptor antagonist,MoA,Phase 1
905,3853,oxytocin receptor antagonist,MoA,Phase 1
79,3854,GABA receptor inverse agonist,MoA,Preclinical
140,3854,GABA receptor inverse agonist,MoA,Preclinical
141,3854,GABA receptor inverse agonist,MoA,Preclinical
142,3854,GABA receptor inverse agonist,MoA,Preclinical
149,3854,GABA receptor inverse agonist,MoA,Preclinical
3855,3856,thromboxane receptor antagonist,MoA,Phase 1
153,3857,glutamate receptor antagonist,MoA,Preclinical
154,3857,glutamate receptor antagonist,MoA,Preclinical
155,3857,glutamate receptor antagonist,MoA,Preclinical
156,3857,glutamate receptor antagonist,MoA,Preclinical
157,3857,glutamate receptor antagonist,MoA,Preclinical
3858,3859,inositol monophosphatase inhibitor,MoA,Preclinical
7,3860,sigma receptor agonist|sigma receptor antagonist,MoA,Preclinical
633,3860,sigma receptor agonist|sigma receptor antagonist,MoA,Preclinical
11,3861,serotonin receptor agonist,MoA,Preclinical
12,3861,serotonin receptor agonist,MoA,Preclinical
13,3861,serotonin receptor agonist,MoA,Preclinical
153,3862,glutamate receptor antagonist,MoA,Preclinical
153,3863,glutamate receptor antagonist,MoA,Preclinical
154,3863,glutamate receptor antagonist,MoA,Preclinical
155,3863,glutamate receptor antagonist,MoA,Preclinical
156,3863,glutamate receptor antagonist,MoA,Preclinical
157,3863,glutamate receptor antagonist,MoA,Preclinical
28,3864,tachykinin antagonist,MoA,Preclinical
78,3864,tachykinin antagonist,MoA,Preclinical
28,3865,tachykinin antagonist,MoA,Preclinical
8,3866,dopamine receptor antagonist,MoA,Preclinical
9,3866,dopamine receptor antagonist,MoA,Preclinical
444,3866,dopamine receptor antagonist,MoA,Preclinical
446,3866,dopamine receptor antagonist,MoA,Preclinical
6,3867,dopamine receptor antagonist,MoA,Preclinical
7,3867,dopamine receptor antagonist,MoA,Preclinical
8,3867,dopamine receptor antagonist,MoA,Preclinical
9,3867,dopamine receptor antagonist,MoA,Preclinical
11,3867,dopamine receptor antagonist,MoA,Preclinical
14,3867,dopamine receptor antagonist,MoA,Preclinical
624,3867,dopamine receptor antagonist,MoA,Preclinical
625,3867,dopamine receptor antagonist,MoA,Preclinical
165,3868,adrenergic receptor agonist,MoA,Preclinical
417,3868,adrenergic receptor agonist,MoA,Preclinical
567,3868,adrenergic receptor agonist,MoA,Preclinical
28,3869,tachykinin antagonist,MoA,Preclinical
815,3870,farnesyltransferase inhibitor,MoA,Phase 1
3871,3870,farnesyltransferase inhibitor,MoA,Phase 1
3872,3870,farnesyltransferase inhibitor,MoA,Phase 1
396,3873,prostanoid receptor antagonist,MoA,Preclinical
79,3874,GABA receptor partial agonist,MoA,Preclinical
140,3874,GABA receptor partial agonist,MoA,Preclinical
141,3874,GABA receptor partial agonist,MoA,Preclinical
142,3874,GABA receptor partial agonist,MoA,Preclinical
3883,3884,immunosuppressant,MoA,Phase 3
631,3886,tropomyosin receptor kinase inhibitor,MoA,Launched
632,3886,tropomyosin receptor kinase inhibitor,MoA,Launched
2698,3886,tropomyosin receptor kinase inhibitor,MoA,Launched
97,3889,glutamate receptor antagonist,MoA,Phase 3
624,3889,glutamate receptor antagonist,MoA,Phase 3
3890,3891,actin polymerization inhibitor,MoA,Phase 1
3892,3891,actin polymerization inhibitor,MoA,Phase 1
3893,3891,actin polymerization inhibitor,MoA,Phase 1
3894,3895,bacterial permeability inducer,MoA,Phase 3
3896,3895,bacterial permeability inducer,MoA,Phase 3
891,3895,bacterial permeability inducer,MoA,Phase 3
3897,3895,bacterial permeability inducer,MoA,Phase 3
2443,3895,bacterial permeability inducer,MoA,Phase 3
2242,3895,bacterial permeability inducer,MoA,Phase 3
1248,3898,monoamine oxidase inhibitor,MoA,Phase 3
1015,3899,XIAP inhibitor,MoA,Phase 2
1018,3899,XIAP inhibitor,MoA,Phase 2
63,3900,diacylglycerol O acyltransferase inhibitor,MoA,Phase 3
1329,3901,protein tyrosine kinase inhibitor,MoA,Preclinical
1331,3901,protein tyrosine kinase inhibitor,MoA,Preclinical
1333,3901,protein tyrosine kinase inhibitor,MoA,Preclinical
1777,3902,haspin kinase inhibitor,MoA,Preclinical
301,3903,bone morphogenic protein inhibitor,MoA,Preclinical
303,3903,bone morphogenic protein inhibitor,MoA,Preclinical
3904,3903,bone morphogenic protein inhibitor,MoA,Preclinical
3125,3905,tissue transglutaminase inhibitor,MoA,Preclinical
303,3906,bone morphogenic protein inhibitor,MoA,Preclinical
2537,3906,bone morphogenic protein inhibitor,MoA,Preclinical
118,3907,retinoid receptor agonist,MoA,Preclinical
241,3909,orexin receptor antagonist,MoA,Launched
243,3909,orexin receptor antagonist,MoA,Launched
77,3913,serotonin receptor antagonist,MoA,Phase 3
128,3916,FLT3 inhibitor|growth factor receptor inhibitor|JAK inhibitor,MoA,Phase 3
631,3916,FLT3 inhibitor|growth factor receptor inhibitor|JAK inhibitor,MoA,Phase 3
2518,3918,nitric oxide production inhibitor|tau aggregation inhibitor,MoA,Phase 3
3922,3923,acetylcholine receptor agonist,MoA,Withdrawn
2301,3924,potassium channel activator,MoA,Phase 3
73,3927,acetylcholine receptor antagonist,MoA,Launched
97,3942,histamine receptor antagonist,MoA,Phase 2
134,3950,Bruton's tyrosine kinase (BTK) inhibitor,MoA,Preclinical
2797,3951,porcupine inhibitor,MoA,Phase 2
2253,3952,casein kinase inhibitor,MoA,Preclinical
596,3953,cytochrome P450 inhibitor,MoA,Phase 2/Phase 3
3954,3953,cytochrome P450 inhibitor,MoA,Phase 2/Phase 3
167,3955,voltage-gated sodium channel blocker,MoA,Phase 3
1280,3956,topoisomerase inhibitor,MoA,Phase 3
403,3957,cyclooxygenase inhibitor|lipoxygenase inhibitor,MoA,Phase 3
610,3957,cyclooxygenase inhibitor|lipoxygenase inhibitor,MoA,Phase 3
171,3957,cyclooxygenase inhibitor|lipoxygenase inhibitor,MoA,Phase 3
672,3960,tumor necrosis factor production inhibitor,MoA,Preclinical
2261,3962,LIM kinase inhibitor,MoA,Preclinical
937,3968,PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,MoA,Phase 3
126,3968,PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,MoA,Phase 3
939,3968,PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,MoA,Phase 3
128,3968,PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,MoA,Phase 3
940,3968,PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,MoA,Phase 3
244,3968,PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,MoA,Phase 3
129,3968,PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,MoA,Phase 3
131,3968,PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,MoA,Phase 3
741,3968,PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,MoA,Phase 3
246,3968,PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,MoA,Phase 3
1312,3969,oxidative stress inducer,MoA,Phase 3
483,3969,oxidative stress inducer,MoA,Phase 3
389,3969,oxidative stress inducer,MoA,Phase 3
3896,3969,oxidative stress inducer,MoA,Phase 3
2282,3969,oxidative stress inducer,MoA,Phase 3
200,3969,oxidative stress inducer,MoA,Phase 3
694,3969,oxidative stress inducer,MoA,Phase 3
629,3970,potassium channel blocker,MoA,Phase 3
630,3970,potassium channel blocker,MoA,Phase 3
1191,3970,potassium channel blocker,MoA,Phase 3
2303,3970,potassium channel blocker,MoA,Phase 3
364,3971,IGF-1 inhibitor,MoA,Phase 3
1672,3971,IGF-1 inhibitor,MoA,Phase 3
3972,3971,IGF-1 inhibitor,MoA,Phase 3
1215,3980,FXR antagonist|vitamin D receptor agonist,MoA,Preclinical
1718,3980,FXR antagonist|vitamin D receptor agonist,MoA,Preclinical
1923,3980,FXR antagonist|vitamin D receptor agonist,MoA,Preclinical
441,3980,FXR antagonist|vitamin D receptor agonist,MoA,Preclinical
821,3981,kinesin-like spindle protein inhibitor,MoA,Phase 2
904,3982,vasopressin receptor antagonist,MoA,Phase 3
632,3983,tropomyosin receptor kinase inhibitor,MoA,Preclinical
3984,3985,survival motor neuron protein modulator,MoA,Phase 1/Phase 2
1145,3986,HDAC inhibitor,MoA,Preclinical
1146,3986,HDAC inhibitor,MoA,Preclinical
3987,3988,neurotrophic agent,MoA,Phase 1
3763,3991,O6-alkylguanine-DNA alkyltransferase inhibitor,MoA,Phase 2
3993,3994,glycinamide ribonucleotide formyltransferase inhibitor,MoA,Phase 2
815,3996,farnesyltransferase inhibitor,MoA,Phase 3
2867,3996,farnesyltransferase inhibitor,MoA,Phase 3
2379,3996,farnesyltransferase inhibitor,MoA,Phase 3
3997,3996,farnesyltransferase inhibitor,MoA,Phase 3
3121,3998,glucokinase inhibitor,MoA,Launched
145,4002,benzodiazepine receptor agonist,MoA,Phase 2
82,4002,benzodiazepine receptor agonist,MoA,Phase 2
79,4003,GABA receptor modulator,MoA,Phase 2
1183,4004,CCK receptor antagonist,MoA,Phase 1
1185,4004,CCK receptor antagonist,MoA,Phase 1
405,4008,p38 MAPK inhibitor,MoA,Phase 3
1623,4012,cysteine peptidase inhibitor,MoA,Preclinical
4014,4015,lysophosphatidic acid receptor antagonist,MoA,Preclinical
2232,4016,leucine rich repeat kinase inhibitor,MoA,Preclinical
160,4017,glutamate receptor positive allosteric modulator,MoA,Preclinical
4018,4019,leukocyte activator,MoA,Phase 2
3442,4019,leukocyte activator,MoA,Phase 2
275,4020,adenosine receptor antagonist,MoA,Phase 2
4022,4023,endonuclease inhibitor,MoA,Phase 2
230,4023,endonuclease inhibitor,MoA,Phase 2
232,4023,endonuclease inhibitor,MoA,Phase 2
1008,4024,FGFR inhibitor|VEGFR inhibitor,MoA,Phase 2
939,4024,FGFR inhibitor|VEGFR inhibitor,MoA,Phase 2
244,4024,FGFR inhibitor|VEGFR inhibitor,MoA,Phase 2
129,4024,FGFR inhibitor|VEGFR inhibitor,MoA,Phase 2
130,4024,FGFR inhibitor|VEGFR inhibitor,MoA,Phase 2
131,4024,FGFR inhibitor|VEGFR inhibitor,MoA,Phase 2
741,4024,FGFR inhibitor|VEGFR inhibitor,MoA,Phase 2
275,4025,adenosine receptor agonist,MoA,Preclinical
276,4025,adenosine receptor agonist,MoA,Preclinical
7,4027,dopamine receptor modulator|serotonin receptor antagonist,MoA,Launched
14,4027,dopamine receptor modulator|serotonin receptor antagonist,MoA,Launched
174,4029,cyclooxygenase inhibitor,MoA,Withdrawn
171,4029,cyclooxygenase inhibitor,MoA,Withdrawn
3452,4030,sodium channel blocker,MoA,Phase 1
230,4032,glucosidase inhibitor,MoA,Phase 2
387,4033,melatonin receptor antagonist,MoA,Preclinical
388,4033,melatonin receptor antagonist,MoA,Preclinical
696,4034,LXR agonist,MoA,Phase 1
3291,4034,LXR agonist,MoA,Phase 1
3293,4034,LXR agonist,MoA,Phase 1
1923,4034,LXR agonist,MoA,Phase 1
423,4034,LXR agonist,MoA,Phase 1
2880,4035,tryptophan hydroxylase inhibitor,MoA,Phase 2
4036,4037,LIM kinase inhibitor|rho associated kinase inhibitor,MoA,Phase 1/Phase 2
839,4037,LIM kinase inhibitor|rho associated kinase inhibitor,MoA,Phase 1/Phase 2
912,4037,LIM kinase inhibitor|rho associated kinase inhibitor,MoA,Phase 1/Phase 2
519,4038,cannabinoid receptor agonist,MoA,Preclinical
32,4040,glycogen synthase kinase inhibitor,MoA,Phase 2
2840,4041,TGF beta receptor inhibitor,MoA,Preclinical
3577,4041,TGF beta receptor inhibitor,MoA,Preclinical
1835,4042,glutamate receptor agonist,MoA,Phase 3
665,4043,glutamate receptor antagonist,MoA,Phase 1
663,4043,glutamate receptor antagonist,MoA,Phase 1
667,4043,glutamate receptor antagonist,MoA,Phase 1
668,4043,glutamate receptor antagonist,MoA,Phase 1
906,4043,glutamate receptor antagonist,MoA,Phase 1
2840,4044,TGF beta receptor inhibitor,MoA,Phase 2/Phase 3
528,4045,FAAH inhibitor|FAAH reuptake inhibitor,MoA,Preclinical
405,4046,p38 MAPK inhibitor,MoA,Phase 2
4018,4047,leukotriene receptor antagonist,MoA,Phase 2
1185,4048,CCK receptor antagonist,MoA,Preclinical
461,4049,glycine transporter inhibitor,MoA,Preclinical
696,4050,androgen receptor modulator,MoA,Phase 2
4018,4051,leukotriene receptor antagonist,MoA,Preclinical
3442,4051,leukotriene receptor antagonist,MoA,Preclinical
1285,4052,ribosomal protein inhibitor,MoA,Phase 1
1026,4053,CHK inhibitor,MoA,Phase 2
1026,4054,CHK inhibitor,MoA,Phase 2
3121,4055,glucokinase activator,MoA,Phase 2
15,4056,serotonin receptor antagonist,MoA,Preclinical
369,4057,JAK inhibitor,MoA,Phase 2
370,4057,JAK inhibitor,MoA,Phase 2
430,4058,MET inhibitor,MoA,Phase 2
979,4059,beta-secretase inhibitor,MoA,Phase 1
517,4060,CDK inhibitor,MoA,Preclinical
1008,4061,FGFR antagonist,MoA,Phase 1
350,4061,FGFR antagonist,MoA,Phase 1
351,4061,FGFR antagonist,MoA,Phase 1
1010,4061,FGFR antagonist,MoA,Phase 1
244,4061,FGFR antagonist,MoA,Phase 1
1185,4062,CCK receptor antagonist,MoA,Preclinical
979,4063,beta-secretase inhibitor,MoA,Phase 1/Phase 2
49,4064,DNA dependent protein kinase inhibitor|mTOR inhibitor|phosphodiesterase inhibitor|PI3K inhibitor|PLK inhibitor,MoA,Preclinical
1026,4064,DNA dependent protein kinase inhibitor|mTOR inhibitor|phosphodiesterase inhibitor|PI3K inhibitor|PLK inhibitor,MoA,Preclinical
32,4064,DNA dependent protein kinase inhibitor|mTOR inhibitor|phosphodiesterase inhibitor|PI3K inhibitor|PLK inhibitor,MoA,Preclinical
1283,4064,DNA dependent protein kinase inhibitor|mTOR inhibitor|phosphodiesterase inhibitor|PI3K inhibitor|PLK inhibitor,MoA,Preclinical
828,4064,DNA dependent protein kinase inhibitor|mTOR inhibitor|phosphodiesterase inhibitor|PI3K inhibitor|PLK inhibitor,MoA,Preclinical
553,4064,DNA dependent protein kinase inhibitor|mTOR inhibitor|phosphodiesterase inhibitor|PI3K inhibitor|PLK inhibitor,MoA,Preclinical
555,4064,DNA dependent protein kinase inhibitor|mTOR inhibitor|phosphodiesterase inhibitor|PI3K inhibitor|PLK inhibitor,MoA,Preclinical
405,4064,DNA dependent protein kinase inhibitor|mTOR inhibitor|phosphodiesterase inhibitor|PI3K inhibitor|PLK inhibitor,MoA,Preclinical
726,4064,DNA dependent protein kinase inhibitor|mTOR inhibitor|phosphodiesterase inhibitor|PI3K inhibitor|PLK inhibitor,MoA,Preclinical
781,4064,DNA dependent protein kinase inhibitor|mTOR inhibitor|phosphodiesterase inhibitor|PI3K inhibitor|PLK inhibitor,MoA,Preclinical
474,4064,DNA dependent protein kinase inhibitor|mTOR inhibitor|phosphodiesterase inhibitor|PI3K inhibitor|PLK inhibitor,MoA,Preclinical
136,4064,DNA dependent protein kinase inhibitor|mTOR inhibitor|phosphodiesterase inhibitor|PI3K inhibitor|PLK inhibitor,MoA,Preclinical
138,4064,DNA dependent protein kinase inhibitor|mTOR inhibitor|phosphodiesterase inhibitor|PI3K inhibitor|PLK inhibitor,MoA,Preclinical
476,4064,DNA dependent protein kinase inhibitor|mTOR inhibitor|phosphodiesterase inhibitor|PI3K inhibitor|PLK inhibitor,MoA,Preclinical
289,4064,DNA dependent protein kinase inhibitor|mTOR inhibitor|phosphodiesterase inhibitor|PI3K inhibitor|PLK inhibitor,MoA,Preclinical
1228,4064,DNA dependent protein kinase inhibitor|mTOR inhibitor|phosphodiesterase inhibitor|PI3K inhibitor|PLK inhibitor,MoA,Preclinical
1284,4064,DNA dependent protein kinase inhibitor|mTOR inhibitor|phosphodiesterase inhibitor|PI3K inhibitor|PLK inhibitor,MoA,Preclinical
1526,4064,DNA dependent protein kinase inhibitor|mTOR inhibitor|phosphodiesterase inhibitor|PI3K inhibitor|PLK inhibitor,MoA,Preclinical
839,4064,DNA dependent protein kinase inhibitor|mTOR inhibitor|phosphodiesterase inhibitor|PI3K inhibitor|PLK inhibitor,MoA,Preclinical
1285,4064,DNA dependent protein kinase inhibitor|mTOR inhibitor|phosphodiesterase inhibitor|PI3K inhibitor|PLK inhibitor,MoA,Preclinical
1705,4064,DNA dependent protein kinase inhibitor|mTOR inhibitor|phosphodiesterase inhibitor|PI3K inhibitor|PLK inhibitor,MoA,Preclinical
1256,4065,glutamate receptor agonist,MoA,Phase 1
1350,4066,cathepsin inhibitor,MoA,Phase 1
946,4067,RAF inhibitor,MoA,Phase 1
948,4067,RAF inhibitor,MoA,Phase 1
781,4068,mTOR inhibitor|PI3K inhibitor,MoA,Phase 2
3405,4069,casein kinase inhibitor|mTOR inhibitor|PI3K inhibitor,MoA,Preclinical
736,4069,casein kinase inhibitor|mTOR inhibitor|PI3K inhibitor,MoA,Preclinical
836,4069,casein kinase inhibitor|mTOR inhibitor|PI3K inhibitor,MoA,Preclinical
13,4070,serotonin receptor antagonist,MoA,Preclinical
519,4071,cannabinoid receptor antagonist,MoA,Preclinical
11,4072,serotonin receptor agonist,MoA,Preclinical
12,4072,serotonin receptor agonist,MoA,Preclinical
13,4072,serotonin receptor agonist,MoA,Preclinical
488,4072,serotonin receptor agonist,MoA,Preclinical
489,4072,serotonin receptor agonist,MoA,Preclinical
14,4072,serotonin receptor agonist,MoA,Preclinical
15,4072,serotonin receptor agonist,MoA,Preclinical
16,4072,serotonin receptor agonist,MoA,Preclinical
625,4072,serotonin receptor agonist,MoA,Preclinical
2840,4073,p38 MAPK inhibitor|TGF beta receptor inhibitor,MoA,Preclinical
12,4074,serotonin receptor antagonist,MoA,Preclinical
13,4074,serotonin receptor antagonist,MoA,Preclinical
14,4074,serotonin receptor antagonist,MoA,Preclinical
15,4074,serotonin receptor antagonist,MoA,Preclinical
665,4075,glutamate receptor positive allosteric modulator,MoA,Preclinical
663,4075,glutamate receptor positive allosteric modulator,MoA,Preclinical
667,4075,glutamate receptor positive allosteric modulator,MoA,Preclinical
668,4075,glutamate receptor positive allosteric modulator,MoA,Preclinical
2117,4076,glutamate receptor antagonist,MoA,Preclinical
77,4077,serotonin receptor agonist,MoA,Preclinical
957,4077,serotonin receptor agonist,MoA,Preclinical
2302,4078,ATP-sensitive potassium channel antagonist,MoA,Phase 2
944,4079,smoothened receptor antagonist,MoA,Preclinical
2164,4079,smoothened receptor antagonist,MoA,Preclinical
1335,4079,smoothened receptor antagonist,MoA,Preclinical
4080,4081,phospholipase activator,MoA,Preclinical
4082,4081,phospholipase activator,MoA,Preclinical
4083,4081,phospholipase activator,MoA,Preclinical
4084,4081,phospholipase activator,MoA,Preclinical
4085,4081,phospholipase activator,MoA,Preclinical
252,4086,HDAC inhibitor,MoA,Preclinical
79,4090,PPAR receptor agonist,MoA,Preclinical
200,4090,PPAR receptor agonist,MoA,Preclinical
262,4096,cytomegalovirus inhibitor|protein kinase inhibitor,MoA,Phase 3
766,4097,matrix metalloprotease inhibitor,MoA,Phase 3
4098,4097,matrix metalloprotease inhibitor,MoA,Phase 3
4099,4097,matrix metalloprotease inhibitor,MoA,Phase 3
197,4097,matrix metalloprotease inhibitor,MoA,Phase 3
767,4097,matrix metalloprotease inhibitor,MoA,Phase 3
2726,4097,matrix metalloprotease inhibitor,MoA,Phase 3
4100,4097,matrix metalloprotease inhibitor,MoA,Phase 3
1111,4097,matrix metalloprotease inhibitor,MoA,Phase 3
4101,4097,matrix metalloprotease inhibitor,MoA,Phase 3
4102,4097,matrix metalloprotease inhibitor,MoA,Phase 3
1112,4097,matrix metalloprotease inhibitor,MoA,Phase 3
4103,4097,matrix metalloprotease inhibitor,MoA,Phase 3
4104,4097,matrix metalloprotease inhibitor,MoA,Phase 3
4105,4097,matrix metalloprotease inhibitor,MoA,Phase 3
4106,4097,matrix metalloprotease inhibitor,MoA,Phase 3
2885,4097,matrix metalloprotease inhibitor,MoA,Phase 3
4107,4097,matrix metalloprotease inhibitor,MoA,Phase 3
4108,4097,matrix metalloprotease inhibitor,MoA,Phase 3
4109,4097,matrix metalloprotease inhibitor,MoA,Phase 3
1826,4097,matrix metalloprotease inhibitor,MoA,Phase 3
4110,4097,matrix metalloprotease inhibitor,MoA,Phase 3
1113,4097,matrix metalloprotease inhibitor,MoA,Phase 3
84,4097,matrix metalloprotease inhibitor,MoA,Phase 3
510,4114,opioid receptor agonist,MoA,Phase 2
160,4115,glutamate receptor antagonist,MoA,Phase 2
744,4117,glucose dependent insulinotropic receptor agonist,MoA,Phase 2
4137,4138,NOD like receptor inhibitor,MoA,Preclinical
1099,4139,nociceptin/orphanin FQ receptor agonist,MoA,Preclinical
11,4140,serotonin receptor agonist,MoA,Phase 2
13,4140,serotonin receptor agonist,MoA,Phase 2
488,4140,serotonin receptor agonist,MoA,Phase 2
14,4140,serotonin receptor agonist,MoA,Phase 2
15,4140,serotonin receptor agonist,MoA,Phase 2
16,4140,serotonin receptor agonist,MoA,Phase 2
624,4140,serotonin receptor agonist,MoA,Phase 2
249,4141,HDAC inhibitor,MoA,Preclinical
4142,4143,NFkB pathway inhibitor,MoA,Phase 1
2583,4144,dynamin inhibitor,MoA,Preclinical
14,4145,serotonin receptor antagonist,MoA,Phase 2
15,4145,serotonin receptor antagonist,MoA,Phase 2
16,4145,serotonin receptor antagonist,MoA,Phase 2
287,4146,glutamate receptor antagonist,MoA,Preclinical
11,4147,serotonin receptor agonist,MoA,Preclinical
11,4148,serotonin receptor antagonist,MoA,Phase 1
2556,4149,PPAR receptor antagonist,MoA,Preclinical
4153,4154,neurotensin receptor antagonist,MoA,Phase 2/Phase 3
3931,4154,neurotensin receptor antagonist,MoA,Phase 2/Phase 3
483,4158,ATP citrase lyase inhibitor,MoA,Phase 2
1306,4164,potassium channel blocker,MoA,Phase 2
477,4165,HMGCR inhibitor,MoA,Launched
227,4166,STAT inhibitor,MoA,Phase 3
849,4167,MEK inhibitor,MoA,Preclinical
234,4178,hypoxia inducible factor inhibitor,MoA,Phase 1
706,4187,vitamin K,MoA,Phase 2
180,4187,vitamin K,MoA,Phase 2
4186,4187,vitamin K,MoA,Phase 2
4189,4190,MALT1 inhibitor (JH),MoA,Phase 2
232,4197,topoisomerase inhibitor,MoA,Phase 2
247,4199,HDAC inhibitor,MoA,Preclinical
249,4199,HDAC inhibitor,MoA,Preclinical
612,4200,inosine monophosphate dehydrogenase inhibitor,MoA,Phase 2
14,4205,dopamine receptor agonist,MoA,Phase 2
15,4205,dopamine receptor agonist,MoA,Phase 2
16,4205,dopamine receptor agonist,MoA,Phase 2
77,4205,dopamine receptor agonist,MoA,Phase 2
957,4205,dopamine receptor agonist,MoA,Phase 2
624,4205,dopamine receptor agonist,MoA,Phase 2
625,4205,dopamine receptor agonist,MoA,Phase 2
174,4207,cyclooxygenase inhibitor|opioid receptor agonist,MoA,Withdrawn
301,4210,Bcr-Abl kinase inhibitor,MoA,Phase 1
1083,4210,Bcr-Abl kinase inhibitor,MoA,Phase 1
45,4211,adrenergic receptor antagonist,MoA,Phase 2
339,4212,immunostimulant,MoA,Phase 2
205,4216,acetylcholinesterase inhibitor,MoA,Phase 2
97,4218,histamine receptor antagonist,MoA,Withdrawn
407,4223,angiotensin converting enzyme inhibitor,MoA,Phase 2
4022,4229,DNA repair enzyme inhibitor,MoA,Phase 2
73,4238,acetylcholine receptor antagonist,MoA,Preclinical
43,4242,acetylcholine receptor antagonist,MoA,Preclinical
11,4249,anti-HCVE2,MoA,Preclinical
12,4249,anti-HCVE2,MoA,Preclinical
13,4249,anti-HCVE2,MoA,Preclinical
488,4249,anti-HCVE2,MoA,Preclinical
489,4249,anti-HCVE2,MoA,Preclinical
14,4249,anti-HCVE2,MoA,Preclinical
15,4249,anti-HCVE2,MoA,Preclinical
16,4249,anti-HCVE2,MoA,Preclinical
17,4249,anti-HCVE2,MoA,Preclinical
624,4249,anti-HCVE2,MoA,Preclinical
625,4249,anti-HCVE2,MoA,Preclinical
174,4255,cyclooxygenase inhibitor,MoA,Launched
171,4255,cyclooxygenase inhibitor,MoA,Launched
205,4256,acetylcholinesterase inhibitor,MoA,Phase 3
477,4259,HMGCR inhibitor,MoA,Preclinical
2556,4261,PARP inhibitor,MoA,Preclinical
596,4262,estrogen receptor agonist,MoA,Phase 3
457,4262,estrogen receptor agonist,MoA,Phase 3
1360,4263,proteasome inhibitor,MoA,Preclinical
43,4264,acetylcholine receptor antagonist,MoA,Preclinical
1329,4265,VEGFR inhibitor,MoA,Preclinical
430,4265,VEGFR inhibitor,MoA,Preclinical
4266,4267,PI4K inhibitor,MoA,Preclinical
665,4269,glutamate receptor modulator,MoA,Phase 2
2596,4270,T-type calcium channel blocker,MoA,Withdrawn
639,4270,T-type calcium channel blocker,MoA,Withdrawn
641,4270,T-type calcium channel blocker,MoA,Withdrawn
642,4270,T-type calcium channel blocker,MoA,Withdrawn
103,4270,T-type calcium channel blocker,MoA,Withdrawn
105,4270,T-type calcium channel blocker,MoA,Withdrawn
106,4270,T-type calcium channel blocker,MoA,Withdrawn
643,4270,T-type calcium channel blocker,MoA,Withdrawn
2562,4270,T-type calcium channel blocker,MoA,Withdrawn
2563,4270,T-type calcium channel blocker,MoA,Withdrawn
2564,4270,T-type calcium channel blocker,MoA,Withdrawn
2565,4270,T-type calcium channel blocker,MoA,Withdrawn
493,4270,T-type calcium channel blocker,MoA,Withdrawn
495,4270,T-type calcium channel blocker,MoA,Withdrawn
496,4270,T-type calcium channel blocker,MoA,Withdrawn
497,4270,T-type calcium channel blocker,MoA,Withdrawn
154,4272,glutamate receptor antagonist,MoA,Phase 3
155,4272,glutamate receptor antagonist,MoA,Phase 3
156,4272,glutamate receptor antagonist,MoA,Phase 3
157,4272,glutamate receptor antagonist,MoA,Phase 3
200,4275,PPAR receptor antagonist,MoA,Phase 2
1248,4280,monoamine oxidase inhibitor,MoA,Phase 3
1258,4284,DNA replication inhibitor,MoA,Preclinical
1003,4284,DNA replication inhibitor,MoA,Preclinical
1004,4284,DNA replication inhibitor,MoA,Preclinical
801,4284,DNA replication inhibitor,MoA,Preclinical
205,4285,serotonin reuptake inhibitor,MoA,Withdrawn
73,4285,serotonin reuptake inhibitor,MoA,Withdrawn
6,4285,serotonin reuptake inhibitor,MoA,Withdrawn
7,4285,serotonin reuptake inhibitor,MoA,Withdrawn
14,4285,serotonin reuptake inhibitor,MoA,Withdrawn
15,4285,serotonin reuptake inhibitor,MoA,Withdrawn
16,4285,serotonin reuptake inhibitor,MoA,Withdrawn
569,4285,serotonin reuptake inhibitor,MoA,Withdrawn
410,4285,serotonin reuptake inhibitor,MoA,Withdrawn
4290,4291,MRE11A exonuclease inhibitor,MoA,Preclinical
4296,4297,antitumor agent,MoA,Phase 2
519,4303,cannabinoid receptor antagonist,MoA,Preclinical
217,4304,niacin receptor agonist,MoA,Phase 2
219,4304,niacin receptor agonist,MoA,Phase 2
696,4305,androgen receptor modulator,MoA,Phase 2
1306,4306,CC chemokine receptor antagonist,MoA,Phase 2
3850,4307,glucagon receptor antagonist,MoA,Phase 2
4308,4309,WEE1 kinase inhibitor,MoA,Phase 2
49,4310,AKT inhibitor,MoA,Phase 2
749,4310,AKT inhibitor,MoA,Phase 2
750,4310,AKT inhibitor,MoA,Phase 2
53,4311,TRPV antagonist,MoA,Phase 2
1008,4312,FGFR inhibitor|VEGFR inhibitor,MoA,Phase 1/Phase 2
350,4312,FGFR inhibitor|VEGFR inhibitor,MoA,Phase 1/Phase 2
351,4312,FGFR inhibitor|VEGFR inhibitor,MoA,Phase 1/Phase 2
939,4312,FGFR inhibitor|VEGFR inhibitor,MoA,Phase 1/Phase 2
128,4312,FGFR inhibitor|VEGFR inhibitor,MoA,Phase 1/Phase 2
940,4312,FGFR inhibitor|VEGFR inhibitor,MoA,Phase 1/Phase 2
244,4312,FGFR inhibitor|VEGFR inhibitor,MoA,Phase 1/Phase 2
1331,4312,FGFR inhibitor|VEGFR inhibitor,MoA,Phase 1/Phase 2
430,4312,FGFR inhibitor|VEGFR inhibitor,MoA,Phase 1/Phase 2
1332,4312,FGFR inhibitor|VEGFR inhibitor,MoA,Phase 1/Phase 2
631,4312,FGFR inhibitor|VEGFR inhibitor,MoA,Phase 1/Phase 2
632,4312,FGFR inhibitor|VEGFR inhibitor,MoA,Phase 1/Phase 2
131,4312,FGFR inhibitor|VEGFR inhibitor,MoA,Phase 1/Phase 2
498,4313,prostaglandin inhibitor,MoA,Preclinical
1233,4314,calcitonin antagonist,MoA,Phase 2
243,4315,orexin receptor antagonist,MoA,Phase 2
4316,4317,bombesin receptor agonist,MoA,Preclinical
3224,4317,bombesin receptor agonist,MoA,Preclinical
4318,4317,bombesin receptor agonist,MoA,Preclinical
452,4319,Aurora kinase inhibitor,MoA,Phase 1
563,4319,Aurora kinase inhibitor,MoA,Phase 1
564,4319,Aurora kinase inhibitor,MoA,Phase 1
298,4320,leukotriene receptor antagonist,MoA,Phase 2
1816,4320,leukotriene receptor antagonist,MoA,Phase 2
241,4321,orexin receptor antagonist,MoA,Phase 2
243,4321,orexin receptor antagonist,MoA,Phase 2
430,4322,c-Met inhibitor,MoA,Phase 1
65,4323,stearoyl-CoA desaturase inhibitor,MoA,Phase 2
452,4324,Aurora kinase inhibitor,MoA,Preclinical
4325,4326,MAP kinase inhibitor,MoA,Preclinical
781,4327,mTOR inhibitor,MoA,Phase 2
474,4327,mTOR inhibitor,MoA,Phase 2
138,4327,mTOR inhibitor,MoA,Phase 2
476,4327,mTOR inhibitor,MoA,Phase 2
474,4328,PI3K inhibitor,MoA,Phase 2
452,4329,Aurora kinase inhibitor,MoA,Phase 1
77,4330,serotonin receptor partial agonist,MoA,Preclinical
957,4330,serotonin receptor partial agonist,MoA,Preclinical
490,4330,serotonin receptor partial agonist,MoA,Preclinical
1618,4331,GTPase inhibitor,MoA,Preclinical
4332,4333,CLK inhibitor|DYRK inhibitor,MoA,Preclinical
1059,4333,CLK inhibitor|DYRK inhibitor,MoA,Preclinical
4334,4335,liver receptor homolog inverse agonist,MoA,Preclinical
525,4336,G protein-coupled receptor antagonist,MoA,Preclinical
4337,4338,transient receptor potential channel antagonist,MoA,Preclinical
1744,4338,transient receptor potential channel antagonist,MoA,Preclinical
1191,4339,potassium channel activator,MoA,Preclinical
103,4340,T-type calcium channel blocker,MoA,Preclinical
105,4340,T-type calcium channel blocker,MoA,Preclinical
106,4340,T-type calcium channel blocker,MoA,Preclinical
234,4341,hypoxia inducible factor activator,MoA,Preclinical
2302,4342,potassium channel activator,MoA,Preclinical
4343,4344,serine/threonine kinase inhibitor,MoA,Preclinical
4345,4346,inward rectifier potassium channel activator,MoA,Preclinical
1775,4347,phospholipase inhibitor,MoA,Preclinical
4153,4348,neurotensin agonist,MoA,Preclinical
4349,4350,ubiquitin specific protease inhibitor,MoA,Preclinical
4351,4352,histone lysine demethylase inhibitor,MoA,Preclinical
421,4353,MAP kinase inhibitor,MoA,Preclinical
553,4353,MAP kinase inhibitor,MoA,Preclinical
555,4353,MAP kinase inhibitor,MoA,Preclinical
405,4353,MAP kinase inhibitor,MoA,Preclinical
303,4354,ALK tyrosine kinase receptor inhibitor,MoA,Preclinical
305,4354,ALK tyrosine kinase receptor inhibitor,MoA,Preclinical
2537,4354,ALK tyrosine kinase receptor inhibitor,MoA,Preclinical
4355,4356,lysophospholipase inhibitor,MoA,Preclinical
692,4357,potassium channel blocker,MoA,Preclinical
693,4357,potassium channel blocker,MoA,Preclinical
946,4358,RAF inhibitor,MoA,Preclinical
948,4358,RAF inhibitor,MoA,Preclinical
798,4359,myosin light chain kinase inhibitor,MoA,Preclinical
222,4360,retinoid receptor antagonist,MoA,Preclinical
11,4361,serotonin receptor antagonist,MoA,Preclinical
2677,4362,tankyrase inhibitor,MoA,Preclinical
247,4363,HDAC inhibitor,MoA,Phase 2
1144,4363,HDAC inhibitor,MoA,Phase 2
249,4363,HDAC inhibitor,MoA,Phase 2
250,4363,HDAC inhibitor,MoA,Phase 2
569,4366,monoamine oxidase inhibitor,MoA,Phase 1
1248,4366,monoamine oxidase inhibitor,MoA,Phase 1
2902,4368,hypoxia inducible factor inhibitor,MoA,Phase 3
821,4373,kinesin inhibitor,MoA,Preclinical
275,4377,cytochrome P450 inhibitor,MoA,Preclinical
116,4377,cytochrome P450 inhibitor,MoA,Preclinical
1674,4377,cytochrome P450 inhibitor,MoA,Preclinical
1292,4377,cytochrome P450 inhibitor,MoA,Preclinical
3914,4377,cytochrome P450 inhibitor,MoA,Preclinical
2622,4378,other antibiotic,MoA,Launched
939,4380,KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,MoA,Phase 3
940,4380,KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,MoA,Phase 3
244,4380,KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,MoA,Phase 3
129,4380,KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,MoA,Phase 3
3484,4381,toll-like receptor agonist,MoA,Phase 2
2117,4385,glutamate receptor antagonist,MoA,Preclinical
2414,4385,glutamate receptor antagonist,MoA,Preclinical
160,4385,glutamate receptor antagonist,MoA,Preclinical
4386,4387,mitotic kinase inhibitor,MoA,Preclinical
4386,4388,monopolar spindle 1 kinase inhibitor,MoA,Preclinical
4386,4389,monopolar spindle 1 kinase inhibitor,MoA,Preclinical
2342,4390,thromboxane synthase inhibitor,MoA,Phase 1
79,4391,GABA receptor inverse agonist,MoA,Phase 1
140,4391,GABA receptor inverse agonist,MoA,Phase 1
141,4391,GABA receptor inverse agonist,MoA,Phase 1
142,4391,GABA receptor inverse agonist,MoA,Phase 1
1196,4392,gamma secretase inhibitor,MoA,Preclinical
276,4393,adenosine receptor antagonist,MoA,Preclinical
277,4393,adenosine receptor antagonist,MoA,Preclinical
277,4394,adenosine receptor antagonist,MoA,Preclinical
4395,4396,purinergic receptor antagonist,MoA,Preclinical
69,4397,adenosine receptor antagonist,MoA,Preclinical
275,4397,adenosine receptor antagonist,MoA,Preclinical
276,4397,adenosine receptor antagonist,MoA,Preclinical
277,4397,adenosine receptor antagonist,MoA,Preclinical
537,4398,CC chemokine receptor antagonist,MoA,Phase 2
1256,4399,glutamate receptor antagonist,MoA,Preclinical
1835,4399,glutamate receptor antagonist,MoA,Preclinical
346,4400,protein tyrosine kinase inhibitor,MoA,Phase 1
348,4400,protein tyrosine kinase inhibitor,MoA,Phase 1
79,4401,benzodiazepine receptor agonist,MoA,Phase 1
140,4401,benzodiazepine receptor agonist,MoA,Phase 1
141,4401,benzodiazepine receptor agonist,MoA,Phase 1
81,4401,benzodiazepine receptor agonist,MoA,Phase 1
142,4401,benzodiazepine receptor agonist,MoA,Phase 1
143,4401,benzodiazepine receptor agonist,MoA,Phase 1
3050,4401,benzodiazepine receptor agonist,MoA,Phase 1
3051,4401,benzodiazepine receptor agonist,MoA,Phase 1
3052,4401,benzodiazepine receptor agonist,MoA,Phase 1
23,4402,phosphodiesterase inhibitor|platelet aggregation inhibitor,MoA,Preclinical
476,4405,androgen receptor agonist|cytochrome P450 inhibitor,MoA,Preclinical
1287,4406,PKC inhibitor,MoA,Preclinical
1284,4406,PKC inhibitor,MoA,Preclinical
694,4407,transient receptor potential channel antagonist,MoA,Preclinical
623,4417,histamine receptor agonist,MoA,Phase 3
3335,4418,ubiquitin ligase transport promoter,MoA,Preclinical
4420,4421,free radical scavenger,MoA,Launched
2986,4421,free radical scavenger,MoA,Launched
426,4421,free radical scavenger,MoA,Launched
1973,4421,free radical scavenger,MoA,Launched
4422,4421,free radical scavenger,MoA,Launched
1980,4421,free radical scavenger,MoA,Launched
4423,4421,free radical scavenger,MoA,Launched
477,4421,free radical scavenger,MoA,Launched
754,4421,free radical scavenger,MoA,Launched
1997,4421,free radical scavenger,MoA,Launched
936,4421,free radical scavenger,MoA,Launched
163,4421,free radical scavenger,MoA,Launched
322,4421,free radical scavenger,MoA,Launched
2073,4421,free radical scavenger,MoA,Launched
799,4421,free radical scavenger,MoA,Launched
7,4426,dopamine receptor antagonist,MoA,Preclinical
8,4426,dopamine receptor antagonist,MoA,Preclinical
11,4426,dopamine receptor antagonist,MoA,Preclinical
510,4436,opioid receptor antagonist,MoA,Preclinical
511,4436,opioid receptor antagonist,MoA,Preclinical
339,4438,opioid receptor antagonist,MoA,Preclinical
510,4438,opioid receptor antagonist,MoA,Preclinical
511,4438,opioid receptor antagonist,MoA,Preclinical
339,4439,opioid receptor antagonist,MoA,Preclinical
510,4439,opioid receptor antagonist,MoA,Preclinical
511,4439,opioid receptor antagonist,MoA,Preclinical
45,4440,serotonin receptor agonist,MoA,Preclinical
47,4440,serotonin receptor agonist,MoA,Preclinical
48,4440,serotonin receptor agonist,MoA,Preclinical
11,4440,serotonin receptor agonist,MoA,Preclinical
489,4440,serotonin receptor agonist,MoA,Preclinical
227,4441,STAT inhibitor,MoA,Phase 3
596,4445,aromatase inhibitor|TRPV antagonist,MoA,Phase 1
753,4445,aromatase inhibitor|TRPV antagonist,MoA,Phase 1
116,4445,aromatase inhibitor|TRPV antagonist,MoA,Phase 1
1087,4445,aromatase inhibitor|TRPV antagonist,MoA,Phase 1
754,4445,aromatase inhibitor|TRPV antagonist,MoA,Phase 1
4448,4449,cytochrome P450 inhibitor,MoA,Preclinical
12,4450,serotonin receptor antagonist,MoA,Preclinical
1185,4451,CCK receptor antagonist,MoA,Phase 2
450,4453,voltage-gated sodium channel blocker,MoA,Preclinical
3507,4454,CC chemokine receptor antagonist,MoA,Phase 2
1011,4454,CC chemokine receptor antagonist,MoA,Phase 2
110,4455,BCL inhibitor,MoA,Phase 2
112,4455,BCL inhibitor,MoA,Phase 2
113,4455,BCL inhibitor,MoA,Phase 2
728,4456,corticotropin releasing factor receptor antagonist,MoA,Preclinical
550,4457,CC chemokine receptor antagonist,MoA,Preclinical
665,4458,glutamate receptor antagonist,MoA,Preclinical
663,4458,glutamate receptor antagonist,MoA,Preclinical
667,4458,glutamate receptor antagonist,MoA,Preclinical
668,4458,glutamate receptor antagonist,MoA,Preclinical
906,4458,glutamate receptor antagonist,MoA,Preclinical
153,4458,glutamate receptor antagonist,MoA,Preclinical
154,4458,glutamate receptor antagonist,MoA,Preclinical
155,4458,glutamate receptor antagonist,MoA,Preclinical
24,4459,GABA receptor antagonist,MoA,Preclinical
26,4459,GABA receptor antagonist,MoA,Preclinical
4460,4459,GABA receptor antagonist,MoA,Preclinical
4461,4462,complement antagonist,MoA,Preclinical
633,4463,sigma receptor antagonist,MoA,Phase 2
73,4465,acetylcholine receptor agonist,MoA,Phase 3
69,4466,adenosine receptor agonist,MoA,Launched
275,4466,adenosine receptor agonist,MoA,Launched
276,4466,adenosine receptor agonist,MoA,Launched
277,4466,adenosine receptor agonist,MoA,Launched
4467,4468,RIPK inhibitor,MoA,Preclinical
3904,4469,necroptosis inhibitor|RIPK inhibitor,MoA,Preclinical
45,4472,adrenergic inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotonin reuptake inhibitor,MoA,Withdrawn
47,4472,adrenergic inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotonin reuptake inhibitor,MoA,Withdrawn
1,4472,adrenergic inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotonin reuptake inhibitor,MoA,Withdrawn
421,4472,adrenergic inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotonin reuptake inhibitor,MoA,Withdrawn
11,4472,adrenergic inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotonin reuptake inhibitor,MoA,Withdrawn
14,4472,adrenergic inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotonin reuptake inhibitor,MoA,Withdrawn
16,4472,adrenergic inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotonin reuptake inhibitor,MoA,Withdrawn
571,4472,adrenergic inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotonin reuptake inhibitor,MoA,Withdrawn
620,4472,adrenergic inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotonin reuptake inhibitor,MoA,Withdrawn
410,4472,adrenergic inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotonin reuptake inhibitor,MoA,Withdrawn
73,4473,acetylcholine receptor agonist|benzodiazepine receptor agonist,MoA,Phase 3
230,4477,topoisomerase inhibitor,MoA,Phase 2
232,4477,topoisomerase inhibitor,MoA,Phase 2
2503,4481,dopamine beta hydroxylase inhibitor,MoA,Phase 2
4485,4486,neural stem cell inducer,MoA,Preclinical
4487,4486,neural stem cell inducer,MoA,Preclinical
247,4489,HDAC inhibitor,MoA,Preclinical
251,4489,HDAC inhibitor,MoA,Preclinical
213,4490,NFkB pathway inhibitor,MoA,Preclinical
1287,4491,nitric oxide synthase inhibitor,MoA,Phase 1
598,4491,nitric oxide synthase inhibitor,MoA,Phase 1
881,4491,nitric oxide synthase inhibitor,MoA,Phase 1
8,4492,dopamine receptor antagonist,MoA,Preclinical
9,4493,dopamine receptor antagonist,MoA,Phase 1
728,4494,corticotropin releasing factor receptor antagonist,MoA,Preclinical
2005,4495,lactate dehydrogenase inhibitor,MoA,Preclinical
4496,4497,bromodomain inhibitor,MoA,Preclinical
4498,4497,bromodomain inhibitor,MoA,Preclinical
4499,4497,bromodomain inhibitor,MoA,Preclinical
2694,4504,monoamine oxidase inhibitor,MoA,Withdrawn
569,4504,monoamine oxidase inhibitor,MoA,Withdrawn
1248,4504,monoamine oxidase inhibitor,MoA,Withdrawn
519,4514,cannabinoid receptor antagonist,MoA,Preclinical
165,4516,adrenergic receptor antagonist,MoA,Launched
417,4516,adrenergic receptor antagonist,MoA,Launched
45,4521,adrenergic receptor antagonist,MoA,Preclinical
571,4530,norepinephrine reuptake inhibitor,MoA,Phase 1
620,4530,norepinephrine reuptake inhibitor,MoA,Phase 1
410,4530,norepinephrine reuptake inhibitor,MoA,Phase 1
2694,4531,catechol O methyltransferase inhibitor,MoA,Phase 2
73,4533,cholinergic receptor antagonist,MoA,Preclinical
4536,4537,nuclear factor erythroid derived|like (NRF2) activator,MoA,Preclinical
2079,4538,adenylyl cyclase inhibitor,MoA,Preclinical
2706,4539,"indoleamine 2,3-dioxygenase inhibitor",MoA,Phase 1
153,4540,glutamate receptor agonist,MoA,Preclinical
154,4540,glutamate receptor agonist,MoA,Preclinical
155,4540,glutamate receptor agonist,MoA,Preclinical
156,4540,glutamate receptor agonist,MoA,Preclinical
157,4540,glutamate receptor agonist,MoA,Preclinical
128,4541,PLK inhibitor,MoA,Phase 2
1228,4541,PLK inhibitor,MoA,Phase 2
1229,4541,PLK inhibitor,MoA,Phase 2
1230,4541,PLK inhibitor,MoA,Phase 2
1628,4542,ATPase inhibitor,MoA,Preclinical
1622,4543,glucosidase inhibitor,MoA,Preclinical
3284,4544,GABA uptake inhibitor|GAT inhibitor,MoA,Preclinical
493,4545,T-type calcium channel blocker,MoA,Preclinical
495,4545,T-type calcium channel blocker,MoA,Preclinical
496,4545,T-type calcium channel blocker,MoA,Preclinical
497,4545,T-type calcium channel blocker,MoA,Preclinical
1099,4546,opioid receptor agonist,MoA,Preclinical
633,4547,GABA uptake inhibitor,MoA,Preclinical
1784,4547,GABA uptake inhibitor,MoA,Preclinical
171,4548,cyclooxygenase inhibitor,MoA,Phase 2
805,4549,MEK inhibitor,MoA,Preclinical
3165,4550,tubulin polymerization inhibitor,MoA,Preclinical
1548,4551,thymidylate synthase inhibitor,MoA,Phase 3
7,4553,dopamine reuptake inhibitor|noradrenaline uptake inhibitor,MoA,Withdrawn
571,4553,dopamine reuptake inhibitor|noradrenaline uptake inhibitor,MoA,Withdrawn
620,4553,dopamine reuptake inhibitor|noradrenaline uptake inhibitor,MoA,Withdrawn
339,4555,opioid receptor antagonist,MoA,Preclinical
510,4555,opioid receptor antagonist,MoA,Preclinical
511,4555,opioid receptor antagonist,MoA,Preclinical
15,4562,selective serotonin reuptake inhibitor (SSRI),MoA,Phase 1
200,4568,ICAM1 antagonist,MoA,Phase 2
2596,4569,chloride channel blocker,MoA,Preclinical
792,4569,chloride channel blocker,MoA,Preclinical
4570,4569,chloride channel blocker,MoA,Preclinical
67,4569,chloride channel blocker,MoA,Preclinical
1530,4571,calcium receptor antagonist,MoA,Preclinical
1707,4572,neuropeptide receptor antagonist,MoA,Preclinical
678,4573,caspase inhibitor,MoA,Preclinical
969,4574,JAK inhibitor,MoA,Phase 1/Phase 2
369,4574,JAK inhibitor,MoA,Phase 1/Phase 2
370,4574,JAK inhibitor,MoA,Phase 1/Phase 2
2872,4574,JAK inhibitor,MoA,Phase 1/Phase 2
1309,4575,calcium-activated potassium channel activator,MoA,Preclinical
617,4576,voltage-gated potassium channel activator,MoA,Preclinical
2297,4576,voltage-gated potassium channel activator,MoA,Preclinical
1309,4576,voltage-gated potassium channel activator,MoA,Preclinical
1309,4577,calcium-activated potassium channel activator,MoA,Preclinical
1243,4578,calcium-activated potassium channel activator,MoA,Preclinical
2349,4578,calcium-activated potassium channel activator,MoA,Preclinical
2351,4578,calcium-activated potassium channel activator,MoA,Preclinical
853,4578,calcium-activated potassium channel activator,MoA,Preclinical
617,4579,voltage-gated potassium channel activator,MoA,Preclinical
59,4580,acetylcholine receptor agonist,MoA,Preclinical
2227,4580,acetylcholine receptor agonist,MoA,Preclinical
628,4581,voltage-gated potassium channel activator,MoA,Preclinical
1309,4582,potassium channel agonist,MoA,Phase 2
1243,4583,calcium-activated potassium channel modulator,MoA,Preclinical
2349,4583,calcium-activated potassium channel modulator,MoA,Preclinical
2351,4583,calcium-activated potassium channel modulator,MoA,Preclinical
61,4584,acetylcholine receptor allosteric modulator,MoA,Preclinical
247,4585,HDAC inhibitor,MoA,Preclinical
766,4586,matrix metalloprotease inhibitor,MoA,Preclinical
262,4587,ACAT inhibitor|sterol regulatory element binding protein (SREBP) inhibitor,MoA,Phase 2
72,4588,CC chemokine receptor agonist,MoA,Preclinical
371,4589,CDK inhibitor,MoA,Preclinical
90,4589,CDK inhibitor,MoA,Preclinical
4590,4591,ubiquitin specific protease inhibitor,MoA,Preclinical
4349,4591,ubiquitin specific protease inhibitor,MoA,Preclinical
4592,4591,ubiquitin specific protease inhibitor,MoA,Preclinical
4593,4591,ubiquitin specific protease inhibitor,MoA,Preclinical
4351,4594,histone demethylase inhibitor,MoA,Preclinical
4595,4594,histone demethylase inhibitor,MoA,Preclinical
4596,4597,CDC inhibitor,MoA,Preclinical
731,4597,CDC inhibitor,MoA,Preclinical
4598,4597,CDC inhibitor,MoA,Preclinical
4599,4600,ubiquitin-conjugating enzyme inhibitor,MoA,Preclinical
4596,4601,CDC inhibitor,MoA,Preclinical
731,4601,CDC inhibitor,MoA,Preclinical
61,4602,acetylcholine receptor antagonist,MoA,Preclinical
503,4602,acetylcholine receptor antagonist,MoA,Preclinical
1707,4603,neuropeptide receptor antagonist,MoA,Preclinical
3931,4604,neurotensin receptor antagonist,MoA,Preclinical
200,4605,PPAR receptor agonist,MoA,Preclinical
364,4606,IGF-1 inhibitor,MoA,Preclinical
366,4607,PARP inhibitor,MoA,Preclinical
2146,4608,cyclin D inhibitor,MoA,Preclinical
371,4608,cyclin D inhibitor,MoA,Preclinical
2146,4609,CDK inhibitor,MoA,Preclinical
371,4609,CDK inhibitor,MoA,Preclinical
1526,4610,DNA dependent protein kinase inhibitor|mTOR inhibitor|PI3K inhibitor,MoA,Preclinical
1526,4611,DNA dependent protein kinase inhibitor,MoA,Preclinical
546,4612,MDM inhibitor,MoA,Preclinical
761,4612,MDM inhibitor,MoA,Preclinical
364,4613,insulin growth factor receptor inhibitor,MoA,Preclinical
364,4614,IGF-1 inhibitor,MoA,Preclinical
1672,4614,IGF-1 inhibitor,MoA,Preclinical
507,4615,HSP inhibitor,MoA,Phase 2
1648,4615,HSP inhibitor,MoA,Phase 2
1020,4616,mTOR inhibitor|PI3K inhibitor,MoA,Phase 3
781,4616,mTOR inhibitor|PI3K inhibitor,MoA,Phase 3
474,4616,mTOR inhibitor|PI3K inhibitor,MoA,Phase 3
138,4616,mTOR inhibitor|PI3K inhibitor,MoA,Phase 3
476,4616,mTOR inhibitor|PI3K inhibitor,MoA,Phase 3
1008,4617,FGFR inhibitor,MoA,Phase 3
350,4617,FGFR inhibitor,MoA,Phase 3
351,4617,FGFR inhibitor,MoA,Phase 3
1010,4617,FGFR inhibitor,MoA,Phase 3
244,4617,FGFR inhibitor,MoA,Phase 3
4618,4619,ephrin inhibitor,MoA,Preclinical
369,4620,JAK inhibitor,MoA,Preclinical
430,4621,MET inhibitor,MoA,Preclinical
469,4622,dipeptidyl peptidase inhibitor,MoA,Phase 2
507,4623,HSP inhibitor,MoA,Phase 1
1648,4623,HSP inhibitor,MoA,Phase 1
2360,4624,protein tyrosine kinase inhibitor,MoA,Preclinical
309,4625,ALK tyrosine kinase receptor inhibitor,MoA,Preclinical
1672,4625,ALK tyrosine kinase receptor inhibitor,MoA,Preclinical
2679,4626,tankyrase inhibitor,MoA,Preclinical
4627,4628,ceramidase inhibitor,MoA,Preclinical
3013,4629,p21 activated kinase inhibitor,MoA,Preclinical
69,4630,adenosine receptor agonist,MoA,Preclinical
275,4630,adenosine receptor agonist,MoA,Preclinical
276,4630,adenosine receptor agonist,MoA,Preclinical
277,4630,adenosine receptor agonist,MoA,Preclinical
2468,4630,adenosine receptor agonist,MoA,Preclinical
1954,4631,alcohol dehydrogenase inhibitor,MoA,Phase 1/Phase 2
4633,4634,Oct activator,MoA,Preclinical
110,4635,BCL inhibitor,MoA,Phase 3
227,4638,STAT inhibitor,MoA,Phase 1
79,4639,GABA receptor modulator,MoA,Phase 3
140,4639,GABA receptor modulator,MoA,Phase 3
141,4639,GABA receptor modulator,MoA,Phase 3
142,4639,GABA receptor modulator,MoA,Phase 3
755,4640,trace amine associated receptor agonist,MoA,Preclinical
2740,4640,trace amine associated receptor agonist,MoA,Preclinical
971,4645,CRTH receptor antagonist,MoA,Phase 2
1093,4646,cathepsin inhibitor,MoA,Phase 3
3560,4647,guanylyl cyclase inhibitor,MoA,Preclinical
1119,4647,guanylyl cyclase inhibitor,MoA,Preclinical
1121,4647,guanylyl cyclase inhibitor,MoA,Preclinical
4496,4648,bromodomain inhibitor,MoA,Preclinical
3218,4649,histone lysine demethylase inhibitor,MoA,Preclinical
4650,4651,WDR5/MLL interaction inhibitor,MoA,Preclinical
744,4654,TRPV agonist,MoA,Preclinical
625,4655,cannabinoid receptor agonist,MoA,Preclinical
2443,4655,cannabinoid receptor agonist,MoA,Preclinical
1215,4656,G protein-coupled receptor agonist,MoA,Preclinical
519,4657,cannabinoid receptor agonist|glucose dependent insulinotropic receptor agonist|potassium channel blocker|PPAR receptor agonist,MoA,Preclinical
744,4657,cannabinoid receptor agonist|glucose dependent insulinotropic receptor agonist|potassium channel blocker|PPAR receptor agonist,MoA,Preclinical
525,4657,cannabinoid receptor agonist|glucose dependent insulinotropic receptor agonist|potassium channel blocker|PPAR receptor agonist,MoA,Preclinical
1218,4657,cannabinoid receptor agonist|glucose dependent insulinotropic receptor agonist|potassium channel blocker|PPAR receptor agonist,MoA,Preclinical
2784,4658,estrogen receptor agonist,MoA,Phase 2
4659,4660,ATP synthase inhibitor|ATPase inhibitor,MoA,Preclinical
512,4664,CDK inhibitor,MoA,Preclinical
371,4664,CDK inhibitor,MoA,Preclinical
514,4664,CDK inhibitor,MoA,Preclinical
828,4664,CDK inhibitor,MoA,Preclinical
1848,4672,nuclear factor erythroid derived|like (NRF2) activator,MoA,Phase 3
519,4673,TRPV agonist,MoA,Preclinical
744,4673,TRPV agonist,MoA,Preclinical
53,4673,TRPV agonist,MoA,Preclinical
407,4674,metalloproteinase inhibitor,MoA,Preclinical
3654,4674,metalloproteinase inhibitor,MoA,Preclinical
744,4676,FAAH inhibitor,MoA,Preclinical
4677,4678,cardiac myosin activator,MoA,Phase 3
4681,4682,AKT inhibitor|MAP kinase inhibitor,MoA,Phase 2
498,4684,prostanoid receptor antagonist,MoA,Preclinical
134,4685,Bruton's tyrosine kinase (BTK) inhibitor,MoA,Phase 1
1113,4686,matrix metalloprotease inhibitor,MoA,Phase 1
394,4687,prostanoid receptor antagonist,MoA,Preclinical
90,4688,CDK inhibitor,MoA,Preclinical
3368,4688,CDK inhibitor,MoA,Preclinical
131,4688,CDK inhibitor,MoA,Preclinical
71,4689,vasopressin receptor antagonist,MoA,Phase 1
904,4689,vasopressin receptor antagonist,MoA,Phase 1
905,4689,vasopressin receptor antagonist,MoA,Phase 1
2694,4690,catechol O methyltransferase inhibitor,MoA,Phase 3
2694,4691,catechol O methyltransferase inhibitor,MoA,Preclinical
452,4692,FGFR inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,MoA,Phase 3
563,4692,FGFR inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,MoA,Phase 3
346,4692,FGFR inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,MoA,Phase 3
1008,4692,FGFR inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,MoA,Phase 3
350,4692,FGFR inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,MoA,Phase 3
244,4692,FGFR inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,MoA,Phase 3
130,4692,FGFR inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,MoA,Phase 3
131,4692,FGFR inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,MoA,Phase 3
3976,4693,angiotensin converting enzyme inhibitor,MoA,Phase 1/Phase 2
14,4694,serotonin receptor agonist,MoA,Phase 2
15,4694,serotonin receptor agonist,MoA,Phase 2
16,4694,serotonin receptor agonist,MoA,Phase 2
996,4695,glycine transporter inhibitor,MoA,Preclinical
1007,4695,glycine transporter inhibitor,MoA,Preclinical
519,4696,cannabinoid receptor modulator,MoA,Preclinical
1,4697,adrenergic receptor antagonist,MoA,Phase 1
110,4698,BCL inhibitor,MoA,Preclinical
1001,4703,NFkB pathway modulator,MoA,Launched
1099,4705,opioid receptor agonist,MoA,Phase 1
511,4705,opioid receptor agonist,MoA,Phase 1
95,4706,androgen biosynthesis inhibitor|androgen receptor antagonist|cytochrome P450 inhibitor,MoA,Phase 3
3218,4707,histone lysine demethylase inhibitor,MoA,Phase 1/Phase 2
11,4711,serotonin receptor agonist,MoA,Phase 2/Phase 3
781,4712,mTOR inhibitor,MoA,Phase 1
346,4713,EGFR inhibitor,MoA,Preclinical
939,4714,KIT inhibitor|VEGFR inhibitor,MoA,Phase 1
244,4714,KIT inhibitor|VEGFR inhibitor,MoA,Phase 1
129,4714,KIT inhibitor|VEGFR inhibitor,MoA,Phase 1
696,4717,androgen receptor modulator,MoA,Phase 3
71,4718,oxytocin receptor antagonist,MoA,Preclinical
905,4718,oxytocin receptor antagonist,MoA,Preclinical
755,4719,coagulation factor inhibitor,MoA,Phase 3
73,4720,acetylcholine receptor antagonist,MoA,Phase 3
74,4720,acetylcholine receptor antagonist,MoA,Phase 3
75,4720,acetylcholine receptor antagonist,MoA,Phase 3
76,4720,acetylcholine receptor antagonist,MoA,Phase 3
170,4720,acetylcholine receptor antagonist,MoA,Phase 3
4722,4723,maternal embryonic leucine zipper kinase inhibitor,MoA,Phase 1/Phase 2
3405,4724,bromodomain inhibitor,MoA,Phase 1/Phase 2
736,4724,bromodomain inhibitor,MoA,Phase 1/Phase 2
836,4724,bromodomain inhibitor,MoA,Phase 1/Phase 2
839,4726,rho associated kinase inhibitor,MoA,Preclinical
912,4726,rho associated kinase inhibitor,MoA,Preclinical
836,4730,bromodomain inhibitor,MoA,Preclinical
2820,4731,carnitine palmitoyltransferase inhibitor,MoA,Phase 1
4732,4731,carnitine palmitoyltransferase inhibitor,MoA,Phase 1
73,4734,acetylcholine receptor agonist,MoA,Preclinical
74,4734,acetylcholine receptor agonist,MoA,Preclinical
75,4734,acetylcholine receptor agonist,MoA,Preclinical
76,4734,acetylcholine receptor agonist,MoA,Preclinical
73,4735,cholinergic receptor agonist,MoA,Preclinical
74,4735,cholinergic receptor agonist,MoA,Preclinical
75,4735,cholinergic receptor agonist,MoA,Preclinical
76,4735,cholinergic receptor agonist,MoA,Preclinical
457,4742,xanthine oxidase inhibitor,MoA,Phase 2/Phase 3
2211,4746,sphingosine 1-phosphate receptor agonist,MoA,Phase 3
4633,4747,Oct inducer,MoA,Preclinical
3763,4748,O6-alkylguanine-DNA alkyltransferase inhibitor,MoA,Phase 3
224,4749,retinoid receptor antagonist,MoA,Preclinical
678,4750,caspase activator,MoA,Phase 1
2978,4752,phospholipase inhibitor,MoA,Preclinical
128,4753,FLT3 inhibitor|JAK inhibitor,MoA,Phase 3
969,4753,FLT3 inhibitor|JAK inhibitor,MoA,Phase 3
369,4753,FLT3 inhibitor|JAK inhibitor,MoA,Phase 3
370,4753,FLT3 inhibitor|JAK inhibitor,MoA,Phase 3
421,4756,dopamine synthesis inhibitor,MoA,Preclinical
521,4757,cannabinoid receptor agonist,MoA,Launched
744,4757,cannabinoid receptor agonist,MoA,Launched
525,4757,cannabinoid receptor agonist,MoA,Launched
781,4758,AKT inhibitor|mTOR inhibitor,MoA,Phase 1
132,4760,urotensin receptor antagonist,MoA,Phase 2
222,4761,retinoid receptor agonist,MoA,Phase 3
7,4766,dopamine receptor modulator,MoA,Preclinical
114,4771,tubulin polymerization inhibitor,MoA,Preclinical
7,4772,dopamine receptor agonist|serotonin receptor agonist,MoA,Phase 3
8,4772,dopamine receptor agonist|serotonin receptor agonist,MoA,Phase 3
9,4772,dopamine receptor agonist|serotonin receptor agonist,MoA,Phase 3
11,4772,dopamine receptor agonist|serotonin receptor agonist,MoA,Phase 3
625,4772,dopamine receptor agonist|serotonin receptor agonist,MoA,Phase 3
247,4777,NFkB pathway inhibitor,MoA,Preclinical
212,4778,NFkB pathway inhibitor,MoA,Preclinical
213,4778,NFkB pathway inhibitor,MoA,Preclinical
101,4784,platelet activating factor receptor antagonist,MoA,Phase 1
247,4785,HDAC inhibitor,MoA,Phase 3
249,4785,HDAC inhibitor,MoA,Phase 3
250,4785,HDAC inhibitor,MoA,Phase 3
251,4785,HDAC inhibitor,MoA,Phase 3
134,4786,Bruton's tyrosine kinase (BTK) inhibitor,MoA,Preclinical
247,4787,HDAC inhibitor,MoA,Preclinical
1143,4787,HDAC inhibitor,MoA,Preclinical
251,4787,HDAC inhibitor,MoA,Preclinical
252,4787,HDAC inhibitor,MoA,Preclinical
2141,4788,potassium channel activator,MoA,Phase 1
805,4789,MEK inhibitor,MoA,Phase 2
76,4790,acetylcholine receptor antagonist,MoA,Preclinical
617,4791,potassium channel activator,MoA,Preclinical
1049,4792,angiotensin antagonist,MoA,Phase 1
7,4793,dopamine receptor agonist,MoA,Preclinical
8,4793,dopamine receptor agonist,MoA,Preclinical
346,4794,EGFR inhibitor,MoA,Phase 1
244,4794,EGFR inhibitor,MoA,Phase 1
238,4795,endothelin receptor antagonist,MoA,Preclinical
240,4795,endothelin receptor antagonist,MoA,Preclinical
346,4796,EGFR inhibitor,MoA,Preclinical
2608,4797,neuropeptide receptor antagonist,MoA,Preclinical
1008,4798,FGFR inhibitor,MoA,Preclinical
346,4799,SRC inhibitor,MoA,Preclinical
1008,4799,SRC inhibitor,MoA,Preclinical
131,4799,SRC inhibitor,MoA,Preclinical
4800,4799,SRC inhibitor,MoA,Preclinical
1054,4799,SRC inhibitor,MoA,Preclinical
4308,4799,SRC inhibitor,MoA,Preclinical
767,4801,collagenase inhibitor|metalloproteinase inhibitor,MoA,Preclinical
1112,4801,collagenase inhibitor|metalloproteinase inhibitor,MoA,Preclinical
1826,4801,collagenase inhibitor|metalloproteinase inhibitor,MoA,Preclinical
7,4802,dopamine receptor agonist,MoA,Preclinical
346,4803,EGFR inhibitor,MoA,Preclinical
348,4803,EGFR inhibitor,MoA,Preclinical
1054,4803,EGFR inhibitor,MoA,Preclinical
7,4804,dopamine receptor antagonist,MoA,Preclinical
9,4804,dopamine receptor antagonist,MoA,Preclinical
1008,4805,FGFR inhibitor|VEGFR inhibitor,MoA,Preclinical
350,4805,FGFR inhibitor|VEGFR inhibitor,MoA,Preclinical
351,4805,FGFR inhibitor|VEGFR inhibitor,MoA,Preclinical
1010,4805,FGFR inhibitor|VEGFR inhibitor,MoA,Preclinical
939,4805,FGFR inhibitor|VEGFR inhibitor,MoA,Preclinical
940,4805,FGFR inhibitor|VEGFR inhibitor,MoA,Preclinical
244,4805,FGFR inhibitor|VEGFR inhibitor,MoA,Preclinical
130,4805,FGFR inhibitor|VEGFR inhibitor,MoA,Preclinical
131,4805,FGFR inhibitor|VEGFR inhibitor,MoA,Preclinical
381,4806,calcium channel blocker,MoA,Preclinical
805,4807,MEK inhibitor,MoA,Phase 2
1031,4807,MEK inhibitor,MoA,Phase 2
1380,4807,MEK inhibitor,MoA,Phase 2
805,4808,MAP kinase inhibitor|MEK inhibitor,MoA,Preclinical
849,4808,MAP kinase inhibitor|MEK inhibitor,MoA,Preclinical
4308,4809,PKC inhibitor,MoA,Preclinical
69,4810,adenosine receptor agonist,MoA,Preclinical
49,4811,MEK inhibitor,MoA,Preclinical
1026,4811,MEK inhibitor,MoA,Preclinical
32,4811,MEK inhibitor,MoA,Preclinical
1283,4811,MEK inhibitor,MoA,Preclinical
805,4811,MEK inhibitor,MoA,Preclinical
828,4811,MEK inhibitor,MoA,Preclinical
553,4811,MEK inhibitor,MoA,Preclinical
555,4811,MEK inhibitor,MoA,Preclinical
405,4811,MEK inhibitor,MoA,Preclinical
726,4811,MEK inhibitor,MoA,Preclinical
1284,4811,MEK inhibitor,MoA,Preclinical
948,4811,MEK inhibitor,MoA,Preclinical
839,4811,MEK inhibitor,MoA,Preclinical
1285,4811,MEK inhibitor,MoA,Preclinical
1705,4811,MEK inhibitor,MoA,Preclinical
1515,4812,phosphodiesterase inhibitor,MoA,Preclinical
528,4813,FAAH activator,MoA,Preclinical
4814,4815,programmed death ligand inhibitor,MoA,Preclinical
14,4818,serotonin receptor antagonist,MoA,Phase 2
346,4819,EGFR inhibitor,MoA,Phase 2
1623,4832,aspartic protease inhibitor,MoA,Preclinical
4833,4832,aspartic protease inhibitor,MoA,Preclinical
1349,4832,aspartic protease inhibitor,MoA,Preclinical
454,4832,aspartic protease inhibitor,MoA,Preclinical
224,4834,retinoid receptor agonist,MoA,Phase 3
45,4835,dopamine receptor agonist,MoA,Withdrawn
47,4835,dopamine receptor agonist,MoA,Withdrawn
48,4835,dopamine receptor agonist,MoA,Withdrawn
1,4835,dopamine receptor agonist,MoA,Withdrawn
3,4835,dopamine receptor agonist,MoA,Withdrawn
4,4835,dopamine receptor agonist,MoA,Withdrawn
6,4835,dopamine receptor agonist,MoA,Withdrawn
7,4835,dopamine receptor agonist,MoA,Withdrawn
8,4835,dopamine receptor agonist,MoA,Withdrawn
9,4835,dopamine receptor agonist,MoA,Withdrawn
10,4835,dopamine receptor agonist,MoA,Withdrawn
11,4835,dopamine receptor agonist,MoA,Withdrawn
12,4835,dopamine receptor agonist,MoA,Withdrawn
13,4835,dopamine receptor agonist,MoA,Withdrawn
14,4835,dopamine receptor agonist,MoA,Withdrawn
15,4835,dopamine receptor agonist,MoA,Withdrawn
16,4835,dopamine receptor agonist,MoA,Withdrawn
49,4837,AKT inhibitor,MoA,Phase 3
815,4838,apoptosis stimulant|farnesyltransferase inhibitor,MoA,Phase 2
407,4840,angiotensin converting enzyme inhibitor,MoA,Phase 2
153,4843,glutamate receptor antagonist,MoA,Phase 2
154,4843,glutamate receptor antagonist,MoA,Phase 2
155,4843,glutamate receptor antagonist,MoA,Phase 2
678,4844,caspase activator,MoA,Preclinical
319,4845,nedd activating enzyme inhibitor,MoA,Phase 3
4846,4845,nedd activating enzyme inhibitor,MoA,Phase 3
126,4847,tyrosine kinase inhibitor,MoA,Launched
128,4847,tyrosine kinase inhibitor,MoA,Launched
129,4847,tyrosine kinase inhibitor,MoA,Launched
405,4848,MAP kinase inhibitor|TIE tyrosine kinase inhibitor,MoA,Phase 1
246,4848,MAP kinase inhibitor|TIE tyrosine kinase inhibitor,MoA,Phase 1
1515,4849,phosphodiesterase inhibitor,MoA,Phase 2
23,4850,phosphodiesterase inhibitor,MoA,Phase 2
3017,4851,p21 activated kinase inhibitor,MoA,Phase 1
452,4852,Aurora kinase inhibitor,MoA,Phase 1
563,4852,Aurora kinase inhibitor,MoA,Phase 1
430,4853,c-Met inhibitor,MoA,Phase 1
395,4854,prostaglandin inhibitor,MoA,Phase 1
1525,4855,phosphodiesterase inhibitor,MoA,Phase 2
528,4856,FAAH inhibitor,MoA,Phase 2
63,4857,diacylglycerol O acyltransferase inhibitor,MoA,Phase 1
781,4858,mTOR inhibitor|PI3K inhibitor,MoA,Phase 2
474,4858,mTOR inhibitor|PI3K inhibitor,MoA,Phase 2
55,4859,voltage-gated sodium channel blocker,MoA,Preclinical
3121,4860,glucokinase activator,MoA,Phase 2
687,4861,growth hormone secretagogue receptor inverse agonist,MoA,Phase 2
781,4862,mTOR inhibitor|PI3K inhibitor,MoA,Phase 2
474,4862,mTOR inhibitor|PI3K inhibitor,MoA,Phase 2
2232,4863,serine/threonine kinase inhibitor,MoA,Preclinical
71,4866,oxytocin receptor antagonist,MoA,Phase 2
905,4866,oxytocin receptor antagonist,MoA,Phase 2
528,4867,FAAH inhibitor,MoA,Preclinical
4868,4869,SREBP inhibitor,MoA,Preclinical
2360,4870,focal adhesion kinase inhibitor,MoA,Preclinical
3102,4870,focal adhesion kinase inhibitor,MoA,Preclinical
1285,4871,ribosomal protein inhibitor,MoA,Preclinical
1026,4872,CHK inhibitor,MoA,Phase 1
1028,4872,CHK inhibitor,MoA,Phase 1
2253,4873,casein kinase inhibitor,MoA,Preclinical
3451,4873,casein kinase inhibitor,MoA,Preclinical
421,4874,cytochrome P450 inhibitor,MoA,Preclinical
1335,4875,smoothened receptor antagonist,MoA,Preclinical
2360,4876,focal adhesion kinase inhibitor,MoA,Phase 1
3102,4876,focal adhesion kinase inhibitor,MoA,Phase 1
512,4877,focal adhesion kinase inhibitor,MoA,Preclinical
371,4877,focal adhesion kinase inhibitor,MoA,Preclinical
515,4877,focal adhesion kinase inhibitor,MoA,Preclinical
32,4877,focal adhesion kinase inhibitor,MoA,Preclinical
212,4877,focal adhesion kinase inhibitor,MoA,Preclinical
2253,4878,casein kinase inhibitor,MoA,Preclinical
3451,4878,casein kinase inhibitor,MoA,Preclinical
528,4879,FAAH inhibitor,MoA,Preclinical
921,4880,autotaxin inhibitor,MoA,Preclinical
202,4881,11-beta hydroxysteroid dehydrogenase inhibitor,MoA,Phase 1
836,4882,bromodomain inhibitor,MoA,Preclinical
4883,4884,bromodomain inhibitor,MoA,Preclinical
4885,4884,bromodomain inhibitor,MoA,Preclinical
4498,4886,bromodomain inhibitor,MoA,Preclinical
4887,4888,phosphofructokinase inhibitor,MoA,Phase 1
4887,4889,phosphofructokinase inhibitor,MoA,Phase 1
4890,4891,JNK inhibitor,MoA,Phase 2
726,4891,JNK inhibitor,MoA,Phase 2
4892,4891,JNK inhibitor,MoA,Phase 2
553,4893,p38 MAPK inhibitor,MoA,Phase 2
405,4893,p38 MAPK inhibitor,MoA,Phase 2
43,4894,nicotinic receptor agonist,MoA,Preclinical
430,4895,c-Met inhibitor,MoA,Preclinical
452,4896,Aurora kinase inhibitor,MoA,Preclinical
563,4896,Aurora kinase inhibitor,MoA,Preclinical
564,4896,Aurora kinase inhibitor,MoA,Preclinical
512,4897,CDC inhibitor,MoA,Preclinical
1285,4897,CDC inhibitor,MoA,Preclinical
512,4898,CDK inhibitor,MoA,Phase 1
371,4898,CDK inhibitor,MoA,Phase 1
90,4898,CDK inhibitor,MoA,Phase 1
514,4898,CDK inhibitor,MoA,Phase 1
515,4898,CDK inhibitor,MoA,Phase 1
517,4898,CDK inhibitor,MoA,Phase 1
371,4899,CDK inhibitor|growth factor receptor inhibitor,MoA,Phase 2
90,4899,CDK inhibitor|growth factor receptor inhibitor,MoA,Phase 2
515,4899,CDK inhibitor|growth factor receptor inhibitor,MoA,Phase 2
631,4899,CDK inhibitor|growth factor receptor inhibitor,MoA,Phase 2
2117,4900,glutamate receptor agonist,MoA,Preclinical
2414,4900,glutamate receptor agonist,MoA,Preclinical
174,4902,cyclooxygenase inhibitor,MoA,Withdrawn
3557,4907,anticancer agent,MoA,Phase 2
2141,4908,AMPK activator,MoA,Withdrawn
290,4908,AMPK activator,MoA,Withdrawn
4520,4913,indicator dye,MoA,Withdrawn
205,4916,acetylcholinesterase inhibitor|beta amyloid synthesis inhibitor,MoA,Phase 3
759,4916,acetylcholinesterase inhibitor|beta amyloid synthesis inhibitor,MoA,Phase 3
2737,4918,cyclooxygenase inhibitor|prostanoid receptor antagonist,MoA,Withdrawn
174,4918,cyclooxygenase inhibitor|prostanoid receptor antagonist,MoA,Withdrawn
171,4918,cyclooxygenase inhibitor|prostanoid receptor antagonist,MoA,Withdrawn
761,4922,p53 stabilizing agent,MoA,Preclinical
4923,4924,sodium/glucose cotransporter inhibitor,MoA,Launched
4925,4924,sodium/glucose cotransporter inhibitor,MoA,Launched
858,4924,sodium/glucose cotransporter inhibitor,MoA,Launched
703,4926,sodium/glucose cotransporter inhibitor,MoA,Preclinical
4927,4926,sodium/glucose cotransporter inhibitor,MoA,Preclinical
1542,4926,sodium/glucose cotransporter inhibitor,MoA,Preclinical
4928,4926,sodium/glucose cotransporter inhibitor,MoA,Preclinical
900,4929,aryl hydrocarbon receptor ligand,MoA,Phase 1
79,4930,GABA receptor antagonist,MoA,Preclinical
145,4930,GABA receptor antagonist,MoA,Preclinical
149,4930,GABA receptor antagonist,MoA,Preclinical
749,4931,AKT inhibitor|pyruvate dehydrogenase inhibitor,MoA,Preclinical
789,4931,AKT inhibitor|pyruvate dehydrogenase inhibitor,MoA,Preclinical
116,4932,estrogen receptor antagonist,MoA,Preclinical
781,4935,mTOR inhibitor|PI3K inhibitor,MoA,Preclinical
474,4935,mTOR inhibitor|PI3K inhibitor,MoA,Preclinical
136,4935,mTOR inhibitor|PI3K inhibitor,MoA,Preclinical
138,4935,mTOR inhibitor|PI3K inhibitor,MoA,Preclinical
476,4935,mTOR inhibitor|PI3K inhibitor,MoA,Preclinical
1526,4935,mTOR inhibitor|PI3K inhibitor,MoA,Preclinical
15,4936,serotonin receptor antagonist,MoA,Phase 2
490,4936,serotonin receptor antagonist,MoA,Phase 2
2419,4937,H+/K+-ATPase inhibitor,MoA,Phase 2
4659,4938,SYK inhibitor,MoA,Preclinical
4939,4938,SYK inhibitor,MoA,Preclinical
4940,4938,SYK inhibitor,MoA,Preclinical
4941,4938,SYK inhibitor,MoA,Preclinical
18,4942,phosphodiesterase inhibitor,MoA,Phase 2
20,4942,phosphodiesterase inhibitor,MoA,Phase 2
21,4942,phosphodiesterase inhibitor,MoA,Phase 2
22,4942,phosphodiesterase inhibitor,MoA,Phase 2
690,4944,GABA receptor antagonist,MoA,Phase 2
994,4944,GABA receptor antagonist,MoA,Phase 2
995,4944,GABA receptor antagonist,MoA,Phase 2
996,4944,GABA receptor antagonist,MoA,Phase 2
690,4945,GABA receptor antagonist,MoA,Preclinical
994,4945,GABA receptor antagonist,MoA,Preclinical
995,4945,GABA receptor antagonist,MoA,Preclinical
996,4945,GABA receptor antagonist,MoA,Preclinical
77,4945,GABA receptor antagonist,MoA,Preclinical
957,4945,GABA receptor antagonist,MoA,Preclinical
761,4954,TP53 inhibitor,MoA,Preclinical
761,4955,TP53 inhibitor,MoA,Preclinical
1244,4956,HSP inhibitor,MoA,Preclinical
761,4956,HSP inhibitor,MoA,Preclinical
474,4957,PI3K inhibitor,MoA,Preclinical
136,4957,PI3K inhibitor,MoA,Preclinical
138,4957,PI3K inhibitor,MoA,Preclinical
476,4957,PI3K inhibitor,MoA,Preclinical
136,4958,PI3K inhibitor,MoA,Preclinical
138,4958,PI3K inhibitor,MoA,Preclinical
476,4958,PI3K inhibitor,MoA,Preclinical
474,4959,DNA protein kinase inhibitor|PI3K inhibitor,MoA,Preclinical
136,4959,DNA protein kinase inhibitor|PI3K inhibitor,MoA,Preclinical
138,4959,DNA protein kinase inhibitor|PI3K inhibitor,MoA,Preclinical
476,4959,DNA protein kinase inhibitor|PI3K inhibitor,MoA,Preclinical
1526,4959,DNA protein kinase inhibitor|PI3K inhibitor,MoA,Preclinical
4266,4960,PI3K inhibitor,MoA,Preclinical
4961,4960,PI3K inhibitor,MoA,Preclinical
476,4960,PI3K inhibitor,MoA,Preclinical
289,4964,Pim kinase inhibitor,MoA,Preclinical
11,4971,adrenergic receptor antagonist|serotonin receptor antagonist,MoA,Phase 2
753,4972,cytochrome P450 inhibitor,MoA,Phase 2
569,4979,monoamine oxidase inhibitor,MoA,Phase 1
1248,4979,monoamine oxidase inhibitor,MoA,Phase 1
53,4979,monoamine oxidase inhibitor,MoA,Phase 1
14,4984,serotonin receptor antagonist,MoA,Preclinical
625,4984,serotonin receptor antagonist,MoA,Preclinical
14,4990,dopamine receptor antagonist|serotonin receptor antagonist,MoA,Phase 2
1218,4991,PPAR receptor agonist,MoA,Preclinical
603,4994,phosphodiesterase inhibitor,MoA,Phase 2
321,4995,purinergic receptor antagonist,MoA,Preclinical
100,4997,histamine receptor antagonist,MoA,Launched
247,5000,HDAC inhibitor,MoA,Phase 2
249,5000,HDAC inhibitor,MoA,Phase 2
250,5000,HDAC inhibitor,MoA,Phase 2
252,5000,HDAC inhibitor,MoA,Phase 2
279,5003,PI4K inhibitor,MoA,Preclinical
5004,5005,PARP inhibitor,MoA,Preclinical
366,5005,PARP inhibitor,MoA,Preclinical
5006,5005,PARP inhibitor,MoA,Preclinical
2556,5005,PARP inhibitor,MoA,Preclinical
693,5007,potassium channel blocker,MoA,Preclinical
2256,5008,benzodiazepine receptor antagonist,MoA,Phase 1
469,5009,dipeptidyl peptidase inhibitor,MoA,Preclinical
346,5010,EGFR inhibitor,MoA,Phase 1
781,5011,mTOR inhibitor|PI3K inhibitor,MoA,Phase 1
65,5017,stearoyl-CoA desaturase inhibitor,MoA,Preclinical
946,5018,RAF inhibitor,MoA,Preclinical
244,5018,RAF inhibitor,MoA,Preclinical
126,5019,receptor tyrosine protein kinase inhibitor,MoA,Preclinical
129,5019,receptor tyrosine protein kinase inhibitor,MoA,Preclinical
946,5020,serine/threonine kinase inhibitor,MoA,Phase 1/Phase 2
3783,5021,glutamate receptor antagonist,MoA,Preclinical
43,5022,acetylcholine receptor agonist,MoA,Preclinical
13,5023,serotonin receptor agonist,MoA,Phase 2
8,5024,dopamine receptor antagonist,MoA,Preclinical
14,5025,serotonin receptor agonist,MoA,Phase 2
15,5025,serotonin receptor agonist,MoA,Phase 2
16,5025,serotonin receptor agonist,MoA,Phase 2
569,5025,serotonin receptor agonist,MoA,Phase 2
1248,5025,serotonin receptor agonist,MoA,Phase 2
43,5026,cholinergic receptor agonist,MoA,Preclinical
1596,5027,beta-catenin inhibitor,MoA,Preclinical
3449,5027,beta-catenin inhibitor,MoA,Preclinical
24,5028,benzodiazepine receptor agonist,MoA,Preclinical
1068,5030,ICAM1 expression inhibitor,MoA,Phase 2
959,5031,immunostimulant,MoA,Preclinical
936,5031,immunostimulant,MoA,Preclinical
262,5031,immunostimulant,MoA,Preclinical
2211,5034,sphingosine 1-phosphate receptor agonist,MoA,Phase 3
61,5037,acetylcholine receptor antagonist,MoA,Phase 2
503,5037,acetylcholine receptor antagonist,MoA,Phase 2
346,5038,EGFR inhibitor,MoA,Phase 2
348,5038,EGFR inhibitor,MoA,Phase 2
349,5038,EGFR inhibitor,MoA,Phase 2
1379,5039,SRC inhibitor,MoA,Preclinical
741,5039,SRC inhibitor,MoA,Preclinical
301,5040,protein tyrosine kinase inhibitor,MoA,Preclinical
346,5040,protein tyrosine kinase inhibitor,MoA,Preclinical
1379,5040,protein tyrosine kinase inhibitor,MoA,Preclinical
244,5040,protein tyrosine kinase inhibitor,MoA,Preclinical
781,5040,protein tyrosine kinase inhibitor,MoA,Preclinical
130,5040,protein tyrosine kinase inhibitor,MoA,Preclinical
474,5040,protein tyrosine kinase inhibitor,MoA,Preclinical
136,5040,protein tyrosine kinase inhibitor,MoA,Preclinical
138,5040,protein tyrosine kinase inhibitor,MoA,Preclinical
476,5040,protein tyrosine kinase inhibitor,MoA,Preclinical
1526,5040,protein tyrosine kinase inhibitor,MoA,Preclinical
1054,5040,protein tyrosine kinase inhibitor,MoA,Preclinical
301,5041,SRC inhibitor,MoA,Preclinical
1283,5041,SRC inhibitor,MoA,Preclinical
3904,5041,SRC inhibitor,MoA,Preclinical
1054,5041,SRC inhibitor,MoA,Preclinical
354,5042,estrogen receptor agonist,MoA,Preclinical
301,5043,Abl kinase inhibitor,MoA,Preclinical
1083,5043,Abl kinase inhibitor,MoA,Preclinical
781,5044,mTOR inhibitor,MoA,Preclinical
5045,5044,mTOR inhibitor,MoA,Preclinical
364,5046,IGF-1 inhibitor,MoA,Preclinical
165,5047,adrenergic receptor antagonist,MoA,Withdrawn
639,5052,calcium channel blocker,MoA,Phase 2
519,5057,cyclooxygenase inhibitor,MoA,Preclinical
521,5057,cyclooxygenase inhibitor,MoA,Preclinical
633,5060,sigma receptor agonist,MoA,Preclinical
7,5061,dopamine receptor agonist,MoA,Phase 2
423,5065,glucocorticoid receptor agonist,MoA,Preclinical
95,5069,GABA receptor negative allosteric modulator,MoA,Preclinical
69,5070,adenosine receptor antagonist,MoA,Phase 3
275,5070,adenosine receptor antagonist,MoA,Phase 3
276,5070,adenosine receptor antagonist,MoA,Phase 3
277,5070,adenosine receptor antagonist,MoA,Phase 3
1674,5071,nitric oxide donor,MoA,Launched
205,5073,TP53 inhibitor,MoA,Preclinical
116,5075,estrogen receptor agonist,MoA,Phase 2
2091,5075,estrogen receptor agonist,MoA,Phase 2
381,5076,sodium channel blocker,MoA,Phase 3
1287,5077,nitric oxide synthase inhibitor,MoA,Preclinical
813,5091,topical anesthetic,MoA,Phase 2
1183,5094,CCK receptor antagonist,MoA,Withdrawn
1185,5094,CCK receptor antagonist,MoA,Withdrawn
417,5108,adrenergic receptor antagonist,MoA,Preclinical
567,5108,adrenergic receptor antagonist,MoA,Preclinical
165,5109,adrenergic receptor antagonist,MoA,Preclinical
11,5109,adrenergic receptor antagonist,MoA,Preclinical
17,5109,adrenergic receptor antagonist,MoA,Preclinical
2201,5109,adrenergic receptor antagonist,MoA,Preclinical
1991,5115,heme oxygenase inhibitor,MoA,Preclinical
100,5117,histamine receptor modulator,MoA,Preclinical
1125,5119,JAK inhibitor|SYK inhibitor,MoA,Phase 2/Phase 3
2337,5120,SYK inhibitor,MoA,Phase 2
3090,5120,SYK inhibitor,MoA,Phase 2
1125,5120,SYK inhibitor,MoA,Phase 2
5121,5122,polycomb repressive complex inhibitor,MoA,Preclinical
14,5124,serotonin receptor antagonist,MoA,Phase 2
16,5124,serotonin receptor antagonist,MoA,Phase 2
15,5125,serotonin receptor antagonist,MoA,Phase 2
5126,5127,NTPDase inhibitor,MoA,Preclinical
69,5128,adenosine receptor antagonist,MoA,Preclinical
275,5128,adenosine receptor antagonist,MoA,Preclinical
277,5128,adenosine receptor antagonist,MoA,Preclinical
69,5129,adenosine receptor antagonist,MoA,Preclinical
276,5129,adenosine receptor antagonist,MoA,Preclinical
277,5129,adenosine receptor antagonist,MoA,Preclinical
69,5130,adenosine receptor antagonist,MoA,Preclinical
275,5130,adenosine receptor antagonist,MoA,Preclinical
276,5130,adenosine receptor antagonist,MoA,Preclinical
277,5130,adenosine receptor antagonist,MoA,Preclinical
69,5131,adenosine receptor antagonist,MoA,Preclinical
275,5131,adenosine receptor antagonist,MoA,Preclinical
276,5131,adenosine receptor antagonist,MoA,Preclinical
277,5131,adenosine receptor antagonist,MoA,Preclinical
744,5132,glucose dependent insulinotropic receptor agonist,MoA,Preclinical
519,5133,cannabinoid receptor modulator,MoA,Preclinical
696,5135,androgen receptor modulator,MoA,Phase 1
5136,5137,hypoxia inducible factor inhibitor,MoA,Phase 1
171,5138,cyclooxygenase inhibitor|PPAR receptor agonist,MoA,Phase 2/Phase 3
507,5139,HSP inhibitor,MoA,Phase 1
77,5140,serotonin receptor agonist,MoA,Phase 2
490,5140,serotonin receptor agonist,MoA,Phase 2
1335,5141,smoothened receptor agonist,MoA,Preclinical
709,5142,protein synthesis inhibitor,MoA,Preclinical
711,5142,protein synthesis inhibitor,MoA,Preclinical
712,5142,protein synthesis inhibitor,MoA,Preclinical
713,5142,protein synthesis inhibitor,MoA,Preclinical
714,5142,protein synthesis inhibitor,MoA,Preclinical
715,5142,protein synthesis inhibitor,MoA,Preclinical
716,5142,protein synthesis inhibitor,MoA,Preclinical
717,5142,protein synthesis inhibitor,MoA,Preclinical
718,5142,protein synthesis inhibitor,MoA,Preclinical
719,5142,protein synthesis inhibitor,MoA,Preclinical
720,5142,protein synthesis inhibitor,MoA,Preclinical
721,5142,protein synthesis inhibitor,MoA,Preclinical
722,5142,protein synthesis inhibitor,MoA,Preclinical
512,5143,CDK inhibitor,MoA,Preclinical
371,5143,CDK inhibitor,MoA,Preclinical
90,5143,CDK inhibitor,MoA,Preclinical
514,5143,CDK inhibitor,MoA,Preclinical
5144,5143,CDK inhibitor,MoA,Preclinical
1224,5143,CDK inhibitor,MoA,Preclinical
1054,5143,CDK inhibitor,MoA,Preclinical
371,5145,tyrosine kinase inhibitor,MoA,Preclinical
90,5145,tyrosine kinase inhibitor,MoA,Preclinical
514,5145,tyrosine kinase inhibitor,MoA,Preclinical
828,5145,tyrosine kinase inhibitor,MoA,Preclinical
829,5145,tyrosine kinase inhibitor,MoA,Preclinical
273,5145,tyrosine kinase inhibitor,MoA,Preclinical
5146,5147,tissue transglutaminase inhibitor,MoA,Phase 2
794,5147,tissue transglutaminase inhibitor,MoA,Phase 2
2626,5147,tissue transglutaminase inhibitor,MoA,Phase 2
519,5148,thioredoxin inhibitor,MoA,Phase 2
2241,5148,thioredoxin inhibitor,MoA,Phase 2
4890,5150,JNK inhibitor,MoA,Preclinical
726,5150,JNK inhibitor,MoA,Preclinical
5151,5150,JNK inhibitor,MoA,Preclinical
4892,5150,JNK inhibitor,MoA,Preclinical
4386,5150,JNK inhibitor,MoA,Preclinical
230,5152,topoisomerase inhibitor,MoA,Phase 2
232,5152,topoisomerase inhibitor,MoA,Phase 2
247,5158,HDAC inhibitor,MoA,Phase 1
202,5159,NFkB pathway inhibitor,MoA,Preclinical
213,5159,NFkB pathway inhibitor,MoA,Preclinical
4593,5161,ubiquitin specific protease inhibitor,MoA,Preclinical
512,5162,CDK inhibitor,MoA,Phase 2
90,5162,CDK inhibitor,MoA,Phase 2
517,5162,CDK inhibitor,MoA,Phase 2
4593,5163,ubiquitin specific protease inhibitor,MoA,Preclinical
2922,5164,NAMPT inhibitor,MoA,Preclinical
603,5165,phosphodiesterase inhibitor,MoA,Phase 2
604,5165,phosphodiesterase inhibitor,MoA,Phase 2
403,5170,leukotriene synthesis inhibitor,MoA,Phase 2
680,5170,leukotriene synthesis inhibitor,MoA,Phase 2
7,5174,dopamine receptor agonist,MoA,Phase 3
8,5174,dopamine receptor agonist,MoA,Phase 3
6,5181,dopamine receptor agonist,MoA,Phase 2
7,5181,dopamine receptor agonist,MoA,Phase 2
8,5181,dopamine receptor agonist,MoA,Phase 2
9,5181,dopamine receptor agonist,MoA,Phase 2
11,5181,dopamine receptor agonist,MoA,Phase 2
14,5181,dopamine receptor agonist,MoA,Phase 2
15,5181,dopamine receptor agonist,MoA,Phase 2
16,5181,dopamine receptor agonist,MoA,Phase 2
11,5182,serotonin receptor agonist,MoA,Preclinical
13,5182,serotonin receptor agonist,MoA,Preclinical
14,5182,serotonin receptor agonist,MoA,Preclinical
15,5182,serotonin receptor agonist,MoA,Preclinical
16,5182,serotonin receptor agonist,MoA,Preclinical
77,5182,serotonin receptor agonist,MoA,Preclinical
957,5182,serotonin receptor agonist,MoA,Preclinical
624,5182,serotonin receptor agonist,MoA,Preclinical
410,5182,serotonin receptor agonist,MoA,Preclinical
126,5183,FLT3 inhibitor,MoA,Phase 3
128,5183,FLT3 inhibitor,MoA,Phase 3
129,5183,FLT3 inhibitor,MoA,Phase 3
130,5183,FLT3 inhibitor,MoA,Phase 3
131,5183,FLT3 inhibitor,MoA,Phase 3
741,5183,FLT3 inhibitor,MoA,Phase 3
405,5184,sodium channel blocker,MoA,Preclinical
2840,5184,sodium channel blocker,MoA,Preclinical
624,5185,serotonin receptor antagonist,MoA,Phase 1
2840,5186,serine/threonine kinase inhibitor,MoA,Preclinical
1329,5187,AXL kinase inhibitor,MoA,Phase 2
5188,5189,diacylglycerol kinase inhibitor|protein kinase inhibitor,MoA,Preclinical
14,5190,serotonin receptor antagonist,MoA,Preclinical
24,5192,GABA receptor positive allosteric modulator,MoA,Preclinical
7,5194,dopamine receptor antagonist,MoA,Launched
8,5194,dopamine receptor antagonist,MoA,Launched
11,5194,dopamine receptor antagonist,MoA,Launched
620,5195,dopamine-norepinephrine reuptake inhibitor,MoA,Phase 2
946,5196,RAF inhibitor|VEGFR inhibitor,MoA,Phase 2
255,5203,aldose reductase inhibitor,MoA,Phase 3
1,5207,adrenergic receptor antagonist,MoA,Preclinical
3,5207,adrenergic receptor antagonist,MoA,Preclinical
4,5207,adrenergic receptor antagonist,MoA,Preclinical
12,5207,adrenergic receptor antagonist,MoA,Preclinical
13,5207,adrenergic receptor antagonist,MoA,Preclinical
488,5207,adrenergic receptor antagonist,MoA,Preclinical
15,5207,adrenergic receptor antagonist,MoA,Preclinical
828,5208,ERK1 and ERK2 phosphorylation inhibitor,MoA,Phase 1
829,5208,ERK1 and ERK2 phosphorylation inhibitor,MoA,Phase 1
1390,5209,Ral GTPase inhibitor,MoA,Preclinical
1392,5209,Ral GTPase inhibitor,MoA,Preclinical
301,5211,Bcr-Abl kinase inhibitor|TIE tyrosine kinase inhibitor|VEGFR inhibitor,MoA,Phase 1/Phase 2
1083,5211,Bcr-Abl kinase inhibitor|TIE tyrosine kinase inhibitor|VEGFR inhibitor,MoA,Phase 1/Phase 2
2337,5211,Bcr-Abl kinase inhibitor|TIE tyrosine kinase inhibitor|VEGFR inhibitor,MoA,Phase 1/Phase 2
128,5211,Bcr-Abl kinase inhibitor|TIE tyrosine kinase inhibitor|VEGFR inhibitor,MoA,Phase 1/Phase 2
1379,5211,Bcr-Abl kinase inhibitor|TIE tyrosine kinase inhibitor|VEGFR inhibitor,MoA,Phase 1/Phase 2
1084,5211,Bcr-Abl kinase inhibitor|TIE tyrosine kinase inhibitor|VEGFR inhibitor,MoA,Phase 1/Phase 2
1054,5211,Bcr-Abl kinase inhibitor|TIE tyrosine kinase inhibitor|VEGFR inhibitor,MoA,Phase 1/Phase 2
45,5213,adrenergic receptor antagonist,MoA,Phase 2
805,5214,MEK inhibitor,MoA,Phase 2
849,5214,MEK inhibitor,MoA,Phase 2
71,5217,vasopressin receptor antagonist,MoA,Phase 2
903,5217,vasopressin receptor antagonist,MoA,Phase 2
904,5217,vasopressin receptor antagonist,MoA,Phase 2
905,5217,vasopressin receptor antagonist,MoA,Phase 2
153,5218,glutamate receptor antagonist,MoA,Phase 3
24,5219,benzodiazepine receptor agonist,MoA,Phase 3
5220,5221,transferase inhibitor,MoA,Preclinical
7,5222,dopamine receptor antagonist,MoA,Withdrawn
8,5222,dopamine receptor antagonist,MoA,Withdrawn
9,5222,dopamine receptor antagonist,MoA,Withdrawn
14,5222,dopamine receptor antagonist,MoA,Withdrawn
633,5222,dopamine receptor antagonist,MoA,Withdrawn
3507,5224,CC chemokine receptor antagonist,MoA,Phase 3
1011,5224,CC chemokine receptor antagonist,MoA,Phase 3
2840,5225,TGF beta receptor inhibitor,MoA,Preclinical
2242,5226,toll-like receptor inhibitor,MoA,Phase 3
2520,5228,toll-like receptor agonist,MoA,Phase 3
3484,5228,toll-like receptor agonist,MoA,Phase 3
247,5229,HDAC inhibitor,MoA,Phase 2
250,5229,HDAC inhibitor,MoA,Phase 2
251,5229,HDAC inhibitor,MoA,Phase 2
252,5229,HDAC inhibitor,MoA,Phase 2
2173,5231,cytochrome P450 inhibitor|SIRT activator,MoA,Launched
1602,5231,cytochrome P450 inhibitor|SIRT activator,MoA,Launched
174,5231,cytochrome P450 inhibitor|SIRT activator,MoA,Launched
171,5231,cytochrome P450 inhibitor|SIRT activator,MoA,Launched
507,5232,HSP inhibitor,MoA,Phase 3
403,5246,leukotriene receptor antagonist|lipoxygenase inhibitor,MoA,Phase 2
1172,5248,MRP inhibitor,MoA,Preclinical
563,5249,Aurora kinase inhibitor,MoA,Preclinical
5250,5249,Aurora kinase inhibitor,MoA,Preclinical
805,5249,Aurora kinase inhibitor,MoA,Preclinical
512,5251,CDK inhibitor,MoA,Phase 1
371,5251,CDK inhibitor,MoA,Phase 1
5252,5251,CDK inhibitor,MoA,Phase 1
90,5251,CDK inhibitor,MoA,Phase 1
514,5251,CDK inhibitor,MoA,Phase 1
92,5251,CDK inhibitor,MoA,Phase 1
515,5251,CDK inhibitor,MoA,Phase 1
517,5251,CDK inhibitor,MoA,Phase 1
128,5251,CDK inhibitor,MoA,Phase 1
32,5251,CDK inhibitor,MoA,Phase 1
369,5251,CDK inhibitor,MoA,Phase 1
5253,5251,CDK inhibitor,MoA,Phase 1
4892,5251,CDK inhibitor,MoA,Phase 1
250,5254,HDAC inhibitor,MoA,Preclinical
949,5255,DNA methyltransferase inhibitor,MoA,Preclinical
2166,5255,DNA methyltransferase inhibitor,MoA,Preclinical
1008,5256,FGFR inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,MoA,Phase 1
350,5256,FGFR inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,MoA,Phase 1
247,5257,HDAC inhibitor,MoA,Phase 1
250,5257,HDAC inhibitor,MoA,Phase 1
925,5258,gamma secretase inhibitor,MoA,Phase 2
546,5259,MDM inhibitor,MoA,Phase 1
4700,5260,triacylglycerol lipase inhibitor,MoA,Preclinical
4701,5260,triacylglycerol lipase inhibitor,MoA,Preclinical
1280,5262,protein tyrosine kinase inhibitor,MoA,Preclinical
396,5276,prostanoid receptor agonist,MoA,Launched
1228,5280,cell cycle inhibitor|PLK inhibitor,MoA,Phase 3
633,5285,sigma receptor antagonist,MoA,Phase 1
1233,5286,calcitonin antagonist,MoA,Launched
519,5288,cannabinoid receptor antagonist,MoA,Withdrawn
525,5288,cannabinoid receptor antagonist,MoA,Withdrawn
79,5291,benzodiazepine receptor agonist,MoA,Phase 2
546,5294,MDM inhibitor,MoA,Preclinical
45,5295,serotonin receptor antagonist,MoA,Phase 3
47,5295,serotonin receptor antagonist,MoA,Phase 3
48,5295,serotonin receptor antagonist,MoA,Phase 3
11,5295,serotonin receptor antagonist,MoA,Phase 3
12,5295,serotonin receptor antagonist,MoA,Phase 3
13,5295,serotonin receptor antagonist,MoA,Phase 3
14,5295,serotonin receptor antagonist,MoA,Phase 3
15,5295,serotonin receptor antagonist,MoA,Phase 3
16,5295,serotonin receptor antagonist,MoA,Phase 3
17,5295,serotonin receptor antagonist,MoA,Phase 3
624,5295,serotonin receptor antagonist,MoA,Phase 3
625,5295,serotonin receptor antagonist,MoA,Phase 3
61,5297,acetylcholine receptor agonist,MoA,Phase 2
503,5297,acetylcholine receptor agonist,MoA,Phase 2
1593,5297,acetylcholine receptor agonist,MoA,Phase 2
5301,5302,rho associated kinase inhibitor,MoA,Preclinical
5303,5302,rho associated kinase inhibitor,MoA,Preclinical
2261,5302,rho associated kinase inhibitor,MoA,Preclinical
1536,5302,rho associated kinase inhibitor,MoA,Preclinical
3013,5302,rho associated kinase inhibitor,MoA,Preclinical
5304,5302,rho associated kinase inhibitor,MoA,Preclinical
839,5302,rho associated kinase inhibitor,MoA,Preclinical
912,5302,rho associated kinase inhibitor,MoA,Preclinical
3218,5305,histone demethylase inhibitor,MoA,Preclinical
1552,5306,TRPV antagonist,MoA,Preclinical
1552,5307,TRPV agonist,MoA,Preclinical
155,5308,glutamate receptor antagonist,MoA,Preclinical
5309,5310,NGF binding inhibitor,MoA,Preclinical
3987,5310,NGF binding inhibitor,MoA,Preclinical
9,5311,dopamine receptor agonist,MoA,Preclinical
499,5312,prostanoid receptor antagonist,MoA,Preclinical
79,5313,GABA benzodiazepine site receptor inverse agonist,MoA,Preclinical
140,5313,GABA benzodiazepine site receptor inverse agonist,MoA,Preclinical
141,5313,GABA benzodiazepine site receptor inverse agonist,MoA,Preclinical
81,5313,GABA benzodiazepine site receptor inverse agonist,MoA,Preclinical
142,5313,GABA benzodiazepine site receptor inverse agonist,MoA,Preclinical
143,5313,GABA benzodiazepine site receptor inverse agonist,MoA,Preclinical
145,5313,GABA benzodiazepine site receptor inverse agonist,MoA,Preclinical
149,5313,GABA benzodiazepine site receptor inverse agonist,MoA,Preclinical
79,5314,GABA benzodiazepine site receptor inverse agonist,MoA,Preclinical
140,5314,GABA benzodiazepine site receptor inverse agonist,MoA,Preclinical
141,5314,GABA benzodiazepine site receptor inverse agonist,MoA,Preclinical
142,5314,GABA benzodiazepine site receptor inverse agonist,MoA,Preclinical
603,5315,phosphodiesterase inhibitor,MoA,Preclinical
18,5315,phosphodiesterase inhibitor,MoA,Preclinical
20,5315,phosphodiesterase inhibitor,MoA,Preclinical
21,5315,phosphodiesterase inhibitor,MoA,Preclinical
22,5315,phosphodiesterase inhibitor,MoA,Preclinical
155,5316,glutamate receptor antagonist|monamine transporter modulator,MoA,Preclinical
3121,5317,glucokinase activator,MoA,Preclinical
35,5318,purinergic receptor antagonist,MoA,Preclinical
512,5319,CDK inhibitor,MoA,Preclinical
5320,5321,oxidosqualene cyclase inhibitor,MoA,Preclinical
805,5322,MEK inhibitor,MoA,Phase 1
946,5323,MEK inhibitor|RAF inhibitor,MoA,Phase 1
805,5323,MEK inhibitor|RAF inhibitor,MoA,Phase 1
849,5323,MEK inhibitor|RAF inhibitor,MoA,Phase 1
948,5323,MEK inhibitor|RAF inhibitor,MoA,Phase 1
14,5324,serotonin receptor agonist,MoA,Preclinical
15,5324,serotonin receptor agonist,MoA,Preclinical
16,5324,serotonin receptor agonist,MoA,Preclinical
5325,5326,kynurenine 3-monooxygenase inhibitor,MoA,Preclinical
2117,5327,glutamate receptor positive allosteric modulator,MoA,Preclinical
1196,5328,beta amyloid protein neurotoxicity inhibitor,MoA,Preclinical
11,5329,serotonin receptor antagonist,MoA,Phase 2
346,5330,EGFR inhibitor,MoA,Phase 3
5332,5333,cyclooxygenase inhibitor,MoA,Withdrawn
171,5333,cyclooxygenase inhibitor,MoA,Withdrawn
371,5338,CDK inhibitor,MoA,Phase 2
517,5338,CDK inhibitor,MoA,Phase 2
483,5339,insulin sensitizer|PPAR receptor agonist,MoA,Withdrawn
200,5339,insulin sensitizer|PPAR receptor agonist,MoA,Withdrawn
1744,5339,insulin sensitizer|PPAR receptor agonist,MoA,Withdrawn
1806,5339,insulin sensitizer|PPAR receptor agonist,MoA,Withdrawn
1292,5340,GABA transaminase inhibitor,MoA,Launched
801,5340,GABA transaminase inhibitor,MoA,Launched
463,5341,ATPase inhibitor,MoA,Phase 2
2211,5347,sphingosine 1-phosphate receptor agonist,MoA,Preclinical
694,5348,transient receptor potential channel antagonist,MoA,Preclinical
2370,5349,glucose 6-phosphate dehydrogenase inhibitor,MoA,Phase 3
45,5350,adrenergic receptor antagonist,MoA,Preclinical
48,5350,adrenergic receptor antagonist,MoA,Preclinical
14,5351,serotonin receptor antagonist,MoA,Preclinical
15,5351,serotonin receptor antagonist,MoA,Preclinical
16,5351,serotonin receptor antagonist,MoA,Preclinical
1306,5352,CCR antagonist,MoA,Preclinical
14,5353,serotonin receptor antagonist,MoA,Phase 1
15,5353,serotonin receptor antagonist,MoA,Phase 1
16,5353,serotonin receptor antagonist,MoA,Phase 1
45,5354,adrenergic receptor antagonist,MoA,Preclinical
48,5354,adrenergic receptor antagonist,MoA,Preclinical
490,5355,serotonin receptor antagonist,MoA,Preclinical
490,5356,serotonin receptor antagonist,MoA,Preclinical
1258,5357,CC chemokine receptor antagonist,MoA,Preclinical
1306,5357,CC chemokine receptor antagonist,MoA,Preclinical
77,5358,serotonin receptor partial agonist,MoA,Preclinical
490,5359,serotonin receptor partial agonist,MoA,Preclinical
490,5360,serotonin receptor partial agonist,MoA,Preclinical
1,5361,adrenergic receptor antagonist,MoA,Preclinical
4536,5362,nitric oxide production inhibitor,MoA,Phase 2
5363,5364,hedgehog pathway inhibitor,MoA,Preclinical
11,5365,serotonin receptor agonist,MoA,Phase 1
12,5365,serotonin receptor agonist,MoA,Phase 1
13,5365,serotonin receptor agonist,MoA,Phase 1
14,5365,serotonin receptor agonist,MoA,Phase 1
15,5365,serotonin receptor agonist,MoA,Phase 1
16,5365,serotonin receptor agonist,MoA,Phase 1
17,5365,serotonin receptor agonist,MoA,Phase 1
624,5365,serotonin receptor agonist,MoA,Phase 1
1545,5366,cytochrome P450 inhibitor,MoA,Phase 2
417,5367,adrenergic receptor agonist,MoA,Phase 2
696,5368,androgen receptor antagonist,MoA,Phase 2
230,5369,topoisomerase inhibitor,MoA,Phase 3
366,5370,PARP inhibitor,MoA,Phase 3
122,5370,PARP inhibitor,MoA,Phase 3
801,5371,tyrosinase inhibitor,MoA,Phase 1
171,5374,cyclooxygenase inhibitor,MoA,Preclinical
969,5377,JAK inhibitor,MoA,Preclinical
369,5377,JAK inhibitor,MoA,Preclinical
2520,5378,toll-like receptor agonist,MoA,Phase 2
1068,5379,integrin inhibitor,MoA,Preclinical
405,5380,MAP kinase inhibitor,MoA,Phase 1
171,5380,MAP kinase inhibitor,MoA,Phase 1
371,5381,CDK inhibitor|DNA synthesis inhibitor,MoA,Phase 1/Phase 2
949,5381,CDK inhibitor|DNA synthesis inhibitor,MoA,Phase 1/Phase 2
45,5382,adrenergic receptor antagonist,MoA,Preclinical
47,5382,adrenergic receptor antagonist,MoA,Preclinical
48,5382,adrenergic receptor antagonist,MoA,Preclinical
1,5382,adrenergic receptor antagonist,MoA,Preclinical
3,5382,adrenergic receptor antagonist,MoA,Preclinical
4,5382,adrenergic receptor antagonist,MoA,Preclinical
371,5383,histone lysine methyltransferase inhibitor,MoA,Preclinical
90,5383,histone lysine methyltransferase inhibitor,MoA,Preclinical
1125,5384,SYK inhibitor,MoA,Phase 1
741,5385,SYK inhibitor,MoA,Phase 1
1125,5385,SYK inhibitor,MoA,Phase 1
512,5386,CDK inhibitor,MoA,Phase 1
371,5386,CDK inhibitor,MoA,Phase 1
90,5386,CDK inhibitor,MoA,Phase 1
515,5386,CDK inhibitor,MoA,Phase 1
881,5387,nitric oxide synthase inhibitor,MoA,Preclinical
1280,5389,nitric oxide stimulant,MoA,Phase 1
1824,5390,CAR antagonist,MoA,Preclinical
366,5391,PARP inhibitor,MoA,Phase 2
11,5392,serotonin receptor agonist,MoA,Preclinical
528,5393,FAAH inhibitor,MoA,Preclinical
185,5394,DNA polymerase inhibitor,MoA,Launched
186,5394,DNA polymerase inhibitor,MoA,Launched
188,5394,DNA polymerase inhibitor,MoA,Launched
1617,5394,DNA polymerase inhibitor,MoA,Launched
24,5395,GABA receptor antagonist,MoA,Preclinical
26,5395,GABA receptor antagonist,MoA,Preclinical
1078,5395,GABA receptor antagonist,MoA,Preclinical
1079,5395,GABA receptor antagonist,MoA,Preclinical
1080,5395,GABA receptor antagonist,MoA,Preclinical
1806,5398,PKC inhibitor,MoA,Phase 1
24,5399,benzodiazepine receptor agonist,MoA,Phase 2
1335,5400,smoothened receptor agonist,MoA,Preclinical
798,5400,smoothened receptor agonist,MoA,Preclinical
1196,5402,beta amyloid protein neurotoxicity inhibitor,MoA,Preclinical
67,5403,mTOR inhibitor,MoA,Phase 2
5405,5406,eukaryotic translation initiation factor inhibitor,MoA,Preclinical
84,5407,EGFR inhibitor|metalloproteinase inhibitor,MoA,Phase 2
339,5408,opioid receptor agonist,MoA,Phase 1
510,5408,opioid receptor agonist,MoA,Phase 1
511,5408,opioid receptor agonist,MoA,Phase 1
3570,5409,eukaryotic translation initiation factor inhibitor,MoA,Preclinical
678,5410,apoptosis stimulant,MoA,Phase 1
5411,5412,smoothened receptor antagonist,MoA,Preclinical
1335,5412,smoothened receptor antagonist,MoA,Preclinical
5411,5413,smoothened receptor antagonist,MoA,Preclinical
1335,5413,smoothened receptor antagonist,MoA,Preclinical
781,5416,PI3K inhibitor,MoA,Phase 1/Phase 2
476,5416,PI3K inhibitor,MoA,Phase 1/Phase 2
301,5417,SRC inhibitor,MoA,Phase 2/Phase 3
1283,5417,SRC inhibitor,MoA,Phase 2/Phase 3
1054,5417,SRC inhibitor,MoA,Phase 2/Phase 3
934,5417,SRC inhibitor,MoA,Phase 2/Phase 3
461,5418,glycine transporter inhibitor,MoA,Phase 2
940,5421,VEGFR inhibitor,MoA,Preclinical
4961,5422,PI3K inhibitor,MoA,Preclinical
546,5423,MDM inhibitor,MoA,Phase 1
839,5424,rho associated kinase inhibitor,MoA,Phase 2
430,5426,c-Met inhibitor,MoA,Phase 3
15,5428,serotonin receptor antagonist,MoA,Preclinical
16,5428,serotonin receptor antagonist,MoA,Preclinical
49,5429,p38 MAPK inhibitor,MoA,Preclinical
403,5429,p38 MAPK inhibitor,MoA,Preclinical
1026,5429,p38 MAPK inhibitor,MoA,Preclinical
32,5429,p38 MAPK inhibitor,MoA,Preclinical
1283,5429,p38 MAPK inhibitor,MoA,Preclinical
828,5429,p38 MAPK inhibitor,MoA,Preclinical
553,5429,p38 MAPK inhibitor,MoA,Preclinical
555,5429,p38 MAPK inhibitor,MoA,Preclinical
405,5429,p38 MAPK inhibitor,MoA,Preclinical
726,5429,p38 MAPK inhibitor,MoA,Preclinical
1284,5429,p38 MAPK inhibitor,MoA,Preclinical
839,5429,p38 MAPK inhibitor,MoA,Preclinical
1285,5429,p38 MAPK inhibitor,MoA,Preclinical
1705,5429,p38 MAPK inhibitor,MoA,Preclinical
490,5430,serotonin receptor antagonist,MoA,Preclinical
49,5431,p38 MAPK inhibitor,MoA,Preclinical
403,5431,p38 MAPK inhibitor,MoA,Preclinical
1026,5431,p38 MAPK inhibitor,MoA,Preclinical
1820,5431,p38 MAPK inhibitor,MoA,Preclinical
421,5431,p38 MAPK inhibitor,MoA,Preclinical
5432,5431,p38 MAPK inhibitor,MoA,Preclinical
32,5431,p38 MAPK inhibitor,MoA,Preclinical
1283,5431,p38 MAPK inhibitor,MoA,Preclinical
828,5431,p38 MAPK inhibitor,MoA,Preclinical
4890,5431,p38 MAPK inhibitor,MoA,Preclinical
553,5431,p38 MAPK inhibitor,MoA,Preclinical
555,5431,p38 MAPK inhibitor,MoA,Preclinical
405,5431,p38 MAPK inhibitor,MoA,Preclinical
726,5431,p38 MAPK inhibitor,MoA,Preclinical
4892,5431,p38 MAPK inhibitor,MoA,Preclinical
1284,5431,p38 MAPK inhibitor,MoA,Preclinical
948,5431,p38 MAPK inhibitor,MoA,Preclinical
3904,5431,p38 MAPK inhibitor,MoA,Preclinical
839,5431,p38 MAPK inhibitor,MoA,Preclinical
1285,5431,p38 MAPK inhibitor,MoA,Preclinical
1705,5431,p38 MAPK inhibitor,MoA,Preclinical
1054,5431,p38 MAPK inhibitor,MoA,Preclinical
672,5431,p38 MAPK inhibitor,MoA,Preclinical
141,5433,GABA receptor modulator,MoA,Preclinical
142,5433,GABA receptor modulator,MoA,Preclinical
143,5433,GABA receptor modulator,MoA,Preclinical
14,5434,serotonin receptor antagonist,MoA,Preclinical
15,5434,serotonin receptor antagonist,MoA,Preclinical
16,5434,serotonin receptor antagonist,MoA,Preclinical
11,5435,serotonin receptor antagonist,MoA,Preclinical
12,5435,serotonin receptor antagonist,MoA,Preclinical
13,5435,serotonin receptor antagonist,MoA,Preclinical
14,5435,serotonin receptor antagonist,MoA,Preclinical
15,5435,serotonin receptor antagonist,MoA,Preclinical
16,5435,serotonin receptor antagonist,MoA,Preclinical
2146,5436,glycogen synthase kinase inhibitor,MoA,Preclinical
371,5436,glycogen synthase kinase inhibitor,MoA,Preclinical
30,5436,glycogen synthase kinase inhibitor,MoA,Preclinical
32,5436,glycogen synthase kinase inhibitor,MoA,Preclinical
1026,5437,CHK inhibitor,MoA,Preclinical
5438,5439,tachykinin antagonist,MoA,Preclinical
14,5440,serotonin receptor antagonist,MoA,Preclinical
15,5440,serotonin receptor antagonist,MoA,Preclinical
16,5440,serotonin receptor antagonist,MoA,Preclinical
5438,5441,tachykinin antagonist,MoA,Preclinical
1011,5442,CC chemokine receptor antagonist,MoA,Preclinical
14,5443,serotonin receptor antagonist,MoA,Preclinical
15,5443,serotonin receptor antagonist,MoA,Preclinical
16,5443,serotonin receptor antagonist,MoA,Preclinical
781,5444,mTOR inhibitor|PI3K inhibitor,MoA,Phase 1
474,5444,mTOR inhibitor|PI3K inhibitor,MoA,Phase 1
136,5444,mTOR inhibitor|PI3K inhibitor,MoA,Phase 1
138,5444,mTOR inhibitor|PI3K inhibitor,MoA,Phase 1
476,5444,mTOR inhibitor|PI3K inhibitor,MoA,Phase 1
553,5445,p38 MAPK inhibitor,MoA,Preclinical
405,5445,p38 MAPK inhibitor,MoA,Preclinical
171,5445,p38 MAPK inhibitor,MoA,Preclinical
1246,5446,p38 MAPK inhibitor,MoA,Phase 1
405,5446,p38 MAPK inhibitor,MoA,Phase 1
14,5447,serotonin receptor inverse agonist,MoA,Phase 1
15,5447,serotonin receptor inverse agonist,MoA,Phase 1
16,5447,serotonin receptor inverse agonist,MoA,Phase 1
624,5447,serotonin receptor inverse agonist,MoA,Phase 1
624,5448,serotonin receptor antagonist,MoA,Preclinical
1233,5449,calcitonin antagonist,MoA,Preclinical
625,5450,serotonin receptor antagonist,MoA,Preclinical
624,5451,serotonin receptor antagonist,MoA,Phase 1
5452,5453,CC chemokine receptor antagonist,MoA,Preclinical
241,5454,orexin receptor antagonist,MoA,Preclinical
243,5454,orexin receptor antagonist,MoA,Preclinical
53,5455,TRPV antagonist,MoA,Preclinical
624,5456,serotonin receptor antagonist,MoA,Preclinical
241,5457,orexin receptor antagonist,MoA,Preclinical
243,5457,orexin receptor antagonist,MoA,Preclinical
30,5458,glycogen synthase kinase inhibitor,MoA,Preclinical
32,5458,glycogen synthase kinase inhibitor,MoA,Preclinical
1285,5458,glycogen synthase kinase inhibitor,MoA,Preclinical
5459,5460,TGF beta receptor inhibitor,MoA,Preclinical
2840,5460,TGF beta receptor inhibitor,MoA,Preclinical
53,5461,TRPV antagonist,MoA,Preclinical
2840,5462,ALK tyrosine kinase receptor inhibitor,MoA,Preclinical
2840,5463,TGF beta receptor inhibitor,MoA,Preclinical
946,5464,RAF inhibitor,MoA,Preclinical
1099,5465,nociceptin/orphanin FQ receptor antagonist,MoA,Preclinical
132,5466,urotensin receptor antagonist,MoA,Preclinical
1263,5467,integrin antagonist,MoA,Phase 1
896,5467,integrin antagonist,MoA,Phase 1
897,5467,integrin antagonist,MoA,Phase 1
5468,5467,integrin antagonist,MoA,Phase 1
53,5469,TRPV antagonist,MoA,Phase 2
132,5470,urotensin receptor antagonist,MoA,Preclinical
624,5471,serotonin receptor antagonist,MoA,Phase 3
821,5472,kinesin-like spindle protein inhibitor,MoA,Phase 1/Phase 2
49,5473,kinase inhibitor,MoA,Preclinical
750,5473,kinase inhibitor,MoA,Preclinical
839,5473,kinase inhibitor,MoA,Preclinical
5474,5473,kinase inhibitor,MoA,Preclinical
1285,5473,kinase inhibitor,MoA,Preclinical
1215,5475,G protein-coupled receptor agonist,MoA,Phase 1
839,5476,rho associated kinase inhibitor,MoA,Preclinical
912,5476,rho associated kinase inhibitor,MoA,Preclinical
247,5477,HDAC inhibitor,MoA,Phase 3
1143,5477,HDAC inhibitor,MoA,Phase 3
249,5477,HDAC inhibitor,MoA,Phase 3
250,5477,HDAC inhibitor,MoA,Phase 3
1145,5477,HDAC inhibitor,MoA,Phase 3
1146,5477,HDAC inhibitor,MoA,Phase 3
251,5477,HDAC inhibitor,MoA,Phase 3
1148,5477,HDAC inhibitor,MoA,Phase 3
1228,5478,PLK inhibitor,MoA,Preclinical
247,5479,HDAC inhibitor,MoA,Preclinical
250,5479,HDAC inhibitor,MoA,Preclinical
1284,5480,protein kinase activator,MoA,Preclinical
5481,5482,dihydroorotate dehydrogenase inhibitor,MoA,Phase 2
394,5483,prostanoid receptor antagonist,MoA,Preclinical
171,5484,cyclooxygenase inhibitor,MoA,Preclinical
394,5485,prostanoid receptor antagonist,MoA,Preclinical
174,5486,cyclooxygenase inhibitor,MoA,Preclinical
1284,5487,protein tyrosine kinase activator,MoA,Preclinical
73,5488,G protein-coupled receptor modulator,MoA,Preclinical
74,5488,G protein-coupled receptor modulator,MoA,Preclinical
6,5488,G protein-coupled receptor modulator,MoA,Preclinical
7,5488,G protein-coupled receptor modulator,MoA,Preclinical
1099,5489,nociceptin/orphanin FQ receptor agonist,MoA,Preclinical
6,5490,dopamine receptor antagonist,MoA,Preclinical
10,5490,dopamine receptor antagonist,MoA,Preclinical
16,5490,dopamine receptor antagonist,MoA,Preclinical
794,5490,dopamine receptor antagonist,MoA,Preclinical
5491,5490,dopamine receptor antagonist,MoA,Preclinical
2419,5492,ATPase inhibitor,MoA,Phase 1
2139,5493,MTH1 inhibitor,MoA,Preclinical
69,5494,adenosine receptor antagonist,MoA,Preclinical
275,5494,adenosine receptor antagonist,MoA,Preclinical
276,5494,adenosine receptor antagonist,MoA,Preclinical
277,5494,adenosine receptor antagonist,MoA,Preclinical
371,5495,CHK inhibitor,MoA,Phase 2
1026,5495,CHK inhibitor,MoA,Phase 2
1020,5496,antioxidant,MoA,Preclinical
73,5500,acetylcholine receptor antagonist,MoA,Preclinical
74,5500,acetylcholine receptor antagonist,MoA,Preclinical
75,5500,acetylcholine receptor antagonist,MoA,Preclinical
76,5500,acetylcholine receptor antagonist,MoA,Preclinical
247,5501,HDAC inhibitor,MoA,Preclinical
249,5501,HDAC inhibitor,MoA,Preclinical
250,5501,HDAC inhibitor,MoA,Preclinical
1145,5501,HDAC inhibitor,MoA,Preclinical
1146,5501,HDAC inhibitor,MoA,Preclinical
251,5501,HDAC inhibitor,MoA,Preclinical
1147,5501,HDAC inhibitor,MoA,Preclinical
252,5501,HDAC inhibitor,MoA,Preclinical
1148,5501,HDAC inhibitor,MoA,Preclinical
405,5502,p38 MAPK inhibitor,MoA,Preclinical
2840,5503,TGF beta receptor inhibitor,MoA,Preclinical
766,5504,matrix metalloprotease inhibitor,MoA,Preclinical
767,5504,matrix metalloprotease inhibitor,MoA,Preclinical
1112,5504,matrix metalloprotease inhibitor,MoA,Preclinical
339,5505,opioid receptor antagonist,MoA,Preclinical
28,5506,tachykinin antagonist,MoA,Phase 1
14,5507,serotonin receptor antagonist,MoA,Preclinical
15,5507,serotonin receptor antagonist,MoA,Preclinical
16,5507,serotonin receptor antagonist,MoA,Preclinical
69,5508,adenosine receptor agonist,MoA,Phase 2
77,5509,serotonin receptor antagonist,MoA,Preclinical
957,5509,serotonin receptor antagonist,MoA,Preclinical
11,5510,adrenergic receptor antagonist|serotonin receptor antagonist,MoA,Preclinical
12,5510,adrenergic receptor antagonist|serotonin receptor antagonist,MoA,Preclinical
153,5511,glutamate receptor antagonist,MoA,Preclinical
153,5512,glutamate receptor antagonist,MoA,Preclinical
79,5514,GABA receptor antagonist|TP53 activator,MoA,Preclinical
460,5515,progesterone receptor agonist,MoA,Launched
154,5518,glutamate receptor antagonist,MoA,Phase 3
155,5518,glutamate receptor antagonist,MoA,Phase 3
156,5518,glutamate receptor antagonist,MoA,Phase 3
157,5518,glutamate receptor antagonist,MoA,Phase 3
805,5520,MEK inhibitor,MoA,Phase 3
925,5521,gamma secretase inhibitor,MoA,Phase 3
405,5522,cytokine production inhibitor|p38 MAPK inhibitor,MoA,Phase 2
1008,5523,VEGFR inhibitor,MoA,Phase 3
939,5523,VEGFR inhibitor,MoA,Phase 3
244,5523,VEGFR inhibitor,MoA,Phase 3
129,5523,VEGFR inhibitor,MoA,Phase 3
130,5523,VEGFR inhibitor,MoA,Phase 3
131,5523,VEGFR inhibitor,MoA,Phase 3
741,5523,VEGFR inhibitor,MoA,Phase 3
1196,5524,beta amyloid inhibitor,MoA,Preclinical
853,5525,intermediate conductance potassium channel blocker,MoA,Phase 3
441,5526,vitamin D receptor agonist,MoA,Phase 3
1176,5527,D-amino acid oxidase Inhibitor,MoA,Phase 1
546,5529,MDM inhibitor,MoA,Phase 1
45,5531,dopamine receptor antagonist|serotonin receptor antagonist,MoA,Withdrawn
47,5531,dopamine receptor antagonist|serotonin receptor antagonist,MoA,Withdrawn
48,5531,dopamine receptor antagonist|serotonin receptor antagonist,MoA,Withdrawn
7,5531,dopamine receptor antagonist|serotonin receptor antagonist,MoA,Withdrawn
8,5531,dopamine receptor antagonist|serotonin receptor antagonist,MoA,Withdrawn
9,5531,dopamine receptor antagonist|serotonin receptor antagonist,MoA,Withdrawn
97,5531,dopamine receptor antagonist|serotonin receptor antagonist,MoA,Withdrawn
11,5531,dopamine receptor antagonist|serotonin receptor antagonist,MoA,Withdrawn
12,5531,dopamine receptor antagonist|serotonin receptor antagonist,MoA,Withdrawn
13,5531,dopamine receptor antagonist|serotonin receptor antagonist,MoA,Withdrawn
488,5531,dopamine receptor antagonist|serotonin receptor antagonist,MoA,Withdrawn
489,5531,dopamine receptor antagonist|serotonin receptor antagonist,MoA,Withdrawn
14,5531,dopamine receptor antagonist|serotonin receptor antagonist,MoA,Withdrawn
16,5531,dopamine receptor antagonist|serotonin receptor antagonist,MoA,Withdrawn
624,5531,dopamine receptor antagonist|serotonin receptor antagonist,MoA,Withdrawn
617,5531,dopamine receptor antagonist|serotonin receptor antagonist,MoA,Withdrawn
971,5533,prostaglandin inhibitor,MoA,Phase 3
2211,5536,lysophospholipid receptor agonist,MoA,Preclinical
5537,5538,neuropeptide receptor antagonist,MoA,Preclinical
2219,5538,neuropeptide receptor antagonist,MoA,Preclinical
3410,5539,bromodomain inhibitor,MoA,Preclinical
2167,5539,bromodomain inhibitor,MoA,Preclinical
5540,5541,protein arginine N-methyltransferase inhibitor,MoA,Preclinical
949,5542,DNA methyltransferase inhibitor,MoA,Preclinical
951,5542,DNA methyltransferase inhibitor,MoA,Preclinical
2166,5542,DNA methyltransferase inhibitor,MoA,Preclinical
128,5543,Pim kinase inhibitor,MoA,Phase 1
289,5543,Pim kinase inhibitor,MoA,Phase 1
964,5543,Pim kinase inhibitor,MoA,Phase 1
965,5543,Pim kinase inhibitor,MoA,Phase 1
24,5544,GABA receptor antagonist,MoA,Preclinical
26,5544,GABA receptor antagonist,MoA,Preclinical
430,5545,hepatocyte growth factor receptor inhibitor,MoA,Phase 1
5546,5547,neuropeptide receptor antagonist,MoA,Preclinical
1476,5548,protein tyrosine kinase inhibitor,MoA,Preclinical
2227,5549,acetylcholine receptor agonist,MoA,Phase 2
160,5550,glutamate receptor antagonist,MoA,Preclinical
2414,5551,glutamate receptor antagonist,MoA,Preclinical
160,5551,glutamate receptor antagonist,MoA,Preclinical
5552,5553,steroidogenic factor antagonist,MoA,Preclinical
603,5554,phosphodiesterase inhibitor,MoA,Phase 1
5560,5561,DNA methyltransferase inhibitor|RNA synthesis inhibitor,MoA,Preclinical
641,5562,voltage-gated sodium channel blocker,MoA,Phase 2
55,5562,voltage-gated sodium channel blocker,MoA,Phase 2
444,5562,voltage-gated sodium channel blocker,MoA,Phase 2
446,5562,voltage-gated sodium channel blocker,MoA,Phase 2
447,5562,voltage-gated sodium channel blocker,MoA,Phase 2
167,5562,voltage-gated sodium channel blocker,MoA,Phase 2
450,5562,voltage-gated sodium channel blocker,MoA,Phase 2
45,5564,sigma receptor antagonist,MoA,Phase 2
47,5564,sigma receptor antagonist,MoA,Phase 2
48,5564,sigma receptor antagonist,MoA,Phase 2
401,5566,SIRT inhibitor,MoA,Preclinical
1286,5567,SIRT inhibitor,MoA,Preclinical
401,5567,SIRT inhibitor,MoA,Preclinical
5568,5569,serine/threonine kinase inhibitor,MoA,Preclinical
2840,5569,serine/threonine kinase inhibitor,MoA,Preclinical
238,5571,endothelin receptor antagonist,MoA,Withdrawn
240,5571,endothelin receptor antagonist,MoA,Withdrawn
5573,5574,MDM inhibitor,MoA,Preclinical
633,5575,sigma receptor agonist,MoA,Phase 1
853,5576,potassium channel activator,MoA,Preclinical
405,5577,p38 MAPK inhibitor,MoA,Preclinical
5,5578,dopamine receptor agonist,MoA,Preclinical
6,5578,dopamine receptor agonist,MoA,Preclinical
10,5578,dopamine receptor agonist,MoA,Preclinical
6,5579,dopamine receptor agonist,MoA,Preclinical
6,5580,dopamine receptor agonist,MoA,Preclinical
10,5580,dopamine receptor agonist,MoA,Preclinical
6,5581,dopamine receptor antagonist,MoA,Preclinical
10,5581,dopamine receptor antagonist,MoA,Preclinical
403,5582,p38 MAPK inhibitor,MoA,Preclinical
405,5582,p38 MAPK inhibitor,MoA,Preclinical
1784,5583,GABA uptake inhibitor,MoA,Preclinical
653,5584,histamine N-methyltransferase inhibitor,MoA,Preclinical
421,5585,calcium channel blocker,MoA,Preclinical
579,5585,calcium channel blocker,MoA,Preclinical
5586,5585,calcium channel blocker,MoA,Preclinical
3652,5585,calcium channel blocker,MoA,Preclinical
4337,5585,calcium channel blocker,MoA,Preclinical
1744,5585,calcium channel blocker,MoA,Preclinical
588,5585,calcium channel blocker,MoA,Preclinical
3463,5587,sphingosine kinase inhibitor,MoA,Preclinical
244,5588,VEGFR inhibitor,MoA,Preclinical
519,5589,cannabinoid receptor antagonist,MoA,Phase 2
7,5589,cannabinoid receptor antagonist,MoA,Phase 2
11,5589,cannabinoid receptor antagonist,MoA,Phase 2
69,5590,adenosine receptor antagonist,MoA,Phase 2
275,5590,adenosine receptor antagonist,MoA,Phase 2
276,5590,adenosine receptor antagonist,MoA,Phase 2
277,5590,adenosine receptor antagonist,MoA,Phase 2
1015,5591,XIAP inhibitor,MoA,Preclinical
1017,5591,XIAP inhibitor,MoA,Preclinical
1018,5591,XIAP inhibitor,MoA,Preclinical
2431,5592,sigma receptor antagonist,MoA,Preclinical
5593,5594,autophagy inducer,MoA,Preclinical
289,5595,Pim kinase inhibitor,MoA,Preclinical
5537,5596,transient receptor potential channel agonist,MoA,Preclinical
1280,5598,nitric oxide donor,MoA,Phase 2
45,5599,adrenergic receptor antagonist,MoA,Preclinical
47,5599,adrenergic receptor antagonist,MoA,Preclinical
48,5599,adrenergic receptor antagonist,MoA,Preclinical
1,5599,adrenergic receptor antagonist,MoA,Preclinical
3,5599,adrenergic receptor antagonist,MoA,Preclinical
4,5599,adrenergic receptor antagonist,MoA,Preclinical
639,5599,adrenergic receptor antagonist,MoA,Preclinical
641,5599,adrenergic receptor antagonist,MoA,Preclinical
354,5602,selective estrogen receptor modulator (SERM),MoA,Preclinical
452,5603,Aurora kinase inhibitor,MoA,Phase 1
563,5603,Aurora kinase inhibitor,MoA,Phase 1
564,5603,Aurora kinase inhibitor,MoA,Phase 1
507,5604,HSP inhibitor,MoA,Phase 1/Phase 2
1648,5604,HSP inhibitor,MoA,Phase 1/Phase 2
3947,5605,thyroid hormone receptor agonist,MoA,Phase 1/Phase 2
3949,5605,thyroid hormone receptor agonist,MoA,Phase 1/Phase 2
759,5606,HDAC inhibitor,MoA,Phase 2
2238,5606,HDAC inhibitor,MoA,Phase 2
2239,5606,HDAC inhibitor,MoA,Phase 2
247,5606,HDAC inhibitor,MoA,Phase 2
249,5606,HDAC inhibitor,MoA,Phase 2
250,5606,HDAC inhibitor,MoA,Phase 2
252,5606,HDAC inhibitor,MoA,Phase 2
969,5614,JAK inhibitor,MoA,Phase 1
255,5620,aldose reductase inhibitor,MoA,Phase 3
703,5621,sodium/glucose cotransporter inhibitor,MoA,Phase 3
1542,5621,sodium/glucose cotransporter inhibitor,MoA,Phase 3
1284,5623,PKC inhibitor,MoA,Phase 2
1699,5623,PKC inhibitor,MoA,Phase 2
358,5623,PKC inhibitor,MoA,Phase 2
359,5623,PKC inhibitor,MoA,Phase 2
5624,5623,PKC inhibitor,MoA,Phase 2
360,5623,PKC inhibitor,MoA,Phase 2
827,5625,NFkB pathway inhibitor,MoA,Preclinical
701,5625,NFkB pathway inhibitor,MoA,Preclinical
546,5626,ubiquitin ligase inhibitor,MoA,Preclinical
232,5628,bacterial DNA gyrase inhibitor,MoA,Withdrawn
188,5629,aspartate carbamoyltransferase inhibitor,MoA,Phase 3
190,5629,aspartate carbamoyltransferase inhibitor,MoA,Phase 3
5630,5631,deubiquitinase inhibitor,MoA,Preclinical
5632,5631,deubiquitinase inhibitor,MoA,Preclinical
794,5633,glutamate receptor modulator,MoA,Preclinical
830,5633,glutamate receptor modulator,MoA,Preclinical
5637,5638,gene expression stimulant,MoA,Preclinical
510,5640,opioid receptor agonist,MoA,Phase 2
45,5644,serotonin receptor antagonist,MoA,Preclinical
47,5644,serotonin receptor antagonist,MoA,Preclinical
48,5644,serotonin receptor antagonist,MoA,Preclinical
1,5644,serotonin receptor antagonist,MoA,Preclinical
3,5644,serotonin receptor antagonist,MoA,Preclinical
4,5644,serotonin receptor antagonist,MoA,Preclinical
11,5644,serotonin receptor antagonist,MoA,Preclinical
15,5644,serotonin receptor antagonist,MoA,Preclinical
1286,5645,SIRT inhibitor,MoA,Preclinical
238,5646,endothelin receptor antagonist,MoA,Phase 3
741,5647,receptor tyrosine protein kinase inhibitor,MoA,Preclinical
5648,5649,bacterial cell wall synthesis inhibitor,MoA,Phase 3
285,5650,adenylyl cyclase inhibitor,MoA,Preclinical
1751,5651,retinoid receptor agonist,MoA,Preclinical
5652,5651,retinoid receptor agonist,MoA,Preclinical
28,5653,neurokinin receptor antagonist,MoA,Phase 2
200,5654,PPAR receptor ligand,MoA,Preclinical
5652,5655,retinoid receptor inverse agonist,MoA,Preclinical
1816,5656,leukotriene receptor antagonist,MoA,Phase 2
1183,5657,CCK receptor antagonist,MoA,Phase 2
4890,5658,JNK inhibitor,MoA,Preclinical
726,5658,JNK inhibitor,MoA,Preclinical
4892,5658,JNK inhibitor,MoA,Preclinical
4890,5659,JNK inhibitor,MoA,Preclinical
912,5660,rho associated kinase inhibitor,MoA,Preclinical
77,5661,serotonin receptor agonist,MoA,Phase 2
165,5662,adrenergic receptor antagonist,MoA,Preclinical
417,5662,adrenergic receptor antagonist,MoA,Preclinical
567,5662,adrenergic receptor antagonist,MoA,Preclinical
73,5663,acetylcholine receptor agonist,MoA,Preclinical
739,5664,SRC inhibitor,MoA,Preclinical
1283,5664,SRC inhibitor,MoA,Preclinical
3904,5664,SRC inhibitor,MoA,Preclinical
5665,5666,serine arginine protein kinase inhibitor,MoA,Preclinical
273,5666,serine arginine protein kinase inhibitor,MoA,Preclinical
1286,5667,SIRT activator,MoA,Preclinical
1286,5668,SIRT activator,MoA,Phase 2
43,5669,acetylcholine receptor agonist,MoA,Phase 2
5670,5671,myeloid differentiation primary response inhibitor,MoA,Preclinical
777,5672,interleukin synthesis inhibitor,MoA,Phase 2
227,5673,STAT inhibitor,MoA,Preclinical
900,5674,aryl hydrocarbon receptor antagonist,MoA,Preclinical
775,5675,serine/threonine kinase inhibitor,MoA,Preclinical
2922,5676,NAMPT inhibitor,MoA,Preclinical
2922,5677,NAMPT inhibitor,MoA,Preclinical
5678,5677,NAMPT inhibitor,MoA,Preclinical
45,5680,adrenergic receptor antagonist,MoA,Phase 2
73,5682,acetylcholine receptor antagonist,MoA,Preclinical
74,5682,acetylcholine receptor antagonist,MoA,Preclinical
75,5682,acetylcholine receptor antagonist,MoA,Preclinical
76,5682,acetylcholine receptor antagonist,MoA,Preclinical
170,5682,acetylcholine receptor antagonist,MoA,Preclinical
1733,5682,acetylcholine receptor antagonist,MoA,Preclinical
3056,5682,acetylcholine receptor antagonist,MoA,Preclinical
690,5682,acetylcholine receptor antagonist,MoA,Preclinical
994,5682,acetylcholine receptor antagonist,MoA,Preclinical
995,5682,acetylcholine receptor antagonist,MoA,Preclinical
996,5682,acetylcholine receptor antagonist,MoA,Preclinical
28,5683,neurokinin receptor antagonist,MoA,Phase 1
78,5683,neurokinin receptor antagonist,MoA,Phase 1
5438,5683,neurokinin receptor antagonist,MoA,Phase 1
5702,5703,antioxidant,MoA,Phase 2/Phase 3
605,5706,dihydrofolate reductase inhibitor,MoA,Phase 2
4536,5715,anticancer agent|aryl hydrocarbon receptor antagonist,MoA,Phase 2
188,5718,carbonic anhydrase inhibitor,MoA,Phase 3
7,5719,dopamine receptor agonist,MoA,Phase 3
5721,5722,calcitonin agonist,MoA,Preclinical
1008,5723,fibroblast growth factor mimetic,MoA,Preclinical
174,5725,cyclooxygenase inhibitor,MoA,Withdrawn
171,5725,cyclooxygenase inhibitor,MoA,Withdrawn
24,5728,GABA receptor inverse agonist,MoA,Phase 2
244,5729,PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,MoA,Phase 2
430,5730,hepatocyte growth factor receptor inhibitor|tyrosine kinase inhibitor,MoA,Preclinical
131,5731,PDGFR tyrosine kinase receptor inhibitor,MoA,Preclinical
726,5732,JNK inhibitor,MoA,Preclinical
244,5733,PDGFR tyrosine kinase receptor inhibitor|tyrosine kinase inhibitor|VEGFR inhibitor,MoA,Preclinical
131,5733,PDGFR tyrosine kinase receptor inhibitor|tyrosine kinase inhibitor|VEGFR inhibitor,MoA,Preclinical
512,5734,CDK inhibitor,MoA,Preclinical
371,5734,CDK inhibitor,MoA,Preclinical
90,5734,CDK inhibitor,MoA,Preclinical
514,5734,CDK inhibitor,MoA,Preclinical
3681,5735,alpha mannosidase inhibitor,MoA,Phase 2
405,5736,MAP kinase inhibitor,MoA,Preclinical
906,5737,kainate receptor antagonist,MoA,Preclinical
1466,5737,kainate receptor antagonist,MoA,Preclinical
3645,5737,kainate receptor antagonist,MoA,Preclinical
3646,5737,kainate receptor antagonist,MoA,Preclinical
3647,5737,kainate receptor antagonist,MoA,Preclinical
1846,5737,kainate receptor antagonist,MoA,Preclinical
665,5738,glutamate receptor antagonist,MoA,Preclinical
663,5738,glutamate receptor antagonist,MoA,Preclinical
667,5738,glutamate receptor antagonist,MoA,Preclinical
668,5738,glutamate receptor antagonist,MoA,Preclinical
2211,5740,sphingosine kinase inhibitor,MoA,Preclinical
665,5741,glutamate receptor modulator,MoA,Phase 2
663,5741,glutamate receptor modulator,MoA,Phase 2
667,5741,glutamate receptor modulator,MoA,Phase 2
668,5741,glutamate receptor modulator,MoA,Phase 2
200,5742,PPAR receptor agonist,MoA,Preclinical
186,5743,carbonic anhydrase inhibitor,MoA,Preclinical
1617,5743,carbonic anhydrase inhibitor,MoA,Preclinical
200,5744,PPAR receptor antagonist,MoA,Preclinical
23,5745,phosphodiesterase inhibitor,MoA,Preclinical
2091,5746,LXR agonist,MoA,Preclinical
3101,5746,LXR agonist,MoA,Preclinical
3291,5746,LXR agonist,MoA,Preclinical
3293,5746,LXR agonist,MoA,Preclinical
1923,5746,LXR agonist,MoA,Preclinical
225,5746,LXR agonist,MoA,Preclinical
827,5747,AP inhibitor,MoA,Phase 2
4036,5748,LIM kinase inhibitor,MoA,Preclinical
275,5749,adenosine receptor modulator,MoA,Phase 2
2253,5750,casein kinase inhibitor|MAP kinase inhibitor,MoA,Preclinical
3451,5750,casein kinase inhibitor|MAP kinase inhibitor,MoA,Preclinical
405,5750,casein kinase inhibitor|MAP kinase inhibitor,MoA,Preclinical
687,5751,growth hormone secretagogue receptor agonist,MoA,Phase 2
247,5753,HDAC inhibitor,MoA,Phase 3
293,5760,phosphorylase inhibitor,MoA,Launched
1515,5761,phosphodiesterase inhibitor,MoA,Phase 2
263,5762,CC chemokine receptor antagonist,MoA,Phase 1
348,5763,EGFR inhibitor,MoA,Phase 1
130,5764,VEGFR inhibitor,MoA,Phase 1
946,5765,RAF inhibitor,MoA,Preclinical
405,5766,p38 MAPK inhibitor,MoA,Phase 2
805,5767,MEK inhibitor,MoA,Phase 1
483,5768,insulin secretagogue,MoA,Phase 3
563,5769,Aurora kinase inhibitor,MoA,Phase 1
1228,5770,PLK inhibitor,MoA,Phase 1
469,5771,dipeptidyl peptidase inhibitor|fibroblast activation protein inhibitor,MoA,Phase 3
944,5772,smoothened receptor antagonist,MoA,Phase 2
2164,5772,smoothened receptor antagonist,MoA,Phase 2
1335,5772,smoothened receptor antagonist,MoA,Phase 2
665,5773,glutamate receptor antagonist,MoA,Phase 2
663,5773,glutamate receptor antagonist,MoA,Phase 2
667,5773,glutamate receptor antagonist,MoA,Phase 2
668,5773,glutamate receptor antagonist,MoA,Phase 2
3954,5774,cytochrome P450 inhibitor,MoA,Phase 2
698,5778,p38 MAPK inhibitor,MoA,Phase 2
553,5778,p38 MAPK inhibitor,MoA,Phase 2
405,5778,p38 MAPK inhibitor,MoA,Phase 2
1768,5778,p38 MAPK inhibitor,MoA,Phase 2
672,5778,p38 MAPK inhibitor,MoA,Phase 2
78,5779,tachykinin antagonist,MoA,Phase 2
5438,5779,tachykinin antagonist,MoA,Phase 2
571,5781,adrenergic inhibitor,MoA,Phase 2
460,5787,progesterone receptor agonist,MoA,Phase 2
126,5789,FLT3 inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor,MoA,Phase 2
128,5789,FLT3 inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor,MoA,Phase 2
129,5789,FLT3 inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor,MoA,Phase 2
5790,5789,FLT3 inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor,MoA,Phase 2
131,5789,FLT3 inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor,MoA,Phase 2
507,5791,HSP inhibitor,MoA,Phase 3
4669,5793,AP inhibitor,MoA,Phase 2
698,5794,anti-inflammatory agent|interleukin inhibitor,MoA,Phase 2/Phase 3
1923,5794,anti-inflammatory agent|interleukin inhibitor,MoA,Phase 2/Phase 3
672,5794,anti-inflammatory agent|interleukin inhibitor,MoA,Phase 2/Phase 3
395,5795,prostaglandin receptor agonist,MoA,Phase 2
75,5796,acetylcholine receptor antagonist,MoA,Phase 2
519,5797,cannabinoid receptor inverse agonist,MoA,Phase 3
881,5798,nitric oxide synthase inhibitor,MoA,Phase 3
296,5799,P glycoprotein inhibitor,MoA,Phase 3
230,5800,topoisomerase inhibitor,MoA,Phase 1
474,5801,PI3K inhibitor,MoA,Phase 3
1145,5803,angiogenesis inhibitor|S100A9 inhibitor,MoA,Phase 3
5804,5805,G protein-coupled receptor agonist,MoA,Phase 1
1765,5805,G protein-coupled receptor agonist,MoA,Phase 1
5080,5805,G protein-coupled receptor agonist,MoA,Phase 1
338,5806,opioid receptor antagonist,MoA,Phase 2
2121,5808,histone lysine methyltransferase inhibitor,MoA,Launched
3743,5809,excitatory amino acid transporter inhibitor,MoA,Preclinical
1846,5809,excitatory amino acid transporter inhibitor,MoA,Preclinical
3801,5809,excitatory amino acid transporter inhibitor,MoA,Preclinical
3802,5809,excitatory amino acid transporter inhibitor,MoA,Preclinical
3803,5809,excitatory amino acid transporter inhibitor,MoA,Preclinical
452,5810,Aurora kinase inhibitor,MoA,Preclinical
5811,5812,MAP kinase inhibitor,MoA,Preclinical
5813,5812,MAP kinase inhibitor,MoA,Preclinical
2310,5814,histone demethylase inhibitor,MoA,Preclinical
4351,5814,histone demethylase inhibitor,MoA,Preclinical
3527,5814,histone demethylase inhibitor,MoA,Preclinical
5815,5814,histone demethylase inhibitor,MoA,Preclinical
3216,5814,histone demethylase inhibitor,MoA,Preclinical
2312,5814,histone demethylase inhibitor,MoA,Preclinical
2313,5814,histone demethylase inhibitor,MoA,Preclinical
1196,5816,gamma secretase modulator,MoA,Preclinical
528,5817,FAAH inhibitor,MoA,Preclinical
5818,5819,formyl peptide receptor agonist,MoA,Preclinical
1,5820,adrenergic receptor agonist,MoA,Preclinical
3,5820,adrenergic receptor agonist,MoA,Preclinical
4,5820,adrenergic receptor agonist,MoA,Preclinical
275,5821,adenosine receptor antagonist,MoA,Preclinical
1215,5822,G protein-coupled receptor agonist,MoA,Preclinical
5823,5824,G protein-coupled receptor agonist,MoA,Preclinical
247,5825,HDAC inhibitor,MoA,Preclinical
249,5825,HDAC inhibitor,MoA,Preclinical
250,5825,HDAC inhibitor,MoA,Preclinical
252,5825,HDAC inhibitor,MoA,Preclinical
1441,5826,integrin inhibitor,MoA,Preclinical
897,5826,integrin inhibitor,MoA,Preclinical
694,5827,transient receptor potential channel antagonist,MoA,Preclinical
694,5828,transient receptor potential channel antagonist,MoA,Preclinical
5829,5830,lysophosphatidic acid receptor antagonist,MoA,Preclinical
4386,5831,monopolar spindle 1 kinase inhibitor,MoA,Preclinical
450,5832,sodium channel blocker,MoA,Preclinical
4153,5833,neurotensin agonist,MoA,Preclinical
3616,5834,G protein-coupled receptor agonist,MoA,Preclinical
71,5835,oxytocin receptor agonist|vasopressin receptor agonist,MoA,Preclinical
5836,5835,oxytocin receptor agonist|vasopressin receptor agonist,MoA,Preclinical
1283,5837,SRC inhibitor,MoA,Preclinical
3671,5838,DYRK inhibitor,MoA,Preclinical
1059,5838,DYRK inhibitor,MoA,Preclinical
1229,5839,PLK inhibitor,MoA,Preclinical
2095,5840,MAP kinase inhibitor,MoA,Preclinical
5136,5841,hypoxia inducible factor inhibitor,MoA,Preclinical
2211,5842,sphingosine 1-phosphate receptor agonist,MoA,Preclinical
154,5843,glutamate receptor antagonist,MoA,Preclinical
2414,5844,glutamate receptor positive allosteric modulator,MoA,Preclinical
251,5845,HDAC inhibitor,MoA,Preclinical
243,5846,orexin receptor antagonist,MoA,Preclinical
289,5847,Pim kinase inhibitor,MoA,Preclinical
32,5848,glycogen synthase kinase inhibitor,MoA,Preclinical
370,5849,JAK inhibitor,MoA,Preclinical
1263,5850,integrin inhibitor,MoA,Preclinical
897,5850,integrin inhibitor,MoA,Preclinical
1451,5851,G protein-coupled receptor agonist,MoA,Preclinical
128,5852,FLT3 inhibitor,MoA,Preclinical
67,5853,transient receptor potential channel antagonist,MoA,Preclinical
979,5854,beta-secretase inhibitor,MoA,Preclinical
61,5855,acetylcholine receptor agonist,MoA,Preclinical
69,5857,adenosine receptor agonist,MoA,Phase 2
1530,5858,calcium-sensing receptor agonist,MoA,Phase 2
617,5859,histamine receptor antagonist,MoA,Phase 3
14,5860,serotonin receptor partial agonist,MoA,Withdrawn
15,5860,serotonin receptor partial agonist,MoA,Withdrawn
16,5860,serotonin receptor partial agonist,MoA,Withdrawn
490,5860,serotonin receptor partial agonist,MoA,Withdrawn
1306,5861,CC chemokine receptor antagonist,MoA,Preclinical
244,5863,KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,MoA,Phase 2
1235,5864,calcitonin antagonist,MoA,Phase 3
1236,5864,calcitonin antagonist,MoA,Phase 3
73,5865,acetylcholine receptor antagonist,MoA,Phase 3
2706,5873,ATPase inhibitor,MoA,Phase 2
794,5875,cyclooxygenase inhibitor,MoA,Phase 3
174,5875,cyclooxygenase inhibitor,MoA,Phase 3
1286,5878,SIRT inhibitor|TP53 activator,MoA,Preclinical
1286,5879,SIRT inhibitor,MoA,Preclinical
401,5879,SIRT inhibitor,MoA,Preclinical
5880,5879,SIRT inhibitor,MoA,Preclinical
5883,5884,pyruvate kinase isozyme activator,MoA,Preclinical
5885,5886,lipoxygenase inhibitor,MoA,Phase 1/Phase 2
512,5886,lipoxygenase inhibitor,MoA,Phase 1/Phase 2
97,5890,histamine receptor antagonist,MoA,Withdrawn
879,5890,histamine receptor antagonist,MoA,Withdrawn
617,5890,histamine receptor antagonist,MoA,Withdrawn
134,5894,Bruton's tyrosine kinase (BTK) inhibitor,MoA,Preclinical
1917,5895,prostanoid receptor antagonist,MoA,Phase 3
1218,5896,insulin sensitizer|PPAR receptor agonist,MoA,Phase 3
200,5896,insulin sensitizer|PPAR receptor agonist,MoA,Phase 3
22,5897,phosphodiesterase inhibitor,MoA,Phase 2
2240,5900,superoxide dismutase inhibitor,MoA,Phase 2/Phase 3
2832,5900,superoxide dismutase inhibitor,MoA,Phase 2/Phase 3
5902,5903,cytidine deaminase inhibitor,MoA,Phase 2
620,5905,calcium channel blocker,MoA,Preclinical
153,5906,glutamate receptor agonist,MoA,Preclinical
154,5906,glutamate receptor agonist,MoA,Preclinical
155,5906,glutamate receptor agonist,MoA,Preclinical
156,5906,glutamate receptor agonist,MoA,Preclinical
157,5906,glutamate receptor agonist,MoA,Preclinical
569,5907,monoamine oxidase inhibitor,MoA,Phase 3
3165,5908,prostaglandin inhibitor,MoA,Preclinical
3668,5909,CLK inhibitor,MoA,Preclinical
4332,5909,CLK inhibitor,MoA,Preclinical
3671,5909,CLK inhibitor,MoA,Preclinical
1059,5909,CLK inhibitor,MoA,Preclinical
512,5910,CDK inhibitor|FLT3 inhibitor|JAK inhibitor,MoA,Phase 1/Phase 2
371,5910,CDK inhibitor|FLT3 inhibitor|JAK inhibitor,MoA,Phase 1/Phase 2
515,5910,CDK inhibitor|FLT3 inhibitor|JAK inhibitor,MoA,Phase 1/Phase 2
517,5910,CDK inhibitor|FLT3 inhibitor|JAK inhibitor,MoA,Phase 1/Phase 2
128,5910,CDK inhibitor|FLT3 inhibitor|JAK inhibitor,MoA,Phase 1/Phase 2
369,5910,CDK inhibitor|FLT3 inhibitor|JAK inhibitor,MoA,Phase 1/Phase 2
244,5911,SRC inhibitor|VEGFR inhibitor,MoA,Preclinical
1054,5911,SRC inhibitor|VEGFR inhibitor,MoA,Preclinical
739,5912,SRC inhibitor|VEGFR inhibitor,MoA,Phase 2
1008,5912,SRC inhibitor|VEGFR inhibitor,MoA,Phase 2
939,5912,SRC inhibitor|VEGFR inhibitor,MoA,Phase 2
940,5912,SRC inhibitor|VEGFR inhibitor,MoA,Phase 2
244,5912,SRC inhibitor|VEGFR inhibitor,MoA,Phase 2
1054,5912,SRC inhibitor|VEGFR inhibitor,MoA,Phase 2
369,5913,JAK inhibitor,MoA,Preclinical
370,5913,JAK inhibitor,MoA,Preclinical
136,5914,PI3K inhibitor,MoA,Preclinical
138,5914,PI3K inhibitor,MoA,Preclinical
474,5915,PI3K inhibitor,MoA,Phase 1/Phase 2
136,5915,PI3K inhibitor,MoA,Phase 1/Phase 2
138,5915,PI3K inhibitor,MoA,Phase 1/Phase 2
476,5915,PI3K inhibitor,MoA,Phase 1/Phase 2
2139,5916,MTH1 inhibitor,MoA,Preclinical
69,5918,phosphodiesterase inhibitor,MoA,Launched
275,5918,phosphodiesterase inhibitor,MoA,Launched
20,5918,phosphodiesterase inhibitor,MoA,Launched
5919,5920,GLCNAC phosphotransferase inhibitor,MoA,Preclinical
100,5931,histamine receptor antagonist,MoA,Preclinical
623,5931,histamine receptor antagonist,MoA,Preclinical
6,5933,dopamine receptor antagonist,MoA,Withdrawn
7,5933,dopamine receptor antagonist,MoA,Withdrawn
8,5933,dopamine receptor antagonist,MoA,Withdrawn
9,5933,dopamine receptor antagonist,MoA,Withdrawn
10,5933,dopamine receptor antagonist,MoA,Withdrawn
97,5933,dopamine receptor antagonist,MoA,Withdrawn
11,5933,dopamine receptor antagonist,MoA,Withdrawn
14,5933,dopamine receptor antagonist,MoA,Withdrawn
16,5933,dopamine receptor antagonist,MoA,Withdrawn
624,5933,dopamine receptor antagonist,MoA,Withdrawn
625,5933,dopamine receptor antagonist,MoA,Withdrawn
3654,5934,membrane metalloendopeptidase inhibitor,MoA,Phase 1
515,5941,CDK inhibitor,MoA,Preclinical
515,5942,CDK inhibitor,MoA,Preclinical
515,5943,CDK inhibitor,MoA,Preclinical
49,5951,AKT inhibitor|TRAIL modulator,MoA,Phase 2
828,5951,AKT inhibitor|TRAIL modulator,MoA,Phase 2
32,5952,glycogen synthase kinase inhibitor,MoA,Phase 2
2191,5953,cytochrome P450 inhibitor|sodium/potassium/chloride transporter inhibitor,MoA,Withdrawn
1056,5953,cytochrome P450 inhibitor|sodium/potassium/chloride transporter inhibitor,MoA,Withdrawn
244,5954,TIE tyrosine kinase inhibitor,MoA,Preclinical
405,5954,TIE tyrosine kinase inhibitor,MoA,Preclinical
192,5955,ATP-sensitive potassium channel agonist,MoA,Phase 1
196,5955,ATP-sensitive potassium channel agonist,MoA,Phase 1
1417,5957,cholesterol inhibitor|lipase clearing factor inhibitor,MoA,Phase 2
99,5959,histamine receptor antagonist,MoA,Phase 2
188,5961,carbonic anhydrase inhibitor,MoA,Preclinical
815,5962,farnesyltransferase inhibitor,MoA,Phase 3
3871,5962,farnesyltransferase inhibitor,MoA,Phase 3
5963,5964,plasminogen activator inhibitor,MoA,Phase 1
165,5965,adrenergic receptor antagonist,MoA,Phase 2
417,5965,adrenergic receptor antagonist,MoA,Phase 2
567,5965,adrenergic receptor antagonist,MoA,Phase 2
167,5966,sodium channel blocker,MoA,Withdrawn
430,5969,tyrosine kinase inhibitor,MoA,Phase 3
2197,5972,cyclophilin inhibitor,MoA,Preclinical
377,5973,methionine aminopeptidase inhibitor,MoA,Phase 2
165,5979,adrenergic receptor antagonist,MoA,Phase 3
417,5979,adrenergic receptor antagonist,MoA,Phase 3
567,5979,adrenergic receptor antagonist,MoA,Phase 3
2694,5983,catechol O methyltransferase inhibitor,MoA,Withdrawn
1084,5984,SRC activator,MoA,Phase 2
1054,5984,SRC activator,MoA,Phase 2
1,5986,adrenergic receptor antagonist,MoA,Launched
2986,5989,aldose reductase inhibitor,MoA,Withdrawn
255,5989,aldose reductase inhibitor,MoA,Withdrawn
5990,5989,aldose reductase inhibitor,MoA,Withdrawn
1816,5993,leukotriene receptor antagonist,MoA,Phase 3
683,5998,cholesteryl ester transfer protein inhibitor,MoA,Phase 3
2639,5999,DNA polymerase inhibitor,MoA,Phase 2
6000,5999,DNA polymerase inhibitor,MoA,Phase 2
781,6002,mTOR inhibitor,MoA,Preclinical
781,6003,mTOR inhibitor,MoA,Preclinical
2853,6004,peptidase inhibitor,MoA,Phase 2
6005,6004,peptidase inhibitor,MoA,Phase 2
6006,6004,peptidase inhibitor,MoA,Phase 2
775,6007,serine/threonine kinase inhibitor,MoA,Phase 1
275,6008,adenosine receptor antagonist,MoA,Phase 3
452,6009,Aurora kinase inhibitor|Bcr-Abl kinase inhibitor|FLT3 inhibitor|JAK inhibitor,MoA,Phase 2
563,6009,Aurora kinase inhibitor|Bcr-Abl kinase inhibitor|FLT3 inhibitor|JAK inhibitor,MoA,Phase 2
564,6009,Aurora kinase inhibitor|Bcr-Abl kinase inhibitor|FLT3 inhibitor|JAK inhibitor,MoA,Phase 2
1283,6009,Aurora kinase inhibitor|Bcr-Abl kinase inhibitor|FLT3 inhibitor|JAK inhibitor,MoA,Phase 2
79,6010,GABA receptor inverse agonist,MoA,Preclinical
140,6010,GABA receptor inverse agonist,MoA,Preclinical
141,6010,GABA receptor inverse agonist,MoA,Preclinical
142,6010,GABA receptor inverse agonist,MoA,Preclinical
1329,6011,AXL kinase inhibitor,MoA,Phase 1/Phase 2
212,6012,IKK inhibitor,MoA,Preclinical
79,6013,GABA receptor modulator,MoA,Phase 2
853,6014,potassium channel antagonist,MoA,Preclinical
853,6015,calcium-activated potassium channel activator,MoA,Preclinical
1196,6017,beta amyloid protein neurotoxicity inhibitor,MoA,Phase 3
1099,6022,nociceptin/orphanin FQ receptor antagonist|opioid receptor antagonist,MoA,Preclinical
155,6025,glutamate receptor antagonist,MoA,Phase 2
23,6030,phosphodiesterase inhibitor,MoA,Phase 1
1602,6031,DNA replication inhibitor,MoA,Phase 2
1555,6038,ribonucleotide reductase inhibitor,MoA,Phase 2
1886,6038,ribonucleotide reductase inhibitor,MoA,Phase 2
247,6040,HDAC inhibitor,MoA,Phase 1
1143,6040,HDAC inhibitor,MoA,Phase 1
249,6040,HDAC inhibitor,MoA,Phase 1
250,6040,HDAC inhibitor,MoA,Phase 1
1145,6040,HDAC inhibitor,MoA,Phase 1
1146,6040,HDAC inhibitor,MoA,Phase 1
251,6040,HDAC inhibitor,MoA,Phase 1
1147,6040,HDAC inhibitor,MoA,Phase 1
252,6040,HDAC inhibitor,MoA,Phase 1
1148,6040,HDAC inhibitor,MoA,Phase 1
49,6041,AKT inhibitor,MoA,Phase 1/Phase 2
749,6041,AKT inhibitor,MoA,Phase 1/Phase 2
750,6041,AKT inhibitor,MoA,Phase 1/Phase 2
605,6058,dihydrofolate reductase inhibitor,MoA,Phase 3
12,6062,serotonin receptor agonist,MoA,Phase 1
13,6062,serotonin receptor agonist,MoA,Phase 1
213,6063,RNA polymerase inhibitor,MoA,Phase 3
4669,6065,cytokine production inhibitor,MoA,Phase 2
700,6065,cytokine production inhibitor,MoA,Phase 2
672,6065,cytokine production inhibitor,MoA,Phase 2
2190,6066,insulin sensitizer|PPAR receptor agonist,MoA,Withdrawn
200,6066,insulin sensitizer|PPAR receptor agonist,MoA,Withdrawn
1806,6066,insulin sensitizer|PPAR receptor agonist,MoA,Withdrawn
77,6071,serotonin receptor antagonist,MoA,Preclinical
957,6071,serotonin receptor antagonist,MoA,Preclinical
174,6072,cyclooxygenase inhibitor,MoA,Launched
171,6072,cyclooxygenase inhibitor,MoA,Launched
232,6076,bacterial DNA gyrase inhibitor,MoA,Withdrawn
511,6077,opioid receptor agonist,MoA,Phase 3
2706,6078,cyclooxygenase inhibitor,MoA,Preclinical
124,6082,retinoid receptor agonist,MoA,Phase 1
118,6082,retinoid receptor agonist,MoA,Phase 1
222,6082,retinoid receptor agonist,MoA,Phase 1
2173,6083,casein kinase inhibitor,MoA,Preclinical
251,6084,HDAC inhibitor,MoA,Preclinical
348,6087,EGFR inhibitor,MoA,Phase 3
483,6088,free fatty acid receptor agonist,MoA,Preclinical
389,6089,free fatty acid receptor agonist,MoA,Preclinical
110,6091,BCL inhibitor,MoA,Preclinical
112,6091,BCL inhibitor,MoA,Preclinical
1292,6091,BCL inhibitor,MoA,Preclinical
32,6092,glycogen synthase kinase inhibitor,MoA,Preclinical
827,6092,glycogen synthase kinase inhibitor,MoA,Preclinical
6093,6092,glycogen synthase kinase inhibitor,MoA,Preclinical
2215,6094,sphingosine 1-phosphate receptor antagonist,MoA,Preclinical
128,6095,FLT3 inhibitor,MoA,Preclinical
346,6096,EGFR inhibitor,MoA,Preclinical
405,6096,EGFR inhibitor,MoA,Preclinical
346,6097,EGFR inhibitor|tyrosine kinase inhibitor,MoA,Preclinical
346,6098,EGFR inhibitor,MoA,Preclinical
348,6099,protein tyrosine kinase inhibitor,MoA,Preclinical
346,6100,protein tyrosine kinase inhibitor,MoA,Preclinical
348,6101,tyrosine kinase inhibitor,MoA,Preclinical
244,6101,tyrosine kinase inhibitor,MoA,Preclinical
631,6101,tyrosine kinase inhibitor,MoA,Preclinical
346,6102,tyrosine kinase inhibitor,MoA,Preclinical
49,6103,MEK inhibitor,MoA,Preclinical
1026,6103,MEK inhibitor,MoA,Preclinical
32,6103,MEK inhibitor,MoA,Preclinical
1283,6103,MEK inhibitor,MoA,Preclinical
805,6103,MEK inhibitor,MoA,Preclinical
849,6103,MEK inhibitor,MoA,Preclinical
6104,6103,MEK inhibitor,MoA,Preclinical
828,6103,MEK inhibitor,MoA,Preclinical
553,6103,MEK inhibitor,MoA,Preclinical
555,6103,MEK inhibitor,MoA,Preclinical
405,6103,MEK inhibitor,MoA,Preclinical
726,6103,MEK inhibitor,MoA,Preclinical
1284,6103,MEK inhibitor,MoA,Preclinical
948,6103,MEK inhibitor,MoA,Preclinical
839,6103,MEK inhibitor,MoA,Preclinical
1285,6103,MEK inhibitor,MoA,Preclinical
1705,6103,MEK inhibitor,MoA,Preclinical
2694,6105,catechol O methyltransferase inhibitor,MoA,Preclinical
185,6106,carbonic anhydrase inhibitor,MoA,Phase 1/Phase 2
186,6106,carbonic anhydrase inhibitor,MoA,Phase 1/Phase 2
188,6106,carbonic anhydrase inhibitor,MoA,Phase 1/Phase 2
1617,6106,carbonic anhydrase inhibitor,MoA,Phase 1/Phase 2
510,6107,opioid receptor agonist,MoA,Preclinical
510,6108,opioid receptor agonist,MoA,Preclinical
687,6109,growth hormone releasing factor agonist,MoA,Phase 1
8,6110,dopamine receptor antagonist,MoA,Preclinical
469,6111,dipeptidyl peptidase inhibitor,MoA,Preclinical
6112,6111,dipeptidyl peptidase inhibitor,MoA,Preclinical
59,6113,acetylcholine receptor agonist,MoA,Preclinical
61,6113,acetylcholine receptor agonist,MoA,Preclinical
503,6113,acetylcholine receptor agonist,MoA,Preclinical
906,6116,glutamate receptor antagonist,MoA,Preclinical
906,6117,glutamate receptor antagonist,MoA,Preclinical
906,6118,glutamate receptor antagonist,MoA,Preclinical
3647,6118,glutamate receptor antagonist,MoA,Preclinical
1018,6119,XIAP inhibitor,MoA,Preclinical
247,6120,HDAC inhibitor,MoA,Preclinical
249,6120,HDAC inhibitor,MoA,Preclinical
250,6120,HDAC inhibitor,MoA,Preclinical
252,6120,HDAC inhibitor,MoA,Preclinical
7,6122,dopamine receptor antagonist,MoA,Preclinical
8,6122,dopamine receptor antagonist,MoA,Preclinical
9,6122,dopamine receptor antagonist,MoA,Preclinical
11,6122,dopamine receptor antagonist,MoA,Preclinical
767,6123,metalloproteinase inhibitor,MoA,Preclinical
2726,6123,metalloproteinase inhibitor,MoA,Preclinical
1112,6123,metalloproteinase inhibitor,MoA,Preclinical
1826,6123,metalloproteinase inhibitor,MoA,Preclinical
84,6123,metalloproteinase inhibitor,MoA,Preclinical
3706,6124,procollagen C-endopeptidase inhibitor,MoA,Phase 1
786,6125,monocarboxylate transporter inhibitor,MoA,Preclinical
37,6128,histone lysine methyltransferase inhibitor,MoA,Preclinical
39,6128,histone lysine methyltransferase inhibitor,MoA,Preclinical
39,6129,histone lysine methyltransferase inhibitor,MoA,Preclinical
39,6130,histone lysine methyltransferase inhibitor,MoA,Preclinical
37,6131,histone lysine methyltransferase inhibitor,MoA,Preclinical
39,6131,histone lysine methyltransferase inhibitor,MoA,Preclinical
37,6132,histone lysine methyltransferase inhibitor,MoA,Preclinical
39,6132,histone lysine methyltransferase inhibitor,MoA,Preclinical
39,6133,histone lysine methyltransferase inhibitor,MoA,Preclinical
37,6134,histone lysine methyltransferase inhibitor,MoA,Preclinical
39,6134,histone lysine methyltransferase inhibitor,MoA,Preclinical
6135,6136,L3MBTL antagonist,MoA,Preclinical
2121,6137,histone lysine methyltransferase inhibitor,MoA,Preclinical
128,6138,FLT3 inhibitor|MER tyrosine kinase inhibitor,MoA,Preclinical
1331,6138,FLT3 inhibitor|MER tyrosine kinase inhibitor,MoA,Preclinical
1331,6139,MER tyrosine kinase inhibitor,MoA,Preclinical
5540,6140,protein arginine N-methyltransferase inhibitor,MoA,Preclinical
6141,6142,phosphatidyl-inositol activator,MoA,Preclinical
6143,6144,L3MBTL antagonist,MoA,Preclinical
6143,6145,MBT inhibitor,MoA,Preclinical
122,6146,PARP inhibitor,MoA,Preclinical
49,6147,AKT inhibitor,MoA,Phase 2
749,6147,AKT inhibitor,MoA,Phase 2
750,6147,AKT inhibitor,MoA,Phase 2
528,6151,FAAH inhibitor,MoA,Phase 1
6152,6151,FAAH inhibitor,MoA,Phase 1
67,6151,FAAH inhibitor,MoA,Phase 1
1858,6156,dopamine receptor agonist,MoA,Phase 2
6157,6156,dopamine receptor agonist,MoA,Phase 2
322,6158,purinergic receptor activator,MoA,Launched
324,6158,purinergic receptor activator,MoA,Launched
325,6158,purinergic receptor activator,MoA,Launched
4395,6158,purinergic receptor activator,MoA,Launched
1864,6158,purinergic receptor activator,MoA,Launched
6159,6160,mixed lineage kinase inhibitor,MoA,Preclinical
2176,6160,mixed lineage kinase inhibitor,MoA,Preclinical
128,6160,mixed lineage kinase inhibitor,MoA,Preclinical
2232,6160,mixed lineage kinase inhibitor,MoA,Preclinical
6161,6160,mixed lineage kinase inhibitor,MoA,Preclinical
6162,6160,mixed lineage kinase inhibitor,MoA,Preclinical
1380,6160,mixed lineage kinase inhibitor,MoA,Preclinical
3090,6160,mixed lineage kinase inhibitor,MoA,Preclinical
273,6160,mixed lineage kinase inhibitor,MoA,Preclinical
202,6164,ATPase inhibitor|NFkB pathway inhibitor|STAT inhibitor,MoA,Phase 2/Phase 3
1770,6164,ATPase inhibitor|NFkB pathway inhibitor|STAT inhibitor,MoA,Phase 2/Phase 3
1280,6164,ATPase inhibitor|NFkB pathway inhibitor|STAT inhibitor,MoA,Phase 2/Phase 3
262,6164,ATPase inhibitor|NFkB pathway inhibitor|STAT inhibitor,MoA,Phase 2/Phase 3
1280,6165,MAP kinase activator,MoA,Preclinical
186,6166,cyclooxygenase inhibitor,MoA,Withdrawn
171,6166,cyclooxygenase inhibitor,MoA,Withdrawn
296,6176,P glycoprotein inhibitor,MoA,Phase 3
620,6192,dopamine reuptake inhibitor,MoA,Phase 3
2443,6195,secretory phospholipase inhibitor,MoA,Phase 3
346,6197,KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,MoA,Phase 3
939,6197,KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,MoA,Phase 3
940,6197,KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,MoA,Phase 3
244,6197,KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,MoA,Phase 3
131,6197,KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,MoA,Phase 3
1623,6198,cathepsin inhibitor,MoA,Preclinical
1349,6198,cathepsin inhibitor,MoA,Preclinical
1350,6198,cathepsin inhibitor,MoA,Preclinical
1020,6199,ATR kinase inhibitor,MoA,Preclinical
1512,6200,ATR kinase inhibitor,MoA,Phase 2
1020,6200,ATR kinase inhibitor,MoA,Phase 2
781,6200,ATR kinase inhibitor,MoA,Phase 2
476,6200,ATR kinase inhibitor,MoA,Phase 2
680,6203,leukotriene synthesis inhibitor,MoA,Phase 3
366,6204,PARP inhibitor,MoA,Phase 3
122,6204,PARP inhibitor,MoA,Phase 3
1707,6205,neuropeptide receptor antagonist,MoA,Phase 2
1244,6209,HSP inhibitor,MoA,Preclinical
507,6210,HSP inhibitor,MoA,Preclinical
6213,6214,CC chemokine receptor antagonist,MoA,Phase 3
3914,6215,urate transporter inhibitor,MoA,Phase 2
114,6217,tubulin polymerization inhibitor,MoA,Phase 2
6218,6219,acetylcholinesterase inhibitor,MoA,Preclinical
2242,6221,tumor necrosis factor receptor antagonist,MoA,Phase 1
263,6222,CC chemokine receptor antagonist,MoA,Phase 3
73,6234,adrenergic receptor antagonist,MoA,Withdrawn
74,6234,adrenergic receptor antagonist,MoA,Withdrawn
75,6234,adrenergic receptor antagonist,MoA,Withdrawn
76,6234,adrenergic receptor antagonist,MoA,Withdrawn
69,6239,adenosine receptor antagonist,MoA,Phase 1
275,6239,adenosine receptor antagonist,MoA,Phase 1
276,6239,adenosine receptor antagonist,MoA,Phase 1
277,6239,adenosine receptor antagonist,MoA,Phase 1
403,6241,LDL oxidation inhibitor|PKC inhibitor,MoA,Launched
5188,6241,LDL oxidation inhibitor|PKC inhibitor,MoA,Launched
1923,6241,LDL oxidation inhibitor|PKC inhibitor,MoA,Launched
6242,6241,LDL oxidation inhibitor|PKC inhibitor,MoA,Launched
6243,6241,LDL oxidation inhibitor|PKC inhibitor,MoA,Launched
1284,6241,LDL oxidation inhibitor|PKC inhibitor,MoA,Launched
1699,6241,LDL oxidation inhibitor|PKC inhibitor,MoA,Launched
6244,6241,LDL oxidation inhibitor|PKC inhibitor,MoA,Launched
6245,6241,LDL oxidation inhibitor|PKC inhibitor,MoA,Launched
6246,6241,LDL oxidation inhibitor|PKC inhibitor,MoA,Launched
761,6247,antitumor agent|ubiquitin C-terminal hydrolase inhibitor,MoA,Phase 1
3585,6247,antitumor agent|ubiquitin C-terminal hydrolase inhibitor,MoA,Phase 1
1228,6249,PLK inhibitor,MoA,Phase 3
14,6250,serotonin receptor antagonist,MoA,Phase 3
15,6250,serotonin receptor antagonist,MoA,Phase 3
16,6250,serotonin receptor antagonist,MoA,Phase 3
617,6250,serotonin receptor antagonist,MoA,Phase 3
232,6254,topoisomerase inhibitor,MoA,Phase 3
781,6258,mTOR inhibitor|PI3K inhibitor,MoA,Phase 2
474,6258,mTOR inhibitor|PI3K inhibitor,MoA,Phase 2
610,6259,beta amyloid antagonist,MoA,Phase 1
1006,6259,beta amyloid antagonist,MoA,Phase 1
95,6260,cytochrome P450 inhibitor,MoA,Phase 2
454,6261,renin inhibitor,MoA,Phase 1
77,6262,serotonin receptor antagonist,MoA,Preclinical
957,6262,serotonin receptor antagonist,MoA,Preclinical
623,6263,histamine receptor agonist,MoA,Preclinical
5012,6264,CC chemokine receptor agonist,MoA,Preclinical
357,6265,phospholipase inhibitor,MoA,Preclinical
170,6266,acetylcholine receptor allosteric modulator,MoA,Preclinical
1453,6267,potassium/chloride cotransporter inhibitor,MoA,Preclinical
160,6268,glutamate receptor positive allosteric modulator,MoA,Preclinical
160,6269,glutamate receptor positive allosteric modulator,MoA,Preclinical
2414,6270,glutamate receptor positive allosteric modulator,MoA,Preclinical
2414,6271,glutamate receptor positive allosteric modulator,MoA,Preclinical
1775,6272,phospholipase inhibitor,MoA,Preclinical
2414,6273,glutamate receptor positive allosteric modulator,MoA,Preclinical
1835,6274,glutamate receptor positive allosteric modulator,MoA,Preclinical
76,6275,acetylcholine receptor allosteric modulator,MoA,Preclinical
76,6276,acetylcholine receptor allosteric modulator,MoA,Preclinical
160,6277,glutamate receptor positive allosteric modulator,MoA,Preclinical
160,6278,glutamate receptor potentiator,MoA,Preclinical
194,6279,potassium channel blocker,MoA,Preclinical
828,6280,MAP kinase inhibitor,MoA,Preclinical
698,6281,p38 MAPK inhibitor,MoA,Phase 2
700,6281,p38 MAPK inhibitor,MoA,Phase 2
553,6281,p38 MAPK inhibitor,MoA,Phase 2
555,6281,p38 MAPK inhibitor,MoA,Phase 2
405,6281,p38 MAPK inhibitor,MoA,Phase 2
672,6281,p38 MAPK inhibitor,MoA,Phase 2
553,6282,p38 MAPK inhibitor,MoA,Phase 2
555,6282,p38 MAPK inhibitor,MoA,Phase 2
405,6282,p38 MAPK inhibitor,MoA,Phase 2
2669,6283,caspase inhibitor,MoA,Phase 2
4461,6284,anaphylatoxin chemotactic receptor antagonist,MoA,Preclinical
11,6286,serotonin receptor antagonist,MoA,Phase 1
16,6287,serotonin receptor agonist,MoA,Preclinical
767,6288,metalloproteinase inhibitor,MoA,Preclinical
348,6289,estrogen receptor agonist,MoA,Preclinical
1035,6289,estrogen receptor agonist,MoA,Preclinical
349,6289,estrogen receptor agonist,MoA,Preclinical
116,6289,estrogen receptor agonist,MoA,Preclinical
86,6290,gonadotropin releasing factor hormone receptor antagonist,MoA,Preclinical
99,6290,gonadotropin releasing factor hormone receptor antagonist,MoA,Preclinical
78,6290,gonadotropin releasing factor hormone receptor antagonist,MoA,Preclinical
7,6291,serotonin receptor agonist,MoA,Preclinical
14,6291,serotonin receptor agonist,MoA,Preclinical
16,6291,serotonin receptor agonist,MoA,Preclinical
624,6291,serotonin receptor agonist,MoA,Preclinical
625,6291,serotonin receptor agonist,MoA,Preclinical
1846,6292,glutamate inhibitor,MoA,Preclinical
6293,6294,secreted frizzled related protein inhibitor,MoA,Preclinical
1718,6295,FXR agonist,MoA,Phase 1
781,6296,mTOR inhibitor,MoA,Preclinical
16,6297,serotonin receptor agonist,MoA,Preclinical
45,6298,adrenergic receptor antagonist,MoA,Preclinical
47,6298,adrenergic receptor antagonist,MoA,Preclinical
48,6298,adrenergic receptor antagonist,MoA,Preclinical
1,6298,adrenergic receptor antagonist,MoA,Preclinical
3,6298,adrenergic receptor antagonist,MoA,Preclinical
4,6298,adrenergic receptor antagonist,MoA,Preclinical
11,6298,adrenergic receptor antagonist,MoA,Preclinical
4650,6299,histone lysine methyltransferase inhibitor,MoA,Preclinical
1283,6300,SRC inhibitor,MoA,Preclinical
1054,6300,SRC inhibitor,MoA,Preclinical
346,6301,JAK inhibitor,MoA,Preclinical
969,6301,JAK inhibitor,MoA,Preclinical
369,6301,JAK inhibitor,MoA,Preclinical
370,6301,JAK inhibitor,MoA,Preclinical
2679,6302,tankyrase inhibitor|WNT pathway inhibitor,MoA,Preclinical
1959,6303,aldehyde dehydrogenase inhibitor,MoA,Preclinical
3432,6304,bradykinin receptor antagonist,MoA,Preclinical
6305,6306,actin related protein inhibitor|neural Wiskott-Aldrich syndrome protein inhibitor,MoA,Preclinical
2797,6307,porcupine inhibitor,MoA,Preclinical
6308,6309,PI3K inhibitor,MoA,Preclinical
4266,6309,PI3K inhibitor,MoA,Preclinical
474,6309,PI3K inhibitor,MoA,Preclinical
138,6309,PI3K inhibitor,MoA,Preclinical
476,6309,PI3K inhibitor,MoA,Preclinical
2162,6309,PI3K inhibitor,MoA,Preclinical
1228,6309,PI3K inhibitor,MoA,Preclinical
1526,6309,PI3K inhibitor,MoA,Preclinical
227,6310,STAT inhibitor,MoA,Phase 1
369,6311,deubiquitinase inhibitor,MoA,Preclinical
6312,6311,deubiquitinase inhibitor,MoA,Preclinical
3585,6311,deubiquitinase inhibitor,MoA,Preclinical
6313,6311,deubiquitinase inhibitor,MoA,Preclinical
6315,6316,carboxylesterase inhibitor,MoA,Preclinical
6317,6318,monoacylglycerol lipase inhibitor,MoA,Preclinical
781,6319,mTOR inhibitor,MoA,Preclinical
781,6320,mTOR inhibitor,MoA,Preclinical
781,6321,mTOR inhibitor,MoA,Preclinical
346,6322,EGFR inhibitor,MoA,Preclinical
346,6323,EGFR inhibitor,MoA,Preclinical
348,6323,EGFR inhibitor,MoA,Preclinical
3368,6324,AMPK inhibitor,MoA,Preclinical
6325,6324,AMPK inhibitor,MoA,Preclinical
346,6326,EGFR inhibitor,MoA,Preclinical
537,6327,CC chemokine receptor antagonist,MoA,Preclinical
11,6328,serotonin receptor agonist,MoA,Phase 3
165,6329,adrenergic receptor agonist,MoA,Phase 3
73,6330,acetylcholine receptor agonist,MoA,Phase 3
74,6330,acetylcholine receptor agonist,MoA,Phase 3
75,6330,acetylcholine receptor agonist,MoA,Phase 3
76,6330,acetylcholine receptor agonist,MoA,Phase 3
170,6330,acetylcholine receptor agonist,MoA,Phase 3
11,6330,acetylcholine receptor agonist,MoA,Phase 3
12,6330,acetylcholine receptor agonist,MoA,Phase 3
13,6330,acetylcholine receptor agonist,MoA,Phase 3
488,6330,acetylcholine receptor agonist,MoA,Phase 3
489,6330,acetylcholine receptor agonist,MoA,Phase 3
14,6330,acetylcholine receptor agonist,MoA,Phase 3
15,6330,acetylcholine receptor agonist,MoA,Phase 3
16,6330,acetylcholine receptor agonist,MoA,Phase 3
624,6330,acetylcholine receptor agonist,MoA,Phase 3
625,6330,acetylcholine receptor agonist,MoA,Phase 3
2677,6331,tankyrase inhibitor,MoA,Preclinical
2679,6331,tankyrase inhibitor,MoA,Preclinical
2256,6332,benzodiazepine receptor ligand,MoA,Phase 2
3405,6333,bromodomain inhibitor,MoA,Preclinical
736,6333,bromodomain inhibitor,MoA,Preclinical
836,6333,bromodomain inhibitor,MoA,Preclinical
3621,6333,bromodomain inhibitor,MoA,Preclinical
2302,6334,potassium channel blocker,MoA,Preclinical
629,6334,potassium channel blocker,MoA,Preclinical
630,6334,potassium channel blocker,MoA,Preclinical
1191,6334,potassium channel blocker,MoA,Preclinical
2303,6334,potassium channel blocker,MoA,Preclinical
969,6336,JAK inhibitor,MoA,Phase 1
369,6336,JAK inhibitor,MoA,Phase 1
370,6336,JAK inhibitor,MoA,Phase 1
474,6337,PI3K inhibitor,MoA,Phase 2
138,6337,PI3K inhibitor,MoA,Phase 2
476,6337,PI3K inhibitor,MoA,Phase 2
364,6338,Abl kinase inhibitor|insulin growth factor receptor inhibitor|SRC inhibitor,MoA,Phase 1
1054,6338,Abl kinase inhibitor|insulin growth factor receptor inhibitor|SRC inhibitor,MoA,Phase 1
781,6339,mTOR inhibitor,MoA,Preclinical
346,6340,EGFR inhibitor|VEGFR inhibitor,MoA,Phase 3
4618,6340,EGFR inhibitor|VEGFR inhibitor,MoA,Phase 3
348,6340,EGFR inhibitor|VEGFR inhibitor,MoA,Phase 3
940,6340,EGFR inhibitor|VEGFR inhibitor,MoA,Phase 3
244,6340,EGFR inhibitor|VEGFR inhibitor,MoA,Phase 3
1299,6341,MAP kinase inhibitor,MoA,Preclinical
6342,6343,MAP kinase inhibitor,MoA,Preclinical
1299,6343,MAP kinase inhibitor,MoA,Preclinical
941,6343,MAP kinase inhibitor,MoA,Preclinical
6344,6343,MAP kinase inhibitor,MoA,Preclinical
2360,6347,focal adhesion kinase inhibitor,MoA,Preclinical
354,6348,estrogen receptor antagonist,MoA,Preclinical
116,6348,estrogen receptor antagonist,MoA,Preclinical
2141,6349,potassium channel activator,MoA,Phase 1
2141,6350,potassium channel activator,MoA,Phase 1
51,6351,rho associated kinase inhibitor,MoA,Preclinical
6352,6351,rho associated kinase inhibitor,MoA,Preclinical
52,6351,rho associated kinase inhibitor,MoA,Preclinical
359,6351,rho associated kinase inhibitor,MoA,Preclinical
839,6351,rho associated kinase inhibitor,MoA,Preclinical
912,6351,rho associated kinase inhibitor,MoA,Preclinical
1088,6353,prolyl endopeptidase inhibitor,MoA,Preclinical
5481,6354,interleukin inhibitor,MoA,Preclinical
839,6355,rho associated kinase inhibitor,MoA,Phase 2
912,6355,rho associated kinase inhibitor,MoA,Phase 2
3560,6356,guanylyl cyclase activator,MoA,Preclinical
1119,6356,guanylyl cyclase activator,MoA,Preclinical
1121,6356,guanylyl cyclase activator,MoA,Preclinical
234,6356,guanylyl cyclase activator,MoA,Preclinical
687,6357,ghrelin receptor antagonist,MoA,Preclinical
6358,6359,apoptosis inhibitor,MoA,Preclinical
6360,6359,apoptosis inhibitor,MoA,Preclinical
1185,6361,CCK receptor antagonist,MoA,Phase 2
5885,6362,survivin inhibitor,MoA,Phase 2
2117,6363,glutamate receptor antagonist,MoA,Preclinical
2117,6364,glutamate receptor antagonist,MoA,Preclinical
596,6365,aromatase inhibitor,MoA,Phase 2
3652,6366,calcium channel blocker,MoA,Preclinical
1744,6366,calcium channel blocker,MoA,Preclinical
280,6366,calcium channel blocker,MoA,Preclinical
2856,6367,ACAT inhibitor,MoA,Phase 1
6368,6369,IL5 inhibitor,MoA,Preclinical
6370,6369,IL5 inhibitor,MoA,Preclinical
18,6371,phosphodiesterase inhibitor,MoA,Phase 1
6372,6373,piezo channel activator,MoA,Preclinical
1509,6377,phosphofructokinase inhibitor,MoA,Preclinical
4887,6377,phosphofructokinase inhibitor,MoA,Preclinical
6378,6379,rho associated kinase inhibitor,MoA,Preclinical
77,6380,serotonin receptor antagonist,MoA,Phase 2
957,6380,serotonin receptor antagonist,MoA,Phase 2
490,6380,serotonin receptor antagonist,MoA,Phase 2
17,6380,serotonin receptor antagonist,MoA,Phase 2
770,6382,calmodulin antagonist,MoA,Phase 3
99,6383,histamine receptor antagonist,MoA,Phase 3
75,6384,acetylcholine receptor antagonist,MoA,Phase 3
1451,6386,phosphodiesterase inhibitor,MoA,Phase 2
1517,6386,phosphodiesterase inhibitor,MoA,Phase 2
22,6386,phosphodiesterase inhibitor,MoA,Phase 2
23,6386,phosphodiesterase inhibitor,MoA,Phase 2
1525,6386,phosphodiesterase inhibitor,MoA,Phase 2
22,6387,phosphodiesterase inhibitor,MoA,Phase 2
3587,6388,HCN channel blocker,MoA,Phase 3
6389,6388,HCN channel blocker,MoA,Phase 3
3589,6388,HCN channel blocker,MoA,Phase 3
3590,6388,HCN channel blocker,MoA,Phase 3
1618,6390,CDC inhibitor,MoA,Preclinical
567,6391,adrenergic receptor agonist,MoA,Phase 2
567,6392,adrenergic receptor agonist,MoA,Phase 1
1047,6393,angiotensin receptor antagonist,MoA,Preclinical
3587,6394,HCN channel blocker,MoA,Phase 2
6389,6394,HCN channel blocker,MoA,Phase 2
3589,6394,HCN channel blocker,MoA,Phase 2
3590,6394,HCN channel blocker,MoA,Phase 2
5902,6395,DNA methyltransferase inhibitor,MoA,Preclinical
949,6395,DNA methyltransferase inhibitor,MoA,Preclinical
238,6396,endothelin receptor antagonist,MoA,Phase 3
569,6400,selective serotonin reuptake inhibitor (SSRI),MoA,Withdrawn
1248,6400,selective serotonin reuptake inhibitor (SSRI),MoA,Withdrawn
410,6400,selective serotonin reuptake inhibitor (SSRI),MoA,Withdrawn
354,6402,estrogen receptor antagonist,MoA,Preclinical
116,6402,estrogen receptor antagonist,MoA,Preclinical
72,6403,CC chemokine receptor antagonist,MoA,Phase 2
79,6404,benzodiazepine receptor agonist,MoA,Phase 3
140,6404,benzodiazepine receptor agonist,MoA,Phase 3
141,6404,benzodiazepine receptor agonist,MoA,Phase 3
142,6404,benzodiazepine receptor agonist,MoA,Phase 3
145,6404,benzodiazepine receptor agonist,MoA,Phase 3
149,6404,benzodiazepine receptor agonist,MoA,Phase 3
79,6405,benzodiazepine receptor antagonist,MoA,Phase 1
140,6405,benzodiazepine receptor antagonist,MoA,Phase 1
141,6405,benzodiazepine receptor antagonist,MoA,Phase 1
142,6405,benzodiazepine receptor antagonist,MoA,Phase 1
290,6406,AMPK activator,MoA,Preclinical
291,6406,AMPK activator,MoA,Preclinical
872,6406,AMPK activator,MoA,Preclinical
69,6407,adenosine receptor antagonist,MoA,Preclinical
275,6407,adenosine receptor antagonist,MoA,Preclinical
276,6407,adenosine receptor antagonist,MoA,Preclinical
277,6407,adenosine receptor antagonist,MoA,Preclinical
346,6408,Abl kinase inhibitor|SRC inhibitor|VEGFR inhibitor,MoA,Preclinical
939,6408,Abl kinase inhibitor|SRC inhibitor|VEGFR inhibitor,MoA,Preclinical
940,6408,Abl kinase inhibitor|SRC inhibitor|VEGFR inhibitor,MoA,Preclinical
244,6408,Abl kinase inhibitor|SRC inhibitor|VEGFR inhibitor,MoA,Preclinical
244,6409,VEGFR inhibitor,MoA,Preclinical
946,6410,RAF inhibitor,MoA,Preclinical
1283,6410,RAF inhibitor,MoA,Preclinical
405,6410,RAF inhibitor,MoA,Preclinical
948,6410,RAF inhibitor,MoA,Preclinical
969,6411,JAK inhibitor,MoA,Preclinical
370,6411,JAK inhibitor,MoA,Preclinical
452,6412,Aurora kinase inhibitor,MoA,Preclinical
563,6412,Aurora kinase inhibitor,MoA,Preclinical
971,6416,prostaglandin synthesis inhibitor,MoA,Withdrawn
586,6417,sodium/hydrogen exchanger inhibitor,MoA,Phase 3
296,6423,P glycoprotein inhibitor,MoA,Phase 3
6424,6423,P glycoprotein inhibitor,MoA,Phase 3
136,6427,PI3K inhibitor,MoA,Phase 1/Phase 2
138,6427,PI3K inhibitor,MoA,Phase 1/Phase 2
476,6427,PI3K inhibitor,MoA,Phase 1/Phase 2
644,6429,N-type calcium channel blocker,MoA,Phase 2
369,6430,JAK inhibitor,MoA,Preclinical
3679,6431,benzodiazepine receptor agonist|gamma hydroxybutyric acid agonist,MoA,Phase 1
2443,6431,benzodiazepine receptor agonist|gamma hydroxybutyric acid agonist,MoA,Phase 1
610,6431,benzodiazepine receptor agonist|gamma hydroxybutyric acid agonist,MoA,Phase 1
3658,6432,glycogen synthase kinase inhibitor,MoA,Preclinical
512,6432,glycogen synthase kinase inhibitor,MoA,Preclinical
514,6432,glycogen synthase kinase inhibitor,MoA,Preclinical
32,6432,glycogen synthase kinase inhibitor,MoA,Preclinical
3681,6433,alpha mannosidase inhibitor,MoA,Preclinical
1243,6434,potassium channel activator,MoA,Preclinical
2349,6434,potassium channel activator,MoA,Preclinical
2351,6434,potassium channel activator,MoA,Preclinical
853,6434,potassium channel activator,MoA,Preclinical
1944,6435,sphingosine 1-phosphate receptor substrate,MoA,Preclinical
2416,6435,sphingosine 1-phosphate receptor substrate,MoA,Preclinical
1054,6436,SRC inhibitor,MoA,Preclinical
77,6438,serotonin receptor agonist,MoA,Preclinical
957,6438,serotonin receptor agonist,MoA,Preclinical
289,6439,AKT inhibitor,MoA,Preclinical
230,6440,topoisomerase inhibitor,MoA,Preclinical
6441,6442,PKC activator,MoA,Phase 2
1552,6442,PKC activator,MoA,Phase 2
1287,6443,nitric oxide synthase inhibitor,MoA,Preclinical
598,6443,nitric oxide synthase inhibitor,MoA,Preclinical
881,6443,nitric oxide synthase inhibitor,MoA,Preclinical
1993,6444,prostanoid receptor agonist,MoA,Phase 2
69,6446,adenosine receptor agonist,MoA,Preclinical
112,6447,BCL-XL downregulator,MoA,Preclinical
2241,6448,thioredoxin inhibitor,MoA,Phase 2
1196,6449,ATP synthase inhibitor,MoA,Preclinical
2499,6450,hemoglobin modulator,MoA,Phase 2
3783,6451,glutamate carboxypeptidase inhibitor,MoA,Phase 1
490,6452,serotonin receptor agonist,MoA,Preclinical
186,6453,carbonic anhydrase inhibitor,MoA,Preclinical
187,6453,carbonic anhydrase inhibitor,MoA,Preclinical
188,6453,carbonic anhydrase inhibitor,MoA,Preclinical
1616,6453,carbonic anhydrase inhibitor,MoA,Preclinical
1617,6453,carbonic anhydrase inhibitor,MoA,Preclinical
5586,6454,"1,4,5-trisphosphate inhibitor",MoA,Preclinical
3652,6454,"1,4,5-trisphosphate inhibitor",MoA,Preclinical
4337,6454,"1,4,5-trisphosphate inhibitor",MoA,Preclinical
1744,6454,"1,4,5-trisphosphate inhibitor",MoA,Preclinical
798,6454,"1,4,5-trisphosphate inhibitor",MoA,Preclinical
587,6454,"1,4,5-trisphosphate inhibitor",MoA,Preclinical
799,6454,"1,4,5-trisphosphate inhibitor",MoA,Preclinical
1806,6454,"1,4,5-trisphosphate inhibitor",MoA,Preclinical
6455,6454,"1,4,5-trisphosphate inhibitor",MoA,Preclinical
53,6454,"1,4,5-trisphosphate inhibitor",MoA,Preclinical
6456,6454,"1,4,5-trisphosphate inhibitor",MoA,Preclinical
1,6457,imidazoline receptor ligand,MoA,Preclinical
3,6457,imidazoline receptor ligand,MoA,Preclinical
4,6457,imidazoline receptor ligand,MoA,Preclinical
569,6457,imidazoline receptor ligand,MoA,Preclinical
1248,6457,imidazoline receptor ligand,MoA,Preclinical
69,6458,adenosine receptor agonist,MoA,Preclinical
275,6458,adenosine receptor agonist,MoA,Preclinical
276,6458,adenosine receptor agonist,MoA,Preclinical
277,6458,adenosine receptor agonist,MoA,Preclinical
69,6459,adenosine receptor agonist,MoA,Preclinical
275,6459,adenosine receptor agonist,MoA,Preclinical
276,6459,adenosine receptor agonist,MoA,Preclinical
7,6460,dopamine receptor antagonist,MoA,Preclinical
9,6460,dopamine receptor antagonist,MoA,Preclinical
5678,6461,glycolysis inhibitor,MoA,Phase 2
6462,6461,glycolysis inhibitor,MoA,Phase 2
6463,6461,glycolysis inhibitor,MoA,Phase 2
6464,6461,glycolysis inhibitor,MoA,Phase 2
696,6466,androgen receptor antagonist,MoA,Phase 2
24,6467,GABA receptor antagonist,MoA,Preclinical
26,6467,GABA receptor antagonist,MoA,Preclinical
1287,6468,nitric oxide synthase inhibitor,MoA,Phase 2
598,6468,nitric oxide synthase inhibitor,MoA,Phase 2
387,6469,melatonin receptor agonist,MoA,Preclinical
388,6469,melatonin receptor agonist,MoA,Preclinical
1602,6469,melatonin receptor agonist,MoA,Preclinical
2694,6470,hypoxia inducible factor inhibitor,MoA,Phase 2
596,6470,hypoxia inducible factor inhibitor,MoA,Phase 2
1158,6470,hypoxia inducible factor inhibitor,MoA,Phase 2
753,6470,hypoxia inducible factor inhibitor,MoA,Phase 2
234,6470,hypoxia inducible factor inhibitor,MoA,Phase 2
114,6470,hypoxia inducible factor inhibitor,MoA,Phase 2
12,6471,serotonin receptor agonist,MoA,Preclinical
13,6471,serotonin receptor agonist,MoA,Preclinical
488,6471,serotonin receptor agonist,MoA,Preclinical
489,6471,serotonin receptor agonist,MoA,Preclinical
77,6471,serotonin receptor agonist,MoA,Preclinical
957,6471,serotonin receptor agonist,MoA,Preclinical
624,6471,serotonin receptor agonist,MoA,Preclinical
744,6472,glucose dependent insulinotropic receptor ligand,MoA,Phase 1
2235,6475,pyruvate dehydrogenase kinase inhibitor,MoA,Preclinical
387,6476,melatonin receptor agonist,MoA,Preclinical
388,6476,melatonin receptor agonist,MoA,Preclinical
45,6477,adrenergic receptor antagonist,MoA,Preclinical
97,6478,histamine receptor agonist,MoA,Preclinical
6479,6480,lipoxygenase inhibitor,MoA,Preclinical
7,6481,dopamine receptor ligand,MoA,Preclinical
160,6482,glutamate receptor modulator,MoA,Preclinical
696,6483,"CHK inhibitor|cytochrome P450 activator|indoleamine 2,3-dioxygenase inhibitor",MoA,Phase 3
234,6483,"CHK inhibitor|cytochrome P450 activator|indoleamine 2,3-dioxygenase inhibitor",MoA,Phase 3
4669,6483,"CHK inhibitor|cytochrome P450 activator|indoleamine 2,3-dioxygenase inhibitor",MoA,Phase 3
6484,6483,"CHK inhibitor|cytochrome P450 activator|indoleamine 2,3-dioxygenase inhibitor",MoA,Phase 3
1837,6485,glutamate receptor agonist,MoA,Preclinical
1837,6486,glutamate receptor agonist,MoA,Preclinical
1054,6487,SRC inhibitor|SYK inhibitor,MoA,Preclinical
1125,6487,SRC inhibitor|SYK inhibitor,MoA,Preclinical
2117,6488,glutamate receptor agonist,MoA,Preclinical
73,6489,dopamine uptake inhibitor,MoA,Preclinical
571,6489,dopamine uptake inhibitor,MoA,Preclinical
620,6489,dopamine uptake inhibitor,MoA,Preclinical
410,6489,dopamine uptake inhibitor,MoA,Preclinical
366,6493,PARP inhibitor,MoA,Phase 2
77,6494,serotonin receptor agonist,MoA,Preclinical
1287,6495,nitric oxide synthase inhibitor,MoA,Preclinical
598,6495,nitric oxide synthase inhibitor,MoA,Preclinical
881,6495,nitric oxide synthase inhibitor,MoA,Preclinical
6496,6497,hexokinase inhibitor,MoA,Preclinical
153,6498,glutamate receptor antagonist,MoA,Preclinical
154,6498,glutamate receptor antagonist,MoA,Preclinical
155,6498,glutamate receptor antagonist,MoA,Preclinical
156,6498,glutamate receptor antagonist,MoA,Preclinical
2117,6499,glutamate receptor antagonist,MoA,Preclinical
160,6499,glutamate receptor antagonist,MoA,Preclinical
4420,6500,adenosylhomocysteinase inhibitor,MoA,Phase 2
2121,6501,histone lysine methyltransferase inhibitor,MoA,Preclinical
2117,6507,glutamate receptor antagonist,MoA,Preclinical
2235,6508,GABA aminotransferase activator,MoA,Preclinical
6484,6509,PI3K inhibitor,MoA,Preclinical
45,6510,adrenergic receptor ligand,MoA,Preclinical
4887,6511,phosphofructokinase inhibitor,MoA,Preclinical
49,6512,casein kinase inhibitor,MoA,Preclinical
1026,6512,casein kinase inhibitor,MoA,Preclinical
2173,6512,casein kinase inhibitor,MoA,Preclinical
32,6512,casein kinase inhibitor,MoA,Preclinical
1283,6512,casein kinase inhibitor,MoA,Preclinical
805,6512,casein kinase inhibitor,MoA,Preclinical
828,6512,casein kinase inhibitor,MoA,Preclinical
553,6512,casein kinase inhibitor,MoA,Preclinical
555,6512,casein kinase inhibitor,MoA,Preclinical
405,6512,casein kinase inhibitor,MoA,Preclinical
726,6512,casein kinase inhibitor,MoA,Preclinical
1284,6512,casein kinase inhibitor,MoA,Preclinical
839,6512,casein kinase inhibitor,MoA,Preclinical
1285,6512,casein kinase inhibitor,MoA,Preclinical
1705,6512,casein kinase inhibitor,MoA,Preclinical
14,6513,serotonin receptor antagonist,MoA,Preclinical
2117,6515,glutamate receptor agonist|glutamate receptor antagonist,MoA,Preclinical
2117,6516,glutamate receptor agonist|glutamate receptor antagonist,MoA,Preclinical
1256,6516,glutamate receptor agonist|glutamate receptor antagonist,MoA,Preclinical
6517,6518,urokinase inhibitor,MoA,Preclinical
2238,6519,free fatty acid receptor agonist,MoA,Preclinical
73,6520,cholinergic receptor antagonist,MoA,Preclinical
74,6520,cholinergic receptor antagonist,MoA,Preclinical
75,6520,cholinergic receptor antagonist,MoA,Preclinical
76,6520,cholinergic receptor antagonist,MoA,Preclinical
170,6520,cholinergic receptor antagonist,MoA,Preclinical
366,6521,PARP inhibitor,MoA,Preclinical
633,6522,sigma receptor agonist,MoA,Preclinical
1509,6524,macrophage migration inhibiting factor inhibitor,MoA,Preclinical
596,6525,protein tyrosine kinase inhibitor,MoA,Preclinical
2271,6525,protein tyrosine kinase inhibitor,MoA,Preclinical
2273,6525,protein tyrosine kinase inhibitor,MoA,Preclinical
356,6525,protein tyrosine kinase inhibitor,MoA,Preclinical
1674,6525,protein tyrosine kinase inhibitor,MoA,Preclinical
623,6526,histamine receptor agonist,MoA,Preclinical
775,6527,IRE1 inhibitor,MoA,Preclinical
387,6528,melatonin receptor antagonist,MoA,Preclinical
388,6528,melatonin receptor antagonist,MoA,Preclinical
633,6529,sigma receptor ligand,MoA,Preclinical
43,6530,nicotinic receptor agonist,MoA,Preclinical
6531,6532,protein synthesis inhibitor,MoA,Preclinical
6531,6533,protein synthesis inhibitor,MoA,Preclinical
6534,6533,protein synthesis inhibitor,MoA,Preclinical
247,6535,HDAC inhibitor,MoA,Phase 1
69,6536,adenosine receptor agonist,MoA,Preclinical
994,6537,glutamate receptor antagonist,MoA,Preclinical
153,6537,glutamate receptor antagonist,MoA,Preclinical
154,6537,glutamate receptor antagonist,MoA,Preclinical
155,6537,glutamate receptor antagonist,MoA,Preclinical
156,6537,glutamate receptor antagonist,MoA,Preclinical
157,6537,glutamate receptor antagonist,MoA,Preclinical
6541,6542,purinergic receptor antagonist,MoA,Preclinical
11,6543,serotonin receptor agonist,MoA,Preclinical
12,6543,serotonin receptor agonist,MoA,Preclinical
13,6543,serotonin receptor agonist,MoA,Preclinical
488,6543,serotonin receptor agonist,MoA,Preclinical
489,6543,serotonin receptor agonist,MoA,Preclinical
14,6543,serotonin receptor agonist,MoA,Preclinical
15,6543,serotonin receptor agonist,MoA,Preclinical
16,6543,serotonin receptor agonist,MoA,Preclinical
17,6543,serotonin receptor agonist,MoA,Preclinical
624,6543,serotonin receptor agonist,MoA,Preclinical
625,6543,serotonin receptor agonist,MoA,Preclinical
1548,6545,thymidylate synthase inhibitor,MoA,Phase 1
75,6546,acetylcholine receptor antagonist,MoA,Phase 1
73,6549,acetylcholine receptor agonist,MoA,Preclinical
74,6549,acetylcholine receptor agonist,MoA,Preclinical
75,6549,acetylcholine receptor agonist,MoA,Preclinical
76,6549,acetylcholine receptor agonist,MoA,Preclinical
387,6550,melatonin receptor agonist,MoA,Preclinical
388,6550,melatonin receptor agonist,MoA,Preclinical
53,6551,TRPV antagonist,MoA,Preclinical
153,6552,glutamate receptor antagonist,MoA,Preclinical
154,6552,glutamate receptor antagonist,MoA,Preclinical
155,6552,glutamate receptor antagonist,MoA,Preclinical
156,6552,glutamate receptor antagonist,MoA,Preclinical
7,6553,dopamine receptor agonist,MoA,Preclinical
8,6553,dopamine receptor agonist,MoA,Preclinical
8,6554,dopamine receptor ligand,MoA,Preclinical
512,6555,CDK inhibitor|CHK inhibitor|PKC inhibitor,MoA,Phase 2
1026,6555,CDK inhibitor|CHK inhibitor|PKC inhibitor,MoA,Phase 2
1028,6555,CDK inhibitor|CHK inhibitor|PKC inhibitor,MoA,Phase 2
32,6555,CDK inhibitor|CHK inhibitor|PKC inhibitor,MoA,Phase 2
1283,6555,CDK inhibitor|CHK inhibitor|PKC inhibitor,MoA,Phase 2
405,6555,CDK inhibitor|CHK inhibitor|PKC inhibitor,MoA,Phase 2
6556,6555,CDK inhibitor|CHK inhibitor|PKC inhibitor,MoA,Phase 2
6557,6555,CDK inhibitor|CHK inhibitor|PKC inhibitor,MoA,Phase 2
789,6555,CDK inhibitor|CHK inhibitor|PKC inhibitor,MoA,Phase 2
1284,6555,CDK inhibitor|CHK inhibitor|PKC inhibitor,MoA,Phase 2
1699,6555,CDK inhibitor|CHK inhibitor|PKC inhibitor,MoA,Phase 2
358,6555,CDK inhibitor|CHK inhibitor|PKC inhibitor,MoA,Phase 2
359,6555,CDK inhibitor|CHK inhibitor|PKC inhibitor,MoA,Phase 2
2702,6555,CDK inhibitor|CHK inhibitor|PKC inhibitor,MoA,Phase 2
205,6558,acetylcholinesterase inhibitor,MoA,Phase 2
1287,6559,nitric oxide synthase inhibitor,MoA,Preclinical
598,6559,nitric oxide synthase inhibitor,MoA,Preclinical
881,6559,nitric oxide synthase inhibitor,MoA,Preclinical
3081,6560,PKA activator,MoA,Preclinical
17,6561,serotonin receptor agonist,MoA,Preclinical
625,6561,serotonin receptor agonist,MoA,Preclinical
7,6562,dopamine receptor ligand,MoA,Preclinical
8,6562,dopamine receptor ligand,MoA,Preclinical
387,6563,melatonin receptor agonist,MoA,Preclinical
388,6563,melatonin receptor agonist,MoA,Preclinical
230,6564,topoisomerase inhibitor,MoA,Phase 2
